

60th ANNUAL MEETING

EASD

9-13 SEPTEMBER 2024

MADRID



60TH EASD ANNUAL MEETING

Content	Page
Welcome Address2
About EASD4
About EFSD5
General Information6
Registration7
Certificates7
In person attendance onsite in Madrid.8
Floorplan	10
Online attendance via Virtual Meeting platform	13
Virtual Meeting App	13
Speakers and Chairpersons.	16
Programme	18
Programme Committee	18
Abstract Review	19
Programme Overview	20
Tuesday, 10 September 2024	28
Claude Bernard Lecture	28
Short Oral Discussions Event A	35
Short Oral Discussions Event B	37
Camillo Golgi Lecture	44
Wednesday, 11 September 2024	48
Albert Renold Lecture	48
Short Oral Discussions Event C	57
Short Oral Discussions Event D	59
Minkowski Lecture.	68
Thursday, 12 September 2024	72
Rising Star Symposium	73
Short Oral Discussions Event E	83
Short Oral Discussions Event F	85
Diabetes Prize for Excellence Lecture.	93
Friday, 13 September 2024	98
Short Oral Discussions	115
Abstract Presenter Index - Orals and Short Orals	220
Invited Speaker Index	232
Satellite Symposia on the occasion of EASD 2024	235
Industry Sessions on the occasion of EASD 2024	255
EASD and EFSD Acknowledgements	308

WELCOME ADDRESS

Dear Members and Guests,

On behalf of the European Association for the Study of Diabetes, it is my honour and pleasure to welcome you to Madrid for the 60th EASD Annual Meeting.



Joining us in Madrid is an excellent opportunity to stay up to date with recent developments in the diabetes field. You will be at the interface between discovery science and clinical practice, where key discussions take place that will move the field forward.

You can look forward to an exceptional scientific programme that extensively covers scientific research, current treatments, technologies, and care. The EASD Annual Meeting provides the perfect setting to exchange ideas and network with peers from all over the world, connecting the global diabetes community, sharing groundbreaking diabetes science and research, and offering educational opportunities.

Celebrate with us the 60th anniversary of EASD's Annual Meetings: I warmly invite you to register for a welcome reception in the Plaza de Toros de las Ventas - the bullring – on the evening of Tuesday, 10 September 2024.

Madrid, Spain's vibrant capital, offers great options outside of the scientific programme hours. Its rich history, stunning architecture, diverse culture, exquisite gastronomy, and lively entertainment provide a variety of choices for how to spend your evenings.

The EASD Board and the entire EASD team look forward to welcoming all of you in Madrid. For those who might not be able to travel, we invite you to join us virtually.

Join us in our mission to promote excellence in diabetes care through research, networking, and education!

Chantal Mathieu
President EASD/EFSD

WELCOME ADDRESS

Dear Colleagues and Friends,

On behalf of the Scientific Programme Committee, I am delighted to welcome you to the EASD Annual Meeting 2024 in Madrid, Spain.



The Scientific Programme Committee, together with the Abstract Review Committee, reviewed more than 2,000 submitted abstracts and selected over 1,000 to create the backbone of the scientific programme. For the first time in the history of EASD Annual Meetings, we have included late-breaking abstracts to ensure we capture the latest hot topics in diabetes research and care.

The programme comprises seven parallel streams featuring inspiring symposia, oral and short oral presentations, award lectures, debates, and discussions. It will undoubtedly provide a great opportunity for participants to update their knowledge about the latest innovations and developments in the treatment of type 1 and type 2 diabetes and their associated complications.

Whether you are a clinician, basic scientist, nurse, healthcare professional, or young academic, I sincerely hope that the scientific programme of the EASD Annual Meeting 2024 will offer everyone interesting topics and an abundance of new knowledge.

Attending the Annual Meeting is more than just following the scientific programme – it is also a unique opportunity to communicate with colleagues from all over the world and learn from each other's experiences and expertise.

We look forward to welcoming you to an exceptional meeting from 9 - 13 September 2024 in Madrid.

Tina Vilsbøll
Honorary Secretary EASD

ABOUT EASD

The European Association for the Study of Diabetes e.V. (EASD) is a membership-based academic non-profit organization. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany.

EASD is a network with active members from all over the world. Membership is open to scientists, physicians, students, postdocs and fellows, allied health professionals and nurses who are interested in the field of diabetes or related diseases.

The EASD Annual Meeting is one of the largest diabetes conferences in the world, attracting thousands of delegates each year. The scientific programme includes hundreds of talks, presentations and discussions on the latest results from basic and clinical diabetes research.

EASD is also a leading player in postgraduate education having trained thousands of healthcare professionals through dedicated training courses and online education activities.

The Association is actively involved in producing and endorsing statements and guidelines translating the latest results from diabetes research into best practices in diabetes management.

By creating the Early Career Academy, EASD has increased its commitment to support, train, mentor, and create opportunities for scientists, clinicians, and students who are at an early or intermediate stage of their career.

EASD is the publisher of the journal *Diabetologia*, a major monthly international diabetes journal with a high and rising impact factor.

For more information, please visit: www.easd.org.

EASD and EFSD Board:

Chantal Mathieu, Belgium (President)
Francesco Giorgino, Italy
Andreas Fidelak, Germany
Kamlesh Khunti, UK
Ruth Loos, Denmark
Julia Mader, Austria
Hindrik Mulder, Sweden
Patrick Schrauwen, Netherlands
Tina Vilsbøll, Denmark

EASD Headquarters:

European Association for the Study of Diabetes (EASD) e.V.

Rheindorfer Weg 3
40591 Düsseldorf
Germany

Phone: +49 211 758 469 0
Email: info@easd.org

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

ABOUT EFSD

The **European Foundation for the Study of Diabetes (EFSD)** was created by EASD to stimulate diabetes research in Europe. EFSD was founded in 2000 and has become a significant European funding agency for diabetes research, and is continually striving to enhance diabetes awareness in Europe.

The Foundation offers support in all areas of diabetes research through a wide range of joint and stand-alone initiatives. Awards are strictly competitive and decisions are based upon a rigorous and fully independent peer-review process.

Funding streams are available throughout the year and since inception, EFSD has committed over €130 million to European diabetes research by way of a wide range of grant and fellowship funding initiatives.

For more information about EFSD and the funding programmes, please visit: www.europeandiabetesfoundation.org.

EFSD Scientific Board:

H. Al-Hasani, Germany
M. Blüher, Germany
F. Bosch, Spain
A. Boulton, UK
M. Donath, Switzerland
G.P. Fadini, Italy
M. Federici, Italy
N. Lalic, Serbia
M. Nauck, Germany
F. Pociot, Denmark
U. Smith, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

GENERAL INFORMATION

Format

The 60th EASD Annual Meeting will take place as a hybrid event from 9 to 13 September 2024, providing the option to join us in person in Madrid, Spain or online via the Virtual Meeting platform.

All sessions in the scientific programme will take place onsite at the meeting venue in Madrid, Spain at the times indicated in the programme and will be live-streamed for delegates attending the meeting virtually.

Recordings of all sessions will be available, access to recordings will be limited to registered delegates until 11 October 2024.

Meeting venue

The in person meeting will take place in halls 9 & 10 and the North Convention Centre at:

IFEMA Convention Center - Feria de Madrid


Avda. del Partenón, 5, 28042 Madrid, Spain

Advisory Note

Please be aware of 'fraudulent' websites and companies offering EASD services e.g. registration or hotel accommodation.

EASD is the official registration provider and all activities are handled via the official EASD website: www.easd.org.

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION



For online attendance, the [Virtual Meeting platform](#) can be accessed directly or via the EASD website www.easd.org.

Registration

Children under the age of 18 are not permitted to access the 60th EASD Annual Meeting.

Types of registration for the Annual Meeting:

In person attendance to join onsite at the meeting venue in Madrid, Spain. In person attendees receive:

- Name Badge / Congress Material
- Access to the Scientific Programme
- Access to the Exhibition
- Public transportation ticket valid for 5 days
- Access to the Virtual Meeting platform (incl. live and on demand sessions, Industry content)
- Certification based on the delegates in person and / or virtual attendance

Virtual attendance to follow the Annual Meeting online. Virtual attendees receive:

- Access to the Virtual Meeting platform (incl. live and on demand sessions, Industry content)
- Certification based on the delegates watch time

All registrations prior to the EASD Annual Meeting dates have to be made by means of the secured online registration system. For more information, please visit: www.easd.org/annual-meeting/easd-2024.html.

During the EASD Annual Meeting dates, in person registrations can be made by the online registration system or at the onsite registration counter at the venue in Madrid, Spain.

Virtual registrations can only be made by the online registration system.

Certificates

Certificates will be available for download via your / the delegate's [MyEASD](#) account. It will be mandatory to complete the congress evaluation survey to receive certification.

In person attendance will be checked. Virtual watch time will be monitored via the MyEASD account. This data will be the basis for certification.

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Certificate of Attendance

The Certificate of Attendance will be available online from 16 September 2024, 10:00 hrs CEST.

A minimum watch time / attendance of 60 minutes from 9 September 2024, 9:00 hrs CEST to 11 October 2024, 23:59 hrs CEST (in person / live stream and on demand sessions) is required to be entitled to receive the Certificate of Attendance.





EASD
EFSD

Information for in person attendance onsite in Madrid


Registration counters are open:

Sunday	8 September 2024	12:00 - 18:00
Monday	9 September 2024	08:00 - 18:00
Tuesday	10 September 2024	08:00 - 19:00
Wednesday	11 September 2024	07:30 - 19:00
Thursday	12 September 2024	08:00 - 19:00
Friday	13 September 2024	08:00 - 15:00

Badges:

			
Delegate	EASD Faculty	Press	Staff

SHORT ORAL
DISCUSSIONS

		
Supervisor	Organiser	Exhibitor

The delegates' name badges serve as an admission pass to all scientific sessions and the exhibition. Delegates are asked to keep their name badges displayed at all times during the meeting. Badges can be replaced and will be charged for.

First Aid:

The First Aid is located on the Mezzanine floor between Halls 7 and Hall 9. In case of emergency, please contact the nearest security or staff member or call the emergency number +34 91 722 54 00

INDUSTRY

PROGRAMME

EXHIBITION

Restaurants:

There are various eateries located along the Avenida.

Cloakroom/Lost and Found Counter:

A cloakroom with facilities for luggage storage and lost and found is located in basement of the North Convention Centre.

Suitcases (except cabin trolleys) are not allowed in the halls.

EASD Community Plaza:

The EASD Community Plaza is located in Hall 10 and includes the **EASD Member Lounge**, the **EASD/EFSD** and **Diabetologia Booth**, **e-Poster Viewing Stations**, seating areas and charging stations for mobile devices.

Opening hours EASD Booth and Member Lounge:

Tuesday	10 September 2024	08:00 - 18:30
Wednesday	11 September 2024	08:00 - 18:30*
Thursday	12 September 2024	08:00 - 18:30
Friday	13 September 2024	08:00 - 15:00

*Member Lounge will close at 18:00 on Wednesday, 11 September 2024

Exhibition - Opening Hours:

Tuesday	10 September 2024	09:00 - 16:30
Wednesday	11 September 2024	09:30 - 16:30
Thursday	12 September 2024	09:30 - 16:30

Hotels:

For **individual accommodation**, please use the [Hotel Booking Page](#) provided by our official hotel booking partner INTERPLAN Congress, Meeting & Event Management AG.

For **group accommodation**, please use the [Hotel Booking Page](#) provided by our official hotel booking partner INTERPLAN Congress, Meeting & Event Management AG or contact them directly by email: hotels.easd@interplan.de

Security:

Any suspicious or unidentified items onsite at the meeting venue are to be reported immediately to the nearest staff member. Security staff are on duty to ensure that all persons entering the venue are wearing a badge. For your safety, it is strongly advised to leave all your valuables in a safe at your hotel.

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

FLOORPLAN



EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS


PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION



Hall 9

Ground floor

1st floor

Speakers' Lounge

EASD / EFSD Offices

Registr

North Conve

Entrance

Wa
2

Entrance So

Halls

MADRID



North

ration

ntion Centre

Ground floor

AVENIDA

uth / Metro

1 - 8



Hall 10

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Insurance:

The registration fees do not include the insurance of participants against accidents, sickness, cancellation, theft, property loss or damage. Participants are advised to take out adequate insurance especially with regards to travel.

Travel

EASD
EFSD

Special Iberia airlines fares:

A 15% discount for bookings made directly on the [Iberia website](#).

Discount is only valid for round trips operated by Iberia, Iberia Express and Air Nostrum within the period 2 - 20 September 2024. Please enter the promotional code EASDIF24 in the designated field during the payment process.

GENERAL
INFO

PROGRAMME

TUESDAY

Special Renfe train fares:

A 5% discount for travelling to Madrid, Spain on AVE (High Speed)-Long Distance trains. Discount is valid for travel between 7 and 15 September 2024.

WEDNESDAY

THURSDAY

Visit the [Renfe website](#) and select the train of your choice by checking any of the available options. Then select the Congress/Events (Congresos/Ferias) fare from the fare drop-down menu on the Discount and Promotion Section of the Passenger Information page. Enter the authorization number 052404685 in the box indicating authorization number (not valid for discount code box).

FRIDAY

SHORT ORAL
DISCUSSIONS

If purchasing from a Renfe ticket office, travel agent/shop, please bring a [printed copy of the voucher](#).

PRESENTER
INDEX

Transportation

SATELLITE
SYMPOSIA

Registered delegates will receive a free pass to the Madrid City Transportation System to easily travel to/from the congress venue.

INDUSTRY

The public transport card covers the metropolitan area (Zona A) and is valid for 5 days.

PROGRAMME

By metro, the venue can be reached using metro line 8. Get off at the Feria de Madrid subway station, access the IFEMA Convention Center at the south entrance and take the hallway through the convention center down to the north entrance.

EXHIBITION

Information for online attendance via the Virtual Meeting platform

Registered delegates can access the [Virtual Meeting platform](#) by using the MyEASD account connected to the registration (respective email is provided on the registration confirmation).

The [Virtual Meeting platform](#) can be accessed directly or via the EASD website www.easd.org.

Technical requirements:

Delegates must ensure at their own expense that they meet the technical requirements necessary for following the EASD Annual Meeting virtually.

In addition to the necessary hardware, the following requirements will be needed:

- A stable internet connection with a minimum of 5 MBITs (data speed) to follow the online programme,
- A browser in an up-to-date version e.g. Chrome®, Firefox® or Safari®.

EASD recommends the participation via PC/Mac Computers and a resolution of Full HD 1920x1080 pixels or higher. Cookie and Pop-Up blocking measures may lead to problems. On smart phone/tablet devices only basic viewing features are being supported. It is recommended to use the Safari® browser for Apple® devices.

Please note: When using the Safari® browser on Apple® devices, you will need to enable pop-ups. Pop-ups are disabled by default in the Safari® browser. Please go to the settings of your Safari® browser and enable pop-ups.

For further instructions how to enable pop-ups, please see [here](#).

EASD is not responsible if delegates are unable to successfully access the virtual meeting platform if they do not fulfil the technical requirements.

EASD Virtual Meeting App

The EASD Virtual Meeting app provides access to the programme, speakers, floorplans, live sessions, on-demand content and other opportunities.

App will be available to download from the Apple Store and Google Play shortly before the Annual Meeting begins.

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION



RED DE METRO Y METRO LIGERO

SIMBOLOGÍA Key

- Estación accesible / ascensor
Step-free access / lift
- Transbordo corto
Metro interchange
- Transbordo largo
Metro interchange with long walking distance
- Cambio de tren
Change of trains
- Metro Ligero
Light Rail
- Cercanías
Suburban railway
- Autobuses interurbanos
Suburban buses
- Autobuses largo recorrido
Interregional bus station
- Terminal autobuses nocturnos
Night bus line terminal
- Autobús expés aeropuerto
Airport express bus
- Estación de tren
Railway station
- Aeropuerto / Airport
Adolfo Suárez Madrid-Barajas

- ZONA A**
ZONA B1
- Zonas tarifarias
Fare zones
- ATENCIÓN A LA TARIFA**
Validación a LA SALIDA
PAY THE RIGHT FARE
Ticket checked at the EXIT
- Atención al cliente
Customer Service
- Oficina de gestión
Tarjeta Transporte Público
Public Transport Card Office
- Objetos perdidos
Lost and found
- Bibliometro**
Metro Library
- Productos oficiales Metro
Official Metro merchandising
- Aparcamiento disuasorio gratuito**
Free park and ride
*Excepto días con evento
*Except days with event
- Aparcamiento disuasorio de pago**
Paid park and ride
- Estacionamiento de bicicletas**
Bicycle parking

- Espacio histórico de Metro
Metro historical space
- Área acceso restringido para vehículos privados
Area with restricted traffic access
- Metroca
- Tramo temporalmente cerrado
Section temporarily closed

- EASD
- EFSD
- GENERAL INFO
- PROGRAMME
- TUESDAY
- WEDNESDAY
- THURSDAY
- FRIDAY
- SHORT ORAL DISCUSSIONS
- PRESENTER INDEX
- SATELLITE SYMPOSIA
- INDUSTRY
- PROGRAMME
- EXHIBITION

HORARIO Opening times
 Todos los días de 06:00 a 01:30 h.
 Every day from 6:00 a.m. to 1:30 a.m.

- 1 Pinar de Chamartín**
Valdecarros
- 2 Las Rosas**
Cuatro Caminos
- 3 Villaverde Alto**
Moncloa
- 4 Argüelles**
Pinar de Chamartín
- 5 Alameda de Osuna**
Casa de Campo
- 6 Circular**
- 7 Hospital del Henares**
Pitis
- 8 Nuevos Ministerios**
Aeropuerto T4
- 9 Paco de Lucía**
Arganda del Rey
- 10 Hospital Infanta Sofía**
Puerta del Sur
- 11 Plaza Elíptica**
La Fortuna
- 12 MetroSur**
- R Ópera**
Príncipe Pio
- 3 Puerta de Boadilla**
- 1 Pinar de Chamartín**
Las Tablas
- 2 Colonia Jardín**
Estación de Aravaca
- 3 Colonia Jardín**
Estación de Aravaca



ERO Metro and Light Rail Network

www.metromadrid.es




¿Necesitas ayuda?
Need help?



Personal de estaciones
e interfonos
Staff and interphones



900 444 404



EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION



PW-000-00-5407 Junio 2024

Depósito Legal M - 18034 - 2013 © Metro de Madrid, S.A.

Speakers and Chairpersons

All speakers and chairpersons are expected to attend the EASD Annual Meeting in Madrid, Spain, in person to participate live at the time indicated in the programme.

Speakers' Lounge:

The Speakers' Lounge is located in Hall 9 on the 1st floor. All speakers are asked to check their presentations at the Speakers' Lounge at least three hours before the scheduled presentation time. If the presentation is scheduled in the morning, speakers are kindly asked to check their presentation at the Speakers' Lounge the day before.

EASD
EFSD

GENERAL
INFO

Speakers' Lounge - Opening Hours:

PROGRAMME	Sunday	8 September 2024	12:00 - 18:00
TUESDAY	Monday	9 September 2024	08:00 - 18:00
WEDNESDAY	Tuesday	10 September 2024	08:00 - 19:00
THURSDAY	Wednesday	11 September 2024	07:00 - 19:00
FRIDAY	Thursday	12 September 2024	08:00 - 19:00
	Friday	13 September 2024	08:00 - 14:00

Short Oral Discussions Events:

Short Oral Discussions rank equally with Oral Presentations. All Short Oral Discussions will take place during six events which will be held on Tuesday, Wednesday and Thursday

SHORT ORAL DISCUSSIONS	Short Oral Discussions Event A	Tuesday	12:30 - 13:30
	Short Oral Discussions Event B	Tuesday	13:45 - 14:45
PRESENTER INDEX	Short Oral Discussions Event C	Wednesday	12:45 - 13:45
	Short Oral Discussions Event D	Wednesday	14:00 - 15:00
SATELLITE SYMPOSIA	Short Oral Discussions Event E	Thursday	12:45 - 13:45
	Short Oral Discussions Event F	Thursday	14:00 - 15:00

Disclaimer

All efforts will be made to adhere to the programme as provided. However, EASD and its agents reserve the right to alter or cancel, without prior notice, any of the arrangements, timetables, plans or other items relating directly or indirectly to the Meeting, for any case beyond their reasonable control. EASD and the local conference organisers are not liable for any other loss or inconvenience caused as a result of such changes.

INDUSTRY

PROGRAMME

EXHIBITION



PROGRAMME COMMITTEE



Tina Vilsbøll,
Denmark, Chair



Sofia Carlsson,
Sweden



Leszek Czupryniak,
Poland



Dana Dabelea,
USA



Eelco De Koning,
Netherlands



Lena Eliasson,
Sweden



Fiona Gribble,
United Kingdom



Niels Jessen,
Denmark



Marit E. Jørgensen,
Greenland



Janaka Karalliedde,
United Kingdom



Tomasz Klupa,
Poland



Beatriz Merino Antolin,
Spain



Timo Müller,
Germany



Niina Sandholm,
Finland



Patrick Schrauwen,
Netherlands



Tsvetalina Tankova,
Bulgaria



Matthias Tschöp,
Germany



Daniël van Raalte,
Netherlands

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

ABSTRACTS

1814 abstracts were received by the Association and 1064 abstracts were accepted for inclusion. All abstracts were reviewed anonymously and scored by the Abstract Review Committee members.

The Programme Committee members designed the programme and created Oral and Short Oral Discussion sessions upon the accepted abstracts.

Publication of Abstracts

Accepted abstracts are published in the Abstract Volume by Diabetologia. Abstracts are also available online.

Embargo Policies

Information contained in abstracts may not be released until 1 July 2024 when the abstracts are published online. Oral Presentations are under embargo until the commencement of the speaker's presentation. Short Oral Discussion Presentations are under embargo until 12:30 CEST on Tuesday, 10 September 2024.

Abstract Review Committee

In addition to the members of the Programme Committee, the Abstract Review Committee comprises the following members:

Alice Adriaenssens, United Kingdom	Sanna Lehtonen, Finland
Paloma Alonso-Madalena, Spain	Timo Otonkoski, Finland
Francesca Amati, Switzerland	Nicolae M. Panduru, Romania
Andreas Andersen, Denmark	Kashyap A. Patel, United Kingdom
Caroline Bonner, France	Lorenzo Piemonti, Italy
Christoffer Clemmensen, Denmark	Thomas Stulnig, Austria
Miriam Cnop, Belgium	Tricia Tan, United Kingdom
Rumyana Dimova, Bulgaria	German Tapia, Norway
Samy Hadjadj, France	Florian Toti, Albania
Sofie Hædersdal, Denmark	Daniel R. Witte, Denmark
Irina Kowalska, Poland	Dorota Zozulinska, Poland

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

TUESDAY, 10 SEPTEMBER 2024

	TIME	MADRID HALL	LONDON HALL	BERLIN HALL	VIENNA HALL
EASD EFSD	09:00 - 09:30	Presidential Address			
GENERAL INFO	09:30 - 10:15	56th Claude Bernard Lecture			
PROGRAMME	10:30 - 12:00	OP 1	OP 2	OP 3	OP 4
TUESDAY		Short Oral Discussion Sessions Event A			
WEDNESDAY	12:30 - 13:30				
THURSDAY		Short Oral Discussion Sessions Event B			
FRIDAY	13:45 - 14:45				
SHORT ORAL DISCUSSIONS					
PRESENTER INDEX	15:15 - 16:45	OP 7	OP 8	OP 9	OP 10
SATELLITE SYMPOSIA					
INDUSTRY	17:15 - 18:15	39th Camillo Golgi Lecture	Adipose tissue control of energy and glucose metabolism	A paradigm change for basal insulin replacement? Results from the QWINT programme of insulin efsitora alfa	Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management and future directions
PROGRAMME					
EXHIBITION					

TUESDAY, 10 SEPTEMBER 2024

SYDNEY HALL	SOFIA HALL	CAIRO HALL	SPOTLIGHT STAGE	TIME
				09:00 09:30
				09:30 10:15
OP 5	OP 6	LBA OP 1		10:30 12:00
Short Oral Discussion Sessions Event A		EASD e-Learning Expert Session	Islet networks regulating insulin secretion: a debate	12:30 13:30
Short Oral Discussion Sessions Event B		EASD e-Learning Expert Session	Global concepts and mechanisms of preventing type 2 diabetes: Can prediabetes remission reduce global diabetes incidence?	13:45 14:45
OP 11	OP 12	LBA OP 2		15:15 16:45
The forgotten few or many? Delivering diabetes care to people at the margins of society	Amylin for treatment of metabolic diseases	Youth-onset type 2 diabetes: a key challenge for the future		17:15 18:15

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

WEDNESDAY, 11 SEPTEMBER 2024

	TIME	MADRID HALL	LONDON HALL	BERLIN HALL	VIENNA HALL
EASD EFSD	09:00 - 10:30	FLOW: the first dedicated kidney outcomes trial with GLP-1 RA, semaglutide, in patients with type 2 diabetes and CKD	18th Albert Renold Lecture (09:00 - 10:00)	Emerging topics in the etiology of type 1 diabetes	EASD/EASL/EASO symposium: a new joint guideline for metabolic dysfunction-associated steatotic liver diseases (MASLD)
GENERAL INFO					
PROGRAMME					
TUESDAY	10:45 - 12:15	OP 13	OP 14	OP 15	OP 16
WEDNESDAY					
THURSDAY		Short Oral Discussion Sessions Event C			
FRIDAY	12:45 - 13:45	Short Oral Discussion Sessions Event C			
SHORT ORAL DISCUSSIONS		Short Oral Discussion Sessions Event D			
PRESENTER INDEX	14:00 - 15:00	Short Oral Discussion Sessions Event D			
SATELLITE SYMPOSIA					
INDUSTRY	15:30 - 17:00	OP 19	LBA OP 3	OP 20	OP 21
PROGRAMME					
EXHIBITION	17:30 - 18:30	59th Minkowski Lecture	Taking a COMBINED approach: insulin icodex and semaglutide	Addressing the lack of treatment options to reduce the morbidity/mortality gap in type 1 diabetes	EASD/ESSM Symposium: When sex is ex (for her or for him)

WEDNESDAY, 11 SEPTEMBER 2024

SYDNEY HALL	SOFIA HALL	CAIRO HALL	SPOTLIGHT STAGE	TIME
EASD/ESC Symposium: Impact of type 2 diabetes prevention on cardiovascular disease	Artificial intelligence and diabetes technology in diabetic complications: Can they shape the future to improve outcomes?	Exercise in diabetes: from bench to clinical practice		09:00 10:30
OP 17	OP 18	EASD General Assembly		10:45 12:15
Short Oral Discussion Sessions Event C		EASD e-Learning Expert Session	Help! I need somebody: Managing complex clinical cases in the Emergency Room	12:45 13:45
Short Oral Discussion Sessions Event D		EASD e-Learning Expert Session	EASD Early Career Academy Symposium: Work-Life-Balance	14:00 15:00
OP 22	OP 23	OP 24		15:30 17:00
Neuroendocrine control of food intake, body weight and glucose metabolism	Mitochondria: Implications in insulin sensitivity	What can we learn about diabetes from population isolates?		17:30 18:30

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THURSDAY, 12 SEPTEMBER 2024

	TIME	MADRID HALL	LONDON HALL	BERLIN HALL	VIENNA HALL
EASD EFSO	09:00 - 10:30	The rise of GIP: from biology to medicine	How is precision medicine advancing our understanding of diabetes aetiology and will it make a difference?	Rising Star Symposium (08:50 - 10:30)	Novel approaches for prediction of microvascular complications - from tears to DNA and MRI
GENERAL INFO					
PROGRAMME					
TUESDAY	10:45 - 12:15	OP 25	LBA OP 4	OP 26	OP 27
WEDNESDAY		Short Oral Discussion Sessions Event E			
THURSDAY	12:45 - 13:45				
FRIDAY					
SHORT ORAL DISCUSSIONS		Short Oral Discussion Sessions Event F			
PRESENTER INDEX	14:00 - 15:00				
SATELLITE SYMPOSIA	15:30 - 17:00	OP 31	LBA OP 5	OP 32	OP 33
INDUSTRY PROGRAMME	17:30 - 18:30	Diabetes Prize for Excellence Lecture	The promise of GIP and GIPR antagonism: bridging the gap	The use of Automated Insulin Delivery (AID) around physical activity and exercise in type 1 diabetes: a position statement of the EASD and ISPAD	Diabetes and cancer: connecting the dots
EXHIBITION					

THURSDAY, 12 SEPTEMBER 2024

SYDNEY HALL	SOFIA HALL	CAIRO HALL	SPOTLIGHT STAGE	TIME
"Old and new" islets for type 1 diabetes	EASD/JDRF Symposium: Do devices really help the person with diabetes?	12th East-West-Forum: Involving the public and patients in shaping diabetes care and research		09:00 10:30
OP 28	OP 29	OP 30		10:45 12:15
Short Oral Discussion Sessions Event E	EFSD Future Leaders Symposium (12:45 - 14:15)	TBA	Pro & Contra: Will next generation obesity drugs make bariatric surgery obsolete?	12:45 13:45
Short Oral Discussion Sessions Event F		EASD e-Learning Expert Session	EUDF Symposium	14:00 15:00
OP 34	OP 35	OP 36		15:30 17:00
EASD/EASO Symposium: Obesity and diabetes: the intertwined syndemic	EASD Early Career Academy Symposium: ERC funding	Insulin secretion in type 1 diabetes		17:30 18:30

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

FRIDAY, 13 SEPTEMBER 2024

	TIME	MADRID HALL	LONDON HALL	BERLIN HALL	VIENNA HALL
EASD EFSD	09:00 - 10:00	Centennial Anniversary Prize Lecture	Prospective study to evaluate individual effects on the relationship of glucose and HBA1c: design, results, and clinical implications	From monogenic to oligogenic forms of diabetes: a continuum?	The sky is the limit
GENERAL INFO					
PROGRAMME					
TUESDAY					
WEDNESDAY					
THURSDAY					
FRIDAY					
	10:30 - 11:30	OP 43	OP 44	OP 45	OP 46
SHORT ORAL DISCUSSIONS					
PRESENTER INDEX					
	12:00 - 13:00	OP 50	OP 51	OP 52	OP 53
SATELLITE SYMPOSIA					
INDUSTRY	13:30 - 15:00	Metabolic medicine 2030: What the future will bring	Can we receive consensus on how glucagon secretion is regulated?	Diabetologia Symposium: Diabetes Technology: a lifelong companion	Heterogeneity of type 2 diabetes: Will seeing type 2 diabetes in HD...
PROGRAMME					
EXHIBITION					

FRIDAY, 13 SEPTEMBER 2024

SYDNEY HALL	SOFIA HALL	CAIRO HALL	SPOTLIGHT STAGE	TIME
Shift from proliferative diabetic retinopathy to early intervention of diabetic eye disease	Generation of pancreatic islets from stem cells	EASD Early Career Academy Symposium: From Rising Star to Principal Investigator		09:00 - 10:00
OP 47	OP 48	OP 49	Double jeopardy: Could SGLT2 inhibitors and/or GLP1RAs improve glycaemic outcomes and QoL in type 1 diabetes?	10:30 - 11:30
OP 54	OP 55	OP 56	Type 1 diabetes and kidney failure: additional donor pancreas or islet transplantation should be the standard treatment of hyperglycaemia	12:00 - 13:00
Metabolic disease and mental illness	Targeting obesity to treat heart failure: dawn of a new era	EASD/ADA Symposium: Consensus report: Transition from paediatric to adult diabetes care		13:30 - 15:00

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

09:00 - 09:30

Madrid Hall

Presidential Address

Speaker: Chantal Mathieu, Belgium
President EASD/EFSD

09:30 - 10:15

Madrid Hall

56th Claude Bernard Lecture

The Claude Bernard Prize recognises an individual's innovative leadership and lifetime achievements in diabetes research.

Chair: Chantal Mathieu, Belgium

Speaker: Roy Taylor, UK:
The aetiology of type 2 diabetes: an experimental medicine odyssey

Roy Taylor qualified in medicine at the University of Edinburgh, and is Professor of Medicine at Newcastle University.



He founded the Newcastle Magnetic Resonance Centre in 2006 to further his research into the nature of type 2 diabetes. He was then able to confirm the predictions of his 2008 Twin Cycle Hypothesis of aetiology, showing type 2 diabetes to be a simple, reversible condition of excess fat within liver and pancreas. This required development of an effective dietary method to achieve the necessary weight loss. Subsequently he applied this knowledge to clinical practice, demonstrating that short term diabetes was most easily reversed to normal, that non-obese people with the condition also responded to weight loss and also, in a collaboration with Prof Michael Lean, that durable remission could be achieved in routine primary care. The totality of the research programme has led to practical application in NHS England with the national 'NHS Type 2 Diabetes Path to Remission' programme now successfully in place.

Between 1986 and 2000, Professor Taylor developed the national system now used for screening for diabetic eye disease and established the profession of retinal screeners, with major reduction in blindness due to diabetes across the UK.

He has published books in lay language explaining type 2 diabetes (eg 'Life Without Diabetes') plus training books on retinal screening. He has been invited to deliver several named lectures including the 2012 Banting Lecture of Diabetes UK. He received the 2023 Robert Turner Award for Research Impact and was the co-recipient of the 2024 Rank Prize for Nutrition. Professor Taylor was made MBE in the King's 2023 New Year Honours.

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

10:30 - 12:00

Madrid Hall

OP 01 New mechanisms and outcomes of treatments for diabetic kidney disease

1 Comparative renal outcomes of matched cohorts of patients with type 2 diabetes receiving SGLT-2 inhibitors or GLP-1 receptor agonists under routine care: the DARWIN-Renal study

G. Fadini, E. Longato, M. Morieri, S. Del Prato, A. Avogaro, A. Solini, Italy

2 Extracellular vesicles as messengers: how canagliflozin improves diabetic podocytes ferroptosis

G. Qin, X. Fan, Y. Song, F. Guo, S. Ma, M. Shao, W. Zhang, Y. Luo, F. Wei, W. Guo, Y. Zhao, China

3 Effects of semaglutide, empagliflozin and their combination on renal diffusion-weighted magnetic resonance imaging and total kidney volume in patients with type 2 diabetes

L. Vernstrøm, S. Gullaksen, S. S. Sørensen, S. Ringgaard, C. Laustsen, H. Birn, K. Funck, E. Laugesen, P. L. Poulsen, Denmark

4 Gastric bypass and sleeve gastrectomy improve albuminuria more than iSGLT-2/GLP-1RA based medical therapy: a randomised clinical trial

J. P. Valderas, C. A. Boza, C. Le Roux, Chile, Ireland

5 SGLT2-inhibitor treatment for nephroprotection can be targeted using eGFR / albuminuria categories and risk scores: precision medicine in type 2 diabetes

T. Jansz, K. Young, R. Hopkins, B. Shields, A. T. Hattersley, R. Oram, J. Dennis, UK

6 Effect of empagliflozin on urinary albumin excretion and hypoxic injury biomarkers of early phase diabetic kidney disease (EUROBEAT study)

H. Makino, M. Kasahara, S. Kasama, N. Ozu, R. Takashima, M. Noguchi, H. Park, Q. Chen, K. Tsuruya, K. Hosoda, Japan

10:30 - 12:00

London Hall

OP 02 Which day of the week is your insulin day?

7 Safety, tolerability, and pharmacodynamics properties of a novel once-weekly insulin GZR4 in healthy subjects

W. Chen, L. Wan, M. Zhu, C. Hao, J. Zhao, A. He, T. Xie, Y. Li, Z.-R. Gan, C. Tang, China

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

8 Effects of insulin Efsitora alfa on frequency and severity of hypoglycaemia under conditions of increased hypo risk compared to glargine in type 2 diabetes

T. Heise, G. Andersen, E. J. Pratt, J. Leohr, T. Fukuda, Q. Wang, C. Kazda, J. Bue-Valleskey, R. Bergenstal, Germany, USA

9 No evidence of increased physical activity-related hypoglycaemia with once-weekly insulin icodec vs once-daily basal insulin in type 1 diabetes: ONWARDS 6

H. Sourij, R. Bracken, M. Asong, L. Carstensen, S. Kehlet Watt, A. Philis-Tsimikas, Austria, UK, Denmark, USA

10 Associations between mean fasting glucose levels and adherence to app-based dose guidance for once-weekly insulin icodec in insulin-naive type 2 diabetes: post hoc analysis of ONWARDS 5

H. Bajaj, A. M. Donatsky, S. Engberg, J. H. Martiny, A. Vianna, I. Lingvay, Canada, Brazil, USA

11 Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes according to baseline sodium-glucose cotransporter-2 inhibitor use: ONWARDS 1-5

R. Goldenberg, K. O. Bangsgaard, A. Fu, M. Kellerer, S. B. Sogaard, T. Vilsbøll, Canada, Denmark, Germany

12 Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes according to baseline glucagon-like peptide-1 receptor agonist use: ONWARDS 1-5

T. Vilsbøll, K. O. Bangsgaard, A. Fu, M. Kellerer, S. B. Sogaard, R. Goldenberg, Denmark, Germany, Canada

10:30 - 12:00

Berlin Hall

OP 03 Liver: the master regulator

13 Pharmacological inhibition of fructose metabolism reduces liver fat and improves insulin sensitivity in participants with MASLD

E. J. Koene, J. Basset Sagarminaga, K. Brouwers, J. Mevenkamp, Y. M. Op den Kamp-Bruls, E. Phielix, V. Schrauwen-Hinderling, P. Schrauwen, M. C. Brouwers, Netherlands

14 Osteoprotegerin regulates hepatic glucose metabolism and insulin sensitivity through mTORC1 signalling pathway

S. Qiu, G. Yang, M. Yang, China

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

15 Investigating whole-body fructose catabolism in vivo using stable isotopes to identify new anti-obesity targets

M. Rios-Morales, F. Westerbeke, D. Van Harskamp, B. Groen, M. Nieuwdorp, Netherlands

16 Increased postprandial succinate levels are associated with hepatic gluconeogenesis regulation via SUCNR1

A. Marsal-Beltran, L. Salmerón-Pelado, A. Ribas-Latre, M.-M. Rodríguez-Peña, C. Núñez-Roa, M. Repollés-de-Dalmau, E. Novoa, R. Nogueiras, R. Bosch, J. Vendrell, V. Ceperuelo-Mallafre, S. Fernández-Veledo, Spain

17 Whole-body insulin sensitivity is lower after 4-week high fructose compared to 4-week high saturated fat consumption in overweight individuals

K. H. Roumans, P. M. Van Lier, E. Phielix, B. Havekes, P. Schrauwen, V. B. Schrauwen-Hinderling, Netherlands

18 Cytoskeleton protein Leupaxin promote hepatic gluconeogenesis through activating HNF4α transitional activity

Z. Zhijian, L. Xiaomin, L. Fang, P. Yongde, China

10:30 - 12:00

Vienna Hall

OP 04 Beyond glucose in diabetes and prediabetes

19 Effects of a randomised controlled dietary intervention high in unsaturated fat, plant protein and fiber on intrahepatic lipid levels at 12 and 36 months

E. Álvarez Hernández, M. Lazaratos, C. Wernicke, A. Pohrt, L. Pletsch-Borba, N. Meyer, J. Machann, A. F. Pfeiffer, J. Spranger, K. Mai, Germany

20 Slower liver growth in-utero predicts the risk of prediabetes at 18 years of age, a DOHaD jump from birth size to organogenesis: novel human data in the Pune Maternal Nutrition Study (PMNS)

C. S. Yajnik, A. Kinare, M. Chinchwadkar, D. Shetty, K. Coyaji, P. Yajnik, R. Ladkat, R. Wagh, C. Osmond, C. H. Fall, India, UK

21 Excessive free fatty acids sensing in pituitary lactotrophs elicits liver steatosis by decreasing prolactin levels

Y. Bi, X. Ji, H. Yin, China

22 The effect of 12-month treatment with glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on cardiac markers and mitochondrial function

L. Pliouta, E. Maratou, G. Pavlidis, A. Kountouri, E. Korakas, J. Thymis, K. Katogiannis, I. Ikonomidis, V. Lambadiari, Greece

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

23 Prolactin deficiency drives diabetes-associated cognitive dysfunction by inducing microglia-mediated synapse loss

Y. Bi, Z. Zhang, J. Jiang, J. Wang, China

24 When does metabolic memory starts? Insights from the AMD Annals initiative

G. Russo, A. Nicolucci, G. Lucisano, M. Rossi, A. Ceriello, F. Prattichizzo, V. Manicardi, A. Rocca, P. Di Bartolo, S. De Cosmo, G. Di Cianni, R. Candido, AMD Annals Study Group, Italy

EASD
EFSD

GENERAL
INFO

10:30 - 12:00

Sydney Hall

OP 05 Can you change what you are by what you eat?

25 Unlocking the potential of urolithins: novel approaches to inhibit IAPP aggregation in diabetes

S. G. Ferreira, A. F. Raimundo, N. Saraiva, C. N. Santos, R. Menezes, Portugal, Spain

26 Effects of a hypocaloric time-restricted feeding diet programme in individuals with metabolic dysfunction-associated steatotic liver disease: preliminary data of a randomised controlled trial

S. Tsitsou, T. Bali, M. Adamantou, A. Saridakis, K.-A. Pouliou, E. Petsiou, E. Papakonstantinou, E. Cholongitas, Greece

27 A fasting-mimicking diet programme reduces liver fat and inflammation/fibrosis measured by MRI-derived biomarkers in patients with type 2 diabetes

E. L. Van den Burg, M. P. Schoonakker, P. G. Van Peet, M. E. Numans, H. Pijl, H. J. Lamb, Netherlands

28 Effects of 12-week supplementation with coffee diterpene cafestol in healthy subjects with increased waist circumference: a randomised, placebo-controlled trial

F. D. Mellbye, M. D. Nguyen, K. Hermansen, P. B. Jeppesen, Z. K. Al-Mashhadi, S. Ringgaard, S. Gregersen, Denmark

29 Meal timing, its relation to metabolism, and heritability in German adult twins

O. Pivovarova-Ramich, J. Vahlhaus, B. Peters, S. Hornemann, A.-C. Ost, M. Kruse, A. Busjahn, A. Pfeiffer, Germany

PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

30 Liver fat as a key target in dietary management of type 2 diabetes and prediabetes using novel diet therapies: a randomised clinical trial (The NAFLDiet study)

U. Riserus, M. Fridén, F. Rosqvist, M. Martinell, P.-O. Carlsson, L. Johansson, H.-E. Johannsson, F. Rorsman, J. Vessby, R. Landberg, L. Lind, M. Orho-Melander, J. Kullberg, H. Ahlström, Sweden

10:30 - 12:00

Sofia Hall

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 06 Maternal influences and prediction in type 1 diabetes

31 Is the relative protective effect of maternal vs paternal type 1 diabetes on risk of type 1 diabetes explained by differences in predisposing genes potentially induced by selective foetal loss?

G. Tapia, A.-K. Rantala, C. Page, T. Skrivarhaug, N. Lund-Blix, K. Størdal, L. Stene, HEDIMED investigators, Norway, Finland

32 Maternal type 1 diabetes confers long-term relative protection against type 1 diabetes in the offspring: results from five cohort studies

L. A. Allen, P. N. Taylor, A. Carlsson, W. A. Hagopian, E. Hedlund, A. V. Hill, A. G. Jones, J. Ludvigsson, G. L. Mortimer, S. Onengut-Gumuscu, M. J. Redondo, S. S. Rich, K. M. Gillespie, C. M. Dayan, R. A. Oram, UK, Sweden, USA

33 Maternal psychosocial stress and risk of childhood-onset type 1 diabetes

L. C. Stene, A.-K. Rantala, M. C. Magnus, G. Tapia, T. Skrivarhaug, N. A. Lund-Blix, K. Størdal, the HEDIMED Investigators, Norway, Finland

34 Trajectory of type 1 diabetes risk shifts after age 10 years between at-risk males and females

E. L. Templeman, L. Ferrat, E. Rideout, N. Thomas, L. Allen, M. Redondo, C. Evans-Molina, J. Sosenko, R. Oram, E. Sims, UK, Switzerland, Canada, USA

35 Screening and monitoring for presymptomatic type 1 diabetes: the DiaUnion project

J. Hviid Klæbel, A. Lind, S. Hamdan, M. N. Scherman, F. Kristensen, J. C. Antvorskov, D. N. Agardh, F. Pociot, Denmark, Sweden

36 Population screening for type 1 diabetes and celiac disease: autoimmunity screening for kids (ASK)

M. Rewers, C. Geno Rasmussen, B. Frohnert, L. Yu, K. Simmons, A. Steck, H. O'Donnell, M. Stahl, E. Liu, USA

10:30 - 12:00

Cairo Hall

LBA OP 1 TBA

Late breaking abstracts

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION

SHORT ORAL DISCUSSIONS EVENT A

12:30 - 13:30	Short Oral Discussion Area	Page
SO 001 - Station 1	Genetic insights into type 2 diabetes: from risk variants to personalized treatment strategies	115
SO 007 - Station 2	Global perspectives on type 2 diabetes: prevalence, risk factors, and predictive tools	121
SO 013 - Station 3	Prevention of type 2 diabetes	128
SO 019 - Station 4	Catching signals to follow the right pathway in islets	134
SO 025 - Station 5	Breaking bad: destruction of beta cells	139
SO 031 - Station 6	All the reasons why exercise is good!	145
SO 037 - Station 7	New approaches in carbohydrate metabolism	151
SO 043 - Station 8	Inflammation and beta cell homeostasis	157
SO 049 - Station 9	Novel clinical insights into adipose tissue function	163
SO 055 - Station 10	Improving metabolism through nutrition	169
SO 061 - Station 11	Novel incretins: focus on kidney, liver and cardiovascular system	175
SO 067 - Station 12	Breaking away with tradition or how to give insulin differently . .	181
SO 073 - Station 13	Diabetes technology - but at a higher level	188
SO 079 - Station 14	From microbiology to MRI in diabetic foot disease	194
SO 085 - Station 15	Clinical data and emerging markers in diabetic foot disease and neuropathy	200
SO 091 - Station 16	A new look at well-known drugs in type 2 diabetes	206
SO 097 - Station 17	Pathogenesis of diabetes complications	212

EASD
EFSD

GENERAL
INFO

PROGRAMME
TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

12:30 - 13:30

Cairo Hall

EASD e-Learning expert session

Chair: TBA

Speaker: TBA

12:45 - 13:30

Spotlight Stage

Islet networks regulating insulin secretion: a debate

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SHORT ORAL DISCUSSIONS EVENT B

13:45 - 14:45	Short Oral Discussion Area	Page
SO 002 - Station 1	Epigenetics and gestational diabetes: from maternal health to newborn outcomes	116
SO 008 - Station 2	Advances type 1 diabetes: genetic, biomarker, and machine learning approaches	122
SO 014 - Station 3	Early factors and family determinants of diabetes	129
SO 020 - Station 4	Holding hands with alpha cells in the islets	135
SO 026 - Station 5	Pregnancy and type 1 diabetes	140
SO 032 - Station 6	Insulin action in peripheral tissues	146
SO 038 - Station 7	Novel pharmacological approaches for the treatment of obesity and diabetes.	152
SO 044 - Station 8	Lipid signatures and ectopic fat	158
SO 050 - Station 9	Understanding and combating adipose tissue dysfunction	164
SO 056 - Station 10	Thinking outside the box to treat obesity and diabetes	170
SO 062 - Station 11	Hot of the press novel incretins	176
SO 068 - Station 12	Playing with food intake and energy expenditure	183
SO 074 - Station 13	It is very hard to beat the system - or is it?	189
SO 080 - Station 14	Diabetic kidney disease: clinical insights from childhood to frailty	195
SO 086 - Station 15	Novel markers and predictors for neuropathy in diabetes	201
SO 092 - Station 16	Divination from a glass ball or something more? Predictive models, biomarkers, genome analysis	207
SO 098 - Station 17	Cancer and diabetes	213

EASD EFSD
GENERAL INFO
PROGRAMME TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION

13:45 - 14:45

Cairo Hall

EASD e-Learning expert session

Chair: TBA

Speaker: TBA

13:45 - 14:30

Spotlight Stage

**Global concepts and mechanisms of preventing type 2 diabetes:
Can prediabetes remission reduce global diabetes incidence?**

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 07 Cardiovascular complications in type 1 diabetes: burden and mechanisms

37 Rapid vs slow plasma glucose decline has no impact on systolic function in individuals with type 1 diabetes

P. G. Hagelqvist, K. Maytham, C. Rode, M. Sengeløv, U. Pedersen-Bjergaard, T. Biering-Sørensen, F. K. Knop, T. Vilsbøll, A. Andersen, Denmark

38 Effects of rapid vs slow plasma glucose decline on haemostasis in individuals with type 1 diabetes

P. G. Hagelqvist, C. R. Andreasen, K. Maytham, F. K. Knop, P. I. Johansson, U. Pedersen-Bjergaard, A. Andersen, T. Vilsbøll, Denmark

39 Coronary arteries assessment in asymptomatic high risk patients with type 1 diabetes using optical coherent tomography

M. Dubsy, R. Roland, N. Marhefková, P. Wohlfahrt, V. Karmazin, P. Novodvorsky, J. Kautzner, M. Haluzík, M. Pazdernik, Czech Republic

40 Automated insulin delivery systems and vascular reactivity in type 1 diabetes: a prospective study

R. Lupoli, C. P. Petrosino, C. Rainone, G. Vallefucio, I. L. Calcaterra, M. N. Di Minno, L. Bozzetto, Italy

41 Incidence and risk of myocardial infarction subtypes in type 1 diabetes

P. Smidtslund, V. Harjutsalo, V. Thorn, F. Jansson Sigfrids, P.-H. Groop, L. M. Thorn, Finland

42 Whole genome sequencing reveals genetic variation associated with coronary artery disease in individuals with type 1 diabetes

A. A. Antikainen, J. Haukka, A. Syreeni, S. Mutter, V. Harjutsalo, P.-H. Groop, N. Sandholm, Finland

15:15 - 16:45 London Hall

OP 08 Genetics and epigenetics in type 2 diabetes

43 Blood-based epigenetic markers associate with future macrovascular events in individuals with type 2 diabetes

S. Garcia-Calzon, A. Maguolo, A. Perfilyev, M. Maziarz, E. Ahlqvist, I. Gonçalves, C. Ling, Spain, Sweden, Italy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

44 An updated meta-analysis of epigenome-wide association study of incident type 2 diabetes reveals 234 novel CpG sites

R. D. Triatin, R. Hillary, E. Fraszczyk, A. Spijkerman, M. Luijten, R. E. Marioni, I. M. Nolte, C. H. Thio, H. Snieder, Netherlands, Indonesia, UK, Poland

EASD
EFSD

45 Allelic expression imbalance in pancreatic islets indicates parent-of-origin effects on type 2 diabetes risk

J. Andersson, G. Hatem, M. Maziarz, M. Lehtovirta, L. Hakaste, T. Tuomi, R. Prasad B, Sweden, Finland

GENERAL
INFO

46 Beta cell dysfunction polygenic risk associates with risk of gestational diabetes and postpartum abnormal glucose intolerance in Chinese

G. Yu, C. H. Tam, C. K. Lim, M. Shi, C. C. Wang, J. C. Chan, W. H. Tam, M. Weedon, R. Oram, R. C. Ma, Hong Kong, UK

PROGRAMME

TUESDAY

47 Loss-of-function mutations of the GIP receptor impair GIP-mediated insulin secretion

H. Kizilkaya, M. H. Michaelsen, H. Reeh, C. Pless, F. Koefoed-Hansen, C. Nielsen, S. Madsbad, B. Hartmann, M. Christensen, F. K. Knop, T. Hansen, J. J. Holst, N. Garup, M. M. Rosenkilde, L. Gasbjerg, Denmark

WEDNESDAY

THURSDAY

FRIDAY

48 Change in telomere length and its implications in type 2 diabetes: the Fremantle Diabetes Study Phase II

M. L. Huang, C.-H. Yang, W. Davis, K. Peters, A. J. Jenkins, T. Davis, Australia

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

15:15 - 16:45

Berlin Hall

OP 09 Drugs you thought you knew all about, but what else do they do?

SATELLITE
SYMPOSIA

49 The effect of sodium-glucose cotransporter-2 inhibitors on graft survival and cardiorenal outcomes in patients with diabetes and heart transplantation

C.-M. Hwu, F.-S. Yen, J.-Y. Huang, C.-C. Hsu, W.-Y. Cheng, J. C.-C. Wei, Taiwan

INDUSTRY

PROGRAMME

EXHIBITION

50 Efficacy and safety of canagliflozin in children and adolescents with type 2 diabetes: a multicentre, randomised, double-blind, parallel-group, phase 3 trial

S. R. Ali, U. Nadgir, J. Gogate, W. Shaw, S. Fonseca, J. Antunes, USA

51 Sodium-glucose cotransporter 2 inhibitor use and risk of dementia and parkinson's disease among patients with type 2 diabetes

H. Kim, G. Biessels, M. Yu, N. Hong, Y.-H. Lee, B.-W. Lee, E. Kang, B.-S. Cha, M. Lee, Republic of Korea, Netherlands

52 Cardiovascular effectiveness of empagliflozin and glucagon-like peptide-1 receptor agonists combination therapy in adults with type 2 diabetes

P. Htoo, D. J. Wexler, H. Tesfaye, S. Schneeweiss, R. Glynn, C. Shay, N. Schmedt, L. Koeneman, J. M. Paik, E. Paterno, USA, Germany

53 Metformin reduces fasting blood glucose independently of endogenous glucose production by promoting glycolysis and glucose clearance in well-controlled type 2 diabetes

T. Sarabhai, T. LaMoia, S. Friesl, M. Jonuscheit, V. Schrauwen-Hinderling, K. Petersen, G. Shulman, M. Roden, Germany, USA

54 Impact of timing of metformin administration on the plasma lactate response to intraduodenal glucose infusion in type 2 diabetes

C. Xie, P. Iroga, Y. Sun, W. Huang, M. J. Bound, J. Grivell, K. Jones, M. Horowitz, C. K. Rayner, T. Wu, Australia

15:15 - 16:45

Vienna Hall

OP 10 Hypothalamic regulation of systems metabolism

55 Prolactin act on POMC neurons to regulate lipid metabolism of liver
Y. Zhu, Y. Bi, China

56 Influence of insulin sensitivity on food cue evoked brain response in children

L. Semeia, R. Veit, S. Zhao, S. Luo, B. Angelo, A. L. Birkenfeld, H. Preissl, A. H. Xiang, S. Kullmann, K. A. Page, Germany, USA

57 Regulation and mechanism of hypothalamic MST1 signalling on energy homeostasis and glucose/lipid metabolism

M. Yang, L. Li, China

58 A hypothalamus-liver-skeletal muscle axis controlled by JNK1 and FGF21 mediates olanzapine-induced insulin resistance in an intraperitoneal treatment in male mice

V. Ferreira, C. Folgueira, A. Montes, A. B. Hitos, R. J. Davis, G. Sabio, P. Rada, Á. M. Valverde, Spain, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

59 In vivo phenotyping of glucose-dependent insulinotropic polypeptide receptor neurocircuitries in distinct hypothalamic nuclei
N. S. Figueredo Burgos, A. Roberts, A. Adriaenssens, F. Reimann, UK

60 Brain-to-periphery crosstalk: exploring sympathetic innervation and dopamine signalling during diet-induced obesity or caloric restriction in male Wistar rats

F. Hukema, C. Kagios, S. Hetty, S. Zellerth, M. J. Pereira, E. Roman, J. W. Eriksson, Sweden

EASD
EFSD

GENERAL
INFO

15:15 - 16:45

Sydney Hall

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

OP 11 Risk factors and treatment opportunities in neuropathy and hypertension

61 Understanding the impact of diabetic peripheral neuropathy and neuropathic pain on quality of life and mental health in people with diabetes

M. Borbjerg, A.-M. L. Wegeberg, A. Nikontovic, C. D. Moerch, N. Ejskjaer, C. Brock, P. Vestergaard, J. Røikjer, Denmark

62 Impact of diabetes on heart rate variability among acutely admitted patients

R. Hadad, A. V. Hviid, M. H. Domínguez, F. E. Nielsen, B. S. Larsen, O. Wendelboe, A. Sajadieh, S. B. Haugaard, Denmark

63 A prognostic tool to predict the risk of 5-year all-cause mortality in diabetic patients with hypertension: evidence from two perspective cohorts

Y. Liu, H. You, J. Yuan, S. Wu, Y. Wu, W. Yang, China

64 Neuropathic pain symptoms in patients with painful diabetic neuropathy followed for 12 months after treatment with high concentration (179 mg) capsaicin patch: a retrospective cohort study

M. Eerdeken, M. A. Überall, S. Engelen, T. Fajri, S. Allen, R. Freitas, L. Garcia Guerra, T. Quandel, Germany, France, USA, Portugal, Spain

65 Risk factor phenotypes for cardiovascular autonomic neuropathy based on indices of heart rate variability in type 1 diabetes

B. Braffett, L. El ghormli, I. Bebu, C. Martin, R. Pop-Busui, DCCT/EDIC Research Group, USA

66 Blood pressure polygenic risk scores associate with treatment-resistant hypertension in individuals with type 1 diabetes

R. Lithovius, H. Sánez Tähtisalo, A. Antikainen, S. Mutter, P.-H. Groop, K. Kontula, T. Hiltunen, N. Sandholm, Finland

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

15:15 - 16:45

Sofia Hall

OP 12 Fatal attraction: immune cells and beta cells

67 Beta cell extracellular vesicle surface PD-L1 is induced by IFN- α treatment and correlates with residual C-peptide in plasma of children with recent-onset type 1 diabetes

E. Sims, C. Rao, D. Cater, J. Xu, A. De Olivera, C. Evans-Molina, D. Eizirik, R. Mirmira, USA, Belgium

68 T cells drive beta cell senescence in type 1 diabetes

J. Pipella, P. Thompson, Canada

69 Insulinitis and exocrinitis in antibody-positive non-diabetic individuals: role of HLA genotypes individuals: role of HLA genotypes

E. Larger, M. Diedisheim, D. Dubois-Laforgue, R. Mallone, France

70 The Hippo pathway terminal effector YAP potentiates enteroviral infection in human islets

F. Atawneh, S. Geravandi, H. Liu, O. Zabad, H. Pahwa, M. Madduri, A. Pugliese, A. Ardestani, K. Maedler, Germany, USA, UK

71 An mRNA vaccine induces immune tolerance and protects against disease in NOD mice

L. P. Pallo, V. Ng, S. Chen, J. Zaifman, A. Nguyen, P. Singh, S. Zhang, Y. C. Tam, H. C. Denroche, C. B. Verchere, Canada

72 Verapamil in combination with low-dose anti-thymocyte globulin reverses hyperglycaemia in newly diagnosed diabetic NOD mice

P.-J. Martens, M. Viaene, L. Degroote, C. Mathieu, C. Gysemans, Belgium

15:15 - 16:45

Cairo Hall

LBA OP 2 TBA

Late breaking abstracts

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

39th Camillo Golgi Lecture

The Camillo Golgi Prize recognises outstanding contributions in the field of histopathology, pathogenesis, prevention and treatment of the complications and comorbidities of diabetes mellitus.

Chair: Chantal Mathieu, Belgium

Speaker: Rodica Pop-Busui, USA:
TBA

Rodica Busui, MD, PhD is the Larry D. Soderquist Professor of Diabetes, Vice Chair Clinical & Health Outcomes Research Department of Internal Medicine, Director Clinical Research Caswell Diabetes Institute at the University of Michigan, and an international leader in the field of diabetes and diabetes complications.



Her research interests involve chronic complications of diabetes, including diabetic neuropathy, diabetic foot complications, diabetic kidney disease, heart failure, cardiovascular disease, as well as use of novel technologies for diabetes management.

She has been PI and member of the Steering Committee in many landmark diabetes clinical trials funded by NIH or Pharma including: ACCORD, DCCT/EDIC, PERL, BARI-2D, GRADE, DEVOTE, REPLACE-BG, WISDM, MOBILE, SOUL. She also designed and leads several investigator-initiated studies to unveil disease modifying agents for diabetic complications, and on the use of diabetes technologies to improve patients' outcomes and diabetes care delivery funded by NIDDK and Pharma. She is the Chair of the Steering Committee of the NIDDK Diabetes Foot Consortium.

Dr. Busui has published more than 300 peer-reviewed manuscripts and book chapters, and had been a member of the EASD since 1993. She received awards for her research and advancement of diabetes care from many organizations including the American Diabetes Association (ADA), the Fulbright Foundation, the Harvard Medical School, the Romanian Diabetes Society, and the University of Michigan. She has been an elected member of the ADA Clinical Practice Committee, chaired the 2017 ADA Position Statement on Diabetic Neuropathy, the ADA Diabetes & Cardiovascular Disease Interest Group, and the ADA/ACC Heart Failure in Diabetes Consensus.

Dr. Busui is the 2023 President for Medicine and Science of the American Diabetes Association.

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:15 - 18:15

London Hall

Adipose tissue control of energy and glucose metabolism

Chair: Andreas L Birkenfeld, Germany

Speaker: Alice Williamson, UK:
Novel candidate genes regulating glucose metabolism

Niklas Mejhert, Sweden:
Adipocyte subpopulations and insulin sensitivity

Laurie J. Goodyear, USA:
Exercise remodeling of adipose tissue

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:15 - 18:15

Berlin Hall

A paradigm change for basal insulin replacement? Results from the QWINT programme of insulin efsitora alfa

Chair: Rory J. McCrimmon, UK

Speaker: Stefano Del Prato, Italy:
Introduction to once-weekly insulins

Harpreet S. Bajaj, Canada:
Background on the efsitora alfa phase 3 QWINT program

Carol Wysham, USA:
Efficacy and safety of efsitora as a weekly basal insulin compared to insulin degludec in insulin-naïve adults with type 2 diabetes (QWINT-2)

Richard Bergenstal, USA:
Efficacy and safety of insulin efsitora alfa as a weekly basal insulin compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy (QWINT-5)

Melanie J. Davies, UK:
Implications for clinical care

Cees J. Tack, Netherlands:
Commentary

17:15 - 18:15

Sydney Hall

Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management and future directions

Chair: TBA

Speaker: TBA

EASD
EFSD

17:15 - 18:15

Sydney Hall

GENERAL
INFO

The forgotten few or many? Delivering diabetes care to people at the margins of society

Chair: Didac Mauricio, Spain

Speaker: Giuseppe Maltese, UK:
The many faces of ageing with diabetes

Andrzej W. Kokoszka, Poland:
Stabilising glucose in unstable minds

Alice Rickford, UK:
Diabetes without a safe house

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

17:15 - 18:15

Sofia Hall

Amylin for treatment of metabolic diseases

Chair: Eelco De Koning, Netherlands

Speaker: Thomas Lutz, Switzerland:
Exploring Amylin's role in type 2 diabetes and obesity

Kirsten Raun, Denmark:
Amylin analogues MoA: unveiling the mechanisms of action

Ania M. Jastreboff, USA:
Clinical insights

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Youth-onset type 2 diabetes: a key challenge for the future

Chair: Tsvetalina Tankova, Bulgaria

Speaker: Orit Pinhas-Hamiel, Israel:
Risk of long- term complications in youth-onset type 2 diabetes

Allison L. B. Shapiro, USA:
Brain and cognitive health in youth onset type 2 diabetes

Amy Shah, USA:
Management of youth onset type 2 diabetes: Should it be different?

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

09:00 - 10:30

Madrid Hall

FLOW: the first dedicated kidney outcomes trial with GLP-1 RA, semaglutide, in patients with type 2 diabetes and CKD

Chair: TBA

Speaker: TBA

EASD
EFSD

09:00 - 10:00

London Hall

GENERAL
INFO

18th Albert Renold Lecture

The Albert Renold Prize recognizes outstanding achievements in the field of pathophysiology and treatment of diabetes mellitus.

PROGRAMME

TUESDAY

Chair: Francesco Giorgino, Italy

WEDNESDAY

Speaker: Lori Sussel, USA:

Regulation of islet cell lineages in health and diabetes

THURSDAY

Lori Sussel is the Research Director of the Barbara Davis Diabetes Center (BDC) and Director of the NIDDK-funded University of Colorado Diabetes Research Center (DRC). She received her graduate degree from Columbia University Medical School and pursued a postdoctoral fellowship at the University of California, San Francisco.



FRIDAY

SHORT ORAL
DISCUSSIONS

Dr. Sussel's research has been funded by throughout her career by the National Institutes of Health (NIH), Juvenile Diabetes Research Foundation (JDRF) and the American Diabetes Association (ADA). Her research focuses on the molecular regulation of pancreatic islet cell differentiation and function, with a focus on understanding how beta cell dysfunction contributes to type 1 and type 2 diabetes.

PRESENTER
INDEX

SATELLITE
SYMPOSIA

Her research programme combines advanced molecular biology techniques, mouse models and human stem cell models to understand the molecular mechanisms that determine the differentiation of the pancreatic islet lineages during fetal development and maintenance of alpha and beta cell function in the adult. These studies have identified several novel proteins, long non-coding RNAs and molecular mechanisms that are involved in islet cell fate decisions during pancreas development and in maintaining the function and/or identity of the beta cell in the adult.

INDUSTRY

PROGRAMME

EXHIBITION

09:00 - 10:30

Berlin Hall

Emerging topics in the etiology of type 1 diabetes

Chair: Lars C. Stene, Norway

Speaker: Heikki A. Hyöty, Finland:
The exposome

Teresa Rodriguez-Calvo, Germany:
The virus hypothesis

Randi K. Johnson, USA:
The diet

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

09:00 - 10:30

Vienna Hall

EASD/EASL/EASO symposium: a new joint guideline for metabolic dysfunction-associated steatotic liver diseases (MASLD)

Chair: TBA

Speaker: TBA

09:00 - 10:30

Sydney Hall

EASD/ESC Symposium: Impact of type 2 diabetes prevention on cardiovascular disease

Chair: Dana Dabelea, USA; Francesco Cosentino, Sweden

Speaker: Amanda I. Adler, UK:
Glycaemic control and CVD prevention

Mark Espeland, USA:
Cardiovascular effects of lifestyle interventions

Simon J. Griffin, UK:
Impact of metformin on CVD

Darren K. McGuire, USA:
Opportunities for the future

09:00 - 10:30

Sofia Hall

Artificial intelligence and diabetes technology in diabetic complications: Can they shape the future to improve outcomes?

Chair: Piya Sen Gupta, UK

Speaker: Tomas Griffin, Ireland:

Using diabetes technology in people on dialysis or with impaired vision: What is possible?

EASD
EFSD

GENERAL
INFO

Sufyan Hussain, UK:

When does technology not help? What more is needed?

Navdeep Tangri, Canada:

Can Artificial Intelligence predict kidney failure and related complications?

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

09:00 - 10:30

Cairo Hall

Exercise in diabetes: from bench to clinical practice

Chair: Juleen R. Zierath, Sweden

Speaker: Lauren M. Sparks, USA:

Exercise as medicine and prevention of disease

SHORT ORAL
DISCUSSIONS

John P. Thyfault, USA:

Exercise to control hepatic lipid metabolism

PRESENTER
INDEX

Mikel Izquierdo, Spain:

How to prescribe physical activity in individuals with diabetes and physical frailty and sarcopenia

SATELLITE
SYMPOSIA

Dominique Hansen, Belgium:

How to prescribe physical activity in individuals with diabetes and chronic coronary syndrome and/or heart failure

INDUSTRY

PROGRAMME

EXHIBITION



10:45 - 12:15

Madrid Hall

OP 13 GLP-1-based polypharmacology: we are not done yet!

73 CagriSema driven weight loss in diet-induced obese rats prevents counter-regulation of weight loss associated reduction in energy expenditure

EASD
EFSD

R. E. Kuhre, J. M. Jacobsen, B. Hald, J. J. Fels, I. Blom, J. Halling, S. Larsen, S. Lundh, M. K. Gerstenberg, A. Secher, K. Raun, Denmark

GENERAL
INFO

74 Safety, tolerability and weight reduction findings of oral amycretin: a novel amylin and glucagon-like peptide-1 receptor co-agonist, in a first-in-human study

A. Gasiorek, A. Heydorn, K. Kirkeby, C. Key, S. Toubro, L. H. Scheffe, K. Dahl, J. B. Hjerpsted, A. Vegge, Denmark, USA

PROGRAMME

TUESDAY

75 CagriSema improves insulin sensitivity in diet-induced obese rats

A. Secher, C. L. Brand, K. Raun, Denmark

WEDNESDAY

76 Survodutide and semaglutide both induce weight loss but show different effects on food preference and dyslipidaemia in the free choice diet-induced obese hamster model

F. Briand, R. Augustin, K. Bleyemehl, B. Bajrami, T. Zimmermann, T. Klöckener, T. Klein, France, Germany

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

77 Impact of GLP-1/GIP receptor signalling on human pancreatic adipose tissue organoids

E. Lorza-Gil, O. Strauss, E. Ziegler, L. Sandforth, A. Sandforth, F. Berlth, S. Singer, A. Mihaljevic, A. Birkenfeld, F. Gerst, Germany

PRESENTER
INDEX

78 Petrelintide induced potent additional weight loss in combination with either semaglutide or tirzepatide in DIO rats

B. Vestergaard, C. Wenander, J. Skarbaliene, J. Griffin, Denmark, Switzerland

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

10:45 - 12:15

London Hall

OP 14 Incretins: How many targets do you need?

79 Short-acting glucagon-like peptide-1 receptor agonist therapy delays gastric emptying during insulin-induced hypoglycaemia as well as euglycaemia in type 2 diabetes

R. J. Jalleh, D. Quast, M. Kamruzzaman, J. Grivell, S. Hatzinikolas, T. A. Murthy, K. L. Jones, M. Horowitz, C. S. Marathe, Australia

EXHIBITION

80 Neither exogenous nor endogenous glucose-dependent insulinotropic polypeptide affects appetite or energy intake acutely in healthy older people

E. Hosseini Marnani, S. Hatzinikolas, A. C. Slavotinek, M. Kamruzzaman, R. J. Jalleh, K. Lange, S. Veedfald, L. S. Gasbjerg, M. M. Rosenkilde, J. J. Holst, T. Wu, C. K. Rayner, C. S. Marathe, M. Horowitz, K. L. Jones, Australia, Denmark

81 Novel unimolecular tetra-agonist peptides targeting GLP-1, GIP, amylin, and calcitonin receptors with enhanced metabolic benefits in animal models of obesity

C. M. Rondinone, M. P. Valdecantos, P. Rada, A. Valverde, S. Ghosh, USA, Spain

82 Characterising the pharmacology of glucagon receptor agonism in a dual GCGR/GLP-1R agonist

T. Kloeckener, T. Zimmermann, P. Haebel, B. Bajrami, R. Augustin, Germany

83 Effects of Liraglutide on GLP-1, GIP and glucagon concentrations in persons with type 2 diabetes with multiple daily insulin injections during a 24-week period

M. Koci, P.-A. Jansson, P. Fatulla, K. Bergqvist, S. Seyed Ahmadi, H. Imberg, I. Hirsch, O. Mellander, M. Lind, Sweden, USA

84 Effects of endogenous and exogenous glucose dependent insulinotropic polypeptide on blood pressure, heart rate, gastric emptying and blood glucose responses to oral glucose in healthy older people

R. J. Jalleh, S. Hatzinikolas, A. C. Slavotinek, M. Kamruzzaman, K. Lange, C. H. Malbert, S. Veedfald, L. S. Gasbjerg, M. M. Rosenkilde, J. J. Holst, C. S. Marathe, T. Wu, C. K. Rayner, M. Horowitz, K. L. Jones, Australia, France, Denmark

10:45 - 12:15

Berlin Hall

OP 15 Cardiovascular risk in patients with type 1 diabetes: What do we know today, how can we modify it tomorrow?

85 All-cause and cause-specific mortality, cardiovascular diseases, and prognostic factors in adult-onset type 1 diabetes

Y. Wei, T. Andersson, T. Tuomi, T. Nyström, S. Carlsson, Sweden, Finland

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION

86 Preclinical carotid atherosclerosis is independently associated with incident cardiovascular events in patients with type 1 diabetes

C. Milad, C. Sola, M. Claro, K. Castillo, T. Serés-Noriega, L. Boswell, C. Viñals, E. Esmatjes, V. Perea, J. Blanco, A. Mesa, I. Conget, M. Giménez, A. Amor Fernandez, Spain

87 People with type 1 diabetes living with overweight or obesity are at increased cardiovascular risk: insights from the SFDT1 cohort

L. Salle, J. Julla, G. Aguayo, S. Tatulashvili, H. Hanaire, L. Sablone, N. Servy, E. Renard, J.-F. Gautier, G. Prevost, N. Jeandidier, B. Guerci, E. Cosson, G. Fagherazzi, J.-P. Riveline, France, Luxembourg

EASD
EFSD

GENERAL
INFO

88 Increased body mass index and risk of developing cardiovascular complications in a cohort of people with type 1 diabetes

E. Soto-Pedre, L. D. Petty, R. J. McCrimmon, E. R. Pearson, UK

89 Evaluation of the Steno-risk in predicting cardiovascular events in young type 1 diabetes and its association with the progression of microvascular complications progression

I. C. Paliaras, P. M. Dualib, L. S. Torres, P. M. Aroucha, J. R. De Sá, S. A. Dib, Brazil

90 Cumulative glycaemic exposure is associated with coronary artery disease in type 1 diabetes: a call for action

R. Bergdal, V. Harjutsalo, P.-H. Groop, S. Mutter, the FinnDiane Study Group, Finland, Australia

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

10:45 - 12:15

Vienna Hall

OP 16 Emerging risk factors and treatment options for diabetic eye disease

91 Semaglutide does not affect central retinal thickness beyond the effect explained by glycaemic change: continuous glucose monitoring in persons with type 2 diabetes

S. Gullaksen, L. Vernstrøm Hald, S. Skovgaard Sørensen, K. Funck, L. Petersen, T. Bek, E. Laugesen, P. Poulsen, Denmark

92 Is early worsening of diabetic retinopathy a concern when starting hybrid closed loop therapy in people with type 1 diabetes?

S. A. Mathara Diddhenipothage, R. Blackhurst, E. M. Dutton, H. Smith, K. Hards, H. Lipinski, M. Matheou, S. Fatum, P. H. Scanlon, A. N. Lumb, G. D. Tan, UK

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

93 Diabetes-related microvascular complications and periodontitis: Health in Central Denmark

F. V. Bitencourt, A. Andersen, L. Bjerg, A. Sandbæk, H. Li, G. G. Nascimento, R. Spin-Neto, M. A. Peres, F. R. Leite, Denmark, Singapore

94 Impact of sleep duration at night on microvascular complications in patients recently diagnosed with type 2 diabetes

M. S. Johansen, J. V. Stidsen, P. Asyaei, F. N. Pedersen, J. Grauslund, M. H. Olsen, K. Højlund, T. B. Olesen, Denmark

95 Pericyte MDM2-knockout prevents retinal fibrosis in the development of diabetic retinopathy via regulating ITGB8-TGF- β 1 axis

J. Lin, Y. Chen, Z. Xu, B. Krämer, Germany

96 Topical administration of sitagliptin prevents neurodegeneration in an experimental model of steroid-induced glaucoma: clinical implications for treating diabetic macular oedema

R. Simo, P. Bogdanov, A. Duarri, M. J. Canz, D. Sabater, H. Isla-Magrané, H. Ramos, A. Deàs-Just, C. Hernández, Spain

10:45 - 12:15

Sydney Hall

OP 17 Type 2 diabetes prediction

97 Screening for type 2 diabetes and population mortality over 20-year follow-up (ADDITION-Cambridge): a cluster-randomised controlled trial

T. F. Marshall-Andon, C. E. Boothby, J. B. Echouffo Tcheugui, L. A. Sargeant, K. M. Williams, T. Prevost, A.-L. Kinmonth, N. J. Wareham, S. J. Griffin, UK, USA

98 A multi-country study of trends in the incidence of end-stage kidney disease among people with diabetes

J. W. Sacre, J. I. Morton, L. Chen, M. E. Pavkov, E. W. Gregg, J. E. Shaw, D. J. Magliano, GLOBODIAB Writing Group, Australia, USA, UK

99 How frequently is early-onset type 2 diabetes misclassified in South Asian and White individuals?

S. A. Jones, H. Cheng, S. Pandya, C. Goodall, S. Misra, UK

100 Diabetes medication is not associated with cancer occurrence in type 2 diabetes patients: a study of the entire Danish population 1996-2022

B. Carstensen, S. Friis, F. Persson, V. Kosjerina, M. Gamborg, L. S. Mørch, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

101 Remnant cholesterol and incident type 2 diabetes: a community-based 14-year prospective cohort study

Y.-C. Hwang, J. Jun, I.-K. Jeong, K. Ahn, H. Chung, Republic of Korea

102 Screening for type 2 diabetes is cost-effective: evidence from a pilot screening study in Denmark

N. C. Mateu, P. Rossing, K. Neergaard, T. Thybo, Denmark

EASD
EFSD

10:45 - 12:15

Sofia Hall

GENERAL
INFO

OP 18 How to blow the low

103 Real-world burden of severe hypoglycaemic events in type 1 diabetes in Germany

R. Ziegler, Q. Zhang, P. Callahan, C. Vetter, E. Garal-Pantaler, A. De Remigis, L. Chen, W. Rathmann, Germany, USA

104 Association of type 1 diabetes duration or duration of advanced technology utilisation with severe hypoglycaemic event frequency

P. Callahan, A. Boateng-Kuffour, K. Chandarana, D. Barry, L. Chen, C. S. Kelly, H. Nguyen, K. Chapman, E. Cornelius, W. A. Wolf, W. Polonsky, USA

105 Residual C-peptide is associated with new and persistent impaired awareness of hypoglycaemia in type 1 diabetes

R. Varkevisser, T. Sas, H.-J. Aanstoot, B. Wolffenbuttel, M. Van der Klauw, Netherlands

106 A single experimental hypoglycaemic event induces acute and prolonged transcriptional changes in circulating monocytes of people with type 1 diabetes and healthy controls

M. S. Hendriksz, R. Siebeler, J. I. Van Heck, C. E. Verhulst, M. A. Hoeksema, M. P. De Winther, B. E. De Galan, C. J. Tack, R. Stienstra, Netherlands

107 Pathophysiological mechanisms of postprandial hypoglycaemia after gastric bypass in type 2 diabetes

D. Trico, L. Sacchetta, E. Rebelos, N. Cimbalo, M. Chiriaco, D. Moriconi, L. Nesti, G. Nesti, S. Frascerra, M. Scozzaro, G. Daniele, S. Baldi, A. Mari, M. Nannipieri, A. Natali, Italy

108 Metoclopramide improves hypoglycaemic counterregulation in diabetic rats

S. J. Fisher, A. N. Iles, L. A. Schoeder, M. B. Music, B. V. Patel, A. R. Marksbury, M. M. Wooten, A. M. Woodcox, Z. Beckner, E. L. Macon, M. M. Devore, USA

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SHORT ORAL DISCUSSIONS EVENT C

12:45 - 13:45	Short Oral Discussion Area	Page
SO 003 - Station 1	The many facets of weight and type 2 diabetes risk	117
SO 009 - Station 2	Treatment of type 1 diabetes	123
SO 015 - Station 3	Genetics and biomarkers for prediction of type 2 diabetes	130
SO 021 - Station 4	Insulin service providers for the body	136
SO 027 - Station 5	Gestational diabetes: clinical perspective	141
SO 033 - Station 6	Understanding insulin sensitivity: What can we learn from human studies?	147
SO 039 - Station 7	Improving metabolic outcome by bariatric surgery	153
SO 045 - Station 8	Preclinical advances to better understand energy, glucose and lipid metabolism.	159
SO 051 - Station 9	Metabolic alterations in obesity and diabetes-linked co-morbidities	165
SO 057 - Station 10	Novel therapeutic avenues for metabolic disease	171
SO 063 - Station 11	More combo's less insulin!	177
SO 069 - Station 12	HbA _{1c} vs CGM: a tie break?	184
SO 075 - Station 13	A lesson in diabetes geography	190
SO 081 - Station 14	Advances in diabetic kidney disease from cells to histology	196
SO 087 - Station 15	Clinical studies on the crosstalk between neuropathy and other systems	202
SO 093 - Station 16	A non-classical look at type 1 diabetes	208
SO 099 - Station 17	A non-traditional look at type 1 diabetes	214

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EASD e-Learning expert session

Chair: TBA

Speaker: TBA

13:00 - 13:45

Spotlight Stage

Help! I need somebody: Managing complex clinical cases in the Emergency Room

Chair: Stephen Thomas, UK

Speaker: Stephen Thomas, UK:

Diabetic ketoacidosis in end stage kidney disease

Aoife M. Egan, USA:

Glycaemic emergencies in pregnancy

Daniel Morganstein, UK:

New cancer drug induced hyperglycaemic emergencies

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SHORT ORAL DISCUSSIONS EVENT D

14:00 - 15:00	Short Oral Discussion Area	Page
SO 004 - Station 1	Diet, lifestyle, and metabolic health: insights into diabetes risk and prevention	118
SO 010 - Station 2	Complications of type 1 diabetes	124
SO 016 - Station 3	Molecular predictors of type 1 diabetes	131
SO 022 - Station 4	Cells in attacking mode and beta cell victims	137
SO 028 - Station 5	Biomarkers and mechanisms in gestational diabetes.	142
SO 034 - Station 6	Novel mechanisms of insulin resistance	148
SO 040 - Station 7	Now the brown fat talks	154
SO 046 - Station 8	What's new on white fat function?.	160
SO 052 - Station 9	Preclinical advances to understand glucose metabolism.	166
SO 058 - Station 10	SGLT2 inhibition: focus on the heart and the kidneys.	172
SO 064 - Station 11	Incretins have more effects than you can imagine	178
SO 070 - Station 12	De-combining CGM and insulin in type 2 diabetes	185
SO 076 - Station 13	Up or down and back	191
SO 082 - Station 14	Predicting and treating renal complications. What's new in 2024?	197
SO 088 - Station 15	Fatty liver in diabetes: pathways and relationships	203
SO 094 - Station 16	Cohorts, trials and cardiovascular disease	209
SO 100 - Station 17	Correlates of fatty liver disease in diabetes	215

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

14:00 - 15:00

Cairo Hall

EASD e-Learning expert session

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

14:00 – 14:45

Spotlight Stage

EASD Early Career Academy Symposium: Work-Life-Balance

Chair: Alexandra M. Smink, Netherlands

Panelists: Anna Krook, Sweden

Benoit Gauthier, Spain

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 19 Prediction and prognosis of type 1 diabetes

109 Pioglitazone amplifies the decrease in HbA_{1c} and prevents the increase in plasma ketone caused by dapagliflozin in type 1 diabetes patients

R. DeFronzo, M. Abdul-Ghani, G. Baskoy, A. Nakhleh, S. Abdelgani, F. Al-Mulla, M. Abu-Farha, F. Alajmi, T. Alessa, N. Shehadeh, USA, Israel, Kuwait,

110 Pancreatic imaging biomarkers of increased fibro-inflammation, low volume and low fat characterise type 1 diabetes: a UK Biobank study

H. Thomaidēs-Brears, E. Jackson, A. Triay-Bagur, F. McCann, T. Mahon, H. Al-Mossawi, M. Pansini, UK, Switzerland

111 Mortality and factors associated with it in Finnish patients with type 1 diabetes

E. Putula, T. Kauppala, S. Vanhamäki, J. Haapakoski, T. Laatikainen, S. Metso, Finland

112 Influence of the type 1 diabetes genetic risk score on response to immunotherapies for type 1 diabetes prevention

M. J. Redondo, B. Bundy, H. Parikh, L. You, T. Triolo, L. Ferrat, E. Templeman, M. Tosur, A. K. Steck, P. Gottlieb, S. Onengut-Gumuscu, S. S. Rich, R. Oram, K. C. Herold, J. P. Krischer, USA, UK

113 Islet Antigen-2A (IA-2A) autoantibody positivity increases risk of progression within and across established stages of type 1 diabetes

E. Sims, D. Cuthbertson, L. Ferrat, E. Bosi, C. Evans-Molina, L. A. DiMeglio, B. Nathan, H. Ismail, L. Jacobsen, M. Redondo, R. Oram, J. Sosenko, USA, Switzerland, Italy, UK

114 Risk of developing type 1 diabetes in individuals with other autoimmune conditions

S. Edelman, D. Agardh, N. Cui, L. Hao, X. Li, M. Wieloch, L. Meneghini, USA, Sweden, France

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

15:30 - 17:00

London Hall

LBA OP 3 TBA

Late breaking abstracts

15:30 - 17:00

Berlin Hall

OP 20 Are you afrAID?

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

115 Quality-of-life benefits for adults living with type 1 diabetes using the Omnipod 5 System compared with insulin pump therapy: results from a randomised controlled trial

J.-P. Riveline, E. Renard, R. S. Weinstock, T. T. Ly, The OP5-003 Research Group, France, USA

116 Early real-world performance of the Omnipod® 5 automated insulin delivery (AID) system in 9,900 people with type 1 diabetes in Europe

E. G. Wilmot, T. Biester, F. M. Campbell, D. Deiss, J. Elliott, F. Gibb, J. Kröger, L. M. Huyett, J. J. Méndez, I. Hadjiyianni, L. R. Conroy, T. T. Ly, UK, Germany, USA

117 Real-world glycaemic and person-reported outcomes one year after Tandem Control IQ™ initiation in children and adults with type 1 diabetes

J. De Meulemeester, L. Valgaerts, C. De Block, L. Van Huffel, D. Ballaux, K. Spincemaille, Y. Taes, B. Lapauw, G. Massa, M. Den Brinker, A. Messaaoui, I. Gies, B. Keymeulen, C. Mathieu, P. Gillard, Belgium

118 Sustained 1-year improvement of glucose control under free-life hybrid closed-loop insulin therapy in children with type 1 diabetes: national observatory of closed-loop in France (OB2F)

E. Renard, J.-P. Riveline, J.-B. Julla, F. Dalla-Vale, A. Spiteri, L. Mathivon, J.-F. Gautier, E. Bonnemaïson, France

119 Glucose control in free-life under hybrid closed loop 6 and 12 months after initiation from a nation-wide survey

J.-P. Riveline, J. Julla, C. Campinos, S. Favre, I. Tauveron, S. Borot, L. Kessler, A. Carlier, M. Giraud, M. Joubert, N. Hamamouche, S. Lablanche, M. Huet, J.-F. Gautier, E. Renard, France, Switzerland

120 Impact on GRI and other metrics in type 1 adult patients switching to advanced hybrid closed-loop systems: a one-year real-life experience

E. Resmini, E. Zarra, S. Dotti, G. Rotondi, A. V. Cornaghi, S. Madaschi, E. Cimino, G. Massari, L. C. Pezzaioli, C. Buoso, M. Sandri, A. Girelli, Italy

15:30 - 17:00

Vienna Hall

OP 21 Cardiovascular risk in diabetes: in search of the holy grail

121 Atherosclerotic cardiovascular disease in familial hypercholesterolemia and diabetes: a nationwide registry study

D. Eriksson Hogling, K. Littmann, G. Kindborg, J. Brinck, Sweden

122 Association of plasma concentrations of MGO-apoB₃₁₈₄₋₃₁₉₄, a signature peptide of glycated apoB100, with cardiovascular events in people living with type 2 diabetes

S. Hadjadj, C. Chevalier, A. Rodrigues Oliveira, M. Wargny, L. Thenaisie, V. Pakulska, Y. Coute, P.-J. Saulnier, A. Pinheiro, C. Le May, B. Cariou, M. Croyal, France

123 The importance of muscle health in type 2 diabetes: adverse muscle composition and all-cause mortality

J. Linge, M. Petersson, O. Dahlqvist Leinhard, Sweden

124 Reduction in ischaemic events with icosapent ethyl in patients with diabetes and prior CABG: REDUCE-IT diabetes-prior CABG

S. Verma, D. L. Bhatt, P. G. Steg, M. Miller, E. A. Brinton, T. A. Jacobson, S. B. Ketchum, A. Lira Pineda, D. Mueller-Wieland, J.-C. Tardif, C. M. Ballantyne, REDUCE-IT Investigators, Canada, USA, France, Germany

125 Risk prediction of type 2 diabetes complications using metabolomic data from the whole UK Biobank cohort

K. Schut, S. Kerminen, L. Jostins-Dean, P. Würtz, J. C. Barrett, Finland

126 Diabetes and trends in survival after acute myocardial infarction, 2011 to 2020

P.-S. Song, M. Kim, S. Lee, Republic of Korea

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 22 Actions of incretins on the brain and pancreas you might not know about

127 Single-dose GLP-1-based pancreatic gene therapy durably maintains body composition and glycaemia after semaglutide withdrawal in a murine model of obesity

A. L. Fitzpatrick, S. Wang, R. Reese, N. Picard, E. Cozzi, T. Kieffer, J. Caplan, H. Rajagopalan, USA, Canada

EASD
EFSD

128 Brain circuitry activated by cagrilintide, semaglutide and CagriSema in mice

T. A. Lutz, G. Lommi, C. Le Foll, A. Secher, K. Raun, M. Hankir, Switzerland, Denmark

GENERAL
INFO

129 A trans-ancestry GLP1R candidate locus study for mental and physical health

M. M. Hayman, R. J. Strawbridge, P. Welsh, UK

PROGRAMME

TUESDAY

130 Assessing GLP1 receptor occupancy in the CNS and pancreas using PET

A. Khalil, I. Veliky, M. Bossart, M. Wagner, O. Eriksson, Sweden, Germany

WEDNESDAY

THURSDAY

FRIDAY

131 Retatrutide, an agonist of GIP, GLP-1, and glucagon receptors, improves markers of pancreatic beta cell function and insulin sensitivity

M. K. Thomas, J. Rosenstock, T. Coskun, M. L. Hartman, J. Lou, Q. Wu, Y. Du, S. Gurbuz, K. Mather, Z. Milicevic, USA

SHORT ORAL
DISCUSSIONS

132 Direct contact between endosomal GLP-1R, ER VAP-B and the AKAP SPHKAP triggers PKA-dependent MIC19 phosphorylation and beta cell mitochondrial remodelling

A. Tomas, G. Austin, L. ElEid, A. Oqua, Y. Manchanda, Y. Poliakova, A. Montoya, B. Jones, S. Millership, I. Prokopenko, UK

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

OP 23 Why exercise?

133 Effects of exercise intensity on the insulin sensitivity and lipid composition in skeletal muscle under the same calorie consumption exercise

S. Kakehi, Y. Tamura, T. Funayama, R. Kawamori, H. Watada, Japan

EXHIBITION

134 Myofiber Piezo1 regulates muscle hypertrophy and metabolism in response to exercise

T. Inoue, Y. Hirata, K. Nomura, N. Kuramoto, T. Nishigaki, K. Hozumi, K. Sugawara, W. Ogawa, Japan

135 Exercise-induced exosomes contribute to the sustained metabolic changes after cessation of exercise training in insulin resistance states

L. Mastrototaro, M. Apostolopoulou, S. Hartwig, K. Strassburger, P. Lipaeva, N. Trinks, Y. Karusheva, S. Gancheva, S. Trenkamp, S. Lehr, H. Al-Hasani, J. Szendroedi, M. Roden, Germany

136 Effects of light-intensity physical activity snacking on cardiometabolic parameters in young adults with overweight/obesity: a randomised controlled crossover trial

S. Sanfilippo, O. Moser, P. Zimmermann, J. Schierbauer, A. Grothoff, N. Wachsmuth, T. Voit, A. Rössler, H. K. Lackner, S. Hoffmann, Germany, Austria

137 The response in insulin sensitivity to different modalities of acute exercise

N. S. Nielsen, J. O. Hvidemose, R. Aarvig, N. G. Skougaard, J. P. Hartmann, K. Husted, R. J. Loos, R. M. Berg, M. Ried-Larsen, Denmark

138 Integrated analysis of the skeletal muscle methylome and transcriptome following exercise in females with type 2 diabetes and normal glucose tolerance

K. MacGregor, J. Zierath, A. Krook, Sweden

15:30 - 17:00

Cairo Hall

OP 24 Islets forever: survival of the beta cells

139 Covid-19 and type 1 diabetes in Denmark: a longitudinal study on beta cell function

M. Bjerregaard-Andersen, P. Emilie Petersen, K. Kolnes, M. Bangshaab, A. Razvan Andries, J. Da Silva, E. Carvalho, T. Krarup Hansen, P. Vestergaard, F. Pociot, K. Højlund, C. B. Juhl, Denmark, Portugal

140 Regular at-home monitoring of stimulated dried blood spot C-peptide levels can detect changes in beta cell function early in individuals with recently diagnosed type 1 diabetes

A. E. Hendriks, M. L. Marcovecchio, P. Barker, M. Evans, C. Mathieu, on behalf of the INNODIA consortium, UK, Belgium

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

141 Characterisation of residual proinsulin and C-peptide after 50 years of insulin dependence: the Joslin Medalist study

M. Yu, T. Chokshi, S. Jangolla, N. Ziemniak, E. Viebranz, I.-H. Wu, H. Shah, S. Bonner-Weir, G. King, USA

142 Assessment of beta cell function and glucose metabolism after near total pancreatectomy: implications of 80% pancreas reduction

L. Soldovieri, G. Di Giuseppe, M. Zidda, M. Brunetti, G. Ciccarelli, S. Moffa, F. Cinti, A. Mari, G. Quero, S. Alfieri, A. Giaccari, T. Mezza, Italy

143 EGFR inhibitor erlotinib downregulates high fat mediated beta cell inflammation, lipid accumulation and augments insulin secretory function

O. Mukherjee, S. Nag, S. Mandal, N. Das, R. Kundu, India

144 Role of autophagy and intermittent fasting in beta cell mass and identity in K_{ATP} -induced neonatal diabetes

E. Castelblanco, Z. A. Shyr, I. Ramirez-Sotero, M. S. Remedi, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION



59th Minkowski Lecture

The Minkowski Prize recognises research which contributes to the advancement of knowledge concerning diabetes mellitus.

Chair: Chantal Mathieu, Belgium

Speaker: Elisa De Franco, United Kingdom:
Finding the missing pieces of the puzzle: gene discovery in neonatal diabetes to gain new insights into beta cell biology

Elisa De Franco studied medical biotechnologies at the University of Turin, Italy, followed by an EU-funded PhD fellowship at the University of Exeter.

She is currently a Senior Research Fellow in Exeter and the recipient of a Diabetes UK RD Lawrence Fellowship and an EFSD/Novo Nordisk Future Leader award.

Dr. De Franco's research uses genome sequencing to discover genes essential for beta-cell development and function. Her work has been recognised by multiple awards, including the EASD Rising Star award in 2018 and the ISPAD Young Investigator Award in 2020.

She has published over 80 papers, including first-author publications in the Lancet and Nature Genetics.



EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:30 - 18:30

London Hall

Taking a COMBINED approach: insulin icodec and semaglutide

Chair: Athena Philis-Tsimikas, USA

Speaker: Liana K. Billings, USA:
Defining the needs for a weekly fixed ratio combination treatment in type 2 diabetes

Linong Ji, China:
Basal insulin intensification by switching to once weekly IcoSema (COMBINE 1)

Ildiko Lingvay, USA:
Intensification with IcoSema in a GLP-1RA experienced population (COMBINE 2)

Liana K. Billings, USA:
IcoSema as an alternative to basal bolus treatment (COMBINE 3)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

17:30 - 18:30

Berlin Hall

Addressing the lack of treatment options to reduce the morbidity/mortality gap in type 1 diabetes

Chair: Daniel H. van Raalte, Netherlands

Speaker: Rory McCrimmon, UK:
Cardiovascular and kidney disease in type 1 diabetes

Anand Srivastava, USA:
Which treatment options in type 2 diabetes could be harnessed for type 1 diabetes?

Peter Rossing, Denmark:
Design of cardiovascular outcome trial in type 1 diabetes

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:30 - 18:30

Vienna Hall

EASD/ESSM Symposium: When sex is ex (for her or for him)

Chair: Leszek Czupryniak, Poland; Giovanni Corona, Italy

Speaker: Aleksandra Uruska, Poland
Is it the body?

EASD
EFSD

Marieke Dewitte, Netherlands:
Is it the mind?

GENERAL
INFO

Zdravko A. Kamenov, Bulgaria:
Is it the drugs?

PROGRAMME

TUESDAY

17:30 - 18:18:30

Sydney Hall

WEDNESDAY

Neuroendocrine control of food intake, body weight and glucose metabolism

THURSDAY

Chair: Nicolai J. Wewer Albrechtsen, Denmark

FRIDAY

Speaker: Daniela Cota, France:
Hypothalamic responses to energy surfeit in the regulation of energy balance

SHORT ORAL
DISCUSSIONS

Ruben Nogueiras, Spain:
Regulation of glucose metabolism by neddylation

PRESENTER
INDEX

Gregory R. Steinberg, Canada:
GFD15 regulation of food intake

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:30 - 18:30

Sofia Hall

Mitochondria: Implications in insulin sensitivity

Chair: Piero Marchetti, Italy

Speaker: Marc Liesa-Roig, Spain:

Mitochondrial dynamics and insulin resistance

Paola Venditti, Italy:

Role of mitochondria in muscle insulin resistance

Gerald I. Shulman, USA:

Novel liver-targeted mitochondrial protonophores in the treatment of type 2 diabetes

Arun Sanyal, USA:

Therapeutic potential of mitochondrial uncouplers in the treatment of insulin resistance

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

17:30 - 18:30

Cairo Hall

What can we learn about diabetes from population isolates?

Chair: Marit E. Jorgensen, Greenland

Speaker: Torben Hansen, Denmark:

Diabetes in Arctic Inuit

Carlos A. Aguilar-Salinas, Mexico:

Indigenous Mexicans

Leslie J. Baier, USA:

Pima Indians

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

09:00 - 10:30

Madrid Hall

The rise of GIP: from biology to medicine

Chair: Timo D. Müller, Germany

Speaker: Michael A. Nauck, Germany:

GIPR/GLP-1R dual agonists: from discovery to approval

Alice E. Adriaenssens, UK:

Central effects of GIPR agonism in control of feeding behaviour

Ruth Gimeno, USA:

Pharmacological use

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

09:00 - 10:30

Madrid Hall

How is precision medicine advancing our understanding of diabetes aetiology and will it make a difference?

Chair: TBA

Speaker: TBA

Rising Star Symposium

The EASD Rising Star Symposium and EFSD Rising Star Fellowship Programme aims to identify promising and innovative young researchers who are developing their research activities in Europe.

Chair: Tina Vilsbøll, Denmark

Speaker: Georgia Colleluori, Italy:
Inter-organ crosstalk in glucose homeostasis



Cintia Folgueira-Cobos, Spain:
Unravelling the central role of p38 α and its implications in metabolic disorders



Sini Marjut Heinonen Finland:
Novel targets to activate adipose tissue metabolism for the treatment of obesity



Borja Martinez-Tellez, Spain:
Revelling a new brown fat depot in young women with type 2 diabetes



EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

09:00 - 10:30

Vienna Hall

**Novel approaches for prediction of microvascular complications
- from tears to DNA and MRI**

Chair: Niina Sandholm, Finland

Speaker: Ulrik B. Andersen, Denmark:

Kidney imaging is the next biomarker in diabetic kidney disease

EASD
EFSD

GENERAL
INFO

Rama Natarajan, USA:

DNA methylation is the next biomarker in diabetic kidney disease

PROGRAMME

TUESDAY

Martina Kropp, Switzerland:

Tear metabolomics reveal the next biomarker in diabetic retinopathy

WEDNESDAY

THURSDAY

09:00 - 10:30

Sydney Hall

FRIDAY

“Old and new” islets for type 1 diabetes

Chair: Eelco De Koning, Netherlands

Speaker: James A. M. Shaw, UK:

Clinical outcome assessment of donor islet transplantation

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

Timothy J. Kieffer, Canada:

Ensuring safety of stem cell-derived islet products

SATELLITE
SYMPOSIA

Trevor W. Reichman, Canada:

Update of clinical stem cell-derived islet trials

INDUSTRY

PROGRAMME

EXHIBITION

09:00 - 10:30

Sofia Hall

EASD/JDRF Symposium: Do devices really help the person with diabetes?

Chairs: Tadej Battelino, Slovenia; Aaron J. Kowalski, USA

Speaker: Lutz Heinemann, Germany:

Connected insulin pens: What are the benefits?

Mark Evans, UK:

What risks to foresee with connected medical devices in diabetes?

Thomas Danne, Germany:

Automated insulin delivery technologies: What is there on the horizon?

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

09:00 - 10:30

Cairo Hall

12th East-West-Forum: Involving the public and patients in shaping diabetes care and research

Chairs: Apostolos Tsapas, Greece; Daisuke Yabe, Japan

Speaker: Sean Dinneen, Ireland:

Building capacity for high quality public and patient involvement in research: the PPI Ignite Network

Yusuke Arai, Japan:

People with type 1 diabetes and their families in diabetes research

Ingrid Willaing Tapager, Denmark:

User involvement in diabetes prevention, research and care

Haruka Nakada, Japan:

Situation of PPI in the field of cancer in Japan

OP 25 Incretin receptor agonists: better and better**145 Comparative efficacy and tolerability of incretin-based therapies for adults with overweight or obesity: a network meta-analysis**

T. Karagiannis, K. Malandris, P. Kakotrichi, D. Vasilakou, I. Avgerinos, K. Tsapa, D. Tsapa, A. Liakos, E. Bekiari, Greece

EASD
EFSD**146 Is semaglutide as effective at reducing major cardiovascular events in the presence of impaired kidney function in people with overweight or obesity? A prespecified analysis from the SELECT trial**

H. M. Colhoun, S. E. Kahn, P. M. Brown, E. T. Olesen, R. Bravo, J. Deanfield, A. Goudev, G. Latkovskis, M. Lehrke, A. M. Lincoff, N. Rathor, C.-C. Wu, I. Lingvay, On behalf of the SELECT investigator group, UK, USA, Denmark, Bulgaria, Latvia, Germany, Taiwan

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

147 ZT002, a novel ultra long-acting GLP-1 receptor agonist in adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1c study

L. Ji, H. Zhou, X. Li, X. Xu, A. Wong, Y. Zu, X. Song, Y. Zhang, S. Lin, X. Zhang, Y. Zhang, China

148 A phase 3 evaluation of cAMP signalling biased GLP-1 analogue ecnoglutide in adults with type 2 diabetes

S. Xu, D. Zhu, S. Bing, Q. Zheng, L. Guan, F. Jiang, X. Liu, Y. Bu, J. Ning, Z. Zhu, L. Yang, M. Yang, M. Fenaux, M. K. Junaidi, Ecnoglutide for T2DM Study Team, USA, China

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA**149 Efficacy and safety of mazdutide in Chinese participants with overweight or obesity (GLORY-1)**

L. Ji, H. Jiang, H. Li, J. Tian, D. Liu, Y. Zhao, W. Qiu, Y. Bi, J. Gu, Z. Liu, H. Deng, Y. Wang, L. Li, L. Qian, The GLORY-1 Investigators, China

150 A triple GIP, GLP-1 and glucagon receptor agonist, retatrutide, decreases inflammatory CV risk biomarkers in people with overweight or obesity, with or without type 2 diabetes

G. Ruotolo, C. Harris, Y. Lin, M. K. Thomas, Y. Qu, J. Wilson, K. Duffin, M. L. Hartman, T. Coskun, Z. Milicevic, A. Haupt, USA

INDUSTRY

PROGRAMME

EXHIBITION

LBA OP 4 TBA

Late breaking abstracts

OP 26 Love goes through the stomach: new roles for GLP-1

151 Alpha-lipoic acid's role in improving GLP-1 agonist treatment tolerability in young overweight patients with prediabetes

L. Jashi, T. Peshkova, T. Shervashidze, R. Kvanchakhadze, K. Dundua, L. Beridze, Georgia,

152 Higher GLP-1R expression in the pituitary of males with type 2 diabetes compared to females determined by [⁶⁸Ga]Ga-NODAGA-exendin-4 PET/CT imaging

S. Tokgöz, L. Deden, R. I. Meijer, C. Tack, B. E. De Galan, M. Boss, M. Gotthardt, Netherlands

153 Serum GLP-1 and thombospondin-2 predict improved metabolism and attenuated liver fibrogenesis in severely obese patients undergoing an intensive weight-loss therapy

N. Rohmann, R. Surabattula, J. Koppenhagen, A. Beckmann, P. Wietzke-Braun, T. Hollstein, S. R. Myneni, K. Hartmann, L. Kruse, K. Schlicht, C. Geisler, K. Türk, D. M. Schulte, D. Schuppan, M. Laudes, Germany, USA

154 Serotonin is a potent stimulator of GLP-1 secretion from the rat perfused intestine

T. A. Cookson, I. M. Modvig, J. J. Holst, Denmark

155 Insulin resistance elicits GLP-1 secretion from pancreatic alpha cells in mice

G. Di Giuseppe, S. Lind Jepsen, J. Vergara Ucin, D. Bjørklund Andersen, B. Hartmann, A. Giaccari, J. J. Holst, T. Mezza, Italy, Denmark

156 Lipidated interleukin-22 reduces body weight through reduced food intake and increased fecal energy loss in a complementary manner to GLP-1 receptor agonists

M. Van de Bunt, D. Haß, M. Rohm, A. Kjølbye, R. Jorgensen, Denmark, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

10:45 - 12:15

Vienna Hall

OP 27 Predictors of diabetic kidney disease progression from omics to ethnicity

157 Redefining the eGFR-albuminuria relationship using genetics: setting stage for precision monitoring

C. H. Naaman, T. W. Hansen, F. Persson, P. Rossing, T. S. Ahluwalia, Denmark

EASD
EFSD

158 Impact of ethnicity on faster progression of kidney function loss and onset of advanced chronic kidney disease in an ethnically diverse cohort of people with type 2 diabetes

T. Alobaid, J. Karalliedde, S. Ayis, M. O'Connell, UK

GENERAL
INFO

159 Proteomic changes prior to onset and progression of albuminuria and end-stage kidney disease in type 1 diabetes

S. Mutter, E. Valo, E. Dahlström, V. Harjutsalo, P.-H. Groop, N. Sandholm, FinnDiane Study Group, Finland, Australia

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

160 Association between serum REG I α and progression of diabetic kidney disease: a prospective cohort study

N. Huang, S. Chen, Z. Shu, L. Li, China

161 Albuminuria trajectories over six years and their determinants in type 2 diabetes: the Fremantle Diabetes Study Phase II

W. A. Davis, T. M. Davis, Australia

SHORT ORAL
DISCUSSIONS

162 HbA_{1c} variability is independently associated with progression of diabetic kidney disease in people with type 1 diabetes

A. Muthukumar, L. Badawy, A. Mangelis, P. Vas, S. Thomas, A. Gouber, S. Ayis, J. Karalliedde, UK

PRESENTER
INDEX

SATELLITE
SYMPOSIA

10:45 - 12:15

Sydney Hall

OP 28 New kids on the block: stem cell islets

163 Metabolic maturation of stem cell derived beta cells upon murine engraftment

E. Vähäkangas, T. Barsby, H. Montaser, S. Euroola, P. Katajisto, J. Saarimäki-Vire, T. Otonkoski, Finland

INDUSTRY

PROGRAMME

EXHIBITION

164 Pro-inflammatory stimuli induce profound transcriptome and translome changes in iPSC-derived beta cells that mimic type 1 diabetes beta cell gene signatures

C. Vinci, F. Szymczak, S. Thomaidou, H. Shakeri, Y. Tong, I. M. Akçay, X. Yi, A. Zaldumbide, D. Eizirik, M. Cnop, Belgium, Netherlands

165 Recruitment of thymic regulatory T cells to stem cell-derived beta cells expressing CCL22

E. Filatov, S. Sasaki, M. Haque, S. Kar, V. Fung, M. Mojibian, N. A. Krentz, K. N. MacDonald, G. Soukhatcheva, D. Dai, P. C. Orban, M. K. Levings, C. B. Verchere, F. C. Lynn, Canada

166 Knock-out of the activating ligand repertoire of human stem cell-derived beta cells avoids chronic allogeneic rejection by NK cells in a diabetic humanised IL-15 NOG mouse model

G. Siracusano, R. Chimienti, M. Certo, C. Volpi, G. Lunetta, L. Perani, A. Palmisano, T. Canu, R. Melzi, F. Deambrogio, V. Sordi, M. Malnati, L. Piemonti, Italy

167 Multi-omic analysis reveals a dual role of PTPN2 in protecting beta cells from inflammatory-induced cell death and promoting stem cell-derived beta like cell maturation

V. Vandenbempt, J. Negueruela, F. Ribeiro-Costa, M. Nunes, S. Singh, L. Martelotto, E. Gurzov, Belgium, Australia

168 Monoclonal antibodies against the immune checkpoints B7-H3 and CD155 enhance engraftment of iPSC-derived pancreatic progenitors into mice humanised with allogeneic PBMCs

R. Chimienti, G. Siracusano, C. Volpi, M. Certo, G. Lunetta, F. Deambrogio, V. Sordi, L. Piemonti, Italy

10:45 - 12:15

Sofia Hall

OP 29 More on hormones

169 Postprandial secretion of GLP-1 and GIP is reduced in recent-onset type 2 diabetes but increased in steatotic liver disease

M. Huttasch, T. Mori, S. Kahl, G. Heilmann, N. Trinks, M. Schön, S. Trenkamp, Y. Kupriyanova, V. Schrauwen-Hinderling, N. J. Wewer Albrechtsen, V. Burkart, R. Wagner, M. Roden, for the GDS group, Germany, Denmark

170 Disparities in GLP-1 and GIP responses to small intestinal glucose infusion between people with well- and poorly-controlled type 2 diabetes

Y. Sun, C. Xie, M. Bound, K. L. Jones, M. Horowitz, R. Young, C. K. Rayner, T. Wu, Australia

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

171 Human GLP-1R expression in several organs outside the pancreas assessed by a biodistribution study of radiolabeled exendin PET/CT imaging

L. Deden, M. Gotthardt, S. Tokgöz, E. Aarts, H. De Boer, C. Tack, M. Buitinga, I. Janssen, E. Hazebroek, B. E. Galan, M. Boss, Netherlands

EASD
EFSD

172 Blocking the effects of endogenous GIP increases fasting plasma glucose levels in individuals with obesity

F. Koefoed-Hansen, H. Kizilkaya, M. Helsted, N. Sørum, F. Dela, M. M. Rosenkilde, J. Holst, B. Hartmann, F. K. Knop, L. Gasbjerg, Denmark

GENERAL
INFO

173 Nutrient sensing mechanisms in human cholecystokinin-secreting cells

M. Santos-Hernandez, N. Guccio, C. Alcaino, C. A. Smith, F. Reimann, F. M. Gribble, UK

PROGRAMME

TUESDAY

174 The effect of hepatic fat content on the hepatic response to glucagon during postprandial conditions

H. E. Christie, S. Mohan, A. M. Egan, A. Vella, USA

WEDNESDAY

THURSDAY

10:45 - 12:15

Cairo Hall

FRIDAY

OP 30 Causes and consequences of gestational diabetes

SHORT ORAL
DISCUSSIONS

175 The effect of a reduced energy diet upon maternal weight and pregnancy outcomes in women with gestational diabetes: the DiGest trial

C. L. Meek, D. L. Jones, N. Atta, E. H. Turner, L. Oude Griep, K. Rennie, E. De Lucia Rolfe, S. Sharp, H. Murphy, R. Taylor, L. C. Kusinski, UK

PRESENTER
INDEX

SATELLITE
SYMPOSIA

176 Reduction of type 2 diabetes can be achieved by lifestyle intervention in young women with previous gestational diabetes

J. Tuomilehto, H. Liu, W. Li, L. Wang, S. Zhang, J. Leng, G. Liu, P. Shao, F. Zhang, H. Tian, Y. Shen, S. Yang, E. Gunderson, X. Yang, G. Hu, Finland, China, USA

INDUSTRY

PROGRAMME

EXHIBITION

177 Achievement of glycaemic control after gestational diabetes diagnosis is associated with a risk of obesity in the offspring similar to that in children of individuals without gestational diabetes

A. Ferrara, R. F. Chehab, M. Greenberg, C. Lee, A. L. Ngo, Y. Zhu, USA

178 Effectiveness of a family-based health promotion intervention on type 2 diabetes risk markers in women with prior gestational diabetes: 1-year follow-up from the Face-it RCT

K. Kragelund Nielsen, I. K. Dahl-Petersen, P. Damm, D. Jensen, P. Ovesen, E. Mathiesen, U. Kampmann, C. Vinter, S. Knorr, L. L. Andersen, H. Støvring, H. T. Maindal, Face-it Study Group, Denmark

179 Partitioned polygenic scores and extremes of polygenic risk provide mechanistic insights into type 2 diabetes and gestational diabetes in British Pakistani and Bangladeshi populations

S. Hodgson, A. Williamson, D. Stow, B. M. Jacobs, M. Samuel, J. Gafton, J. Zollner, M. Spreckler, C. Langenberg, D. A. Van Heel, R. Mathur, M. K. Siddiqui, S. Finer, Genes & Health Research Team, UK

180 Breast cancer in women with previous gestational diabetes: a nationwide register-based cohort study from Denmark

M. H. Christensen, C. A. Vinter, T. B. Olesen, M. H. Petersen, E. A. Nohr, K. H. Rubin, M. S. Andersen, D. M. Jensen, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION



ИЗДАТЕЛЬСТВО
ИЗДАТЕЛЬСТВО

ПАННИС

SHORT ORAL DISCUSSIONS EVENT E

12:45 - 13:45	Short Oral Discussion Area	Page
SO 005 - Station 1	Unraveling monogenic diabetes: from genetic variants to innovative diagnostic tools.	119
SO 011 - Station 2	Disease progression and mortality in diabetes	125
SO 017 - Station 3	Long-term complications and outcomes in type 2 diabetes: vascular health, kidney function, and mortality	132
SO 023 - Station 4	Keeping islet cell identity under different circumstances	137
SO 029 - Station 5	On the young ones...	143
SO 035 - Station 6	Non-insulin hormones	149
SO 041 - Station 7	Towards a better understanding of the adipose tissue - liver axis	155
SO 047 - Station 8	Novel mechanisms regulating energy and glucose metabolism	161
SO 053 - Station 9	Oral agents to control glucose metabolism	167
SO 059 - Station 10	Pleiotropic effects of SGLT2 inhibition.	173
SO 065 - Station 11	Advanced real life in type 1 diabetes	179
SO 071 - Station 12	How universal can CGM be?	186
SO 077 - Station 13	Continuous monitoring of CGM	192
SO 083 - Station 14	The four M's of microvascular complications: MRI, Mitochondria, Models, and iMaging	198
SO 089 - Station 15	Brain matters in diabetes	204
SO 095 - Station 16	Other complications of type 2 diabetes	210
SO 101 - Station 17	MASLD: now an established complication of diabetes	216

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

12:45 - 14:15

Sofia Hall

EFSD Future Leaders Symposium

Chair: Fatima Bosch, Spain

13:00 - 13:45

Spotlight Stage

EASD
EFSD

Pro & Contra: Will next generation obesity drugs make bariatric surgery obsolete?

GENERAL
INFO

Chair: Matthias Blüher, Germany

Speaker: Francesco Rubino, UK:

Pro

Louis J. Aronne, USA:

Contra

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SHORT ORAL DISCUSSIONS EVENT F

14:00 - 15:00	Short Oral Discussion Area	Page
SO 006 - Station 1	Advancements in predicting type 1 diabetes	120
SO 012 - Station 2	Health interactions and risks in diabetes: from cancer survival to chronic conditions	127
SO 018 - Station 3	Diabetes management and outcomes: societal, behavioral, and clinical influences	133
SO 024 - Station 4	Improving islet transplantation.	138
SO 030 - Station 5	Investigating impact of gestational diabetes	144
SO 036 - Station 6	Keeping your beta cells alive	150
SO 042 - Station 7	How lifestyle affects our health	156
SO 048 - Station 8	Novel mechanisms controlling glucometabolic health	162
SO 054 - Station 9	Improving metabolism via the gut	168
SO 060 - Station 10	Novel incretins: it is all about clinical outcomes.	174
SO 066 - Station 11	Pumping without bumping.	180
SO 072 - Station 12	The future of diabetes science is here	187
SO 078 - Station 13	More stress on distress	193
SO 084 - Station 14	Mechanisms and treatment for microvascular complications; nerves, eyes, and blood vessels	199
SO 090 - Station 15	Skeletal muscles and subcutaneous adipose tissue: important players in diabetes management	205
SO 096 - Station 16	A non-traditional look at type 2 diabetes	211
SO 102 - Station 17	Addressing risk and consequences of liver pathology in diabetes	217

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

14:00 - 15:00

Cairo Hall

EASD e-Learning expert session

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

14:00 – 14:45

Spotlight Stage

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

EUDF Symposium: AI-Driven clinical decision support systems: Potential, concerns and what should it bring to people living with diabetes?

Speaker: Stefano Del Prato, Italy:
Welcome and introduction

Alfonso Galderisi, USA:
Implications of using AI-CDSS in diabetes care

Peter E.H. Schwarz, Germany:
What should AI-CDSS deliver in diabetes care?TBA

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

OP 31 Macrovascular outcomes of diabetes: a holistic view

181 The relationship between serum HDL-cholesterol, cardiovascular disease and mortality in community-based people with type 2 diabetes: the Fremantle Diabetes Study phase II

T. M. Davis, W. A. Davis, Australia

182 Association between metabolic dysfunction-associated steatotic liver disease and ischemic stroke in patients with type 2 diabetes

M. Jang, G. Kim, K.-N. Lee, K. Han, R. Oh, S. Cho, J. Kim, Y.-B. Lee, S.-M. Jin, K. Hur, J. Kim, Republic of Korea

183 Risk for cardiovascular disease and all-cause mortality in type 1 compared with type 2 diabetes patients: a nationwide register-based study

V. Patsoukaki, L. Lind, R. Kristófi, S. Radhi, K. Eeg-Olofsson, B. Eliasson, J. W. Eriksson, Sweden

184 Prospective associations between markers of low-grade inflammation and major cardiovascular events and mortality in recently diagnosed type 2 diabetes: a Danish nationwide cohort study

S. L. Domazet, A. Sharfo, T. B. Olesen, J. V. Stidsen, J. S. Nielsen, R. W. Thomsen, N. Jessen, P. Vestergaard, M. K. Andersen, T. Hansen, C. Brøns, V. H. Jensen, A. A. Vaag, M. H. Olsen, K. Højlund, Denmark, Sweden

185 The interaction between type 2 diabetes and chronic kidney disease on heart failure outcomes: observational study from the Swedish Heart Failure and the Swedish National Diabetes Registries

A. Merolla, V. Valente, L. Benson, U. Dahlström, L. H. Lund, S. Gudbjörnsdóttir, F. Cosentino, G. Savarese, G. Ferrannini, Sweden, Italy

186 Prevalence and prognostic significance of diabetes-related complications in patients with newly diagnosed type 2 diabetes in Sweden

S. Karayiannides, N. Widén, N. Rajamand-Ekberg, S.-B. Catrina, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

15:30 - 17:00

London Hall

LBA OP 5 TBA

Late breaking abstracts

15:30 - 17:00

Berlin Hall

EASD
EFSD

OP 32 Fine tuning CGMing

187 How variable is the glycaemic variability? Analysis of CGM data over one year

E. Schupp, R. Stienstra, C. J. Tack, R. I. Meijer, Netherlands

GENERAL
INFO

188 The relationship between time in tight range and the presence of chronic complications in adults with type 1 diabetes: a retrospective cross-sectional real-world study

J. De Meulemeester, S. Charleer, M. Visser, C. De Block, C. Mathieu, P. Gillard, Belgium

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

189 Inpatient accuracy of continuous glucose monitors in people with type 1 diabetes: a multi-centre retrospective study

R. Wang, A. Connell, C. Chiang, J. Tjahyadi, M. Kyi, S. Furlanos, Australia

190 Impact of continuous glucose monitoring on hospitalisations in people with type 2 diabetes: real-world analysis

S. Garg, I. B. Hirsch, E. Repetto, J. Snell-Bergeon, B. Ulmer, C. Perkins, R. Bergenstal, USA

SHORT ORAL
DISCUSSIONS

191 Impact of continuous glucose monitoring use on glycated haemoglobin (HbA_{1c}) in people with type 2 diabetes: real-world analysis

R. M. Bergenstal, I. B. Hirsch, E. Repetto, J. Snell-Bergeon, B. Ulmer, C. Perkins, S. K. Garg, USA

PRESENTER
INDEX

SATELLITE
SYMPOSIA

192 Time above range and not time below range is associated with mortality in older patients with type 2 diabetes: results from the HYPOAGE study

S. Smati, A.-S. Boureau, B. Guyomarch, I. Allix, C. Annweiler, N. Cervantes, I. Delabrière, P. Gourdy, S. Guyonnet, R. Litke, M. Paccalin, A. Penforinis, P.-J. Saulnier, S. Hadjadj, B. Cariou, France

INDUSTRY

PROGRAMME

EXHIBITION

15:30 - 17:00

Vienna Hall

OP 33 Emerging science in diabetic kidney disease from fasting to autophagy

193 Study of the A_{2b} adenosine receptor in profibrotic activation of glomerular parietal epithelial cells in experimental diabetes

C. Jara, D. Moscol, P. D. Sastre, A. Torres-Arevalo, I. Arias, C. Cappelli, R. San Martin, Chile

194 WWP2-induced pericytes to myofibroblast transition contributes to the progression of fibrosis in CKD in diabetes

F. Conserva, A. Cicirelli, G. Sclavo, M. Venneri, R. Franzin, A. Stasi, E. Squicciarro, A. Gallone, M. Fiorentino, F. Pesce, L. Gesualdo, P. Pontrelli, Italy

195 Mechanisms of PERK/ATF4 axis-targeted ATG4B autophagy signalling pathway in promoting diabetic kidney disease

Q. Huang, X. Fei, J. Gong, Y. Chen, X. Wu, China

196 Renal gluconeogenesis maintains body fluids during fasting

K. Kaneko, M. Yamato, H. Katagiri, Japan

197 Is NOX5 potentially a better therapeutic target than NOX4 in renal complications of diabetes?

J. Jha, S. L-Trevino, A. Dai, J. Vincent, J. Meister, M. E. Cooper, K. Jandeleit-Dahm, Australia, Switzerland, Germany

198 Does the expression of glucagon-like peptide-1 receptor on bone marrow derived cells influence the onset and progression of diabetic kidney disease?

K. C. Sourris, C. Bertuzzo Veiga, P. Kantharidis, C. J. Rosado, M. Bose, A. Dimitropoulos, Y. Xu, Y. Zhang, M. T. Coughlan, M. Aziz, P. Morgan, D. J. Drucker, A. J. Murphy, K. A. Jandeleit-Dahm, M. E. Cooper, Australia, Canada

15:30 - 17:00

Sydney Hall

OP 34 [B]reaking [F]at

199 Metabolic remodelling in adipose tissue: insights from Roux-en-Y gastric bypass surgery on fructose production

A. Reis-Costa, P. Katsogiannos, M. Pereira, J. Jones, J. Eriksson, Portugal, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

200 Exercise training regulates long noncoding RNAs expression in subcutaneous WAT of obese participants

P. Nigro, T. Caputo, L. K. Simpson, M. M. Columbus, J. Ding, M. F. Hirshman, R. J. Middelbeek, L. J. Goodyear, USA

201 Multi-omics analysis of human brown fat reveals novel candidates for the thermogenic activation of adipose tissue

M. Balaz, L. Petriskova, D. Olesova, A. Ghosh, A. Kvasnicka, N. Palesova, P. Stefanicka, L. Varga, A. Jancovicova, P. Makovicky, D. Dobesova, D. Friedecky, C. Wolfrum, L. Balazova, Slovakia, Switzerland, Czech Republic

EASD
EFSD

GENERAL
INFO

202 A multi-omics approach to understand the underlying mechanisms of obesity

J. Niu, C. Gieger, A. Peters, S. Sharma, H. Grallert, Germany

203 HOOK1: A potential novel target gene for obesity?

S. I. Svensson, S. Saeed, T. Valderhaug, M. Dahl, B. Bai, A. Cayir, T. Rønningen, Y. Böttcher, Norway

204 Differences in adipose tissue-, liver- and jejunal gene expression between obese patients with and without glomerular hyperfiltration

S. T. Jagroep, M. Koning, V. E. Gerdes, M. Nieuwdorp, A. S. Meijnikman, D. H. Van Raalte, Netherlands

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

15:30 - 17:00

Sofia Hall

OP 35 Insulin: ready, steady, go!

205 P21-activated kinase: a novel regulator of the FGF1/PDE4D anti-lipolytic pathway and insulin resistance

J. Seigner, J. Krier, D. Spähn, J. L. Nono, R. Lukowski, A. L. Birkenfeld, G. Sancar, Germany

206 Investigating insulin-lowering mechanisms of SGLT2-inhibition in individuals with postbariatric hypoglycaemia

E. Faggionato, D. Herzig, C. Dalla Man, L. Bally, M. Schiavon, Italy, Switzerland

207 Insulin-degrading enzyme couples glucagon and insulin-mediated regulation of mitochondrial dynamics in hepatocytes

P. Cámara-Torres, S. Hernández de la Red, B. Merino, J. Santo-Domingo, M. De la Fuente, A. Alonso, I. Cózar-Castellano, G. Perdomo, Spain

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

208 Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes

S. Mäkinen, S. Sree, T. Ala-Nisula, H. Kultalahti, P. Koivunen, H. A. Koistinen, Finland

209 Characterisation of new tissue-specific insulin resistance clusters in persons with and without diabetes and their relationship to comorbidities

K. B. Bódis, K. Prystupa, O. P. Zaharia, M. Schön, V. Schrauwen-Hinderling, G. J. Bönhof, H. J. Hauner, S. Meyhöfer, A. L. Birkenfeld, A. F. Pfeiffer, M. Blüher, S. R. Bornstein, J. Szendródi, M. Roden, R. Wagner, Germany

210 The gut epithelium-specific mTORC1 activation improves glucose metabolism selectively in male mice

R. Kawahara, Y. Fujita, T. Yanagimachi, S. Kusui, S. Ida, N. Ohashi, K. Murata, K. Morino, S. Kume, Japan

15:30 - 17:00

Cairo Hall

OP 36 Inside information on beta cell regulation

211 Structure, interaction, and nervous connectivity of beta cell primary cilia

A. Mueller, N. Klena, S. Pang, L. Galicia Garcia, O. Topcheva, S. Aurrecochea Duran, H. Mziaut, J. Weitz, M. Distler, T. Kurth, D. Schmidt, H. F. Hess, C. Xu, G. Pigino, M. Solimena, Germany, Italy, USA

212 Somatostatin secretion at synapse like structures triggers primary cilia signalling to modulate beta cell function

C. Incedal Nilsson, O. Dumral, B. Xie, A. Müller, G. Sanchez, M. Solimena, H. Ren, O. Idevall Hagen, Sweden, China, Germany

213 Primary cilia regulate GLP-1 signalling in pancreatic beta cells

I. Melena, L. Zhu, J. Cho, S. Adamson, J. Hughes, USA

214 GPR180 receptor controls insulin production and secretion

M. Antal, P. Makovicky, T. Dahlby, C. Wolfrum, M. Balaz, L. Balazova, Slovakia, Switzerland

215 The type 2 diabetes-associated K⁺channel TALK-2 reduces beta cell endoplasmic reticulum Ca²⁺ stores and cytosolic Ca²⁺ entry, which limit insulin secretion

J. R. Dobson, P. K. Dadi, A. Y. Nakhe, D. A. Jacobson, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

216 Mitochondrial fission process 1 regulates glucose stimulated insulin secretion in pancreatic beta cells

S. Sarwat, C. Zhang, R. M. Alonso, A. Mihalovits, M. Yang, G. Rutter, T. A. Rodriguez, A. Martinez-Sanchez, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Diabetes Prize for Excellence Lecture

The Diabetes Prize for Excellence recognises outstanding achievements in research which has led to significant advances in the understanding, prevention or treatment of diabetes or its complications.

Chair: Chantal Mathieu, Belgium

Speaker: Juleen R. Zierath, Sweden:

Deconvoluting signals and metabolic rhythmicity of insulin- and exercise-action in type 2 diabetes

Juleen R. Zierath is Professor of Clinical Integrative Physiology at Karolinska Institutet, Stockholm, and Professor and Executive Director at the Novo Nordisk Foundation Center for Basic Metabolic Research at University of Copenhagen.

She is a member of the Nobel Assembly for Physiology or Medicine, the Royal Swedish Academy of Sciences, EMBO, Academia Europaea and the Keystone Symposia Board of Directors.

Prof. Zierath performs translational research to delineate mechanisms for type 2 diabetes pathogenesis. Her current work is focused on the interaction between circadian rhythms and exercise training and the control of metabolism in diabetes and obesity.



EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:30 - 18:30

London Hall

The promise of GIP and GIPR antagonism: bridging the gap

Chair: TBA

Speaker: TBA

EASD
EFSD

17:30 - 18:30

Berlin Hall

The use of Automated Insulin delivery (AID) around physical activity and exercise in type 1 diabetes: a position statement of the EASD and ISPAD

Chair: TBA

Speaker: TBA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

17:30 - 18:30

Vienna Hall

Diabetes and cancer: connecting the dots

Chair: Bendix Carstensen, Denmark

Speaker: Cathy J. Bradley, USA:

Access to state of the art cancer services: Is diabetes a barrier?

Magdalena Taube, Sweden:

Metabolic surgery and cancer

Simon Lord, UK:

Is there a role for metformin in cancer prevention and therapy?

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

17:30 - 18:30

Sydney Hall

EASD/EASO Symposium: Obesity and diabetes: the intertwined syndemic

Chairs: Christine Andreasen, Denmark; Volkan D. Yumuk, Turkey

Speaker: Gema Frühbeck, Spain:
Obesity, an adiposity based chronic disease: clinical implications for diabetes treatment

Luca Busetto, Italy:
The difficulties in obesity definition in terms of anthropometric measures

Mikael Rydén, Sweden:
Management of obesity in people with pre-diabetes to prevent type 2 diabetes

17:30 - 18:30

Sofia Hall

EASD Early Career Academy Symposium: ERC funding

Chair: Jan Gojda, Czech Republic

Speaker: Fiona Kernan, Belgium:
Annual work programme of ERC funding

Emma Börgeson, Denmark:
How to get your Starting Grant in life science

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Insulin secretion in type 1 diabetes

Chair: James A.M. Shaw, UK

Speaker: Tiinamaija Tuomi, Finland:
Residual insulin secretion in individuals with type 1 diabetes

Sarah J. Richardson, UK:
Pancreatic pathology in type 1 diabetes

Malin Flodstrom Tullberg, Sweden:
Impact of coxsackievirus on insulin secretion

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION



09:00 - 10:00

Madrid Hall

TBA

Chair: TBA

Speaker: TBA

EASD
EFSD

09:00 - 10:00

London Hall

Prospective study to evaluate individual effects on the relationship of glucose and HBA_{1c}: design, results, and clinical implications

Chair: TBA

Speaker: TBA

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

09:00 - 10:00

Berlin Hall

From monogenic to oligogenic forms of diabetes: a continuum?

Chair: TBA

Speaker: TBA

SHORT ORAL
DISCUSSIONS

09:00 - 10:00

Vienna Hall

The sky is the limit

Chairs: Chantal Mathieu, Belgium; Christian Collin, Denmark

Speaker: Bruce King, Australia:

Pilots and passengers: the ups and downs

David Russell-Jones, UK:

Flying with diabetes

Julia K. Mader, Austria:

Diabetes technology in aviation

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

09:00 - 10:00

Sydney Hall

Shift from proliferative diabetic retinopathy to early intervention of diabetic eye disease

Chair: Cristina Hernandez, Spain

Speaker: Rafael Simo, Spain:

Neurons at the origin of diabetic retinal disease

Sobha Sivaprasad, UK:

Emerging strategies for early intervention for diabetic retinopathy

EASD
EFSD

GENERAL
INFO

09:00 - 10:00

Sofia Hall

Generation of pancreatic islets from stem cells

Chair: Françoise Carlotti, Netherlands

Speaker: Raphael Scharfmann, France:

Lessons learned from embryonic islet formation

Valeria Sordi, Italy:

Generation of stem-cell derived islets from pluripotent stem cells

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EASD Early Career Academy Symposium: From Rising Star to Principal Investigator

Chair: Simon Dreher, Germany

Speaker: Ruben Nogueiras, Spain:

Role of p53 family members on hepatic steatosis and insulin sensitivity

Niina Sandholm, Finland:

Dissection of genetic background of diabetic nephropathy in subjects with type 1 diabetes

Hanieh Yaghootkar, UK:

Using human genetics to understand the underlying mechanisms that protect some obese people from type 2 diabetes

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

10:30 - 11:30

Madrid Hall

OP 37 Protection in islet transplantation

217 Islet transplantation vs insulin alone in patients with type 1 diabetes and a kidney transplant: a French nationwide study on behalf of the Trepid group

M. Maanaoui, R. Lenain, Y. Foucher, F. Buron, S. Lablanche, G. Blanco, S. Caillard, L. Kessler, A. Brodin-sartorius, M. Chetboun, J. Kerr-conte, T. Berney, M.-C. Vantyghem, M. Hazzan, F. Pattou, France

218 Effect of islet transplantation on the incidence of diabetic complications and mortality in patients with unstable type 1 diabetes

Q. Perrier, C. Jambon-Barbara, L. Kessler, O. Villard, F. Burron, F. Pattou, B. Guerci, M. Roustit, E. Berishvili, L. Rakotoarisoa, M.-C. Vantyghem, E. Renard, T. Berney, P.-Y. Benhamou, S. Lablanche, France, Switzerland

219 Ado12, a non-fibrotic immunoprotective hydrogel containing human islets shows efficient and sustained in vivo functionality for clinical use

A.-L. Gaffuri, X. Gaume, J. Brun, R. Besnard, C. Gautier, O. Jouannot, N. Laurent, R. Eloy, K. Bouzakri, O. Soula, France, USA

220 Functional islet transplantation into immunocompetent diabetic animals using hydrogel encapsulation without the need for immunosuppression

H. Stöver, Canada

10:30 - 11:30

London Hall

OP 38 New insights into CNS regulation of energy and glucose metabolism

221 Effects of activation of peripheral sympathetic nerve on glycaemic control in standard chow- and high-fat-fed rats

D. Sato, L. Miyamoto, R. Banno, M. Kusunoki, Japan

222 Genetic dissection of serum pro-neurotensin implicates its causal effects on brain structure

J. Breitfeld, K. Horn, V. Witte, F. Beyer, A. Velluva, J. Pott, D. LeDuc, R. Baber, M. Stumvoll, O. Melander, P. Kovacs, M. Scholz, A. Tönjes, Germany, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

223 Characterising central cell types accessed by peripherally-administered incretin receptor analogues

A. Roberts, C. Blouet, J. Broichhagen, D. Hodson, A. Adriaenssens, UK, Germany

224 fNIRS demonstrates over activation of the dorsolateral prefrontal cortex following OGTT in youths with obesity and reduced insulin sensitivity

M. Manco, G. Scozia, A. Aureli, D. Menghini, D. Fintini, S. Lasaponara, Italy

EASD
EFSD

GENERAL
INFO

10:30 - 11:30

Berlin Hall

OP 39 Novel insights in monogenic diabetes

225 MODY is polygenic as well as monogenic! Polygenic background strongly contributes to genetically confirmed MODY and clinical cases without a monogenic cause

J. Murray Leech, A. M. Arni, K. Chundru, R. N. Beaumont, K. Colclough, A. R. Wood, A. T. Hattersley, M. N. Weedon, K. A. Patel, UK

226 A specific de novo ACTB variant is a novel cause of syndromic neonatal diabetes

S. Ahmed, V. Lewis, J. Russ-Silby, M. N. Wakeling, A. T. Hattersley, K. Patel, S. E. Flanagan, E. De Franco, UK

227 Last exon truncating variants in INS and PDX1 cause MODY whereas heterozygous WFS1 variants do not cause MODY

A. Sriram, M. Wakeling, K. Colclough, A. Hattersley, M. N. Weedon, T. W. Laver, K. Patel, UK

228 Impact of SGLT2 inhibition on glucosuria in MODY3

H. Maagensen, J. S. Jensen, S. O. Høyerup, A. C. Thuesen, J. Krogh, P. Rossing, T. Hansen, F. K. Knop, S. Hædersdal, T. Vilsbøll, Denmark

10:30 - 11:30

Vienna Hall

OP 40 Around liver fat: the fight is on

229 Tirzepatide for treatment of metabolic dysfunction-associated steatohepatitis: relationship between metabolic and histological responses

C. Caussy, M. L. Hartman, M. K. Thomas, K. J. Mather, Y. Tang, R. Loomba, A. J. Sanyal, France, USA

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

230 Hepatic glucose production is increased in MASH with significant fibrosis even in absence of diabetes

S. Sabatini, P. Sen, F. Carli, S. Pezzica, E. Lembo, C. Rosso, A. Daly, S. Cockel, O. Govaere, T. Hyötyläinen, G. Mingrone, E. Bugianesi, Q. M. Anstee, M. Orešič, A. Gastaldelli, Italy, Finland, UK, Sweden

231 The hepatoprotective HSD17B13 splice variant rs72613567:TA suggests enhanced lactate clearance

D. M. Mendez Cardenas, K. Bodis, M. Bombrich, K. Prystupa, I. Yurchenko, M. Schön, O. Zaharia, D. Pesta, M. Heni, Y. Kupriyanova, V. Schrauwen-Hinderling, H. Al-Hasani, M. Roden, B. Knebel, R. Wagner, Germany

232 Genetically determined circulating metabolite levels and risk of metabolic dysfunction-associated steatotic liver disease (MASLD): a mendelian randomisation study

K. Deng, A. V. Vlieg, F. R. Rosendaal, D. O. Mook-Kanamori, K. Willems van Dijk, R. Li-Gao, Netherlands

10:30 - 11:30

Sydney Hall

OP 41 Turning back the biological clock - or merely slowing it?

233 Oral insulin delay of stage 3 type 1 diabetes revisited in HLA DR4-DQ8 participants in the TrialNet oral insulin prevention trial (TN-07)

L. Zhao, G. K. Papadopoulos, J. S. Skyler, D. Geraghty, H. Parikh, B. Kwok, A. Lernmark, USA, Greece, Sweden

234 C-peptide persistence is associated with lower HbA_{1c}, higher time in range and low rates of hypoglycaemia in adults with type 1 diabetes

F. W. Gibb, A. R. Dover, M. S. Jeeyavudeen, R. Wright, S. Forbes, M. J. Lyall, R. H. Stimson, M. W. Strachan, UK

235 Digital delivery of type 2 diabetes remission programme in the UK: clinically significant weight loss and improved glycaemic control

D. H. Laursen, S. B. Bendtsen, S. Johnson, C. Brandt, E. Heath, Denmark, UK

236 Predictive factors for type 2 diabetes remission: insights from a digital twin intervention programme at 18 months

P. Shamanna, M. Dharmalingam, A. Vadavi, A. Keshavamurthy, S. Bhonsley, M. Thajudeen, A. Balasubramanian, S. Joshi, India

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

10:30 - 11:30

Sofia Hall

OP 42 New factors in the control of glucose tolerance

237 Exploring the roles of carbonic anhydrase VIII in hepatic glucose production and its potential for diabetes treatment

M. Fauzi, T. Murakami, R. Usui, D. Otani, K. Sakaki, S. Tokumoto, M. Ogura, N. Inagaki, D. Yabe, Japan

EASD
EFSD

238 Glucose-lowering by colesevelam in type 2 diabetes is related to a reduction in circulating serotonin

C. Xiang, C. Xie, W. Huang, K. Jones, M. Horowitz, C. Rayner, T. Wu, China, Australia

GENERAL
INFO

PROGRAMME

TUESDAY

239 Genetic deletion of hyaluronan receptor RHAMM improves glucose tolerance and cardiac performance in vivo

A. K. Banah, X. Weng, C. Murdoch, L. Kang, UK

WEDNESDAY

THURSDAY

240 Circulating Netrin-4 levels and influencing factors in women with PCOS and the role of anti-insulin resistance therapy

S. Xue, L. Li, China

FRIDAY

10:30 - 11:30

Cairo Hall

LBA OP 6 TBA

Late breaking abstracts

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Double jeopardy: Could SGLT2 inhibitors and/or GLP1RAs improve glycaemic outcomes and QoL in type 1 diabetes?

Chair: Tomasz Klupa, Poland

Speaker: Bruce A. Perkins, Canada:

Yes: benefits overcome risks

Martin Haluzik, Czech Republic:

No: risks overcome benefits

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

12:00 - 13:00

Madrid Hall

OP 43 Treating type 1 diabetes: What else does the future hold?

241 A novel small-molecule activator of Lyn kinase for the treatment of type 1 diabetes

H. Huang, Q. Wang, J. Buteau, Canada

EASD
EFSD

242 ILC3 stimulation by a novel FFAR2 agonist ameliorates type 1 diabetes in C57BL/6 mice

I. Koprivica, N. Jonić, N. Radulović, I. Pilipović, D. Mićanović, T. Saksida, B. Jevtić, G. L. Fraser, D. Miljković, I. Stojanović, Belgium

GENERAL
INFO

243 Efficacy of semaglutide and tirzepatide by insulin delivery in overweight and obese adults with type 1 diabetes

J. Snell-Bergeon, F. Dong, G. Kaur, D. Renner, H. Akturk, S. Garg, USA

PROGRAMME

TUESDAY

244 Dapagliflozin reduces endogenous glucose production during a period of acute insulin deprivation and development of ketoacidosis in people with type 1 diabetes

E. Svehlikova, W. Regittnig, C. Gatschelhofer, V. Höller, G. Fluhr, B. Lackner, C. Magnes, A. Eberl, T. R. Pieber, Austria

WEDNESDAY

THURSDAY

FRIDAY

12:00 - 13:00

London Hall

OP 44 The unforgettable alpha cells

245 Patch-seq reveals alpha cell electrical dysfunction linked to alterations in identity, paracrine signalling, metabolism, immune response, and mTOR activity in type 1 diabetes

T. Dos Santos, X. Q. Dai, C. Ellis, A. Bautista, R. C. Jones, J. Camuñas-Soler, S. Quake, P. E. MacDonald, Canada, USA, Sweden

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

246 Glucagon induced CREB-dependent delta cell hyperactivity underlies impaired glucagon secretion in recurrent hypoglycaemia

R. Gao, S. Acreman, J. Ma, P. Rorsman, Q. Zhang, UK, Sweden, Portugal

247 The effect of obesity on the alpha cell response to amino acids in the presence of hyperglycaemia

S. Mohan, F. Boscolo, H. Christie, A. Egan, M. Laurenti, C. Dalla Man, A. Vella, USA, Italy

248 The glucagon-like peptide-1 receptor antagonist, exendin (9-39) amide, improves the impaired glucagon response to hypoglycaemia in the non-obese diabetic mouse model of type 1 diabetes

T. G. Hill, A. Clark, C. Miranda, P. Rorsman, UK, Sweden

12:00 - 13:00

Berlin Hall

OP 45 How smart an insulin pen can be?

249 Improvement in time in range after smart insulin pen initiation in Austria

J. K. Mader, N. V. Hartvig, A. Kaas, N. N. Knudsen, Y. Winhofer, Austria, Denmark

250 Real world results from the first 845 European InPen smart MDI system users: behaviour has a substantial effect on outcomes

F. Di Piazza, B. Voelker, S. Edd, A. Arrieta, T. Van den Heuvel, J. Castaneda, O. Cohen, J. Shin, Switzerland

251 Multinational analysis of factors associated with missed bolus insulin injections using smart pen data

F. J. Ampudia-Blasco, M. L. Jensen, A. Kaas, N. N. Knudsen, R. Nishimura, Spain, Denmark, Japan

252 Enabling continuous glucose monitoring users with multi-horizon glucose predictive capabilities: the Accu-Chek®SmartGuidePredict App

P. Herrero, M. Andorrà, N. Babion, H. Bos, M. Koehler, Y. Klopfenstein, P. Lustenberger, A. Peak, C. Ringemann, T. Glatzer, Spain, Germany, Netherlands, Switzerland

12:00 - 13:00

Vienna Hall

OP 46 Pregnancy: taking care of the future

253 Placental expression of glucose transporters mRNA (GLUT-1, GLUT-3 and GLUT-4) and transcriptome profiling with microarrays in pregnant patients with diabetes

R. Sibiak, P. Gutaj, U. Mantaj, L. Adamczak, M. Blatkiewicz, M. Rucinski, E. Wender-Ozegowska, Poland

254 Impact of gestational diabetes on infant fat and fat-free mass: findings from a prospective cohort study (PEAPOD)

P. Saravanan, N. Periyathambi, Y. Weldeselassie, S. Pandya, C. Bagias, N. Sukumar, UK,

255 Myoinositol modulates endothelial extracellular vesicles release in gestational diabetes

M. Baldassarre, F. Carrieri, P. Di Tomo, N. Di Pietrantonio, D. De Bellis, P. Lanuti, A. Pandolfi, A. Consoli, G. Formoso, Italy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

256 Maternal HbA_{1c} and BMI and risk of congenital malformations in type 1 diabetes: a cohort study

I. H. Thorius, J. Petersen, L. N. Husemoen, A. N. Alibegovic, M.-A. Gall, P. Damm, E. Mathiesen, Denmark

12:00 - 13:00

Sydney Hall

EASD
EFSD

OP 47 Inflammatory mechanisms regulating systems metabolism

GENERAL
INFO

257 Soluble CD52 suppresses hepatic chronic inflammation in obese mice

T. Wada, Y. Miyazawa, Y. Onogi, H. Tsuneki, T. Sasaoka, Japan

PROGRAMME

258 Integrating immune-inflammatory profile to define endotypes of type 2 diabetes

TUESDAY

B. T. Vuong, J. B. Julla, M. Diedisheim, C. Bleriot, F. Alzaid, C. Potier, K. Khider, A. Bonnefond, L. Potier, F. Ginhoux, J. F. Gautier, N. Venteclef, France

WEDNESDAY

THURSDAY

259 The RAGE antagonist Azeliragon prevents adiposity and metaflammation in diet-induced obese mice

R. Mastrocola, E. Porcietto, P. I. Rivas Navarrete, J. L. Scheijen, E. Aimaretti, C. Ceccopieri, M. Aragno, C. Cifani, C. Schalkwijk, M. Collino, Italy, Netherlands, Poland

FRIDAY

SHORT ORAL
DISCUSSIONS

260 Vildagliptin: the good guy in improving pancreatic beta cell function by lowering pro-inflammatory macrophage accumulation and polarisation

S. Nag, S. Mandal, O. Mukherjee, R. Kundu, India

PRESENTER
INDEX

SATELLITE
SYMPOSIA

12:00 - 13:00

Sofia Hall

INDUSTRY

OP 48 Managing diabetic foot disease: clinical studies and omics predictors

PROGRAMME

261 A single centre, randomised controlled trial on the efficacy of regenerating tissue agents technology in diabetic foot ulcers

G. Samakidou, I. Eelftheriadou, I. A. Anastasiou, O. Kosta, A. Tentolouris, K. Evangelou, N. Tentolouris, Greece

EXHIBITION

262 Elevated triglyceride levels correlate with a unique swap and plasma biomarker profile in diabetic foot ulcers

M. Petkovic, J. A. Raguz, A. Rasmussen, K. K. Møller, R. R. Christensen, H. Jenssen, J. A. Andersen, T. R. Suviavaara, C. Legido-Quigley, T. Kümler, P. Rossing, A. Veves, L. T. Dalgaard, T. S. Ahluwalia, Denmark, USA

263 Novel proteomic markers of diabetic foot ulcer healing time

T. S. Ahluwalia, S. Jain, M. Petkovic, J. A. Raguz, G. Kaur, R. R. Jersie-Christensen, K. Kirketerp-Møller, J. A. Andersen, A. Veves, A. Rasmussen, L. T. Dalgaard, P. Rossing, Denmark, USA

264 Care pathway and risk of amputation after diabetic foot ulcer: data from the French national claim data (SNDS)

J.-B. Bonnet, C. Duflos, H. Huguet, S. Tournayre, A. Avignon, A. Sultan, France

12:00 - 13:00

Cairo Hall

LBA OP 7 TBA

Late breaking abstracts

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION



Type 1 diabetes and kidney failure: additional donor pancreas or islet transplantation should be the standard treatment of hyperglycaemia

Chair: Lorenzo Piemonti, Italy

Speaker: Thierry Berney, France:
Pro

Anne Wojtusciszyn, Switzerland:
Con

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

13:30 - 15:00

Madrid Hall

Metabolic medicine 2030: What the future will bring

Chair: Matthias H. Tschöp, Germany

Speaker: Anette-Gabriele Ziegler, Germany:
The future of type 1 diabetes therapy

David A. D'Alessio, USA:
The future of type 2 diabetes therapy

Matthias Blüher, Germany:
The future of obesity therapy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

13:30 - 15:00

London Hall

Can we receive consensus on how glucagon secretion is regulated?

Chair: Anders Tengholm, Sweden

Speaker: Patrik Rorsman, UK:
The KATP-channel and glucagon secretion

Jakob G. Knudsen, Denmark:
Fatty acids as regulator of glucagon secretion

Danielle Dean, USA:
Amino acids as regulators of glucagon secretion

13:30 - 15:00

Berlin Hall

Diabetologia Symposium: Diabetes Technology: a lifelong companion

Chair: Anna Krook, Sweden

Speaker: Helen R. Murphy, UK:
Benefits, barriers and pitfalls of diabetes technology use in pregnancy

Marc D. Breton, USA:
Use of technology in children with type 1 diabetes

Alan J. Sinclair, UK:
The use of diabetes in technology in older people

Hood Thabit, UK:
Technology use in hospitalised inpatients

Partha Kar, UK; Chantal Mathieu, Belgium:
Panel discussion

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

13:30 - 15:00

Vienna Hall

Heterogeneity of type 2 diabetes: Will seeing type 2 diabetes in HD...

Chair: Shivani Misra, UK

Speaker: John Dennis, UK:
... help choose the best treatment?

Tuomas O. Kilpeläinen, Denmark:
... improve diabetes prevention efficacy?

Emma Ahlqvist, Sweden:
... be the obvious way to see it?

13:30 - 15:00

Sydney Hall

Metabolic disease and mental illness

Chair: TBA

Speaker: TBA

EASD
EFSD

13:30 - 15:00

Sofia Hall

Targeting obesity to treat heart failure: dawn of a new era

Chair: TBA

Speaker: TBA

GENERAL
INFO

PROGRAMME

TUESDAY

13:30 - 15:00

Cairo Hall

EASD/ADA/ISPAD Symposium: Consensus report: Transition from paediatric to adult diabetes care

Chair: TBA

Speaker: TBA

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 001 Genetic insights into type 2 diabetes: from risk variants to personalized treatment strategies

265 The diabetes-associated genetic variants rs111669836 and rs17791513 modulate the incretin effect in individuals with normal glucose tolerance

D. S. Mathiesen, A. Lund, A. E. Junker, L. L. Gluud, T. Idorn, M. Hornum, A. Jonsson, T. Hansen, J. L. Forman, J. J. Holst, T. Vilsbøll, J. I. Bagger, F. K. Knop, Denmark

EASD
EFSD

266 Combining next-generation sequencing and metabolic phenotyping to elucidate reduced mitochondrial respiration in type 2 diabetes

M. Schön, D. Oehler, I. Yurchenko, A. Lang, N. Trinks, C. Granata, O. Zaharia, L. Mastrototaro, B. Dewidar, K. Bódis, R. Westenfeld, V. Burkart, R. Wagner, M. Roden, J. Szendroedi, Germany

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

267 Effect of fetal alpha-ketoglutarate dependent dioxygenase (FTO) gene obesity risk variant on maternal postload glucose levels at OGTT during pregnancy

G. Firneisz, Á. Nádasdi, B. A. Nemes, L. Németh, K. Rosta, J. Harreiter, A. Kautzky-Willer, A. Somogyi, Z. Benyó, Hungary, Austria

SHORT ORAL
DISCUSSIONS

268 Multiple genetic factors: the key to detect early type 2 diabetes

L. Alonso, M. A. Pérez, C. Salvaro, L. Ruiz, J. L. Berral, J. R. González, I. Morán, D. Torrents, Spain

PRESENTER
INDEX

269 Genetic susceptibility to beta cell dysfunction and adipose tissue mediated insulin resistance modifies the benefit of physical activity on type 2 diabetes

X. Zhou, G. D. Carrasquilla, M. R. Christiansen, R. A. Smit, R. J. Loos, T. O. Kilpeläinen, J. Merino, Denmark

SATELLITE
SYMPOSIA

270 Dissecting the causal association between spleen iron concentration and type 2 diabetes using mendelian randomisation

M. A. Abdalla, M. AbuFarha, J. Abubaker, M. Abdulghani, F. Almulla, Kuwait, UK, USA

INDUSTRY

PROGRAMME

271 Genome-wide association analysis of age of diabetes diagnosis in Hong Kong Chinese

B. Fan, C. H. Tam, M. Shi, C. K. Lim, C. O. H. Wu, E. Y. Chow, A. P. Kong, R. C. Ma, A. O. Luk, J. C. Chan, China

EXHIBITION

272 Genetic markers of response to treatment of type 2 diabetes with novel antihyperglycaemic drugs: prospective interventional genetic association study

G. Tonin, V. Dolžan, J. Klen, Slovenia

Short Oral Event B

Tuesday, 13:45 - 14:45

EASD
EFSD

SO 002 Epigenetics and gestational diabetes: from maternal health to newborn outcomes

GENERAL
INFO

273 Insulin levels in pregnant women with obesity are associated with higher abdominal fat deposition in newborns and with DNA methylation in cord blood

A. Maguolo, J. Jönsson, A. Perfilyev, A. Vaag, E. Malchau Carlsen, K. Nørgaard, P. W. Franks, K. Renault, C. Ling, Sweden, Italy, Denmark

PROGRAMME

TUESDAY

274 Investigating DNA methylation of metabolic and inflammatory genes with therapeutic potential for obesity: a cohort study in south African women

A. Shaik, F. Essop, C. Pheiffer, T. Willmer, South Africa

WEDNESDAY

THURSDAY

FRIDAY

275 Risk of gestational diabetes and neonatal outcomes in migrants: a retrospective cohort study

F. Citro, N. Placenza, M. Aragona, L. Battini, P. Marchetti, C. Bianchi, A. Bertolotto, Italy

SHORT ORAL
DISCUSSIONS

276 Identification of epigenetic marks shared between mothers with gestational diabetes and their offspring, and their association with newborn anthropometric variables

T. Linares-Pineda, N. Peña-Montero, A. Piserra, M. Estébanez Prieto, M. Suárez-Arana, M. Molina Vega, M. Picón César, S. Morcillo Espina, Spain

PRESENTER
INDEX

SATELLITE
SYMPOSIA

277 Epigenome-wide association study identifies a specific panel of DNA methylation signatures associated with gestational diabetes

C. Thirumorthy, S. Kuldeep, M. Deepa, P. Nikhil, S. Sharma, G. Ball, H. Grallert, U. Ram, R. Anjana, M. Balasubramanyam, V. Mohan, P. Saravanan, G. Kuppan, India, Germany, UK

INDUSTRY

PROGRAMME

EXHIBITION

278 Exploration of epigenetic loci in individuals with and without diabetes from Northern Ireland

L. J. Smyth, Y. Gupta, C. Hill, A. Deb, K. Quinn, J. Kilner, G. McKay, A. Maxwell, A. McKnight, GENIE Consortium, NICOLA collaborative team, UK

279 First-trimester DNA methylome profiling identifies novel predictors of gestational diabetes in Indian women

K. Gokulakrishnan, C. Thirumoorthy, M. Deepa, S. Kuldeep, U. Venkatesh, B. N. Srikumar, V. Radha, S. Sapna, B. Graham, U. Ram, R. M. Anjana, M. Balasubramanyam, V. Mohan, N. Tandon, P. Saravanan, India, UK

280 Identifying novel predictors of gestational diabetes in early pregnancy through DNA methylome profiling and artificial neural networks

S. Sharma, G. Ball, T. Chinnasamy, M. Deepa, K. Sharma, P. Nikhil, H. Grallert, U. Ram, R. Anjana, M. Balasubramanyam, V. Mohan, P. Saravanan, G. Kuppan, Germany, UK, India

Short Oral Event C

Wednesday, 12:45 - 13:45

SO 003 The many facets of weight and type 2 diabetes risk

281 Obesity measures and risk of diabetes, early-onset diabetes: insights from a large cohort study

W. Zheng, L. He, K. Qiu, W. Zhang, Q. Liu, Y. Ren, W. Kong, T. Zeng, China

282 Is weight reduction associated with a lower risk of diabetes in middle-aged non-diabetic overweight people who gained 10 kg or more weight from age 20? A population-based cohort study of Japanese

M. Noguchi, A. Oyama, H. Iso, Japan

283 Associations between chronotype waist circumference, visceral fat, liver fat, and incidence of type 2 diabetes

J. H. Van der Velde, F. Rutters, F. R. Rosendaal, H. J. Lamb, A. Kalsbeek, R. De Mutsert, Netherlands

284 Dissociation of static and dynamic associations of liver fat content and visceral fat mass with insulin resistance and type 2 diabetes risk

V. Minelli Faiao, A. Sandforth, M. Ganslmeier, L. Sandforth, S. Katzenstein, C. Dannecker, A. Vosseler, A. Fritsche, A. Peter, J. Machann, F. Schick, H. Preissl, N. Stefan, A. Birkenfeld, R. Jumpertz-von Schwarzenberg, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

285 Birthweight and risk of chronic kidney disease after being diagnosed with type 2 diabetes

A. L. Hansen, C. F. Christiansen, C. Brøns, L. Engelhard, T. Hansen, J. S. Nielsen, P. Vestergaard, K. Højlund, N. Jessen, M. H. Olsen, H. T. Sørensen, P. Rossing, R. Thomsen, A. Vaag, Denmark, Sweden

286 Amelioration of the thrifty ('thin-fat') phenotype in Indians by socioeconomic development and a primordial micronutrient intervention: Escaping the curse?

C. S. Yajnik, R. Wagh, S. Otiv, P. C. Yajnik, R. Ladkat, D. Bhat, K. Kumaran, C. H. Fall, India, UK

287 Severe insulin resistant diabetes shows increased visceral adipose tissue volume as compared to other diabetes endotypes

O. P. Zaharia, Y. Kupriyanova, P. Bobrov, T. Mori, M. Schön, C. Möser, D. Mendez, N. Trinks, S. Trenkamp, K. Bódis, V. Schrauwen-Hinderling, R. Wagner, M. Roden, Germany

288 Lifetime healthcare costs of female obesity: modelling of England Data shows that quality of life must be included to show the cost-effectiveness of GLP-1 analogues

A. Heald, M. Stedman, M. Whyte, M. Rutter, M. Gibson, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Short Oral Event D

Wednesday, 14:00 - 15:00

SO 004 Diet, lifestyle, and metabolic health: insights into diabetes risk and prevention

289 Food consumption associated with the risk of islet autoimmunity and type 1 diabetes

S. M. Virtanen, E. J. Peltonen, L. Hakola, S. Niinistö, H.-M. Takkinen, S. Ahonen, M. Akerlund, U. Uusitalo, M. Mattila, T. E. Salo, J. Ilonen, J. Toppari, R. Veijola, M. Knip, J. Nevalainen, Finland, USA

290 The associations of plasma carotenoids and alpha-tocopherol concentrations with fasting glucose in adults in Cameroon

C. M. Mba, A. Koulman, F. K. Assah, J. C. Mbanya, N. J. Wareham, UK, Cameroon

291 Plasma metabolomics of meat intake: a Swedish population-based study

G. Arage, K. Dekkers, U. Ericson, H. Engel, S. Larsson, G. Baldanzi, K. Pertiwi, L. Lind, J. Sundström, J. Smith, G. Engström, J. Ärnlöv, M. Orho-Melander, T. Fall, S. Ahmad, Sweden

292 The role of remnant cholesterol in prediabetes exceeds low-density lipoprotein cholesterol in different metabolic states

L. He, W. Zheng, K. Qiu, W. Kong, T. Zeng, China

293 Meat intake, gut microbiota and biomarkers of cardiometabolic health in the population-based Swedish CardioPulmonary biolmage Study

S. Ahmad, U. C. Ericson, K. Dekkers, S. Sayols-Baixeras, B. Nielsen, J. Holm, U. Riserus, K. Michaëlsson, J. Sundstrom, J. Smith, G. Engström, J. Ärnlöv, T. Fall, M. Orho-Melander, S. C. Larsson, Sweden, Denmark

294 Alcohol consumption, genetic susceptibility to diabetes, and risk of LADA and type 2 diabetes: findings from a Swedish case-control study and the Norwegian HUNT study

A.-M. Lampousi, E. Ahlqvist, L. Alfredsson, J. Askling, J. Edstorp, D. Di Giuseppe, V. Grill, J. E. Löfvenborg, L. Padyukov, E. P. Sørgjerd, T. Tuomi, B. O. Åsvold, S. Carlsson, Sweden, Norway, Finland

295 The effects of Mediterranean-style diet with or without high intensity interval exercise on metabolic variables in overweight post-menopausal women: a randomised control trial

R. Churm, A. Tan, S. L. Prior, M. D. Campbell, R. Bracken, UK

296 Risk of type 2 diabetes according to patterns of lifestyle combination among middle-aged Korean men: findings based on the Korean Genome and Epidemiology Study (KoGES) cohort

H. Lim, I. Lee, Republic of Korea

Short Oral Event E

Thursday, 12:45 - 13:45

SO 005 Unraveling monogenic diabetes: from genetic variants to innovative diagnostic tools

297 Motilin and Semaphorin 4C: an exciting new blood test for MODY

A. M. Arni, G. Hawkes, L. N. Sharp, K. Colclough, A. T. Hattersley, M. N. Weedon, R. N. Beaumont, K. A. Patel, UK

298 Genetic spectrum of monogenic diabetes in Slovakia: 20 years of experience

D. Gasperikova, M. Skopkova, T. Valkovicova, Z. Dobiasova, L. Valentinova, Slovak Group for the Study of Monogenic Diabetes, J. Stanik, I. Klimes, Slovakia

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

299 A recessive HNF1A variant associated with young-onset diabetes induces beta cell dysfunction and bias towards alpha cell differentiation

I. Cherkaoui, Q. Du, C. Dion, H. Leitch, D. M. Egli, S. Misra, G. Rutter, Canada, USA, UK

300 Integrating biomarkers with clinical features improves discrimination in MODY calculator

J. Knupp, P. Cardoso, T. J. McDonald, K. Patel, A. Jones, E. R. Pearson, A. T. Hattersley, T. J. McKinley, B. Shields, UK

EASD
EFSD

GENERAL
INFO

301 Biomarker selection testing plus targeted next-generation sequencing identifies 2.0% monogenic diabetes amongst individuals with young-onset diabetes in a sub-Saharan African setting

J. C. Katte, M. Y. Dehayem, A. B. Chetcha, K. Colclough, A. T. Hattersley, T. J. McDonald, A. G. Jones, E. Sobngwi, UK, Cameroon

PROGRAMME

TUESDAY

302 Heterozygous HNF1A-MODY mice exhibit hyperglucagonemia preceding insulin secretory defects

I. Louvet, A. Acosta-Montalvo, M. Moreno-Lopez, J. Thevenet, M. Chiral, N. Delalleau, V. Gmyr, J. Kerr-Conte, F. Pattou, M. Pontoglio, C. Saponaro, A. Liston, C. Bonner, France, Belgium, UK

WEDNESDAY

THURSDAY

FRIDAY

303 Early onset diabetic phenotype and impaired beta cell maturation in two novel MIDY mouse models

M. Schmidtke, A. Harten, A.-L. Amend, G. K. Przemeck, M. Hrabě de Angelis, Germany

SHORT ORAL
DISCUSSIONS

304 MDFiNE (monogenic diabetes finder-north east): pilot of a novel digital search tool to enhance diagnostic rates for monogenic diabetes

A. Al-Sharefi, R. Haines, A. Porter, M. Houseman, V. Kumar, C. Bradshaw, A. Curry, F. Haque, S. Tee, UK

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

Short Oral Event F

Thursday, 14:00 - 15:00

PROGRAMME

SO 006 Advancements in predicting type 1 diabetes

305 Polygenic risk scores for pre-selection of children for population-based primary prevention trials and islet autoantibody screening

J. Zapardiel-Gonzalo, C. Winkler, F. Haupt, N. Friedl, K. Hatzikotoulas, A.-G. Ziegler, E. Bonifacio, Germany

EXHIBITION

306 A multi-omics integration approach does not discern endotypes in childhood type 1 diabetes

A. Petrelli, V. Codazzi, N. Baldoni, G. M. Scotti, A. Giovenzana, A. Rigamonti, G. Frontino, C. Bechi Genzano, I. Marzinotto, V. Lampasona, P. Fiorina, A. Giustina, M. Battaglia, M. Morelli, R. Bonfanti, Italy, Belgium

307 Enhancing precision of metabolic staging to predict progression to stage 3 type 1 diabetes

S. Hummel, C. Winkler, M. Köger, A. Weiß, J. Stock, F. Reinmüller, M. Kohls, P. Achenbach, E. Bonifacio, A. G. Ziegler, Fr1da Study Group, Germany

308 Discovery of multi-omics signatures in children and adolescents with recent-onset type 1 diabetes

H. Tan, T. Yue, Y. Shi, L. Pan, D. Zheng, Y. Ding, S. Luo, X. Zheng, J. Weng, China

309 Neutrophil enriched circulating miRNAs identify individuals at risk for stage 3 type 1 diabetes onset in a specific timeframe

E. Pedace, M. Toniolli, G. Grieco, D. Fignani, G. Licata, A. Berteramo, M. Bruttini, A. Mori, M. Marcovecchio, C. Mathieu, G. Sebastiani, F. Dotta, Italy, UK, Belgium

310 Continuous glucose monitoring in children with presymptomatic early stage type 1 diabetes

E. Huber, T. Singh, M. Bunk, M. J. Hebel, A. Weiß, M. Köger, J. M. Zapardiel Gonzalo, P. Achenbach, E. E. Bonifacio, A.-G. Ziegler, Germany

311 Screening children for paediatric diabetes in the UK (ELSA Study): accessing underserved communities

L. Quinn, S. M. Greenfield, A. Richter, R. Dias, P. Narendran, UK

312 Development, validation, and applicability of a miRNA-based dynamic risk score (DRS) for type 1 diabetes

A. Hardikar, M. Joglekar, W. Wong, P. S. Kunte, on behalf of the PREDICT T1D Study Group, Australia

Short Oral Event A

Tuesday, 12:30 - 13:30

SO 007 Global perspectives on type 2 diabetes: prevalence, risk factors, and predictive tools

313 Type 2 diabetes in Greenland: prevalence and risk factors

M. Harder, P. Bjerregaard, M. E. Joergensen, N. Senftleber, S. Byberg, T. Hansen, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

314 Understanding pathophysiological heterogeneity in populations before diagnosis of type 2 diabetes through multi-omics profiling

A. Hameete, K. Deng, D. O. Mook-Kanamori, F. R. Rosendaal, K. Willems van Dijk, R. De Mutsert, R. Li-Gao, Netherlands

315 The effects of baseline haemoglobin A_{1c} on diabetes incidence by low socioeconomic, immigration status, and ethnic origin

G. S. Fazli, L. Lipscombe, B. Shah, L. C. Rosella, C. Kenaszchuk, D. Thiruchelvam, F. Ali, C. Ke, G. L. Booth, Canada

EASD
EFSD

GENERAL
INFO

316 Modified cardiovascular health metrics including psychosocial stress, and incident diabetes and cardiovascular disease: a population-based cohort study

S. Han, N. Lee, Y. Choi, H. Kim, K.-W. Lee, Republic of Korea

PROGRAMME

TUESDAY

317 Prevalence and trends of diabetes in Thi-Qar, Southern Iraq

A. G. Mohammed, M. Altemimi, D. K. Al-Waeli, S. A. Alhatemy, I. H. Tahir, S. Odhaib, Iraq

WEDNESDAY

318 Bioelectrical phase angle as a marker for incident type 2 diabetes and glycaemic deterioration: results from the MONICA/KORA studies

F. Ai, M.-T. Huemer, W. Rathmann, M. Roden, J. Nano, M. Drey, A. Peters, B. Thorand, Germany

THURSDAY

FRIDAY

319 Performance of the 1h OGTT in predicting type 2 diabetes in Asians

M. H. Lee, E. Febriana, M. Lim, S. Baig, L. Shen, M. Dalakoti, N. Chew, J. Halter, F. Magkos, S.-A. Toh, Singapore, USA, Denmark

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

320 Identifying high risk adults for progression to diabetes for early intervention using Hong Kong territory-wide electronic health records and machine learning algorithm

T. Chen, A. Yang, M. Shi, S. Lau, H. Wu, C. Wong, N. Lui, C. Ma, P. Kong, O. Luk, C. Chan, Y. Chow, China

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

Short Oral Event B

Tuesday, 13:45 - 14:45

SO 008 Advances type 1 diabetes: genetic, biomarker, and machine learning approaches

321 Automatic immune phenotyping of type 1 diabetes samples from a validation study using a machine learning analysis workflow

J. Vera-Ramos, B. Prietl, V. Pfeifer, L. Herbsthofer, T. Pieber, Austria

EXHIBITION

322 Detecting pre-clinical type 1 diabetes in adults: using type 1 diabetes genetic risk to enrich for islet autoantibodies in a general population

N. Thomas, K. Gillespie, A. E. Long, A. Hill, D. Fraser, T. J. McDonald, R. Oram, UK

323 Mir-150-5p and mir-375-3p are increased in plasma of young children (<7y) with recent onset stage 3 type 1 diabetes

M. Tonioli, G. E. Grieco, S. Auddino, M. Bruttini, A. Mori, G. Licata, L. Nigi, C. Formichi, C. Mathieu, N. Morgan, G. Sebastiani, F. Dotta, Italy, Belgium, UK

324 Postprandial C-peptide in provider-diagnosed pediatric type 1 diabetes and type 2 diabetes

M. J. Redondo, K. K. Harrall, S. Bird, M. Tosur, S. Uysal, A. Siller, J. Velasquez, A. Muir, K. Vehik, T. Brusko, M. A. Atkinson, D. Dabelea, W. Hagopian, R. Oram, USA, UK

325 Reshaping the diagnostic algorithm to improve differentiation between type 1 and type 2 diabetes

M. Ganslmeier, K. Bodis, R. Wagner, M. Schön, C. Möser, A. Fritsche, A. L. Birkenfeld, M. Roden, R. Jumpertz von Schwartzberg, Germany

326 Higher circulating anti-GAD levels are associated with higher levels of C-peptide and proinsulin, and show a similar decline in a cross-sectional cohort of 444 individuals with type 1 diabetes

D. F. De Wit, C. M. Fuhri Snethlage, R. Minab, E. Rampanelli, P. De Groen, D. Van Raalte, C. B. Verchere, M. Nieuwdorp, N. M. Hanssen, Netherlands, Canada

327 Smoking, GAD65 autoimmunity and risk of adult-onset diabetes in the EPIC-InterAct case-cohort study

E. Keysendal, Sweden

328 Continuous glucose monitoring in first degree relatives with stage 2 diabetes

L. Marcovecchio, J. Tajcs, K. Dovc, E. Hendriks, C. Mathieu, T. Battelino, on behalf of the INNODIA consortium, UK, Belgium, Slovenia

Short Oral Event C

Wednesday, 12:45 - 13:45

SO 009 Treatment of type 1 diabetes

329 Clinical characteristics of malnutrition related insulin requiring ketotic resistant diabetes in India

S. Gupta, S. Gupta, K. Gupta, R. Mutkure, P. Bamrah, S. S. Gupta, India

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

330 Multimorbidity disease clusters and their association with increased mortality in type 1 diabetes

A. Ylinen, S. Mutter, S. Hägg-Holmberg, S. Satuli-Autere, V. Harjutsalo, P.-H. Groop, L. M. Thorn, FinnDiane Study Group, Finland

331 Exploring HLA genotype variations in type 1 diabetes: implications for precision medicine and immunotherapy response

U. Hannelius, P. F. Teixeira, L. Eriksson, A. Lindqvist, P. Råden, C. Nowak, J. Ludvigsson, Sweden

332 Prevalence of actionable HbA_{1c} levels in immune mediated inflammatory diseases: Is HbA_{1c} screening warranted for early pre-diabetes detection?

L. D. Ferguson, C. Celis-Morales, J. Anderson, N. Sattar, UK

333 Glucocorticoid-induced diabetes among adults hospitalised in the Oxford University Hospitals NHS Foundation Trust (England, United Kingdom): a matched cohort study

R. Golubic, H. Mumbole, R. Coleman, R. Rea, R. Caleyachetty, R. Mathur, A. Adler, UK

334 Factors predicting persistently high HbA_{1c} levels in adults with type 1 diabetes

H. L. Lee, L. L. Chan, L. E. Watson, R. J. Jalleh, P. Lee, C. Shoubridge, A. T. Zimmermann, Australia

335 Multi-omics profiling of extended honeymoon unveils new therapeutic targets

A. Abdelsalam, C. Lorelli, M. Ben Nasr, V. Usuelli, E. Assi, M. Zocchi, A. Petrazzuolo, M. Nardini, S. Lodovichi, A. Petitti, G. Cannalire, F. D'Addio, C. Mameli, P. Fiorina, Italy, USA

336 Contrasting autoantibody and risk profiles in at-risk adult vs paediatric populations

E. Templeman, L. Ferrat, N. Thomas, C. Speake, J. W. Wentworth, D. Wherrett, J. Sherr, M. Redondo, C. Evans-Molina, J. Sosenko, E. Sims, R. Oram, UK, Switzerland, USA, Australia, Canada

Short Oral Event D

Wednesday, 14:00 - 15:00

SO 010 Complications of type 1 diabetes

337 Comparison of serum creatinine and cystatin C based eGFR and their prediction of incident moderate albuminuria in individuals with type 1 diabetes

P.-H. Groop, L. Thorn, V. Harjutsalo, Finland

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

338 Incidence of diabetic foot complications in a type 1 and type 2 diabetes population: a Danish register-based cohort study

A. Akerkar, P. Falberg Rønn, V. Kosjerina, C. Stevns Hansen, A. Hulman, A. Rasmussen, P. Rossing, T. S. Ahluwalia, Denmark

339 Characteristics of above 65-year-olds with type 1 diabetes in the Finnish Diabetic Nephropathy Study

E. Franzén, S. Satuli-Autere, M. Eriksson, A. Ylinen, P.-H. Groop, L. Thorn, Finland

340 Exploring the association between oxidative stress biomarkers, inflammation, and carotid intima-media thickness in young people with type 1 diabetes and initial microvascular complications

V. Kumar, S. Prasad, N. Kumar, India

341 Severity of diabetes-related complications and quality of life in people with type 1 diabetes: findings from the SFDT1 cohort study

S. Barraud, G. Aguayo, E. Cosson, P. Massin, S. Feldman, L. Kessler, H. Hanaire, C. Amouyal, B. Vergès, A. Sola, A. Vambergue, E. Lecornet-Sokol, C. Vatie, J.-P. Riveline, G. Fagherazzi, France, Luxembourg

342 Interacting effects of HLA DR3DQ2 and DR4DQ8 on diabetic phenotype and comorbidity in LADA patients: a HUNT study

V. Grill, B. E. Lønnum, E. Soergjerd, I. K. Hals, Norway

343 Prevalence of retinopathy and microalbuminuria in people living with type 1 diabetes 15 years after diagnosis by decade of diagnosis: a cross-sectional, real-world observational study

A. Lavens, L. Crenier, C. De Block, P. Oriot, J.-C. Phillips, M. Vandembroucke, A. Verhaegen, A.-S. Vanherwegen, F. Nobels, C. Mathieu, Belgium

344 Population with type 1 diabetes is ageing rapidly in Finland: national registry study on diabetes-related complications from 2014 to 2021

H. Vessari, E. J. Peltonen, E. Pimiä, I. Iso-Mustajärvi, I. Vauhkonen, H. Luoto, T. Saukkonen, Finland

Short Oral Event E

Thursday, 12:45 - 13:45

SO 011 Disease progression and mortality in diabetes

345 Time trends in mortality in people treated for diabetes in the entire France before and during the COVID-19 pandemic: a nationwide study from 2013-2021

E. Cosson, M. Guion, S. Gorla, S. Fosse-Edorth, France

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

346 Prediction of disease progression with artificial intelligence algorithms in patients with type 2 diabetes in Finland: the initial screening for associations

K. Nygård, J. Mehtälä, R. Ryhänen, K. Järvinen, A. Kortteenniemi, S. Pakarinen, T. Kovalainen, A. Vesikansa, M. Koivusalo, A. Tirronen, L. Stenman, E. Aslannaj, J. Tuominen, Finland, Netherlands

347 Mendelian Randomisation provides evidence that higher BMI, but not mild hyperglycaemia, may be a causal risk factor for severe infection

R. Hopkins, E. De Villiers, M. N. Weedon, B. M. Shields, A. P. McGovern, J. M. Dennis, H. D. Green, UK

348 Diabetes and incident stroke and mediation by microvascular dysfunction: pooled analysis of three population-based studies

I. L. Steens, S. Sedaghat, Y. Ji, J. Pankow, B. E. Klein, A. J. Houben, A. Koster, H. Bosma, M. Cotch, R. L. McClelland, K. M. Hayden, T. M. Hughes, M. P. Bancks, B. E. De Galan, T. T. Van Sloten, Netherlands, USA

349 Sex differences in the characteristics, comorbidities, pharmacotherapy and prevalence of diabetes-related complications in patients with newly diagnosed type 2 diabetes in Sweden

N. Rajamand Ekberg, N. Widén, S. Karayiannides, S. Catrina, Sweden,

350 Cross-sectional associations of 24h blood pressure with retinal arteriolar narrowing and urinary albumin excretion are modified by (pre)diabetes: The Maastricht Study

K. Wang, A. A. Kroon, B. E. Galan, T. T. Berendschot, M. T. Schram, A. J. Houben, M. M. Greevenbroek, Netherlands

351 Glucose levels at hospital admission are associated with mortality beyond the admission

N. Cheung, P. McElduff, G. Fulcher, S. Middleton, The NSW Emergency BGL Trialists, Australia

352 Vaccinome landscape in nearly 620.000 patients with diabetes

E. Lazzaroni, F. D'addio, M. Lunati, G. Preziosi, L. Montefusco, I. Pastore, P. Morpurgo, A. Rossi, A. Gandolfi, C. Tinari, M. Ben Nasr, C. Loretelli, C. Berra, P. Fiorina, Italy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 012 Health interactions and risks in diabetes: from cancer survival to chronic conditions

353 Association between gastrectomy and the risk of type 2 diabetes in gastric cancer survivors: a nationwide cohort study

G. Kim, M. Jang, K.-D. Han, J. Kim, Republic of Korea

354 Glucocorticoid treatment and hyperglycaemia in people living with chronic obstructive pulmonary disease: systematic review and meta-analysis

R. Golubic, H. Mumbole, R. Coleman, N. Rahman, R. Caleyachetty, A. Adler, UK

355 Clinical phenotyping of people living with type 1 diabetes according to their levels of diabetes-related distress: results from the SFDT1 cohort study

D. Canha, G. Aguayo, E. Cosson, A. Sola-Gazagnes, I. Guilhem, E. Renard, S. Hadjadj, L. Potier, B. Verges, S. Lablanche, P.-Y. Benhamou, H. Hanaire, Y. Reznik, J.-P. Riveline, G. Fagherazzi, Luxembourg, France

356 Sarcopenia and frailty is associated to higher mortality risk in individuals with type 2 diabetes: Insights from the UK Biobank study

M. T. Guerrero-Wyss, F. K. Ho, S. R. Gray, B. Jani, C. Celis-Morales, UK, Chile

357 Circulating inflammatory markers and all cause death in type 2 diabetes: evidence for an intertwined relationship with tryptophan metabolism

C. Menzaghi, A. Marucci, M. Mastroianno, G. Di Ciaccia, M. Armillotta, L. Salvemini, D. Mangiacotti, A. Fontana, S. De Cosmo, O. Lamacchia, M. Copetti, V. Trischitta, Italy

358 Prevalence of pre-heart failure among individuals with type 2 diabetes within primary care: insights from the Mexico cohort iCaReMe registry

R. Silva-Tinoco, A. Galindez-Fuentes, A. Orea-Tejeda, R. Sanchez-Santillan, A. Ramírez, V. De la Torre, E. Guzman, B. Valderrabano, Á. Montañez, L. Jiménez, D. González, C. Juárez, S. Benitez, J. Orozco-Gutiérrez, T. Cuatecontzi, Mexico

359 The association between asthma and type 2 diabetes: a systematic review and meta-analysis including 17 million individuals

N. N. Nguyen, D. S. Ho, M. T. Nguyen, T. D. Nguyen, T. Q. Tran, Y.-C. Chen, Taiwan, Viet Nam

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

360 The survivors of pulmonary tuberculosis are at risk of newly developed type 2 diabetes

J. Yoo, C. Kim, C. Hwang, C. Yim, Republic of Korea

Short Oral Event A

Tuesday, 12:30 - 13:30

SO 013 Prevention of type 2 diabetes

EASD
EFSD

361 Using a machine learning-based model to categorise progression risks and customise interventions for prediabetes: a post-hoc analysis of DPP and DPPOS

S. Wang, Q. Huang, Y. Luo, Z. Lian, Y. Luo, L. Ji, X. Zou, China

GENERAL
INFO

362 Metabolically unhealthy and low skeletal muscle mass: crucial contributors to diabetes, particularly early-onset diabetes

L. He, W. Zheng, K. Qiu, W. Zhang, Q. Liu, Y. Ren, W. Kong, T. Zeng, China

PROGRAMME

TUESDAY

363 Prediabetes management in Indian adults: a quasi-

experimental study on effectiveness of integrated intensive lifestyle intervention

M. Ganla, P. Tripathi, D. Tiwari, N. Kadam, A. Vyawahare, B. Sharma, T. Kathrikolly, B. Saboo, India

WEDNESDAY

THURSDAY

FRIDAY

364 RCT on effects of guided self determination in primary health care, to reduce risk of coronary heart disease and prediabetes

E. Arnardottir, A. K. Sigurdardottir, T. C. Skinner, M. Graue, B.-C. H. Kolltveit, Iceland, Denmark, Australia, Norway

SHORT ORAL
DISCUSSIONS

365 Can we screen for type 2 diabetes using voice? Findings from the Colive Voice study

G. Fagherazzi, V. Despotovic, M. Pizzimenti, G. Aguayo, A. Fischer, H. Ayadi, F. Mauvais-Jarvis, J.-P. Riveline, A. Elbeji, Luxembourg, USA, France

PRESENTER
INDEX

SATELLITE
SYMPOSIA

366 A part for the whole: using the post-breakfast glucose response pattern in real-life to predict the daily glucose profile in non-diabetic individuals

A. Giosuè, V. Skantze, R. Giacco, M. Vitale, G. Costabile, R. E. Bergia, W. W. Campbell, G. Riccardi, R. Landberg, Italy, Sweden, USA

INDUSTRY

PROGRAMME

367 Diurnal glucose responses to meals with different carbohydrate content and glycaemic index and their effects on beta cell dysfunction: the OmniCarb trial

Y. Heianza, V. Carey, L. J. Appel, F. M. Sacks, L. Qi, USA

EXHIBITION

368 The conundrum of what determines return to normal glucose handling in people with non-diabetic hyperglycaemia: prospective analysis of outcomes in 1,367 men

F. Wilkinson, A. Innes, B. Kelly, J. Sarginson, B. Ollier, A. Heald, UK

Short Oral Event B

Tuesday, 13:45 - 14:45

SO 014 Early factors and family determinants of diabetes

369 Maternal age at delivery and type 2 diabetes in adult offspring: longitudinal sibling comparison register study

V. Ahuja, A. Hiyoshi, H. Backman, D. Simmons, S. Montgomery, Sweden, Australia

370 Using multistate models and polygenic risk scores to understand cardiometabolic disease in British Pakistani and Bangladeshi populations: showcasing the Genes and Health cohort

D. Stow, R. S. Tsang, I. K. Katzourou, F. Eto, M. Samuel, The Genes and Health Research Team, The LINC consortium, P. A. Holmans, M. B. Van den Bree, M. K. Siddiqui, I. Barroso, N. J. Timpson, H. C. Martin, R. Mathur, S. Finer, UK

371 Parent-of-origin effects in the lifecourse evolution of cardiometabolic traits

R. H. Wagh, G. Hatem, P. S. Kunte, C. S. Yajnik, R. Prasad B, India, Sweden, Australia

372 Environmental neglect: endocrine disruptors as under appreciated but potentially important diabetogens in HNF1A-MODY cell model

T. A. Legøy, L. Unger, J. Paulo, L. Ghila, S. Chera, Norway, USA

373 Weight gain and ethnic background as determinants of HbA_{1c} 11-years after pregnancy: the STORK-Groruddalen follow-up study

C. Waage, C. Sommer, I. Mdala, S. Lee-Ødegård, A. M. Brænd, A. K. Jennum, K. I. Birkeland, Norway

374 Impact of family history of young-onset type 2 diabetes on utility of 1-hour post-load plasma glucose in predicting risk of incident diabetes

C. O. B. Fan, J. Ho, E. S. Lau, J. N. Lui, E. Y. Chow, A. P. Kong, R. C. Ma, A. O. Luk, J. C. Chan, Hong Kong

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

375 Trajectories of glucose excursions in early childhood and the risk of abnormal glucose tolerance in adolescence

Y. Zhang, E. S. Lau, C. H. Tam, N. Y. Ng, A. Yang, A. Y. Tsang, C. L. Yuen, H. Wu, E. Y. Chow, A. O. Luk, A. P. Kong, C. Wang, J. C. Chan, W. Tam, R. C. Ma, Hong Kong

Short Oral Event C

Wednesday, 12:45 - 13:45

EASD
EFSD

SO 015 Genetics and biomarkers for prediction of type 2 diabetes

GENERAL
INFO

376 Sex-specific associations of contaminant and essential metals with fasting plasma glucose: a cross-sectional analysis of the Hong Kong school children cohort

A. Yang, T. Chen, H. Tam, H. Cheung, C. Ma, P. Kong, Y. Chow, H. Chan, C. Chan, China

PROGRAMME

TUESDAY

WEDNESDAY

377 Impact of glucocorticoids on islet function: role of SRD5A1 as a modulator of glucocorticoids bioavailability

O. K. Tijani, C. Saponaro, M. Moreno-Lopez, I. Louvet, A. Acosta, V. Gmry, A. Coddeville, J. Kerr Conte, F. Pattou, C. Bonner, S. Espiard, France

THURSDAY

FRIDAY

378 Gut microbiota clusters and metabolic health: characterising associations in a large cohort study

C. Geisler, K. Schlicht, N. Rohmann, K. Hartmann, K. Türk, U. Settgest, T. Hollstein, L. Kruse, M. Solano Marchini, W. Diederich, D. Schulte, A. Franke, K. Schwarz, M. Laudes, Germany

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

379 Prediction of oral glucose tolerance test response by fasting glycosaminoglycans-bound protein levels

M. Alonso-Sampedro, O. Lado-Baleato, S. Lopez-Gonzalez, A. Gonzalez-Quintela, F. Gude, Spain

SATELLITE
SYMPOSIA

380 Subgroups of adult diabetes show phenotypic differences before diabetes onset

L. Hakaste, M. Andersen, H. Maalmi, J. Vangipurapu, T. Ozgumus, A. Mollsten, Prediabetic Phenotype Working Group, E. Ahlqvist, T. Tuomi, Finland, Denmark, Germany, Norway, Sweden

INDUSTRY

PROGRAMME

EXHIBITION

381 Association of coagulation factor levels and thrombin generation potential with the incidence of type 2 diabetes: mediating role of glycoprotein acetylation

J. Han, A. Van Hylckama Vlieg, R. De Mutsert, F. R. Rosendaal, J. H. Van der Velde, S. C. Boone, E. Winters -van Eekelen, S. Le Cessie, R. Li-Gao, Netherlands

382 Type 2 diabetes and 2-h postload glucose are inversely associated with endothelial glycocalyx thickness: The Maastricht Study

X. Zhao, C. Schalkwijk, B. Kroon, M. Schram, B. Houben, Netherlands

383 Role of glucagon in the development of type 2 diabetes in 548 participants with prediabetes: a post-hoc analysis of two randomised controlled trials

M. Csanalosi Artigas, S. Kabisch, C. Honsek, A. Sachno, M. Kemper, C. Gerbracht, U. Dambeck, M. A. Osterhoff, M. O. Weickert, A. F. Pfeiffer, Germany

Short Oral Event D

Wednesday, 14:00 - 15:00

SO 016 Molecular predictors of type 1 diabetes

384 Effect of the autoimmune-associated C1858T variant of PTPN22 on neutrophil activation and function in type 1 diabetes patients

A. Fierabracci, A. Cudini, E. Belcastro, S. Petrini, R. Schiaffini, V. D'Oria, M. Scarsella, A. Lo Russo, Italy

385 Inflammation in the exocrine and endocrine pancreas is potentiated by the Hippo pathway effector YAP and associated with type 1 diabetes

H. Pahwa, S. Geravandi, H. Liu, M. K. Madduri, O. Zabad, F. Atawneh, A. Pugliese, K. Maedler, A. Ardestani, Germany, USA, UK

386 Genetic underpinnings of pediatric onset type 1 diabetes in the Canary Islands

I. Marcelino-Rodriguez, Y. Novóa Medina, S. González Barbuzano, R. Molina Suarez, N. Martel Suarez, I. García de Pablo, P. Pedrianes Martin, O. Guillen Diaz, M. Alberiche Ruano, A. Corrales, A. M. Wägner, M. Boronat, C. Flores Infante, Spain

387 The TEAD activator TT-10 promotes human beta cell regeneration and protects from diabetes induction

K. Maedler, M. Madduri, H. Pahwa, H. Liu, S. Geravandi, S. Baskaran, G. Rodrigues, R. Indranuj, D. Kagambo, S. Yator, S. Banerjee, A. Zupanc, R. Choudhury, A. Ardestani, Germany

388 Continuous glucose monitoring metrics can replace HbA_{1c} in composite scores assessing beta cell function

A. L. Carr, A. Lam, P. N. Taylor, A. Lindqvist, J. Ludvigsson, U. Hannelius, C. M. Dayan, P. A. Senior, Canada, UK, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

389 The type 1 diabetes candidate genes PTPN2 and BACH2 cooperate for the modulation of the JAK/STAT and MAPKs pathways in human beta cells

A. Roca-Rivada, E. Martín-Vázquez, J. G. Oliveira, A. Coomans de Brachène, P. L. Zimath, J. M. Costa-Junior, D. L. Eizirik, Belgium

390 Role of ZNF808 in early pancreatic cell fate specification

S. Muralidharan, E. Ryhänen, H. Montaser, J. Saarimäki-Vire, H. Ibrahim, S. Eurola, E. De Franco, N. Owens, M. Imbeault, A. Hattersley, T. Otonkoski, D. Balboa, Finland, UK

EASD
EFSD

GENERAL
INFO

391 Loss of RFX6 function impairs islet development, resulting in hypoplastic islet organoids derived from iPSCs, while maintaining pancreatic progenitor formation

E. M. Abdelalim, N. Aldous, A. K. Elsayed, B. Memon, S. Ijaz, H. Sikander, Qatar, Germany

PROGRAMME

TUESDAY

Short Oral Event E

Thursday, 12:45 - 13:45

WEDNESDAY

SO 017 Long-term complications and outcomes in type 2 diabetes: vascular health, kidney function, and mortality

THURSDAY

FRIDAY

392 Incidence rates of vascular complications in a cohort of people with type 2 diabetes from the Swedish National Diabetes Register

S. Khare, K. Boye, J. Lebec, K. T. Ranta, A. Toll, B. K. Bjerregaard, R. Cordtz, B. Eliasson, J. Redig, UK, USA, France, Finland, Sweden, Denmark

SHORT ORAL
DISCUSSIONS

393 Glomerular filtration rate decline predicts all cause mortality and mediates the effect of tryptophan metabolism on the risk of death in patients with type 2 diabetes

C. Menzaghi, O. Lamacchia, M. Copetti, M. Mastroianno, C. Corsano, A. Fontana, V. Trischitta, S. De Cosmo, Italy

PRESENTER
INDEX

SATELLITE
SYMPOSIA

394 Association of glycaemic control with intraocular pressure in a large general population: results from the UK Biobank

Q. Liu, P. Welsh, C. Celis-Morales, N. Sattar, UK, Chile

INDUSTRY

PROGRAMME

395 Association between kidney function and mortality in type 2 diabetes patients: a 10-year prospective cohort study

J. He, X. Fan, H. Yu, Y. Qin, S. Jian, J. Zhou, Y. Lu, E. Pan, D. Hang, C. Shen, M. Wu, China

EXHIBITION

396 Prevalence and long term mortality of burnt-out diabetes in end stage kidney disease

J. Navarrete, R. J. Galindo, R. McCoy, P. Vellanki, L. Peng, G. Umperiez, USA

397 Genes involved in the manifestation of proliferative diabetic retinopathy in people with diabetic retinopathy

Q. Liu, A. Aman, C. Celis-Morales, P. Welsh, UK, Chile

398 Temporal trajectories of hospitalisations for traditional and non-traditional complications in people with type 2 diabetes in Hong Kong

H. Wu, H. Zhou, C. Huang, A. Yang, E. S. Lau, X. Zhang, J. N. Lui, B. Fan, M. Shi, R. C. Ma, A. P. Kong, E. Chow, W.-Y. So, J. C. Chan, A. O. Luk, Hong Kong, China

399 Microvascular disease incidence over a 34-year period among Chinese with newly diagnosed diabetes and impaired glucose tolerance: the China Da Qing Diabetes and IGT Study 1986-2020

Q. An, X. Qian, S. Zhou, X. Li, S. He, X. Feng, J. Xu, Y. Chen, G. Li, China

Short Oral Event F,

Thursday, 14:00 - 15:00

SO 018 Diabetes management and outcomes: societal, behavioral, and clinical influences

400 Initiation of cardioprotective glucose-lowering drugs according to sex and educational level: a Danish nationwide cohort study

E. Calderon, L. Bjerg, A. A. Isaksen, A. Sandbæk, K. L. Funck, E. L. Grove, Denmark

401 Clinical implications of intentional weight loss in people living with type 2 diabetes: a CPRD Aurum database study

C. Kruse, U. C. Braae, E. Nørtoft, P. N. Kristensen, N. F. Nielsen, Denmark

402 Racial and ethnic differences in pharmacy dispensing of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes

L. Rodriguez, H. Finertie, R. S. Neugebauer, B. J. Gosiker, T. Thomas, A. J. Karter, L. K. Gilliam, C. E. Oshiro, J. X. An, G. D. Simonson, A. E. Cassidy-Bushrow, S. Dombrowski, M. B. Nolan, P. J. O'Connor, J. Schmittiel, USA

403 Cytokine profiling according to glycaemic status and COVID-19 severity in patients with diabetes

D.-H. Lee, Y. Kim, K. Yoo, Republic of Korea

404 Trends in physical activity before and after the COVID-19 pandemic shelter-in-place mandate among adults with prediabetes in an integrated health care system in northern California

L. A. Rodriguez, M. Yassin, O. Duru, R. S. Neugebauer, S. D. Brown, Y. Castellon-Lopez, J. Schmittiel, USA

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION

405 What is the impact of structural changes in society on diabetes self-management and HbA_{1c} trajectories? A cohort study during the COVID-19 pandemic in people with diabetes at outpatient clinics
M. G. Rasmussen, E. Just-Østergaard, J. V. Stidsen, I. Willaing, G. S. Pedersen, Denmark

EASD
EFSD

406 Treatment discontinuation among users of SGLT2 inhibitors and GLP-1 receptor agonists in a national population of patients with type 2 diabetes

C.-E. Lim, B. Pasternak, B. Eliasson, P. Ueda, Sweden

GENERAL
INFO

407 Routine clinical features are associated with short-term discontinuation of GLP1-RA but are of limited utility to predict individuals unlikely to tolerate therapy

P. Cardoso, K. G. Young, R. Hopkins, A. T. Hattersley, E. R. Pearson, A. Jones, T. J. McKinley, B. Shields, J. Dennis, UK

PROGRAMME

TUESDAY

Short Oral Event A

Tuesday, 12:30 - 13:30

WEDNESDAY

THURSDAY

SO 019 Catching signals to follow the right pathway in islets

FRIDAY

408 Regulating the pancreatic beta cell functionality through nanotopographical cues: focus on organelles organisation and crosstalk

A. Galli, N. Dule, E. Maffioli, P. Marciani, M. Castagna, P. Milani, C. Lenardi, G. Tedeschi, C. Perego, Italy

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

409 Targeting SIKs for improving beta cell function and glycaemic control

K. Loh, Australia

SATELLITE
SYMPOSIA

410 Turnover of mRNA mediated by RNA modification regulates pancreatic beta cell function and identity

Y. Tara, T. Yamamoto, Japan

INDUSTRY

PROGRAMME

411 Ca²⁺-dependent oscillations of cytoplasmic pH in glucose-stimulated pancreatic beta cells

O. Dyachok, A. Tengholm, Sweden

EXHIBITION

412 EPDR1, an obesity-induced protein in human islets, maintains mitochondrial function by promoting mitophagy flux in beta cells

F. A. Munoz, M. Fex, T. Moritz, H. Mulder, L. R. Cataldo, Sweden, Denmark

413 A dual GLP-1/GIP agonist may encompass most of the beneficial effects of both incretins on pancreatic beta cell signalling and survival

M. A. Ravier, N. Zaïmia, S. El Mallem, F. Playe, S. Costes, France

414 Pyruvate kinase controls cAMP production and amplifies insulin secretion downstream of the GLP-1 receptor in beta cells

H. R. Foster, R. E. Kirchner, S. L. Lewandowski, M. E. Capozzi, J. E. Campbell, M. J. Merrins, USA

415 Exploring sonic hedgehog signalling and HNF1A crosstalk in HNF1A-MODY stem cell islets

L. Unger, T. Legøy, S. Chera, L. Ghila, Norway

Short Oral Event B

Tuesday, 13:45 - 14:45

SO 020 Holding hands with alpha cells in the islets

416 Sex differences in the plasma glucagon responses to a high carbohydrate meal and a glucose drink in type 2 diabetes

W. Huang, C. Xie, K. L. Jones, M. Horowitz, C. K. Rayner, T. Wu, Australia

417 Circadian rhythms of pancreatic alpha and beta cell dynamics and protein landscape

C. Jiménez-Sánchez, V. Petrenko, N. Phillips, M. Stolovich-Rain, Y. Dor, Y. Wu, C. Dibner, Switzerland, Israel

418 Using engineered pseudoislets to study the role of gap junction channels in human islet function

C. H. Levitt, T. Gaia Oliveira, C. Birznieks, D. Bell, R. K. Benninger, USA

419 Semaphorin signalling alters the function of islet alpha and beta cells

S. Acreman, S. Nawaz, U. Ghose, J. Yu, H. Abozendah, T. Zarganis-Tzitzikas, P. Brennan, A. Nevado-Holgado, Q. Zhang, P. Rorsman, Y. Jones, C. Van Duijn, B. Hastoy, UK, Portugal, Sweden

420 Characterisation of the secretion of glucagon from the pancreas of GCGRKO alpha cells in mice

J. Vergara Ucin, D. B. Andersen, J. J. Holst, Denmark

421 Ghrelin and LEAP2 affect insulin and glucagon secretion in mouse but not in human islets, and their effects in mouse islets are mediated by somatostatin

Y. Murdasov, P. Gilon, Belgium

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

422 Urocortin-3 regulates glucagon secretion through an inhibitory beta to δ to alpha cell axis in mice, but not in rats

J. Vergara Ucin, D. B. Andersen, G. Di Giuseppe, T. Mezza, J. J. Holst, Denmark, Italy

423 Regulation of alpha cell glucagon exocytosis by TMEM55A

X. Liu, A. F. Spigelman, S. Duckett, T. Dos Santos, P. E. MacDonald, Canada

EASD
EFSD

Short Oral Event C

Wednesday, 12:45 - 13:45

GENERAL
INFO

SO 021 Insulin service providers for the body

424 Cav1.3 calcium channel regulates pancreatic beta cell gene transcription, electrical activity, and insulin release

P. Tuluc, C. Plattner, N. Jacobo-Piqueras, N. J. Ortner, S. M. Geisler, Z. Trajanoski, T. Theiner, Austria

PROGRAMME

TUESDAY

WEDNESDAY

425 Islet sodium/potassium ATPase as a key transducer of secretagogue signal strength

M. Dickerson, P. Dadi, J. R. Dobson, S. Behera, D. A. Jacobson, USA

THURSDAY

FRIDAY

426 Roles of Exophilin5 in insulin vesicle fusion without stable docking to the plasma membrane

H. Wang, China

SHORT ORAL
DISCUSSIONS

427 Altered BAG3/insulin colocalisation is associated with reduced 1st phase insulin secretion in humans

M. Brunetti, G. Di Giuseppe, V. Damiani, E. Di Piazza, L. Soldovieri, G. Ciccarelli, A. Mari, V. De Laurenzi, A. Giaccari, T. Mezza, Italy

PRESENTER
INDEX

428 Mitochondrial AASS-dependent lysine metabolism potentiates insulin secretion

L. Cataldo, Denmark

SATELLITE
SYMPOSIA

INDUSTRY

429 NCK1 modulates pancreatic beta cell insulin secretion in a sex-dependent manner

L. Montelliet, N. Jouviet, C. Baldwin, J. Estall, Canada

PROGRAMME

430 Investigating the role of N6-methyladenosine on chromatin-associated RNA (caRNA) in regulating transcription in human pancreatic beta cells

N. Shukla, C.-W. Ju, C. He, R. N. Kulkarni, USA

EXHIBITION

SO 022 Cells in attacking mode and beta cell victims**431 Tolerisation for treating type 1 diabetes**

M. Garcia Toscano, A. Crespo Barreda, A. Dorransoro Gonzalez, J. Van der Velden, T. Gerritzen, P. De Haan, Spain, Netherlands

432 Characterising lymphocytes in newly diagnosed type 1 diabetes patients during and after treatment with the JAK inhibitor baricitinib

L. Sanz Villanueva, P. Trivedi, S. Litwak, T. Catterall, S. Lai, M. Waibel, B. Krishnamurthy, H. Thomas, T. Kay, Australia

433 Activated human T cells express glutamic acid decarboxylase 67 and secrete endogenous GABA

Z. Jin, B. Birnir, Sweden

434 Human fecal microbiome transplantation alters the incidence of diabetes in non-obese diabetic mice

R. Minab, E. Rampanelli, N. Hanssen, C. Fuhri Snethlage, D. Van Raalte, B. O. Roep, B. Vallance, M. Nieuwdorp, B. Verchere, Canada, Netherlands

435 Type 1 diabetes onset is prevented in offspring of NOD mouse mothers treated with statins

S. Muntoni, E. Schirru, R. Rossino, M. F. Marongiu, C. Catia, F. Manchinu, L. Atzori, M. Piludu, M. Pala, F. Secci, M. Zoledziwska, S. Uzzau, F. Pili, F. Cucca, M. Congia, Italy

436 The maternal and fetal metabolic and immune landscape of gestational diabetes

R. Nanan, D. Ni, Australia

SO 023 Keeping islet cell identity under different circumstances**437 The role of MafB transcription factor in endocrine cell differentiation**

S. Bsharat, L. Brouty, I. Artner, K. Achanta, Sweden

438 Conversion of human alpha cells into insulin-producers

C. Renaud, E. Bru-Tari, K. Furuyama, F. Thorel, P. Herrera, Switzerland, Japan

439 Mitochondrial fission promotes loss of beta cell identity

K. Rivera, E. Montanya, Spain

EASD
EFSDGENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

440 Roux-en-Y-gastric bypass induces a significant reduction of pancreatic noradrenergic innervation and beta cell redifferentiation, leading to remission of type 2 diabetes

A. Avolio, C. Morciano, S. Gugliandolo, U. Capece, A. Splendore, M. Brunetti, T. Mezza, S. Moffa, G. Di Giuseppe, G. Ciccarelli, L. Soldovieri, A. Giaccari, F. Cinti, Italy

441 Pleiotrophin deletion, islet architecture, and function: insights into high-fat diet effect

C. Ballesteros-Pla, M. I. Sanz-Cuadrado, J. Sevillano, M. Sánchez-Alonso, M. Limones, J. Pita, G. Herradón, M. Ramos Álvarez, Spain

442 Periodic fasting-mimicking diet increases Insulin⁺ and BRN4⁺ cells in murine endocrine pancreas

C. M. Harer, J. Krstic, B. Ehall, L. Herbsthofner, K. Bounab, J. Franz, P. Kotzbeck, A. Prokesch, B. Prietl, T. R. Pieber, Austria

443 Impact of NOTCH2 polymorphisms on endocrine pancreas development and type 2 diabetes risk

D. Matas-Aguado, M. Hernanz, M. Mirasierra, M. Vallejo, U. B. Pajvani, A. Bartolomé, Spain, USA

444 High-resolution 3D calcium time course imaging sheds new light on beta cell heterogeneity

J. K. Briggs, E. Jin, M. J. Merrins, R. K. Benninger, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

Short Oral Event F,

Thursday, 14:00 - 15:00

SO 024 Improving islet transplantation

445 Females undergoing islet transplantation using CNI-based immunosuppression may be at higher risk of progressing to reduced kidney function

A. L. Carr, B. Marfil-Garza, A. Lam, K. Dajani, T. Kin, B. Anderson, D. O'Gorman, D. Bigam, S. B. Ahmed, A. M. Shapiro, P. A. Senior, Canada, Mexico

446 Development of high-throughput platform for KIR genotyping and expression analysis to infer the outcome of islet transplantation according to recipient/donor KIR/HLA mismatches

R. Chimienti, G. Siracusano, G. Lunetta, C. Volpi, M. Certo, S. Tentori, R. Melzi, R. Biassoni, R. Caldara, M. Malnati, L. Piemonti, Italy

447 Islet allotransplantation into pre-vascularised Sernova Cell Pouch™: interim results

P. Witkowski, N. Wojcik, S. Gondek, J. Tomecki, K. Milejczyk, B. Juengel, L. Wang, J. J. Fung, R. Barth, USA

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

448 Porous hydrogel microcarriers with human islet organoids for diabetes modelling

J. Li, L. Li, China

449 Injectable self-healing hydrogel encapsulation of pancreatic islets for diabetic cell therapy

Z. Huan, L. Li, China

450 From aesthetic medicine to islet transplantation: nanofat improves the success of islet transplantation

S. Wrublewsky, A. Weinzierl, M. Menger, M. Laschke, E. Ampofo, Germany

451 Meal-like stimulation protocol of beta cells in islets-on-chip and a human in-silico simulator

D. Chapeau, L. Olçomendy, M. Lallouet, T. Sawatani, M. Monchablon, R. Lartigue, A. Pirog, M. Cnop, J. Lang, S. Renaud, M. Raoux, France, Belgium

Short Oral Event A

Tuesday, 12:30 - 13:30

SO 025 Breaking bad: destruction of beta cells

452 The crosstalk between the JAK/STAT and MAPKs pathways is essential for STAT1 activation in human beta cells

A. Roca-Rivada, J. G. Oliveira, E. Martín-Vázquez, A. Coomans de Brachène, P. L. Zimath, J. M. Costa-Junior, D. L. Eizirik, Belgium

453 Unveiling the methylglyoxal contribution to beta cell failure and glucose intolerance in Glo1KD mice

C. Nigro, A. Leone, I. Prevenzano, A. Nicolò, M. Longo, D. Conza, A. Croce, F. Beguinot, C. Miele, Italy

454 Recovery of human beta cell functional damage induced by cytokines and glucotoxicity

M. Tesi, M. Suleiman, R. Semeraro, C. De Luca, E. Bosi, S. Del Guerra, A. Magi, F. Cardarelli, M. Cnop, D. Eizirik, L. Marselli, P. Marchetti, Italy, Belgium

455 Long non-coding RNA MALAT1 prevents hypoxia damage in human islets via HIF1A

W. K. Wong, N. H. PHAM, V. Saini, T. Loudovaris, H. E. Thomas, A. A. Hardikar, M. V. Joglekar, Australia

456 Concentration-dependent dual effects of ROS on insulin secretion mechanisms

X.-Q. Dai, A. F. Spigelman, K. Suzuki, P. E. MacDonald, Canada

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

457 The organisational and activational effects of testosterone contribute to diabetes development and progression in a mouse model of beta cell endoplasmic reticulum stress

L. F. Daniels Gatward, L. Doherty, A. J. King, UK

458 Perilyosomal Ca²⁺ overload and mechanistic target of rapamycin C1 activation impair autophagic degradation in beta cell lipotoxicity

K.-S. Park, H. T. Nguyen, A. Wiederkehr, C. B. Wollheim, Republic of Korea, Switzerland

EASD
EFSD

GENERAL
INFO

459 IAPP and beta cell dysfunction in diabetes: a cross-sectional study

E. B. Alves, A. Gomes, R. Andrade, J. F. Raposo, R. T. Ribeiro, R. Menezes, Portugal

PROGRAMME

TUESDAY

Short Oral Event B, Tuesday

13:45 - 14:45

WEDNESDAY

SO 026 Pregnancy and type 1 diabetes

THURSDAY

460 Maternal glycaemic and neonatal outcomes in pregnant women with type 1 diabetes treated with an advanced hybrid closed-loop vs non-algorithmic approach

V. Resi, A. Gaglio, Y. Pigotskaya, V. Grancini, E. Orsi, Italy

FRIDAY

SHORT ORAL
DISCUSSIONS

461 Impact of pre-eclampsia and hypertensive disorders of pregnancy on cardiovascular disease risk and all-cause mortality in women with type 1 diabetes

K. Rimpeläinen, D. Gordin, M. M. Klemetti, F. Jansson Sigfrids, V. Harjutsalo, P.-H. Groop, L. Thorn, Finland

PRESENTER
INDEX

462 Sensor-derived glycaemic metrics in pregnant women with type 1 diabetes randomised to faster-acting insulin aspart or insulin aspart: a secondary analysis of the CopenFast trial

J. C. Søholm, S. K. Nørgaard, K. Nørgaard, T. D. Clausen, P. Damm, E. Mathiesen, L. Ringholm, Denmark

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

463 Sensor-derived glycaemic metrics in women with type 1 diabetes using insulin degludec vs other basal insulin analogs during pregnancy: a post hoc analysis of the CopenFast trial

J. C. Søholm, S. K. Nørgaard, K. Nørgaard, T. D. Clausen, P. Damm, E. Mathiesen, L. Ringholm, Denmark

EXHIBITION

464 Impact of birthweight on neonatal complications in babies born to patients with type 1 diabetes

A. Vambergue, E. Gnana, M. Lemaitre, E. Cailliau, F. Toulali, F. Baudoux, M. Niyitegeka, D. Subtil, France

465 Time in Tight Range in pregnant women with type 1 diabetes: Are stricter targets achievable with hybrid closed loop systems?

O. Bitterman, A. G. Napoli, C. Giuliani, R. Fresa, Italy

466 The relationship between good glycaemic control achieved in different stage of pregnancy and the risk of complications rate in patients with preexisting diabetes

N. G. Asatiani, R. B. Kurashvili, E. Shelestova, S. Kublashvili, Georgia

467 Pregnancy after gastric bypass surgery and traits associated with maternal hypoglycaemia

T. Linder, D. Eppel, G. Kotzaeridi, A. Piersanti, M. Morettini, A. Tura, C. S. Göbl, Austria, Italy

EASD
EFSD

GENERAL
INFO

Short Oral Event C

Wednesday, 12:45 - 13:45

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 027 Gestational diabetes: clinical perspective

468 The trends of development of diabetes in women with previous gestational diabetes thus increasing their risk of diabetes: a 15-year clinical observational study

A. Mukunda, J. Chacko James, A. Nayak, L. Varadhan, UK

469 Abnormal glucose values at the various OGTT time points and neonatal outcomes in pregnancies complicated by gestational diabetes

K. I. Athanasiadou, S. A. Paschou, V. Vasileiou, F. Kanouta, M. Mitropoulou, P. Antsaklis, M. Theodora, T. Psaltopoulou, D. G. Goulis, G. Daskalakis, E. Anastasiou, Greece

470 The prevalence of gestational diabetes more than doubled during the last decade: a nationwide study in France

E. Cosson, E. Lebreton, L. Tang, S. Fosse-Edorth, N. Regnault, France

471 Clinical profile of women requiring insulin therapy during gestational diabetes

S. Nouira, T. Ach, R. Khochteli, O. Zarrouk, A. Ben Abdelkrim, M. Chaieb, K. Ach, Tunisia

472 Performance of the Monash gestational diabetes risk scoring tool in identifying women at-risk of developing gestational diabetes across four countries involved in the Bump2Baby and Me study

S. L. O'Reilly, L. Davies, F. McAuliffe, C. Burden, C. Campoy, H. Teede, M. Garcia Bermudez, D. Hjorth Jensen, H. T. Maindal, T. Skinner, on behalf of the IMPACT DIABETES B2B Collaboration Group., Ireland, Australia, UK, Spain, Denmark

473 Risk of gestational diabetes in twin pregnancy: a retrospective case-control study

C. Bianchi, F. Citro, T. Belcari, L. Battini, P. Marchetti, M. Aragona, A. Bertolotto, Italy

474 Joint association of maternal preconceptional overweight and gestational diabetes on offspring adiposity trajectory from birth to 11 years

Y. Deng, C. H. Tam, A. Yang, M. Shi, L. Yuen, N. Y. Ng, A. Y. Tsang, R. Ozaki, A. M. Li, E. Chow, L. L. Hui, J. C. Chan, C. C. Wang, W. H. Tam, R. C. Ma, Hong Kong

EASD
EFSD

GENERAL
INFO

475 Effect of diagnosing and management of early gestational diabetes using HbA_{1c} of 42-47mmol/L

S. Pandya, N. Periyathambi, Y. Weldeselassie, N. Sukumar, V. Patel, P. Saravanan, UK

PROGRAMME

TUESDAY

WEDNESDAY

Short Oral Event D

Wednesday, 14:00 - 15:00

THURSDAY

SO 028 Biomarkers and mechanisms in gestational diabetes

FRIDAY

476 Cannabidiolic acid mitigates postpartum development of metabolic dysfunction-associated steatotic liver disease in a lean mouse model of gestational diabetes

J. K. Kruit, K. Hribar, A. Giralt, A. Van Oosten, N. L. Mulder, M. H. Koster, M. Smit, L. Bongiovanni, M. Sanders, A. De Bruin, M. C. Kraus, E. M. Van der Beek, Netherlands, Switzerland

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

477 Pregnancy in an obese and gestational diabetes context: epigenetic regulation of adipose tissue

P. Corrales, G. Llauro, P. Fernández García, N. Vilanova, M. Ballesteros, D. Sánchez-Infantes, A. Megia, G. Medina Gómez, Spain

SATELLITE
SYMPOSIA

INDUSTRY

478 The effect of maternal thyroid function and lipid metabolism in early pregnancy on the risk of gestational diabetes

M. Zhi, X. Zhu, L. Li, China

PROGRAMME

479 Gestational diabetes is associated with activation of circulating innate lymphoid cells

J. Sbierski-Kind, S. Schlickeiser, L. Semeia, U. Ferrari, S. Harada, C. Gar, A. Lechner, J. Seißler, Germany

EXHIBITION

480 The effect of bile acid-RNA methylation on intergenerational inheritance of diabetes by microbiotavertical transmission

H. Yuan, Q. Xie, China

481 Serum resistin and adipocyte fatty acid binding protein level in different trimesters of gestational diabetes

T. Ferdousi, S. Jahan, M. A. Hasanat, Bangladesh

482 Long-term multi-omics signatures from gestational diabetes in postpartum women

A. D. Biancolin, C. Jiménez-Sánchez, N. E. Phillips, F. Sinturel, O. Fiammingo, D. Gendre, S. Blanc, J. Mareschal, CeMM of the Austrian Academy of Sciences, iGE3 Center, C. Meek, P. Maechler, A. Kramer, T.-H. Collet, J. J. Puder, C. Dibner, Switzerland, UK, Germany

483 From womb to weight gain: the connection between foetal biomarkers and child growth

N. Kabbani, M. Blüher, H. Stepan, T. Ebert, W. Kiess, M. Vogel, R. Baber, U. Lößner, A. Tönjes, S. Schrey-Petersen, Germany

Short Oral Event E

Thursday, 12:45 - 13:45

SO 029 On the young ones...

484 Real-world total daily insulin dose in 14,358 young individuals with type 1 diabetes in the US: data from the T1D Exchange Quality Improvement Collaborative

O. Ebekoziën, S. Rompicherla, S. Dei-Tutu, J. Indyk, J. Sanchez, A. Mekhoubad, M. Wilkes, R. Bhak, D. McGill, T. Gupta, Y. Zhang, J. Gaglia, USA

485 Screening for autoimmune thyroid disease, celiac disease and type 1 diabetes using multiplex ADAP assays: TRIAD2023 study

S. Hamdan, M. N. Scherman, A. Lind, D. Agardh, Sweden

486 Cytokine signature of diabetic ketoacidosis in children and adolescents

A. Rewers, Z. Chaffin, S. Ghetti, D. Tancredi, A. Mahon, S. Gilles, B. Ander, J. Dadra, N. Glaser, USA

487 Patterns of insulin discontinuation in youth with new onset type 2 diabetes presenting with and without diabetic ketoacidosis

P. Vellanki, A. L. Westbrok, C. Sinha, D. Hsia, S. Hao, USA

488 Distinct cord blood lipid signatures and its insights into childhood metabolic health

J. Zheng, X. Xiao, J. Zhang, China

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

489 Using maternal glycosylated haemoglobin as well as glucose tolerance tests identified significantly more mothers with high birth weight in their offspring

P. Wu, M. Stedman, A. Fryer, L. Green, D. Holland, J. Scargill, S. Pankaja, S. Christian, A. Heald, UK

490 Performance of Automated Insulin Delivery systems during a winter ski camp in children and adolescents with type 1 diabetes: the InSki trial

O. Moser, A. Mueller, E. Andritz, E. Wurm, A. Grothoff, E. Fröhlich-Reiterer, P. Pferschy, M. Fritsch, N. Tripolt, J. Schierbauer, S. E. Hofer, S. Sanfilippo, T. Voit, H. Sourij, Germany, Austria

491 The function of 1,5 anhydroglucitol in assessing beta cell and glucose intolerance in women with gestational diabetes

D. Quansah, C. Jimenez-Sanchez, J. Puder, P. Maechler, Switzerland

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Short Oral Event F

Thursday, 14:00 - 15:00

SO 030 Investigating impact of gestational diabetes

492 Can we encourage severe weight restriction in women with obesity and gestational diabetes?

S. Pandya, N. Periyathambi, Y. Weldeselassie, N. Sukumar, V. Patel, P. Saravanan, UK

493 Is 1 year post-partum follow-up after gestational diabetes useful for investigating glycaemic changes?

A. Gaglio, Y. Pigotskaya, V. Grancini, E. Orsi, V. Resi, Italy

494 Continuous glucose monitoring metrics and suboptimal pregnancy outcomes in women with gestational diabetes: secondary analysis of the DiGest trial

C. L. Meek, N. Atta, D. L. Jones, E. H. Turner, H. Murphy, R. Taylor, L. C. Kusinski, UK,

495 Heterogeneity of metabolic phenotype and pregnancy outcome in gestational diabetes characterised by isolated fasting hyperglycaemia or isolated post-load hyperglycaemia

Y. Gong, Y. Liu, Q. Wang, C. Li, R. Kang, J. Wang, T. Wei, Q. Wang, X. Li, X. Zheng, Y. Ding, China

496 Low mid-pregnancy serum albumin levels associated with higher incidence of postpartum diabetes in women with gestational diabetes

Y. Su, N. Li, M. Lai, J. Yang, G. Liang, Y. Wang, China

497 Comparison of glycaemic responses following meal tolerance testing during early and late second trimester with oral glucose tolerance characteristics in overweight pregnant women

P. Arum, A. Kdekian, M. K. Veenstra, M. Sietzema, H. L. Lutgers, J. K. Kruit, E. M. Van der Beek, Netherlands

498 Foetal abdominal obesity and adverse pregnancy outcomes in women with gestational impaired glucose tolerance

W. Kim, Republic of Korea

499 Prediction of gestational diabetes in early pregnancy by fasting and dynamic parameters of glucose metabolism

C. Göbl, L. Weidinger, G. Kotzaeridi, T. Linder, T. Fischer, M. Todesco Bernasconi, M. Kunze, N. Ochsenbein-Koelble, B. Winzeler, I. Hösli, E. Huhn, A. Tura, Austria, Switzerland, Germany, Italy

Short Oral Event A

Tuesday, 12:30 - 13:30

SO 031 All the reasons why exercise is good!

500 The effects of pre-meal and post-meal exercise on postprandial glucose excursions in women with type 1 diabetes: the MERIT1D study

P. Acosta Manzano, J. Wenninger, J. Lex, A. Gjergji, M. Flor-Aleman, P. Birnbaumer, G. Tschakert, P. Hofmann, M. N. Van Poppel, Austria, Spain

501 Myokine secretion and metabolic pathways under resting and contractile conditions in primary human myotubes: A matter of oxygen level?

L. Mennens, N. Hoebbers, J. W. Jocken, K. Verboven, G. H. Goossens, Netherlands, Belgium

502 Sex-related differences in cardiorespiratory capacity and ventilatory function in people with type 1 diabetes

L. Brugnara, H. Marí, V. Ribas, S. Murillo, J.-M. Servitja, A. Novials, Spain

503 CEFIP-deficient mice exhibit compromised physical fitness but improved glucose tolerance associated with enhanced exercise-inducible insulin sensitisation

M. Kanzaki, M. R. Nyasha, J. Tachikawa, H. Komatsuzaki, W. Chen, M. Onodera, D. Kojima, Japan

504 Does better cardiorespiratory fitness extend the duration of partial clinical remission in adults with type 1 diabetes?

J. Flotyńska, D. Naskręć, P. Niedźwiecki, A. Grzelka-Woźniak, A. Kaczmarek, A. Pypec, A. Cieluch, D. Zozulińska-Ziólkiewicz, A. Uruska, Poland

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

505 Carbohydrate ingestion before or during exercise on gastrointestinal mediated glucose metabolism in type 1 diabetes

O. M. McCarthy, S. Tawfik, M. Bechmann Christensen, K. Birch Kristensen, A. Ranajn, S. Schmidt, B. Hartmann, J. J. Holst, S. Bain, K. Noergaard, R. Bracken, Denmark, UK

506 The exerkine meteorin-like protein is a mediator of the protective effects of exercise against cytokine-induced human beta cell death

J. M. Costa-Junior, A. Coomans de Brachène, A. E. Musuaya, J. Carpentier, V. Faoro, M. Klass, M. Cnop, D. L. Eizirik, Belgium

EASD
EFSD

GENERAL
INFO

507 GDF15 is dispensable for the insulin-sensitising effects of chronic exercise

A. Labour, L. Frassin, M. Lac, C. Moro, France

PROGRAMME

TUESDAY

Short Oral Event B

Tuesday, 13:45 - 14:45

WEDNESDAY

SO 032 Insulin action in peripheral tissues

THURSDAY

508 Physical and functional interactions between angiotensin converting enzyme 2 and GLUT4 in 3T3L1 adipocytes

H. Sato, T. Fukushima, G. W. Gould, M. Kanzaki, Japan, UK

FRIDAY

509 Reduced insulin-induced capillary recruitment as a key defect in glucose extraction in type 2 diabetes

A. C. Hesp, L. Snel, B. Ariëns, A. H. Hulst, J. Hermanides, L. A. Schwarte, P. R. Schober, R. W. Ten Kate, D. Van Raalte, Netherlands, Austria,

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

510 The role of insulin on the hepatic translome

P. D. Teixeira, R. Meurs, G. Lucibello, G. Ursino, D. Gatfield, G. Ramadori, R. Coppari, Switzerland

SATELLITE
SYMPOSIA

511 Hepatic insulin clearance is associated with pancreatic fat fraction in ketosis-prone diabetes

P. Vellanki, D. A. Reiter, S. J. Edwards, E. E. Ray, O. Oladejo, D. Stefanovski, USA

INDUSTRY

PROGRAMME

512 The oxidized linoleic acid metabolite 9-hydroxyoctadecadienoic acid promotes metabolic adaptations in skeletal muscle

X. Yu, A. Krook, J. R. Zierath, N. J. Pilon, Sweden

EXHIBITION

513 Metabolic adaptations in the maintenance of body weight and glycaemia in food-restricted mice with physical exercise

S.-P. Chen, Z. Boudra, N. Kassis, J. Vily Petit, O. Viltart, G. Mithieux, C. Magnan, C. Cruciani-Guglielmacci, France

514 Investigating the role of TSC22D4 phosphorylation in metabolic control

S. Demir, J. Szendrödi, S. Herzig, B. Ekim, Germany

515 Genetic variation at RAB3GAP2 is associated with skeletal muscle capillary density

B. A. Mir, K. Ström, N. Oskolkov, S. Kalamajski, O. Ekström, P. Franks, O. Hansson, Sweden

Short Oral Event C

Wednesday, 12:45 - 13:45

EASD
EFSD

SO 033 Understanding insulin sensitivity: What can we learn from human studies?

GENERAL
INFO

516 Impact of low-calorie diets and bariatric surgery on organ-specific insulin sensitivity in the liver and skeletal muscle

M. Mori, Y. Takeshita, D. Matsubara, M. Okumura, S. Tokuno, H. Goto, Y. Nakano, T. Takamura, Japan

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

517 Measures of insulin clearance, insulin sensitivity, and insulin secretion and association with incident diabetes in older adults: a cardiovascular health study

S. Sarma, M. Biggs, D. Siscovick, J. Barzilay, R. Retnakaran, C. Kramer, L. Djousse, J. Ix, K. Jorge, K. Mukamal, USA, Canada

SHORT ORAL
DISCUSSIONS

518 NPH increases the risk of insulin resistance in type 1 diabetes

L. V. Silva, Liana C França, Paulo Z Silvano, Robson Barth, Gustavo J dos Santos., Brazil

PRESENTER
INDEX

519 Insulin resistance is associated with 31 diseases and all-cause mortality in females in the UK Biobank: a prospective cohort study

J. Wu, Y. Song, China

SATELLITE
SYMPOSIA

520 Assessing the cardiovascular implications of insulin resistance and adipose tissue distribution: a hospital-based investigation into the role of ectopic fat deposition

N. Kumar, A. Sinha, S. Jha, India

INDUSTRY

PROGRAMME

EXHIBITION

521 Plasma metabolomics and transcriptional profiling of adipose tissue in humans with inherited insulin resistance

P. M. Møller, R. Kruse Sørensen, A. B. Hansen, K. Brusgaard, J. Havelund, N. J. Færgeman, K. Højlund, Denmark

522 In monozygotic twin pairs discordant for BMI, six months of exercise training modulate microbiota composition and stimulate colon insulin sensitivity in leaner twins

M. Lietzén, M. Guzzardi, R. Ojala, J. Hentilä, M. C. Collado, R. Lautamäki, E. Löyttyniemi, K. H. Pietiläinen, J. Kaprio, L. Lahti, J. O. Rinne, T. Malm, P. Iozzo, J. C. Hannukainen, Finland, Italy, Spain

523 Estimation of muscle and hepatic insulin sensitivity in type 1 diabetes adults using clinical and research biomarkers

A. S. Januszewski, J. R. Snaith, G. Kowalski, C. Bruce, D. J. Holmes-Walker, A. J. Jenkins, J. R. Greenfield, Australia

EASD
EFSD

GENERAL
INFO

Short Oral Event D

Wednesday, 14:00 - 15:00

PROGRAMME

SO 034 Novel mechanisms of insulin resistance

TUESDAY

524 Elucidating the molecular mechanisms of obesity-induced insulin resistance: the role of NEDD4-2 in calcium homeostasis
S.-H. Kim, H.-O. Gu, J.-W. Lee, H. Rhu, H. Ahn, O.-H. Kim, B.-C. Oh, Republic of Korea

WEDNESDAY

THURSDAY

FRIDAY

525 Ramulus mori alkaloids improve intestinal oxidative stress and inflammation by regulating the gut microbiota and circle metabolites in PCOS

S. Geng, Y. Wang, China

SHORT ORAL
DISCUSSIONS

526 Impact of therapeutic use of levothyroxine in treatment on insulin resistance in untreated primary hypothyroidism patients

N. Kumar, S. Jha, A. Sinha, India

PRESENTER
INDEX

527 The mechanism of hepatic selenoprotein S deficiency aggravating insulin resistance based on transcriptomics

J. Du, L. Qiao, L. Men, X. Xie, China

SATELLITE
SYMPOSIA

528 Pharmacological intervention in insulin resistance: the role of angiotensin-II-receptor blockers in correcting intracellular Ca²⁺ dysregulation

B.-C. Oh, S.-H. Kim, J.-W. Lee, S. Noh, B. Amgalan, Y. Kim, S.-S. Im, O.-H. Kim, Republic of Korea

INDUSTRY

PROGRAMME

EXHIBITION

529 Multi-omics reveals tissue-specific mechanisms of hyperinsulinaemia and sucrose-induced insulin resistance

H. Cen, L. Hall, V. R. Richard, Y. Xia, S.-Y. Chen, S. Skovsø, J. Botezelli, X. Hu, J. Collier, R. P. Zahedi, C. H. Borchers, J. D. Johnson, Canada, USA

530 Unravelling the paracrine role of endothelial IGF-1R in basal hepatic insulin signalling

C. Luk, K. I. Bridge, N. Y. Yuldasheva, S. B. Wheatcroft, P. Sukumar, L. D. Roberts, R. M. Cubbon, M. T. Kearney, N. J. Haywood, UK

531 Impact of elevated branched-chain amino acid levels on insulin signalling and metabolic function: a preliminary in vitro study

F. Vanweert, A. Gemmink, G. Schaart, N. Gharahdaghi, K. Smith, D. Wilkinson, P. J. Atherton, L. J. Dubois, M. K. Hesselink, E. Phielix, Netherlands, UK

Short Oral Event E

Thursday, 12:45 - 13:45

SO 035 Non-insulin hormones

532 Serum 25-hydroxy vitamin D level is associated with elastography detected liver fibrosis in patients with type 2 diabetes, in a gender dependent pattern

X. Wu, N. Huang, L. Li, China

533 Pander interplay with il-6 in regulation of GLP-1 secretion

X. Cao, Z. Li, L. Pei, F. Lai, N. Chen, C. Xu, S. Liang, China

534 Age-related changes in glucagon secretion and effects of preservation of beta cell function on muscle mass in people with type 2 diabetes

K. Motohashi, S. Tokumoto, Y. Sogawa, S. Kaneko, Japan

535 Upregulation of portal GLP-1r density by targeted administration of dihydrotestosterone induces remission in a large animal model of type 2 diabetes

C. Malbert, R. Allouche, M. Horowitz, K. Jones, France, Australia

536 Fragmentation of circulating IGFBP-2 upon obesity and bariatric surgery

F. Picard, J. Faramia, S. Miard, Canada

537 The gut peptide Neurotensin stimulates the release of pancreatic polypeptide in healthy young men

S. Veedefald, C. Martinussen, M. Svane, T. Justinussen, M. Hindsø, N. Hedbäck, H. H. Thomsen, N. J. Albrechtsen, K. N. Bojsen-Moeller, B. Hartmann, J. F. Rehfeld, S. Madsbad, J. J. Holst, Denmark

538 Use of LC-MS/MS to quantify metabolically important pancreatic and enteroendocrine hormones in human plasma

C. Bannon, A. Punnoose, R. Kay, P. Fletcher, L. Moreno Lopez, F. Reimann, F. M. Gribble, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

539 The separate and combined effects of glucose-dependent insulinotropic polypeptide and alanine on plasma glucose during fasting in healthy individuals

A. M. Thomas, J. V. Warnøe, D. S. Mathiesen, E. M. Preskou, T. F. Dejgaard, A. B. Lund, J. Størling, M. B. Christensen, L. S. Gasbjerg, F. K. Knop, Denmark

Short Oral Event F

Thursday, 14:00 - 15:00

EASD
EFSD

GENERAL
INFO

SO 036 Keeping your beta cells alive

540 Irisin restores the secretory function of pancreatic beta cells in experimental and human type 2 diabetes

N. Marrano, A. Borrelli, G. Biondi, M. Rella, L. Roberto, L. Vincenti, A. Cignarelli, S. Perrini, L. Laviola, F. Giorgino, A. Natalicchio, Italy

541 Persistence of beta cells secreting proinsulin in long-standing patients with minimal residual insulin secretion

E. Larger, F. Bonnet, S. Daclin, R. Mallone, J. Guibourdenche, France

542 Prediction of insulin requirement in type 2 diabetes patients using a glucagon test

J.-L. Nguewa, S. Kadiri, N. Legros, N. Venteclef, J. Julla, J. Gautier, G. Velho, P. Boudou, France

543 Variability in beta cell function trajectories following surgical-induced beta cell mass reduction

R. Bizzotto, G. Di Giuseppe, C. Rossi, L. Soldovieri, F. Cinti, S. Moffa, M. Brunetti, G. Ciccarelli, S. Alfieri, G. Quero, A. Mari, A. Giaccari, T. Mezza, Italy

544 HMB, lysine, and arginine: a combination of ingredients that potentiates the glucose-stimulated insulin secretion via ERK1/2 activation in pancreatic beta cells

J. M. López-Pedrosa, M. Manzano, R. Salto, M. D. Girón, P. Bueno-Vargas, R. Rueda, Spain

545 Improvement of beta cell function and glucagon secretion by dietary weight loss of >10 kg in patients with type 2 diabetes

E. Lalama, J. Zhang, B. Schuppelius, K. Rütther, M. Csanalosi-Artigas, N. Kraenkel, S. Kabisch, K. Mai, E. Latz, A. Christ, D. Trico, A. Mari, A. F. Pfeiffer, Germany, Italy

546 Hormone characteristics of post-acute pancreatitis diabetes: insulin resistance accompanied by dysregulated glucagon and pancreatic polypeptide secretion

Y. Lv, L. Li, China

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

547 Non-targeted metabolomic profiling reveals novel metabolite biomarkers of post-acute pancreatitis diabetes compared with type 2 diabetes

Y. Lv, L. Li, China

Short Oral Event A

Tuesday, 12:30 - 13:30

SO 037 New approaches in carbohydrate metabolism

548 Gut microbial flora and development of diabetes and obesity in rodents

Z. Boudra, S.-P. Chen, I. Raho, C. Cruciani-Guglielmacci, C. Magnan, France

549 Diabetes in the outcome of chronic pancreatitis: specific features course and therapy

K. Amikishieva, A. Ametov, A. Shabunin, E. Pashkova, Russian Federation

550 Ace2 modulates diabetes-associated gluconeogenesis in the kidneys

T. J. Block, C. Tikellis, M. C. Thomas, Australia

551 Experienced blood glucose regulation after menopause: a cross-sectional survey in women with type 1 diabetes

E. M. Speksnijder, S. Simsek, P. H. Bisschop, D. J. Stenvers, S. E. Siegelaar, Netherlands

552 Modulation of gut microbiota homeostasis as a strategy to prevent diabetes progression: the role of dietary carbohydrate quality

J. M. López-Pedrosa, M. Manzano, M. T. García-Corcoles, R. Rueda, Spain

553 Relative contributions of fasting vs postprandial hyperglycaemia to overall glycaemic control in newly-diagnosed type 2 diabetes before and following 3 months' treatment

Y. Sun, Y. Luo, C. Xie, J. Ma, K. Jones, M. Horowitz, C. Rayner, T. Wu, Australia, China

554 Characteristics of glucokinase regulatory protein missense mutations with distinct effects on hepatic lipid metabolism suggest a gene regulatory function of glucokinase

S. Langer, D. Jagdhuhn, R. Waterstradt, J. Gromoll, M. Müller, M. G. Rees, A. L. Gloyn, S. E. Baltrusch, Germany, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 038 Novel pharmacological approaches for the treatment of obesity and diabetes

555 Dual amylin and calcitonin receptor agonist treatment increases proton leak of skeletal muscle in obesity rat model

E. A. Petersen, I. Blom, S. Cubranovic, S. Larsen, M. A. Karsdal, K. Henriksen, A. T. Larsen, Denmark, Poland, Switzerland

EASD
EFSD

556 The dual amylin and calcitonin receptor agonist KBP-336 induces significant weight loss with preserved muscle function and strength

A. T. Larsen, K. Mohamed, E. Petersen, M. A. Karsdal, K. Henriksen, Denmark, Switzerland

GENERAL
INFO

PROGRAMME

TUESDAY

557 Pemvidutide preserves lean body mass during weight loss in patients with overweight and obesity: results of a phase 2, MRI-based body composition sub-study

S. Heymsfield, J. Suschak, J. Kasper, J. Gutierrez, S. Tomah, L. Johansson, E. Johansson, J. Yang, S. Keeton, M. Roberts, M. Harris, S. K. Browne, USA, Sweden

WEDNESDAY

THURSDAY

FRIDAY

558 Petrelintide significantly reduces fat mass while preserving lean mass and selectively reducing intake of high fat diet in DIO rats

B. Vestergaard, T. Baader-Pagler, J. Griffin, Denmark, Germany

SHORT ORAL
DISCUSSIONS

559 The novel Cannabinoid receptor 1 inverse agonist, INV-347, improves metabolic outcomes in obese mice

A. Vivoli, F. Paré, V. Facca, G. Gaucher, G. Crater, G. Lim, Canada

PRESENTER
INDEX

560 FGF21 gene therapy: a single administration treatment strategy to treat severe obesity and associated comorbidities

E. Talamonti, X.-R. Peng, T. Hagstedt, C. Binny, L. Bergenholm, A.-C. Andreasson, I. Ahlstedt, L. Aasehaug, A. Ahnmark, B. Zarrouki, Sweden, UK

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

561 No clinically relevant QTc prolongation with cagrilintide: a thorough QT study in healthy participants

M. B. Gabe, R. Fuhr, A. Sinn, A. Eliassen, K. K. Berthelsen, A. B. Kuhlman, T. A. Bækdal, A. B. Nejad, Denmark, Germany

EXHIBITION

562 Amino acids plasma levels do not correlate with lean mass loss in weight matched DIO mice treated with survodutide or semaglutide

K. Klepac-Bartl, M. Pereira, T. Zimmermann, W. Rist, B. Bajrami, T. Kloeckner, T. Klein, Germany

SO 039 Improving metabolic outcome by bariatric surgery

563 Impact of pre-surgery post prandial hypoglycaemia on metabolic outcomes after surgery: a 2yr follow-up study

L. Bonvicini, D. Moriconi, P. Troia, C. Moretto, M. Nannipieri, Italy

564 Changes in beta cell mass in remission of type 2 diabetes after Roux-en-Y gastric bypass surgery, quantified in vivo by

⁶⁸Ga-exendin-4 PET/CT

L. Deden, M. Boss, S. Tokgöz, H. De Boer, E. Aarts, A. Van Bon, I. Janssen, F. Berends, B. E. Galan, E. Hazebroek, M. Gotthardt, Netherlands

565 Gastro-intestinal effects of metformin on glucose homeostasis and enterohormone secretions after bariatric surgery

M. Hirlemann, A. Willemetz, L. Ribeiro-Parenti, T. Bertrand, J. Movassat, C. Carette, M. Le Gall, France

566 Effects and safety of bariatric surgery in obese individuals with type 2 diabetes: a nationwide, matched, observational cohort study

A. Mejaddam, H. K. Carlsen, G. Höskuldsdóttir, J. Ottosson, E. Stenberg, B. Eliasson, Sweden

567 Sleeve gastrectomy alters intestinal morphology and the number and localisation of incretin-producing cells

N. Wada, N. Harada, T. Hatoko, S. Kiyobayashi, T. Yasuda, K. Yamamoto, X. Lu, Y. Seno, T. Kurihara, S. Yamane, Y. Hayashi, N. Inagaki, D. Yabe, Japan

568 Assessment of the quality of life in patients with morbid obesity and type 2 diabetes after bariatric surgery

Z. Shamansurova, E. Adilkhodjaeva, U. Bozorov, Uzbekistan

569 Ultra-processed food consumption and indicators of adiposity in South Asia: findings from the South Asia Biobank in Bangladesh, India, Pakistan, and Sri Lanka

D. Bhagtani, J. Adams, A. Lahiri, K. I. Khawaja, V. Jha, A. Kasturiratne, P. Katulanda, M. K. Mridha, R. M. Anjana, J. C. Chambers, N. G. Forouhi, UK, Pakistan, India, Sri Lanka, Bangladesh, Singapore

570 Comparative analysis of DNA methylation patterns in adipose tissue and blood following bariatric surgery: insights into inflammatory state reflection

L. Müller, A. Hoffmann, S. H. Bernhart, A. Gosh, J. Zhong, W. Sun, H. Dong, F. Noé, C. Wolfrum, A. Dietrich, L. Massier, M. Blüher, P. Kovacs, R. Chakaroun, M. Keller, Germany, Switzerland, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

571 Canagliflozin or acarbose vs placebo to ameliorate post-bariatric hypoglycaemia: the HypoBar I randomised clinical trial
 C. B. Lobato, C. T. Winding, K. N. Bojsen-Møller, B. Hartmann, C. Martinussen, S. Veedfald, J. J. Holst, S. Madsbad, N. B. Jørgensen, C. Dirksen, Denmark

Short Oral Event D

Wednesday, 14:00 - 15:00

EASD
EFSD

SO 040 Now the brown fat talks

GENERAL
INFO

572 Acute cold exposure differentially affects fasting and postprandial hormone secretion in participants with obesity compared to leans

M. Monfort-Pires, T. Saari, M. U-Din, F. Acosta Manzano, J. Örling, S. E. Zaidi, M. Karjalainen, K. Pohjanoksa, A. Tornio, K. A. Virtanen, Finland

PROGRAMME

TUESDAY

573 Higher brown adipose tissue glucose uptake is related to better glycaemic control

T. Saari, M. Karjalainen, J. Örling, A. K. Kirjavainen, M. Monfort-Pires, F. M. Acosta, M. U-Din, K. A. Virtanen, Finland

WEDNESDAY

THURSDAY

FRIDAY

574 Neuronostatin modulates proliferation and differentiation of rat primary brown preadipocytes

M. Krążek, T. Wojciechowicz, J. Fiedorowicz, M. Z. Strowski, K. W. Nowak, M. Skrzypski, Poland, Germany

SHORT ORAL
DISCUSSIONS

575 Adipocyte-specific deletion of PGC-1 co-activators disrupts brown adipose tissue secretory function and induces glucose intolerance

J. A. Villena, M. Velilla, N. Tellez, R. Pardo, Spain

PRESENTER
INDEX

576 Analysis of age-related metabolic changes in thermogenic adipocytes

J. Heida, S. Gohlke, T. Schulz, Germany

SATELLITE
SYMPOSIA

INDUSTRY

577 Serotonin transporter expression relates to cold-stimulated brown fat metabolism in adult humans

M. U-Din, J. R. Raiko, T. Niemi, T. Fromme, O. Eskola, M. Klingenspor, P. Nuutila, K. A. Virtanen, Finland, Germany

PROGRAMME

EXHIBITION

SO 041 Towards a better understanding of the adipose tissue - liver axis

578 A clinically relevant variant of SHP-1 preserves glucose homeostasis and hepatic insulin sensitivity during aging despite B cell infiltration and matrix deposition

B. Laborit Labrada, K. Bellmann, M. Pineault, M. Schwab, A. Kumar, M. Laplante, M. C. Morissette, A. Marette, Canada

579 Impact of sarcopenic obesity on metabolism-associated fatty liver disease (MAFLD) and glucose metabolism

J. Xia, China

580 Impact of hepatic steatosis and senescence on dynamic glucagon secretion: A potential mechanism of hypoglycaemic risk in metabolic dysfunction-associated steatotic liver disease?

S. Kim, M. Lee, S. Choi, B.-W. Lee, E. Kang, B.-S. Cha, Y.-H. Lee, Republic of Korea

581 The impact of exercise training on hepatic fibrosis based on serum proteomic analysis

Z. Cai, Q. Wang, X. Zhou, C. Ni, H. Wang, X. Wang, Y. Yuan, Z. Sun, China

582 P62-mediated proteasomal degradation of perilipin 1 enhances anti-obesity effects by boosting lipolysis in white adipose tissue

S.-H. Go, J.-Y. Yun, Y. Cho, E. Koh, Republic of Korea

583 Adaptive metabolic responses facilitate blood-brain barrier repair in ischaemic stroke via BHB-mediated epigenetic modification of ZO-1 expression

Y. Huang, R. Li, Y. Liu, China

584 Early dynamics in ectopic fat in multiple organs during individualised weight loss in obese individuals with non-alcoholic fatty liver disease and the metabolic syndrome

M. Ulanowska, M. Gjela, A. Askeland, R. W. Rasmussen, P. Vestergaard, J. Brøndum Frøkjær, M. Møllergaard, A. Handberg, Denmark

585 Age-related epigenetic marks in muscle and liver have functional and clinical consequences in subjects before and after obesity surgery

A. Khamis, M. Boissel, L. Ning, L. Maurin, V. Raverdy, B. Staels, L. Philippe, F. Pattou, A. Bonnefond, P. Froguel, France, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 042 How lifestyle affects our health**586 Exercise training does not reverse the obesity-induced increase in insulin-stimulated brain glucose uptake but improves cognition in MZ-twin pairs discordant for BMI**

J. Hentilä, J. Tuisku, R. Ojala, M. S. Lietzén, R. Lautamäki, K. Koskensalo, E. Löyttyniemi, R. Parkkola, L. Nummenmaa, K. H. Pietiläinen, J. Kaprio, L. Lahti, J. O. Rinne, T. Malm, J. C. Hannukainen, Finland

EASD
EFSDGENERAL
INFO**587 Impact of the time-restricted eating on the lipid metabolism in subjects with high diabetes risk**

K. Szekely, M. J. Gerl, B. Peters, J. Schwarz, B. Schuppelius, C. Klose, K. Simons, A. F. Pfeiffer, A. Kramer, A. Michalsen, O. Pivovarova-Ramich, Germany

PROGRAMME

TUESDAY

WEDNESDAY

588 The correlation between households food insecurity and obesity in youth in the United States: findings from the NHANES 2017-2018 survey

S. Gheibi, A. Mokari-Yamchi, A. Faghfour, Netherlands, Iran, Islamic Republic of

THURSDAY

FRIDAY

589 Long-term effects of sweeteners and sweetness enhancers consumption after weight loss on the gut microbiota composition in individuals with overweight or obesity: the SWEET study

M. Pang, J. Bastings, A. Umanets, M. Maurer-Sost, L. Kjølbæk, A. Martinez, Y. Manios, S. Navas-Carretero, E. Feskens, J. A. Harrold, J. C. Halford, T. Adam, G. Goossens, A. Raben, E. E. Blaak, Netherlands, Denmark, Spain, Greece

SHORT ORAL
DISCUSSIONSPRESENTER
INDEXSATELLITE
SYMPOSIA**590 Maternal over-nutrition exacerbated offspring hepatic lipid accumulation via butyrate-AMPK-pHDAC5 pathway**

J. Zheng, J. Zhang, L. Zhang, S. Zhang, China

INDUSTRY

PROGRAMME

591 The role of weight loss and diabetes duration for the remission of human type 2 diabetes in response to three months of very low caloric formula diets

B. Schuppelius, E. Lalama, J. Zhang, K. Rütter, M. Csanalosi, S. Kabisch, K. Mai, A. F. Pfeiffer, Germany

EXHIBITION

592 Skeletal muscle mitochondria respond differently to weight loss induced by bariatric surgery or caloric restriction

B. W. Van der Kolk, S. Heinonen, J. White, A. Wagner, J. Karppinen, M. Muniandy, S. Saari, T. Saarinen, C. Le Roux, K. A. Virtanen, N. G. Docherty, E. Pirinen, A. Juuti, K. H. Pietiläinen, Finland, Ireland

593 Effect of time restricted feeding (TRF) on REV/ROR alpha gene on CYP11a1 protein expression in the ileum epithelium cells and rhythmic abundance of gut microbiota in pre-diabetic mice
 B. Anjum, K. Ahmad, S. Tiwari, R. Sinha, M. Godbole, India

Short Oral Event A,

Tuesday, 12:30 - 13:30

SO 043 Inflammation and beta cell homeostasis

594 The effect of ketogenic diet vs Mediterranean diet on clinical and biochemical markers of inflammation in patients with obesity and psoriatic arthritis

A. Kountouri, P. Katsimbri, E. Korakas, L. Pliouta, E. Maratou, G. Pavlidis, A. Papathanasi, I. Ikonomidis, E. Papadavid, S. Malisova, D. Vlachos, V. Lambadiari, Greece

595 Omega-3 fatty acids partially reverts the inflammation and insulin resistance in the hippocampus of obese and diabetic mice through GPR120 receptor

D. E. Cintra, M. Sant'Anna, K. C. Rodrigues, L. Moura, J. R. Pauli, E. R. Ropelle, A. S. Silva, M. Balthazar, Brazil

596 A deeper understanding of the role of circulating cell free DNA in obesity: a potent immune activator

P. Apalaki, C. M. Cheimonidi, K. Stratigi, G. Chatzinikolaou, M. Karaglani, G. Tarapatzi, M. Panagopoulou, E. A. Chatzaki, Greece

597 Exploring the molecular mechanisms underlying the role of GRK2 in macrophage activation

R. Santos-Clemente, F. Mayor Jr, I. García-Higuera, Spain

598 Transfer RNA fragments induced during obesity hold regulatory functions in islet macrophage activation and beta cell homeostasis

C. Cosentino, R. Klein, V. Menoud, A. Galli, F. Brozzi, S. Poddar, C. Guay, R. Regazzi, Switzerland

599 The transcription factor p53 regulates adipose tissue macrophages' phenotype and their capacity to handle lipids

J. Jager, I. Mucel, M. Gaudfrin, J. Frère, J. Gilleron, J.-F. Tanti, M. Cormont, France

600 Role of miRNAs and tRNA fragments in senescence-induced deregulation of pancreatic beta cell function

C. Guay, V. Menoud, C. Aguayo-Mazzucato, S. Bonner-Weir, R. Regazzi, Switzerland, USA

EASD EFSD
GENERAL INFO
PROGRAMME
TUESDAY
WEDNESDAY
THURSDAY
FRIDAY
SHORT ORAL DISCUSSIONS
PRESENTER INDEX
SATELLITE SYMPOSIA
INDUSTRY
PROGRAMME
EXHIBITION

601 Impact of liver fat content on serum levels of plasminogen activator inhibitor-1, fibroblast growth factor 21 and cerebral microcirculation in type 2 diabetes and obesity

M. Káplár, R. Esze, L. Rajnai, S. Somodi, G. Paragh, M. Katkó, Z. Képes, L. Balkay, I. Garai, M. Emri, P. Fülöp, Hungary

Short Oral Event B

Tuesday, 13:45 - 14:45

EASD
EFSD

SO 044 Lipid signatures and ectopic fat

GENERAL
INFO

602 Association of serum sclerostin levels in type 1 and type 2 diabetes with low muscle density and high visceral fat: the Diafall study

N. Rasmussen, A. Vestergaard Kvist, J. Van den Bergh, P. Vestergaard, Denmark, Netherlands

PROGRAMME

TUESDAY

603 Lipid signature of changes women with gestational diabetes in response to puerperal exclusive breastfeeding

L. Li, J. He, X. Cui, C. Ji, China

WEDNESDAY

THURSDAY

604 Expression of adipocytokines in human peri-pancreatic adipose tissue and correlations with beta cell function

M. Suleiman, G. Gambino, M. Tesi, C. De Luca, R. Del Testa, S. Del Guerra, L. Marselli, P. Marchetti, L. Rossi, Italy

FRIDAY

SHORT ORAL
DISCUSSIONS

605 Lipolysis-dependent lipids secretion mediate adipose tissue and pancreas crosstalk in early stages of insulin resistance

F. Almeida-Oliveira, J. M. Alves, P. H. Melo, N. Pereira, T. T. Gonçalves, A. M. Pinto, A. Saghatelian, S. Offermanns, L. O. Leiria, Brazil, Germany, USA

PRESENTER
INDEX

SATELLITE
SYMPOSIA

606 Risk factors for predicting visceral fat in type 2 diabetes individuals with normal body mass index

Y. Li, M. Jiao, Y. Yang, W. Tao, Y. Feng, X. Wang, China

INDUSTRY

PROGRAMME

607 Characterisation of extracellular matrix remodelling in adipose tissue of diet-induced obese mice using an untargeted proteomics approach

D. Sarnobat, X. Weng, R. Stimpson, L. Kang, UK

EXHIBITION

608 Defective G-CSF in the secretome of epicardial adipose cells favors apoptosis and cellular stress of cardiac progenitor cells in human obesity

G. Palma, C. Caccioppoli, R. D'Oria, V. Genchi, I. Calderoni, T. Bottio, A. Braun, G. Santarpino, A. Cignarelli, A. Natalicchio, L. Laviola, A. Pezzolla, A. M. Valverde, F. Giorgino, S. Perrini, Italy, Spain

609 12,13-diHOME protects against obesity-related kidney disease by regulating PLIN5-mediated lipid metabolism

X. Sun, K. Zhang, W. Zhang, H. Qiu, J. Shi, J. Zhang, C. Kan, F. Han, N. Hou, Z. Guo, China

Short Oral Event C

Wednesday, 12:45 - 13:45

SO 045 Preclinical advances to better understand energy, glucose and lipid metabolism

610 Combinations of the mitochondrial protonophore TLC-6740 and/or the ACC2 inhibitor TLC-3595 provide additive glycaemic benefits to glucagon-like-peptide-1 receptor agonist in db/db mice

A. Vijayakumar, N. Sroda, E. Murakami, S. Weng, R. P. Myers, G. M. Subramanian, G. I. Shulman, USA

611 TLC-6740, a liver-targeted mitochondrial protonophore, increases energy expenditure and lipid utilisation in obese mice

A. Vijayakumar, N. Sroda, E. Murakami, S. Weng, G. I. Shulman, R. P. Myers, G. M. Subramanian, USA

612 Characterisation of intestinal K/I cells utilising GIP/CCK double reporter mice

Y. Seno, N. Harada, E. Ikeguchi-Ogura, X. Lu, K. Yamamoto, T. Yasuda, H. Tatsuoka, T. Kato, N. Inagaki, D. Yabe, Japan

613 Intergenerational and transgenerational inheritance of obesity in a mouse model of childhood obesity: role of germline small non-coding RNAs

M. Mourin, F. Palmieri, I. Palacios-Marin, M. Ramon-Krauel, C. Lerin, J. Jimenez Chillaron, Spain

614 Modelling type 2 diabetes remission: the NONcNZO10/LtJ polygenic mouse model is ideal to study de novo lipogenesis

L. Zhang, S. Kaluzny, A. Onishi, J. Junior, A. Von Kriegsheim, N. M. Morton, A. H. Al-Mrabeh, UK

615 IGF2 deficiency promotes obesity by inhibiting testosterone synthesis through suppression of autophagy

X. Lin, C. Zhou, W. Gui, F. Wu, China

616 Lipoxins-mediated restoration of lymphatic functions in an experimental model of obesity

M. Clark, Y. Subashi, K. Fujita, S. Tavajoh, A. Peluzzo, B. E. Suur, M. Quiding-Järbrink, S. Karaman, S. Lange, E. Börgeson, Denmark, Finland, USA, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

617 The impact of early vs postponed statin therapy after ovarian cycle loss on insulin resistance parameters in a prediabetes model
M. Hüttl, I. Markova, H. Malinska, D. Miklankova, K. Cerna, T. Hlinka, J. Pitha, Czech Republic

Short Oral Event D

Wednesday, 14:00 - 15:00

EASD
EFSD

SO 046 What's new on white fat function?

618 Decoding transcriptional regulatory circuits associated with energy expenditure in human adipocytes and implications for diabetes risk

M. Verma, D. P. Hupkes, L. Pagie, A. Chandran, G. Atla, M. Ramírez, W. Gan, C. Vangjeli, T. H. Meek, J. Van Arensbergen, E. M. Toledo, C. Åmmälä, UK, Netherlands

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

619 Association between longitudinal changes of targeted metabolites and of insulin clearance in non-diabetic individuals: an IMI DIRECT study

C. Rossi, M. Haid, S. Sharma, J. Adam, J. Adamski, D. Tricò, E. R. Pearson, A. Mari, R. Bizzotto, Italy, Germany, UK

620 The sartorius fat fraction is independently associated with myocardial fibrosis in Chinese patients with obesity

Z. Wang, J. Yue, Q. Lu, Y. Qi, H. Zhao, M. Jiang, J. Bu, J. Ma, China

621 Transcriptomic reveals new keys in the subcutaneous adipose depot remodeling after bariatric surgery

E. Martínez, P. Fernández García, D. Rodríguez, S. Martínez, M. Álvarez Antolinez, M. Ros, P. Corrales-Cordon, D. Sánchez-Infantes, Spain

622 Extracellular vesicles mediate the communication of adipose tissue with hypothalamus and involved in maintaining energy homeostasis

J. Wang, Y. Bi, China

623 Subcutaneous adipose tissue aromatase expression and oestrogen signalling: potential contributors to insulin resistance in men with obesity and type 2 diabetes

M. J. Pereira, F. Ahmed, R. Laterveer, S. Hetty, A. Mathioudaki, E. Hornbrinck, V. Patsoukaki, M. Sundbom, M. K. Svensson, J. W. Eriksson, Sweden

624 Metabolic function of MLKL, the mediator of necroptosis, in adipose tissue

V. Pistorio, J. Tokgozoglu, P.-A. Soret, V. Steunou, L. Serfaty, V. Ratziu, J. Gautheron, France

625 Analysing epigenetic contributions to diabetes and obesity across generations in families with metabolic disorder

A. Shankar, S. Kumar, A. Das, India

Short Oral Event E

Thursday, 12:45 - 13:45

SO 047 Novel mechanisms regulating energy and glucose metabolism

626 Role of endoplasmic reticulum stress activation in diabetes related intestinal barrier dysfunction

F. De Vito, A. Facciolo, E. Suraci, R. Marasco, F. Luzzza, M. L. Hribal, G. Sesti, F. Andreozzi, T. V. Fiorentino, Italy

627 ARHGEF3 plays multifaceted roles in adipogenesis through its interplay with YAP and PPAR γ

M.-S. Yoon, Republic of Korea

628 Role of FKBP5 in adipose tissue function: implications for obesity and insulin sensitivity

R. Laterveer, S. Hetty, M. Lundqvist, P. Katsogiannos, J. W. Eriksson, M. J. Pereira, Sweden

629 Olfactory system is a target to control lipid and glucose homeostasis in mice

M. Sugiyama, H. Tsuneki, T. Yamagishi, K. Onishi, T. Wada, T. Sasaoka, Japan

630 Targeting BRD4-HK2 reverses perivascular adipose tissue meta-inflammation shift and rescues cardiometabolic vascular dysfunction

A. Mengozzi, S. Costantino, A. Mongelli, E. Duranti, S. A. Mohammed, E. Gorica, F. Cappelli, C. M. Matter, S. Taddei, S. Masi, F. Ruschitzka, A. Virdis, F. Paneni, Italy, Switzerland

631 Hypothalamic fibroblast growth factor-1 regulates energy homeostasis

H. Shin, J. Suh, Republic of Korea

632 The DNER/NOTCH-1 couple contributes to adipose tissue inflammation and insulin resistance in obesity

F. Blangero, J. Pestel, B. Le Magueresse-Battistoni, Y. Gouriou, M. Robert, H. Vidal, L. Pirola, A. Eljaafari, France

633 Multilevel involvement of Alx3 in the regulation of glucose-induced insulin secretion

M. Mirasierra, A. Bartolomé, M. Vallejo, Spain

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 048 Novel mechanisms controlling glucometabolic health

634 Longitudinal analysis of microbial metabolites in a prediabetes mouse model

M. V. Joglekar, N. H. Pham, M. Thanki, E. Alvandi, W. K. Wong, A. Hardikar, Australia

EASD
EFSD

635 Subcutaneous adipose tissue expression of the Notch signalling pathway genes in relation to insulin sensitivity, obesity, and markers of adipogenesis

N. Matulewicz, M. Dobrzycka, M. Stefanowicz, P. Mysliwiec, J. Dadan, I. Kowalska, M. Karczewska-Kupczewska, Poland

GENERAL
INFO

PROGRAMME

TUESDAY

636 Unravelling p53's role in AGE-induced adipose tissue dysfunction

N. Kavin, N. Kislev, D. Benayahu, Israel

WEDNESDAY

THURSDAY

637 B cell-derived Nociceptin contributes to immune cell trafficking and insulin resistance in obesity

S. Puente-Ruiz, A. Hoffmann, P. Czechowski, M. Blüher, N. Klötting, F. Wunderlich, J. Brüning, A. Jais, Germany

FRIDAY

638 Deletion of miR-494 promotes skeletal muscle mitochondrial biogenesis and extends a healthy lifespan in mice

L. Sugawara, K. Morino, H. Iwasaki, M. Lemecha, S. Ida, D. Yanagisawa, H. Maegawa, S. Kume, Japan, USA

SHORT ORAL
DISCUSSIONS

639 The LMK-235, an HDAC inhibitor, prevented diabetic skeletal muscle atrophy

K.-W. Lee, S. Park, Y. Kim, Y. Kim, S.-E. Choi, Y. Son, T. Kim, S. An, N. Lee, J. Jeon, S. Han, H. Kim, D. Kim, Republic of Korea

PRESENTER
INDEX

SATELLITE
SYMPOSIA

640 N-acetylaspartylglutamic acid: A novel hippocampal compensatory mechanism against glucose intolerance in obesity?

B. Caramelo, V. Mendes, A. Cortez, T. Monteiro-Alfredo, J. Sereno, J. Martins, M. Castelo-Branco, P. Matafome, B. Manadas, Portugal, Brazil

INDUSTRY

PROGRAMME

641 The NPY/melanocortin system in white adipose tissue is regulated by ghrelin and leptin and is impaired in patients with insulin resistance

D. Rosendo-Silva, E. Lopes, T. Monteiro-Alfredo, I. Falcão-Pires, H. C. Eickhoff, S. Viana, F. Reis, A. Pires, A. Abrantes, F. Botelho, R. Seça, P. Matafome, Portugal

EXHIBITION

SO 049 Novel clinical insights into adipose tissue function

642 Liver fat content, regulated by BMI, as a potential marker for subclinical myocardial remodelling and dysfunction in obese adults

X. Wan, J. Yue, Q. Lu, H. Zhao, S. He, Y. Qi, M. Yang, J. Che, M. Jiang, J. Bu, J. Ma, China

643 In type 2 diabetes, epicardial adipose tissue displays enhanced senescence of mesenchymal stem cells

G. Ferraro, S. Cabaro, S. Romano, R. De Martino, V. D'Esposito, V. Parisi, M. F. Di Tolla, F. Mormone, C. Morelli, F. Oriente, D. Leosco, F. Beguinot, P. Formisano, Italy

644 Body fat distribution differs between people with autoimmune diabetes and healthy controls

R. Amendolara, R. Risi, A. Balena, M. Watanabe, D. Masi, L. D'Onofrio, L. Gnessi, R. Buzzetti, E. Maddaloni, Italy

645 The serum-derived extracellular vesicle lipidome is altered in people with type 2 diabetes

D. Paget, A. Checa, K. MacGregor, H. Wallberg-Henriksson, J. R. Zierath, A. Krook, Sweden

646 Sodium-glucose cotransporter 2 inhibitors attenuate cellular senescence through regulation of TonEBP expression in obesity and diabetic kidneys

S. KIM, J. Kim, J. Bae, M. Lee, Y. Kang, D. Yi, D. Kim, Republic of Korea

647 Correlation between of IGF2 and testosterone in overweight and obese adolescent boys

C. Zhou, D. Wu, X. Lin, China

648 Metabolic dysfunction-associated fatty liver disease and obesity can modify the inflammation and complement activation in type 2 diabetes

E. Sipter, L. Barkai, K. Babayigit, D. Csuka, Z. Prohaszka, N. Hosszufalusi, Hungary

649 Circadian rhythmicity in human subcutaneous und visceral adipocytes

O. Pivovarova-Ramich, L. Meyer, V. Lange, C. Dibner, Germany, Switzerland

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 050 Understanding and combating adipose tissue dysfunction**650 Plakoglobin ablation in adipocytes exacerbates high-fat diet induced weight gain**

F. Abou Azar, F. Paré, W. Shou, G. Lim, Canada, USA

EASD
EFSD

651 SVEP1-based peptide modulates adipose tissue dysfunction and insulin resistance via macrophage-driven inflammation inhibition

N. Kislev, N. Kavin, D. Benayahu, Israel

GENERAL
INFO

652 Novel genotype profiles in digenic triallelic obesity: coexistence of ciliopathy syndromes with PSCK1 mutations

S. Dagdelen, N. Basmaci, S. H. Oguz, Turkey

PROGRAMME

TUESDAY

653 CLDN1 and its novel role in adipose tissue physiopathology: studies in a mice aging model

P. Fernández-García, P. Corrales, M. Martín-Taboada, J. Tarascó, S. Pellitero, M. Ros, R. Cereijo, F. Villarroya, G. Medina, D. Sánchez-Infantes, Spain

WEDNESDAY

THURSDAY

FRIDAY

654 Empagliflozin, an SGLT2 inhibitor, prevented palmitate-induced lipotoxicity through enhanced fatty acid oxidation and reduced stress signals

T. Kim, Y. Kim, S. Park, Y. Kim, S.-E. Choi, Y. Son, S. An, J. Jeon, N. Lee, S. Han, H. Kim, D. Kim, K.-W. Lee, Republic of Korea

SHORT ORAL
DISCUSSIONS

655 Adipose Angptl8 controls glucose and energy metabolism and its suppression in mice improves diet induced obesity

M. Abu-Farha, A. Ghosh, I. Chenier, Y. Leung, A. Oppong, M.-L. Peyot, M. S. Madiraju, I. Al-Khairi, J. Abubaker, F. Al-Mulla, M. Prentki, Kuwait, USA, Canada

PRESENTER
INDEX

SATELLITE
SYMPOSIA

656 Early liver lipidome markedly contributes to the development of diabetes mediated by an active adipose-liver interaction

R. Sehgal, M. Jähnert, M. Lazaratos, T. Speckmann, M. Ouni, W. Jonas, A. Schürmann, Germany

INDUSTRY

PROGRAMME

EXHIBITION

657 Regulation of adipogenesis by 14-3-3ζ scaffold protein occurs via modulation of chromatin accessibility in the initial phases of adipocyte differentiation

S. Rial, Z. You, A. Vivoli, D. Sean, A. Al-khoury, G. Lavoie, M. Civelek, A. Martinez-Sanchez, P. P. Roux, T. T. Durcan, G. Lim, Canada, France, USA, UK,

658 Changes in human serum VEGFb levels by preferential oil intake might be related to fatty acid effects on adipocyte's VEGFb gene methylation, expression and protein levels

W. Oualla-Bachiri, A. Lago-Sampedro, S. Valdés, C. Maldonado-Araque, I. González-Molero, G. Rojo-Martínez, S. Garcia-Serrano, E. Garcia-Escobar, Spain

Short Oral Event C

Wednesday, 12:45 - 13:45

SO 051 Metabolic alterations in obesity and diabetes-linked co-morbidities

659 Association between diabetes and sarcopenic obesity in older outpatients in Vietnam

T. N. Nguyen, H. T. Nguyen, T. X. Nguyen, H. T. Vu, Viet Nam

660 Identification of transcriptome alterations in the central amygdala of rats with painful diabetic neuropathy

X. Nie, China

661 Cardio-metabolic risk in patients with grade III obesity before and after weight loss

A. Penesová, L. Kubanova, M. Páleník, J. Babjakova, I. Hric, V. Bielík, Slovakia

662 Exploring inflammatory resolution pathways in patients with elevated systemic inflammation and cardiometabolic diseases

S. Tavajoh, M. Clark, A. Becerril-Campos, B. E. Suur, P.-A. Jansson, M. Soták, E. Börgeson, Denmark, Sweden

663 The anti-senescence effect of DPP-IV inhibitor gemigliptin on vascular tissue

M.-K. Kim, J. Park, Republic of Korea

664 Patient in a dish: mimicking patient phenotypes in 3D adipocyte spheroids

B. E. Suur, S. Tavajoh, M. Clark, A. Becerril-Campos, M. R. Rajan, B. Medelyte, A. Maestri, P.-A. Jansson, M. Soták, C. E. Hagberg, E. Börgeson, Denmark, Sweden

665 The efficacy and safety of liraglutide 3.0 mg for weight management as an add-on treatment in obese adolescents with type 1 diabetes

N. Elbarbary, S. Abouelnasr, Egypt

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

666 Adipose tissue in patients with morbid obesity with or without chronic kidney disease: differences in circulating adipocytokines, miRNAs, isomiRs and adipose tissue gene expression

R. Vila Bedmar, M. Martin-Taboada, B. Lanzón, I. González de Pablos, L. Torres, P. Corrales, P. Gomez-Rodríguez, E. Rodríguez-Cuéllar, E. Morales, G. Medina-Gómez, Spain

EASD
EFSD

Short Oral Event D

Wednesday, 14:00 - 15:00

GENERAL
INFO

SO 052 Preclinical advances to understand glucose metabolism

PROGRAMME

667 Acetyl-coa carboxylase 1 phosphorylation at serine1215 by AMPK-activated protein kinase plays a critical role in embryonic development and glucose homeostasis in mice

TUESDAY

J. Cantley, V. A. Morfin, R. B. Bakar, D. G. Hardie, UK

WEDNESDAY

668 FFA-fetuin-a mediated lipid accumulation and insulin secretory defect in pancreatic beta cells: dissecting the possible crosstalk of CD36 and TLR4

THURSDAY

R. Kundu, S. Mandal, S. Nag, India

FRIDAY

669 Cytoskeletal protein Leupaxin promote hepatic gluconeogenesis through activating HNFA4 α transitional activity

SHORT ORAL
DISCUSSIONS

X. Luo, Fang Liu, Guoqiang Li, Caizhi Liu, Min Tang, Yueyin Yang, Xiaoying Ding, Yufan Wang, Xinran Ma, Yan Lu, Zhijian Zhang, Yongde Peng, China

PRESENTER
INDEX

670 ITIH5 is required for adipocyte differentiation and diet-induced obesity by modulating PI3K/AKT signalling

J. Li, D. Li, L. Li, China

SATELLITE
SYMPOSIA

671 Metabolic syndrome and hepatic steatosis in a diet-induced minipig model

Y. Eckstein, A. Blutke, B. Dobenecker, S. Fiedler, S. Renner, Germany

INDUSTRY

PROGRAMME

672 The relationship between glucagon and VFA in type 2 diabetic patients

P. Huang, X. Zhao, Y. Sun, T. Xu, Y. Gu, China

EXHIBITION

SO 053 Oral agents to control glucose metabolism

673 Efficacy and safety of pioglitazone add-on in patients with type 2 diabetes inadequately controlled with metformin and dapagliflozin: a randomised, double-blind, and placebo-controlled study

Y. Cho, K.-S. Kim, B.-W. Lee, J. Hong, J. Yu, S. Lim, Y. Kim, C. Lee, S. Kim, S. Kwak, W. Lee, Republic of Korea

EASD
EFSD

674 Effect of acarbose on glycaemic status and variability in patients of type 1 diabetes: a randomised, placebo controlled study

A. Rizvi, M. Mittal, R. Shukla, M. K. Garg, India

GENERAL
INFO

675 Distinct effects of imeglimin on insulin, GLP-1 and GIP secretion compared to metformin: a randomised controlled trial

M. Imura, R. Usui, Y. Hamamoto, Y. Omori, Y. Kurotobi, H. Kuwata, H. Tatsuoka, K. Shimomura, K. Murotani, Y. Yamada, Y. Seino, Japan

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

676 Polychemotherapy to induce remission of newly diagnosed type 2 diabetes: the MIRACLE trial

A. Dei Cas, R. Aldigeri, M. Garofolo, G. Daniele, M. Trombetta, A. Csermely, G. Maglietta, C. Caminiti, G. Moschione, E. Saudelli, P. Di Bartolo, M. Caletti, M. Monesi, S. Galvan, R. C. Bonadonna, Italy

SHORT ORAL
DISCUSSIONS

677 Chronic treatment of alfa-glucosidase inhibitor alters intestinal morphology and sugar transport gene expression under high-sucrose diet feeding

K. Yamamoto, N. Harada, T. Yasuda, T. Hatoko, N. Wada, X. Lu, Y. Seno, T. Kurihara, S. Yamane, D. Yabe, N. Inagaki, Japan

PRESENTER
INDEX

678 A multicenter, randomised controlled trial in individuals with type 2 diabetes to evaluate the efficacy of imeglimin on time in range

M. Ueda, Y. Hirota, K. Yokota, K. Kouyama, M. Mihara, S. Nakajima, K. Miyakoda, W. Ogawa, Japan

SATELLITE
SYMPOSIA

679 Machine learning methods to identify C-peptide as a clinical predictor of glycaemic response to sulphonylureas in type 2 diabetes

S. Garg, R. Gupta, R. R. Kitchen, L. A. Donnelly, E. R. Pearson, UK,

INDUSTRY

PROGRAMME

EXHIBITION

680 Efficacy and safety of sitagliptin in preserving bone mineralisation in women with type 2 diabetes: the SLOWDOWN randomised clinical trial

I. Barchetta, F. A. Cimini, S. Dule, G. Passarella, F. Sentinelli, A. Oldani, T. Filardi, V. Venditti, E. Bleve, E. Romagnoli, A. Lenzi, S. Morano, M. G. Baroni, M. G. Cavallo, Italy

SO 054 Improving metabolism via the gut**681 Effect of microencapsulated oral sodium butyrate on GI signs, SIBO and diabetic control: a randomised, placebo controlled study**

E. Franek, P. Panufnik, M. Wiecek, P. Szwarc, M. Kaniewska, K. Lewandowski, G. Rydzewska, Poland

EASD
EFSD

682 Weight-independent effects of very low-carbohydrate vs Mediterranean diet on glucose tolerance and free-living glucose control in individuals at risk for type 2 diabetes

N. Cimbalo, M. Masoni, G. Nesti, L. Sacchetta, M. Chiriaco, M. Scozzaro, S. Gallo, L. Nesti, A. Mengozzi, S. Baldi, D. Tricò, A. Natali, Italy,

GENERAL
INFO

683 Replacing sugar with isomaltulose reduces postprandial blood glucose response in school children: results from a double-blind, randomised, controlled cross-over study

L. Schweitzer, S. Theis, Germany

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

684 Effects of well and poorly absorbed low-calorie sweeteners on insulin secretion and sensitivity in type 2 diabetes

C. Xie, T. Li, M. Bound, J. Grivell, Y. Sun, K. L. Jones, M. Horowitz, C. K. Rayner, T. Wu, Australia

685 Gut microbiome composition is linked with Mediterranean diet adherence and blood glucose control in adults with type 1 diabetes

J. Abuqwider, E. Pasolli, G. Scidà, A. Corrado, G. Costabile, A. Rivellese, D. Ercolini, F. De Filippis, L. Bozzetto, Italy

SHORT ORAL
DISCUSSIONS

686 Canola oil as a source of GPCR ligands regulating carbohydrate metabolism

A. K. Drzazga, P. Bernat, G. Dabrowski, E. Gendaszewska-Darmach, M. M. Rosenkilde, M. Koziolkiewicz, Poland, Denmark

687 Impact of starch digestibility modulation on glycaemic variability and control and the cardiometabolic profile in type 2 diabetes

M. Chisbert, A.-L. Castell, L. Van Den Berghe, N. Feugier, C. Cuerq, O. Brack, M. Laville, A. Meynier, S. Vinoy, J.-A. Nazare, France

688 Finding the sweet spot: comparing lower carbohydrate diets for the management of type 2 diabetes using CGM and time in range

K. M. Oetsch, E. Parr, S. Flint, A. Petrushevski, L. Smith, T. Cyriac, L. Roach, M. E. Francois, Australia

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 055 Improving metabolism through nutrition**689 Time restricted eating improves glycaemic variability, independently of energy intake, in adults at risk of type 2 diabetes**

K. A. Bowden Davies, J. Pratt, A. Sanderson, N. Hodson, S. Joannisse, A. H. Heald, K. Smith, W. Peeters, D. J. West, UK

690 Postprandial glucose control with different hybrid closed-loop systems in adults with type 1 diabetes

G. Scidà, A. Corrado, J. Abuqwider, G. Annuzzi, L. Bozzetto, Italy

691 Joint association of diet quality scores physical activity status with all-cause mortality among individuals with or without diabetes

C. Liu, Z. Xin, L. Hua, China

692 A low-intensity structured weight management programme with partial diet replacement for type 2 diabetes in Chinese population: an open-label, randomised wait-list controlled trial

C. Yuan, Community Health Service Centers in Hongkou District, Y. Ding, W. Xiang, J. Pan, H. Yu, G. Zong, China, USA

693 Co-existence of food insecurity and obesity in type 2 diabetes is associated with worse glycaemic control in Bangladesh

M. Kamruzzaman, M. Horowitz, K. L. Jones, C. Marathe, Australia, Bangladesh

694 The effect of a dietary intervention on insulin sensitivity in type 1 diabetes and the role of dietary advanced glycation end-products: a 12-week randomised clinical trial

H. Kahleova, T. Znayenko-Miller, N. D. Barnard, USA,

695 A randomised controlled trial on low, moderate and high carbohydrate diet in adults with type 1 diabetes: 3-month preliminary results from the DANCE study

A. A. Barouti, A. Björklund, Sweden

696 Six-year follow-up of an intensive lifestyle intervention in persons with type 2 diabetes: an extension study of the U-TURN randomised trial

M. Ried-Larsen, M. Y. Johansen, K. Karstoft, K. Hansen, N. Pilmark, C. S. MacDonald, R. Christensen, T. Almdal, A. Vaag, B. K. Pedersen, C. G. Durrer, Denmark, Sweden

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 056 Thinking outside the box to treat obesity and diabetes

697 Enhancing glucose homeostasis via oral administration of milk-derived extracellular vesicles

S. Weksler-Zangen, R. Lax, M. Musseri, S. Reif, R. Golan, Israel

EASD
EFSD

698 The plant-based substance TOTUM-63 reduces fasting plasma glucose and HbA_{1c} in people with prediabetes or type 2 diabetes: a 24-week, 600-people randomised controlled trial (REVERSE-IT)

Y. F. Otero, P. Sirvent, O. Johansen, V. Chavanelle, V. Sapone, A. Bouchard-Mercier, N. Boisseau, M. Cazaubiel, B. Pereira, B. Guigas, S. Peltier, J.-M. Bard, H.-J. Woerle, S. Hadjadj, A. Marette, France, Switzerland, Canada, Netherlands

GENERAL
INFO

PROGRAMME

TUESDAY

699 Durable effects of duodenal ablation using electroporation combined with Semaglutide to eliminate insulin therapy in patients with type 2 diabetes; 24-month results

C. B. Busch, K. Van den Hoek, A. C. Van Baar, S. Meiring, F. Holleman, M. Nieuwdorp, J. J. Bergman, Netherlands

WEDNESDAY

THURSDAY

FRIDAY

700 Dorzagliatin in combination with sitagliptin improves insulin sensitivity and beta cell function in patients with type 2 diabetes

Y. Zhang, L. Feng, J. Zhang, H. Liu, M. Jiang, L. Chen, D. Liu, China

SHORT ORAL
DISCUSSIONS

701 Vicious cycle-breaking lipid nanoparticles remodelling intercellular crosstalk to reverse pancreatic fibrosis

W. Hui, L. Li, L. Qi, China

PRESENTER
INDEX

702 Diet-driven succinate production by intestinal microbiota stimulates GLP-1 secretion by colonic enteroendocrine cells via SUCNR1

T. Villanueva-Carmona, L. Cedó, C. Núñez-Roa, M.-M. Rodríguez-Peña, R. Bosch, J. A Koehler, N. Rahimi, M. Santos-Hernández, F. Gribble, F. Reimann, D. J. Drucker, S. Fernández-Veledo, J. Vendrell, Spain, Canada, UK

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

703 RKER-065, a novel ActRII-Fc ligand trap, increased lean mass and improved fat mass loss in obese mice treated with semaglutide

R. Nathan, M. Cahill, E. Lema, S. Macaluso, R. Todorova, J. Seehra, J. Lachey, L. Lerner, F. Fisher, USA

EXHIBITION

704 Safety of teplizumab in stage 2 and stage 3 type 1 diabetes: integrated analysis of clinical trials

C. Dayan, K. C. Herold, K. M. Simmons, Z. Sumnik, L. A. Knecht, L. Popescu, W. Tian, O. Gonzalez, O. Kordonouri, E. Niemoeller, S. E. Gitelman, UK, USA, Czech Republic, Romania, Germany

Short Oral Event C

Wednesday, 12:45 - 13:45

SO 057 Novel therapeutic avenues for metabolic disease

705 An optimised methylglyoxal scavenging peptide improves insulin sensitivity and glucose tolerance in mice with diet induced obesity independent of food intake or weight loss

S. Brings, M. Campos, W. Mier, S. Herzig, J. Szendrödi, P. P. Nawroth, T. Fleming, Germany

706 Discovery and characterisation of HDM1005, a novel dual GLP-1 and GIP receptor agonist for the treatment of type 2 diabetes and obesity

C. Jiang, N. Zhang, L. Teng, L. Guo, H. Pan, Z. Zhang, Z. Dong, D. Liu, China

707 Characterisation of AZD6234, a novel amylin receptor selective agonist peptide, in rodent models of weight loss and aversion

D. Hornigold, S. Genapathy, G. Geoghegan, S. Hansson, P. Gennemark, C. Hilgendorf, K. Mather, C. Brighton, K. Sigfridsson, X. Tan, S. Omar, D. Baker, S. Will, UK, USA, Sweden

708 Berberine ursodeoxycholate (HTD1801) provides a unique therapeutic approach for patients with metabolic diseases and severe insulin resistance

L. MacConell, A. Liberman, A. Flyer, K. Liu, USA, China

709 Ultrasound combined with microbubbles has no therapeutic effect on atherosclerotic plaques of the aorta in diabetic ApoE^{-/-} mice

A. Korn, S. Simsek, M. D. Fiet, I. S. Waas, K. Kooiman, H. W. Niessen, P. A. Krijnen, Netherlands

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

710 SYNCHRONIZE™-CVOT: study design of a phase 3, randomised, event-driven, CV outcome trial of survodutide in adults living with overweight or obesity, and CVD, CKD or with risk factors for CVD

M. N. Kosiborod, S. Wharton, C. Le Roux, E. Platz, M. Brueckmann, A. M. Jastreboff, S. Ajaz Hussain, S. D. Pedersen, A. Unseld, E. Startseva, L. M. Kaplan, on behalf of the SYNCHRONIZE(TM)–CVOT trial committees and investigators, USA, Canada, Ireland, Germany

EASD
EFSD

711 Efficacy of berberine ursodeoxycholate (HTD1801) in Chinese and Western patients with type 2 diabetes

S. Gan, L. Ji, J. Ma, Z. Cheng, N. T. Gunn, G. W. Neff, K. Liu, L. MacConell, China, USA

GENERAL
INFO

712 Exploring the mechanism behind the novel FGF1 analogue in treating metabolic syndrome-related conditions in db/db mouse model

E. Swiderska, M. Janiszewski, T. Jaworski, V. Vialichka, E. Mroz, M. Choros, J. Hucz-Kalitowska, B. Miedziak, M. Marczak, O. Abramczyk, A. Czyrek, M. Zakrzewska, D. Krowarsch, J. Otlewski, M. Wieczorek, Poland

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

Short Oral Event D

Wednesday, 14:00 - 15:00

SO 058 SGLT2 inhibition: focus on the heart and the kidneys

713 Long-term maintenance of coronary flow reserve improvement in type 2 diabetes patients after dapagliflozin treatment: results from the 4-years DAPAHEART follow-up study

C. Morciano, F. Cinti, G. Sorice, L. Leccisotti, S. Gugliandolo, U. Capece, L. Cappannoli, D. D'Amario, G. Di Giuseppe, T. Mezza, G. Ciccarelli, L. Soldovieri, F. Crea, A. Giordano, A. Giaccari, Italy

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

714 Cardiovascular outcomes with SGLT2 inhibitors in patients with atrial fibrillation and type 2 diabetes

S. Kim, Y. Cho, Y. Suh, D. Seo, Y. Kim, S.-H. Shin, Republic of Korea

INDUSTRY

PROGRAMME

715 Cardiovascular, kidney outcomes and mortality by SGLT2 inhibitors in patients with type 2 diabetes undergoing percutaneous coronary intervention

H.-S. Kwon, Republic of Korea

EXHIBITION

716 Sodium glucose cotransporter-2 inhibitors reduce salt-sensitivity of blood pressure in type 2 diabetes

M. Chiriaco, L. Sacchetta, L. Nesti, N. Cimbalo, L. Santoni, S. Gallo, S. Baldi, D. Tricò, A. Natali, Italy

717 Empagliflozin limits AKI incidence and severity following cardiac surgery: an open-label phase IV randomised pilot study

L. I. Snel, M. J. Oosterom, E. Rampanelli, Y. Lankedava, M. P. Plummer, B. Preckel, J. Hermanides, D. Van Raalte, A. Hulst, Netherlands, Australia

718 Empagliflozin's heart shield: unlocking Sirtuins and ncRNA regulators for myocardial infarction recovery

A. Nowak, Z. Wicik, C. Eyileten, S. Ahmadova, J. Siller-Matula, D. Von Lewinski, H. Sourij, M. Postula, Poland, Austria

719 The effect of SGLT2-inhibition on the kidney perfusion, diffusion and oxygenation in patients with type 2 diabetes

B. Ariëns, A. C. Hesp, L. I. Snel, A. De Boer, G. D. Laverman, A. J. Nederveen, D. H. Van Raalte, O. J. Gurney-Champion, Netherlands

720 Impact of dapagliflozin on cardiometabolic outcomes after acute myocardial infarction according to baseline glycaemic status and body mass index: a DAPA-MI substudy

R. Storey, J. Deanfield, S. James, R. A. Ajjan, N. Eriksson, D. Erlinge, M. De Belder, C. P. Gale, A. Zaman, R. Hofmann, Y. Jiang, A. Langkilde, E. Parvaresh Rizi, J. Oldgren, D. K. McGuire, UK, Sweden, USA

Short Oral Event E

Thursday, 12:45 - 13:45

SO 059 Pleiotropic effects of SGLT2 inhibition

721 Effect of dapagliflozin on serum metabolome in patients with type 2 diabetes

V. Tsimihodimos, A. Dimou, E. Bairaktari, S. Filippas-Ntekouan, Greece

722 Effect of sotagliflozin, a dual SGLT 1 and 2 inhibitor, on continuous glucose monitoring in basal insulin-treated type 2 diabetes

M. Hardin, A. Peters, A. K. Carroll, M. Davies, M. Girard, J. Buse, M. Davies, H. Bajaj, P. Banks, J. Rosenstock, USA, UK, Canada

723 Glucagon as a potential promoter of sodium-glucose co-transporter 2 induced ketogenesis via effect on lipolysis

E. Svehlikova, W. Regitnig, C. Gatschelhofer, V. Höller, G. Fluhr, B. Lackner, C. Magnes, A. Eberl, T. R. Pieber, Austria

724 Haematocrit trends and risk of erythrocytosis in persons with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitors in real world clinical practice

A. R. Gosmanov, D. E. Gemoets, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

725 Characteristics of Sodium Glucose Co-Transporter 2 inhibitor associated diabetic ketoacidosis among hospitalised patients and compared to all hospital prescriptions

N. S. Lau, V. W. Wong, J. H. Lam, Australia

726 Transient elevation of minerals and bone resorption during 48-week treatment with an SGLT2 inhibitor tofogliflozin in people with type 2 diabetes

S. Tokuno, Y. Takeshita, M. Okumura, H. Goto, Y. Nakano, T. Takamura, Japan

EASD
EFSD

GENERAL
INFO

727 Empagliflozin increases the probability of higher C-peptide levels during follow-up in patients with type 2 diabetes: a retrospective cohort study

D. Cuevas-Ramos, R. Flores-Cárdenas, F. González-Valdivia, M. A. Gómez-Sámamo, P. Almeda-Valdés, S. Rodríguez-Carranza, F. J. Gómez-Pérez, Mexico

PROGRAMME

TUESDAY

728 An alteration of intestinal morphology and sugar transporters by long-term administration of SGLT2 inhibitor

T. Yasuda, N. Harada, T. Hatoko, X. Lu, K. Yamamoto, N. Wada, Y. Seno, T. Kurihara, S. Yamane, N. Inagaki, D. Yabe, Japan

WEDNESDAY

THURSDAY

FRIDAY

Short Oral Event F

Thursday, 14:00 - 15:00

SHORT ORAL
DISCUSSIONS

SO 060 Novel incretins: it is all about clinical outcomes

729 Long-term safety of dapagliflozin or saxagliptin in paediatric patients with type 2 diabetes: 104-week follow-up of the phase 3 T2NOW trial

N. Shehadeh, P. Galassetti, N. Iqbal, C. Karlsson, J. Monyak, J. Ostridge, M. Bolin, T. Barrett, Israel, USA, Sweden, UK

PRESENTER
INDEX

SATELLITE
SYMPOSIA

730 Effects of triple-hormone receptor agonist retatrutide on lipid profiling in participants with obesity

V. Pirro, M. J. Pearson, Y. Lin, M. L. Hartman, K. Roth, K. L. Duffin, J. Willency, A. Haupt, G. Ruotolo, USA

INDUSTRY

PROGRAMME

731 Glucagon-like peptide-1 receptor agonists as add-on therapy to insulin for type 1 diabetes: a systematic review and meta-analysis

E. Rebelos, I. Anastasiou, N. Tentolouris, T. Karagiannis, A. Tsapas, E. Ferrannini, A. Liakos, Greece, Italy

EXHIBITION

732 Efficacy and safety of HS-20094 in patients with type 2 diabetes: a randomised double-blind, placebo-controlled, phase 2 trial

L. Liu, X. Shi, Z. Cheng, W. Song, Z. Wang, F. He, Y. Cui, J. Zhang, China

733 A phase 2 study of mazdutide 9 mg in Chinese adults with BMI \geq 30 kg/m²

H. Jiang, L. Ji, Y. Zhang, Z. Cheng, S. Pang, X. Li, W. Qiu, Q. Ma, Z. Liu, Y. Wang, H. Deng, L. Qian, China

734 Mazdutide reduces body weight in adults with overweight or obesity: a multiple-dose study

S. N. Bhattacha, L. Tham, Y. Li, L. Chua, S. Ng, Y. Tang, H. Ibriga, W. Ni, M. K. Thomas, K. J. Mather, USA

735 Optimising use of SGLT2 inhibitors and GLP1 receptor agonists across patients with type 2 diabetes

M. Evans, P. McEwan, V. Foos, R. Jenkins, G. Roberts, M. Jones, J. Chen, UK, USA

736 Phase 1 topline safety, efficacy, and pharmacokinetics of oral ecnoglutide

M. K. Junaidi, Z. Zhu, Y. Li, W. Guo, Q. Zheng, J. Deng, E. Adegbite, S. Ross, L. Telusca, C. L. Jones, M. Fenaux, S. Xu, USA, China

Short Oral Event A

Tuesday, 12:30 - 13:30

SO 061 Novel incretins: focus on kidney, liver and cardiovascular system

737 Retatrutide, an agonist of GIP, GLP-1 and glucagon receptors, improves lipoprotein biomarkers associated with cardiovascular risk in participants with obesity or overweight

G. Ruotolo, V. Pirro, Y. Lin, J. Wilson, K. Duffin, E. Y. Zhen, C. Harris, M. K. Thomas, M. L. Hartman, T. Coskun, Z. Milicevic, A. Haupt, S. J. Nicholls, USA, Australia

738 Utreglutide (GL0034), a novel GLP-1RA, increases liver FGF-21 and demonstrates significant efficacy on weight loss, HbA_{1c}, and triglycerides in db/db mice

R. Thennati, V. Burade, M. Natarajan, A. Garcia-Ocaña, G. Rutter, R. E. Pratley, B. Thorens, T. Vilsbøll, India, USA, UK, Canada, Switzerland, Denmark

739 Effects of Orforglipron, a novel oral GLP-1 receptor agonist, on metabolic dysfunction-associated steatotic liver disease related biomarkers

A. Sanyal, R. Loomba, Y. Lin, K. Duffin, J. M. Wilson, H. Banerjee, K. J. Mather, C. Kazda, M. Konig, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

740 Orforglipron, an oral GLP-1RA, improves CV risk biomarkers in patients with obesity

K. Mather, S. Wharton, J. Rosenstock, Y. Lin, K. Duffin, J. Wilson, H. Banerjee, C. Kazda, M. Konig, USA, Canada

741 Effect of tirzepatide on kidney parameters in people with excess body weight and type 2 diabetes: a post-hoc analysis of the SURMOUNT-2 trial

H. J. Heerspink, A. N. Friedman, P. Bjornstad, D. H. Van Raalte, D. Cao, L.-E. García-Pérez, A. Stefanski, I. Turfanda, M. C. Bunck, I. Benabbad, C. Piras de Oliveira, R. Griffin, Netherlands, USA

EASD
EFSD

GENERAL
INFO

742 Glucagon-like peptide-1 receptor agonist exendin-4 improves chronic kidney disease through restoration of lysosomal function and autophagy

E. Y. Lee, H. Jeong, S. Son, S. Lee, J. Kang, C. H. Chung, Republic of Korea

PROGRAMME

TUESDAY

743 Effect of retatrutide on kidney parameters in people with type 2 diabetes and/or obesity: a post-hoc analysis of two phase 2 trials

H. Heerspink, Z. Lu, Y. Du, K. Duffin, T. Coskun, A. Haupt, M. L. Hartman, Netherlands, USA

WEDNESDAY

THURSDAY

744 Improvement of liver steatosis by mazdutide in Chinese participants with overweight or obesity: an exploratory analysis of GLORY-1

L. Gao, L. Ji, H. Jiang, Y. Zhang, L. Lv, J. Gu, Z. Liu, H. Deng, Y. Wang, L. Qian, China

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

Short Oral Event B

Tuesday, 13:45 - 14:45

SATELLITE
SYMPOSIA

SO 062 Hot of the press novel incretins

745 GLP-1 and glucagon receptor agonist mazdutide improves markers of metabolic function in adults with overweight or obesity

L. Tham, S. N. Bhattachar, Y. Li, L. Chua, S. Ng, Y. Tang, H. Ibriga, W. Ni, M. K. Thomas, USA

INDUSTRY

PROGRAMME

746 Development of a once-a-month formulation of semaglutide from an innovative injectable and biodegradable hydrogel

A. Marechal, R. Besnard, J. Eroles, U. Naessens, S. Hakim, E. Dauty, M. Gaudier, C. Mégret, O. Soula, France

EXHIBITION

747 Efficacy and safety of efsabaglutide alfa as add-on to metformin in patients with type 2 diabetes

Q. Wang, Y. Bao, S. Chen, J. Zhou, D. Anwar, W. Jia, China

748 A multicenter, blinded, placebo-controlled, randomised single- and multiple-ascending dose study of orforglipron, an oral GLP-1 receptor agonist, in Japanese patients with type 2 diabetes

K. Ohwaki, C. Nakamura, R. Nasu, K. Takenouchi, T. Hirase, Japan

749 A phase 1, randomised, double-blind trial of the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral small molecule GSK-1290 in Japanese and non-Japanese healthy volunteers

B. Coll, L. J. Seman, H. Yue, A. Barth, L. Ibarra, M. Bach, USA

750 WITHDRAWN

751 Safety, tolerability and metabolic effects of once weekly GL0034 (Utgrelutide) in individuals with obesity: a multiple ascending dose study

R. Thennati, V. Burade, M. Nagarajan, P. Shahi, R. Nagaraja, S. Agrawal, T. Duvauchelle, A. Garcia-Ocana, G. Rutter, R. E. Pratley, B. Thorens, T. Vilsbøll, India, France, USA, UK, Canada, Switzerland, Denmark

752 WITHDRAWN

Short Oral Event C

Wednesday, 12:45 - 13:45

SO 063 More combo's less insulin!

753 The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Events Reporting System (FAERS) database

I. Caruso, L. Di Gioia, S. Di Molfetta, M. Caporusso, A. Cignarelli, G. Sorice, L. Laviola, F. Giorgino, Italy

754 Tirzepatide as an add-on for participants with inadequate glycaemic control using basal insulin: pooled subgroup analysis of SURPASS-5 and -6

A. Rodriguez, H. Bajaj, L. K. Billings, M. Liu, J. A. Levine, H. Patel, USA, Canada

755 Near-normoglycaemia and insulin regression induced by tirzepatide in basal insulin-treated type 2 diabetes

H. Patel, S. Tofé, C. Wysham, V. T. Thieu, J. Kiljanski, C. Lee, H. Wang, J. Rosenstock, USA, Spain

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

756 Body weight reduction with tirzepatide by sex: a subgroup analysis of the SURMOUNT clinical trials

L.-E. García-Pérez, A. Chao, R. Taylor, D. Mojdami, T. Forrester, F. Chigutsa, R. Malik, USA

757 Predictors of achieving and sustaining glycaemic control and weight loss with tirzepatide in individuals with type 2 diabetes and increased cardiovascular risk (SURPASS-4)

S. E. Kahn, S. Del Prato, I. Pavo, D. R. Franco, J. Zheng, C. Nicolay, A. Hemmingway, R. J. Wiese, E. R. Pearson, USA, Italy, Brazil, UK

EASD
EFSD

GENERAL
INFO

758 Efficacy and safety of tirzepatide in participants who achieved fasting serum glucose targets at 52 weeks in SURPASS-3 and SURPASS-4

A. Y. Kwan, A. Cheng, J. Green, J. M. Maldonado, M. Liu, R. Silva, USA, Canada

PROGRAMME

TUESDAY

759 Insulin therapy DE-intensification with iGlarLixi: the IDEAL randomised controlled trial

M. Haluzík, L. Thieme, I. Laňková, A. Veselá, E. Záhumenský, T. Edelsberger, M. Löblová, F. Hrubý, M. Mráz, P. Novodvorský, Czech Republic

WEDNESDAY

THURSDAY

FRIDAY

Short Oral Event D

Wednesday, 14:00 - 15:00

SHORT ORAL
DISCUSSIONS

SO 064 Incretins have more effects than you can imagine

760 Blocking glucagon receptor improves hyperglycaemia to larger extent after bariatric surgery

G. Angelini, S. Russo, A. Gastaldelli, G. Mingrone, M. Salehi, Italy, USA

PRESENTER
INDEX

SATELLITE
SYMPOSIA

761 Effects of empagliflozin vs sitagliptin on exercise macronutrient oxidation rates in type 2 diabetes

L. Santoni, L. Nesti, N. Pugliese, S. Frascerra, D. Tricò, M. Chiriaco, L. Sacchetta, S. Baldi, A. Natali, Italy

INDUSTRY

PROGRAMME

762 The central vs peripheral mediated effects of liraglutide enhancement on insulin secretion is dependent on the stage of diabetes

C. Saponaro, M. Imbernon, I. Louvet, E. Deligia, S. Chen, E. Wemelle, F. Pfrieger, R. Nogueiras, M. Schwaninger, J. Kerr-Conte, C. Knauf, B. Jones, F. Pattou, V. Prevot, C. Bonner, France, UK, Spain, Germany

EXHIBITION

763 Corneal nerve loss and regeneration after GLP-1 therapy in children with simple and monogenic obesity

H. Gad, H. Dauleh, S. Chirayath, G. Mohamadsalih, R. Amin, M. Pasha, I. Mohammed, T. Al-Barazenji, E. Elgassim, I. N. Petropoulos, G. Ponirakis, K. Hussain, R. A. Malik, Qatar, UK

764 Intestinal L-cell timekeepers: roles in GLP-1 secretion in physiology and type 2 diabetes

A. D. Biancolin, C. Dibner, Switzerland

765 Semaglutide normalises increased cardiac myocyte calcium transients in a rat model of high fat diet-induced obesity

U. Dischinger, K. Ermer, J. Theisen, M. Oertel, A. Xu, D. Weissman, K. Ecker, J. Dudek, M. Fassnacht, A. G. Nickel, M. Kohlhaas, C. Maack, V. Sequeira, Germany

766 Elucidation of a new mechanism of action of GLP-1 focusing on pancreatic islet blood flow: investigation by in vivo imaging

T. Kimura, K. Kidokoro, Y. Iwamoto, H. Iwamoto, K. Dan, Y. Fushimi, J. Sanada, Y. Katakura, M. Shimoda, S. Nakanishi, T. Mune, K. Kaku, N. Kashihara, H. Kaneto, Japan

767 Organ-on-a-chip recapitulating the gut-islets axis for endocrine hormones secretion regulators evaluation

J. Sun, L. Ling, China

Short Oral Event E

Thursday, 12:45 - 13:45

SO 065 Advanced real life in type 1 diabetes

768 Real world experience using advanced closed-loop hybrid systems vs other automated insulin delivery systems for pregnant women with type 1 diabetes

A. Gómez, D. Henao, D. Parra, B. Grassi, M. N. Serrano, M. Rondon, Colombia, Chile,

769 Hybrid closed loop in adolescents and young adults with type 1 diabetes: a real world study

M. Ung, A. Penfornis, C. Amadou-Kerangoarec, J. Eroukhmanoff, France

770 Real-world experience of Omnipod 5 hybrid closed loop system in a UK Diabetes centre

S. Hussain, C. Willis, L. Anthony, J. Pichierri, C. Hume, M. Ford-Adams, R. Amin, R. Abraham, P. Choudhary, S. Greene, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

771 Open-label, descriptive, sequential study in type 1 diabetes patients to evaluate the Mylife™-Dose app with ISCI and compare it to a hybrid continuous insulin infusion system (CamAPS): Dose Human Loop study

E. L. Menéndez Torre, P. Pujante Alarcón, M. Moreira Rodríguez, N. Bau Serrallonga, J. Ruiz Palomar, D. Martín Iglesias, C. Navarro Hoyas, O. Simó Servat, G. Kyriakos, L. Cotovad Bellas, R. Corcoy Pla, T. Martínez Ramonde, M. Laínez López, B. Soldevilla Madorell, J. Girbés Borrás, Spain

EASD
EFSD

GENERAL
INFO

772 Switch of open-source automated insulin delivery system - AndroidAPS to commercially available AID systems in type 1 diabetes: the extension of the CODIAC study

D. Q. Do, A. Hásková, L. Radovnická, E. Horová, J. Konečná, G. Grunberger, C. Parkin, M. Prazny, J. Šoupal, Czech Republic, USA

PROGRAMME

TUESDAY

773 Characteristics associated with decreased time in range in people with type 1 diabetes using automated insulin delivery systems

R. Bem, D. Vávra, M. Kahle, M. Dubsy, M. Haluzik, Czech Republic

WEDNESDAY

THURSDAY

774 Use of an advance hybrid closed loop system during marathon running: case series and clinical implications

M. T. Onetto, B. Grassi, D. Montt, C. Berget, K. Strodthoff, Chile, USA

FRIDAY

775 GLP-1 receptor agonist effects in people with type 2 diabetes using MiniMed™ advanced hybrid closed-loop therapy

J. J. Shin, A. S. Rhinehart, A. Keiter, H. Ma, T. L. Cordero, R. A. Vigersky, IMPACT2 Study Group, USA

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

Short Oral Event F

Thursday, 14:00 - 15:00

SATELLITE
SYMPOSIA

SO 066 Pumping without bumping

776 Insulin pump therapy in type 1 diabetes: a real-world study of mortality and clinical outcomes

A. Iqbal, S. Haughton, D. Riley, M. F. Arshad, S. Azmi, R. A. Malik, U. Alam, UK, Qatar

INDUSTRY

PROGRAMME

EXHIBITION

777 Efficacy and safety of the Omnipod 5 System compared with insulin pump therapy in adults with type 1 diabetes: sub-analysis of French participants in a randomised controlled trial

A. Penforinis, E. Renard, R. S. Weinstock, J.-P. Riveline, C. Thivolet, T. T. Ly, The OP5-003 Research Group, France, USA

778 HbA_{1c} outcomes across gender, ethnicity, deprivation and age with hybrid-closed loop in the association of British clinical diabetologist's audit of the NHS England pilot

T. S. Crabtree, T. Griffin, G. Gallen, A. Liarakos, S. Hussain, S. Saraf, C. Philbey, E. Gurnell, A. N. Lumb, B. Ryder, P. Choudhary, E. G. Wilmot, UK

779 Management of prolonged aerobic exercise in people with type 1 diabetes on hybrid closed-loop systems: a randomised controlled study

A. Corrado, G. Scidà, J. Abuqwidar, L. Bozzetto, G. Annuzzi, Italy

780 Simplified meal announcement in adolescents with type 1 diabetes using the MiniMed 780G: 18-month follow-up analysis

G. Petrovski, J. Campbell, M. Pasha, K. Hussain, Sidra Diabetes Group, Qatar

781 Postprandial insulin strategy for improving glycaemic control after a missed meal bolus in persons with type 1 diabetes users of the Advanced Hybrid Closed Loop (AHCL) Minimed 780G™ system

B. A. Grassi, M. Onetto, G. Mora, N. Tapia, M. Castro, N. Kurtz, R. Vigersky, O. Cohen, Chile, USA, Switzerland

782 Real-world performance of the MiniMed™ 780G safe meal bolus feature

V. Putcha, A. Benedetti, A. Roy, L. Lintereur, B. Grosman, K. Turksoy, N. Sathiyathan, M. Liu, Z. Dai, J. Shin, F. Diaz-Garelli, O. Cohen, R. Vigersky, USA, Switzerland

783 Clinical and economic impact of lifelong use of AID by different patient patient groups from the Swedish health care perspective

J. Jendle, M. Syleouni, G. Brusaferrri, A. Khan Miron, Sweden, Switzerland

Short Oral Event A

Tuesday, 12:30 - 13:30

SO 067 Breaking away with tradition or how to give insulin differently

784 Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in individuals with type 2 diabetes by kidney function: ONWARDS 1-5

A. Y. Cheng, P. Rossing, M. Benamar, C. Laugesen, P. H. Nielsen, H. S. Bajaj, Canada, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

785 Efficacy and safety of once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes by ethnicity and race: ONWARDS 1-5

I. Lingvay, K. O. Bangsgaard, C. Desouza, M. Fragao-Marques, A. Navarria, A. Vianna, USA, Denmark, Brazil

786 Impact of age on the efficacy and safety of once-weekly insulin icodec vs once-daily insulin in type 2 diabetes: ONWARDS 1-5

A. G. Vianna, C. Desouza, C. Laugesen, M. Fragao-Marques, P. H. Nielsen, S. Shaikh, I. Lingvay, Brazil, USA, Denmark, India

EASD
EFSD

787 No evidence of increased physical activity-related hypoglycaemia with once-weekly insulin icodec vs once-daily basal insulin in type 2 diabetes: ONWARDS 1-5

M. C. Riddell, S. Heller, M. Asong, L. Carstensen, S. Kehlet Watt, V. C. Woo, Canada, UK, Denmark

GENERAL
INFO

PROGRAMME

TUESDAY

788 Pharmacokinetic and pharmacodynamic properties of a novel once-weekly insulin analogue GZR4 in people with type 2 diabetes

X. Wang, F. Guo, C. Tang, C. Huang, C. Hao, J. Zhao, A. He, T. Xie, Y. Li, W. Chen, Z.-R. Gan, China

WEDNESDAY

THURSDAY

789 Evaluation of the pharmacokinetic profile of insulin efsitora alfa (efsitora) administered subcutaneously at different injection sites

J. Leohr, S. Suriyapperuma, A. Ghosh, D. Waters, T. Fukuda, USA

FRIDAY

790 Efficacy and safety of iGlarLixi vs IDegAsp in Chinese people with type 2 diabetes suboptimally controlled with oral antidiabetic drug(s): the SoliD randomised controlled trial

Y. Li, W. Gu, L. Chen, H. Kuang, J. Du, A. Alvarez, F. Lauand, E. Souhami, J. Zhang, W. Xu, Q. Du, Y. Mu, M. Liu, China, Spain, France

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

791 Soli-switch: efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes

M. Haluzik, S. Lim, K. Cypryk, A. Alvarez, F. Lauand, V. Corp-dit-Genti, O. S. Bakiner, Czech Republic, Republic of Korea, Poland, France, Turkey

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 068 Playing with food intake and energy expenditure

792 Duodenal jejunal bypass liner treatment for type 2 diabetes and obesity: comparison between 9 and 12 months implantation using data from a worldwide registry

R. E. Ryder, R. Lopez-Gonzalez, C. Lazzara, J. P. Gebelli, L. Munro, H. Frydenberg, J. Stein, T. Battelino, S. Fishman, J. Byrne, C. De Jonge, J.-W. Greve, R. Cohen, M. Yadagiri, P. Sen Gupta, UK, Spain, Australia, Germany, Slovenia, Israel, Netherlands, Brazil

793 Recurrent postprandial hypoglycaemia after gastric bypass impairs hypoglycaemia awareness and dietary habits in type 2 diabetes

L. Sacchetta, E. Rebelos, N. Cimbalo, M. Chiriaco, D. Moriconi, L. Nesti, G. Nesti, S. Frascerra, M. Scozzaro, G. Daniele, S. Baldi, A. Mari, M. Nannipieri, A. Natali, D. Tricò, Italy

794 Experience of bariatric surgery in patients living with type 1 diabetes

A. Soghomonian, P. Darmon, E. Disse, A. Dutour, France

795 Advancing individualised treatment and data-driven healthcare management: benefits of the national Danish diabetes digital PROMS-tool

N. Ejlskjaer, Presented on behalf of the VBS-PRO-DIA Research Team (VBHC-PROMS-DIABETES) Aalborg, Denmark, Denmark

796 Evaluating the impact of a digital twin intervention on type 2 diabetes remission at 18 months: a cluster-specific analysis

S. Joshi, M. Dharmalingam, A. Vadavi, A. Keshavamurthy, S. Bhonsley, M. Thajudeen, A. Balasubramanian, P. Shamanna, India

797 Gender based impact of personalised coaching in diabetes management through sugarfit's diabetes reversal and management programme

C. Mehra, A. Mattilda Raymond, S. Kumar, A. Sequeira, S. Mehra, India, USA

798 Demographic differences in adherence to physical activity and screen time recommendations among youth: insights from NHANES 2017-2018

A. Mokari-Yamchi, K. Brazendale, A. Faghfour, S. Gheibi, Iran, Islamic Republic of, USA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

799 Further phenotyping of eating disorders and diabulimia is required in persons living with type 1 diabetes: results from SFDT1, a French national cohort

P. Ritz, G. Aguayo, H. Hanaire, E. Sonnet, K. Bilariki, L. Marchand, D. Gouet, N. S. Chevalier, S. Borot, S. Franc, V. Rigalleau, J.-P. Riveline, E. Cosson, G. Fagherazzi, France, Luxembourg

Short Oral Event C

Wednesday, 12:45 - 13:45

EASD
EFSD

GENERAL
INFO

SO 069 HbA_{1c} vs CGM: a tie break?

800 Predictors of discordance between CGM and HbA_{1c}: lower haemoglobin glycation is associated with a higher risk of proliferative diabetic retinopathy

F. W. Gibb, A. R. Dover, S. Forbes, M. W. Strachan, M. J. Lyall, M. S. Jeeyavudeen, R. J. Wright, R. H. Stimson, UK

801 The link between age, sex, fasting plasma glucose and glycated haemoglobin (HbA_{1c})

M. Stedman, A. Heald, D. Holland, I. Halsall, L. Green, P. Wu, J. Scargill, F. Hanna, K. Colclough, M. Gibson, A. Fryer, UK

802 Analytical performance of 10 HbA_{1c} point-of-care devices in a comparative evaluation study

P. Singh, B. Vetter, E. Lenters-Westra, Switzerland, Netherlands

803 The combined effect of CGM with anti-diabetes medications and the association with improved HbA_{1c} in people with type 2 diabetes not on insulin

P. Nemlekar, K. Hannah, G. J. Norman, USA

804 Average glucose and HbA_{1c} display a nonlinear and variable relationship: implications for clinical practice

Y. Xu, T. Dunn, R. Bergenstal, R. Ajjan, USA, UK

805 Personalised adjustment to improve accuracy of HbA_{1c} at reflecting hyperglycaemic exposure in different racial groups: a prospective clinical study

P. Choudhary, T. Dunn, Y. Xu, R. Ajjan, UK, USA

806 Feasibility of calibration-free intradermal glucose monitoring using a sensor microarray

M. Christiansen, N. Bhavaraju, S. Sattayasamitsathit, A. Campbell, R. Gottlieb, A. VandenBerg, K. Nogueira, M. Brister, R. Yang, J. Tangney, USA

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

SO 070 De-combining CGM and insulin in type 2 diabetes

807 Association of educational level with clinical presentation and pharmacological treatment in 10,020 individuals with recently diagnosed type 2 diabetes

R. W. Thomsen, M. T. Sørensen, F. P. Kristensen, J. S. Nielsen, D. H. Christensen, S. K. Nicolaisen, H. Beck-Nielsen, P. Vestergaard, N. Jessen, M. H. Olsen, T. Hansen, A. Vaag, H. T. Sørensen, Denmark, Sweden

EASD
EFSD

GENERAL
INFO

808 Insulin therapy de-intensification with iGlarLixi (IDEAL) randomised controlled trial: CGM-related outcomes

P. Novodvorský, L. Thieme, I. Laňková, A. Veselá, E. Záhumenský, T. Edelsberger, M. Löblová, F. Hrubý, M. Mráz, M. Haluzík, Czech Republic

PROGRAMME

TUESDAY

809 Efficacy and safety of insulin glargine 300 U/mL in insulin-naive people with type 2 diabetes with/without prior use of glucagon-like peptide-1 receptor agonist therapy

A. Cheng, D. Mauricio, R. Ritzel, M. E. Al-Sofiani, T. Bailey, M. Mabunay, M. Bonnemaire, M.-M. Lydie, S. Mimouni, M. Davies, Canada, Spain, Germany, Saudi Arabia, USA, Singapore, France, Algeria, UK

WEDNESDAY

THURSDAY

FRIDAY

810 Cost-effectiveness of Dexcom real-time continuous glucose monitoring vs self-monitoring of blood glucose in patients with type 2 diabetes on intensive insulin therapy in Estonia

S. Ilham, H. Alshannaq, G. J. Norman, USA

SHORT ORAL
DISCUSSIONS

811 Frontier - Freestyle Libre use in Ontario among patients with type 2 diabetes in the IC/ES database - evidence from real-world practice: patients aged ≥ 66 years on basal insulin \pm GLP-1 RA

S. Harris, Y. Poon, R. Rabasa-Lhoret, A. Ratzki-Leewing, Canada

PRESENTER
INDEX

SATELLITE
SYMPOSIA

812 A prospective cohort study with continuous glucose monitoring and education in type 2 diabetes and prediabetes

J. Ko, W. Lee, K. Oh, C.-Y. Park, E. Rhee, S.-E. Park, H. Kwon, S. Moon, H. Jang, Republic of Korea

INDUSTRY

PROGRAMME

813 Association of CGM use with glycaemic outcomes for people with type 2 diabetes: a multi-centre observational longitudinal study

O. Ebekoziem, A. Mungmode, O. Odugbesan, M. Basina, S. Tsai, R. Weinstock, USA

EXHIBITION

814 Long-term improvement in Time In Range and Time in Tight Range with Dexcom CGM use in adults with type 2 diabetes not treated with insulin: real-world data

J. E. Layne, L. Jepson, A. Carite, R. Bergenstal, USA

Short Oral Event E

Thursday, 12:45 - 13:45

EASD
EFSD

SO 071 How universal can CGM be?

GENERAL
INFO

815 Hypoglycaemia measured by continuous glucose monitoring in people with insulin-treated type 2 diabetes and chronic kidney disease: post hoc analysis from the HypoMETRICS study

J. M. Brøsen, P. Divilly, G. Martine-Edith, N. Zaremba, N. Ali, M. Evans, R. McCrimmon, S. Heller, B. De Galan, J. Mader, E. Renard, A. A. Vaag, P. Choudhary, U. P. Bjergaard, Denmark, UK, Ireland, Netherlands, Austria, France

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

816 Continuous glucose monitoring improves postoperative glucose control in liver transplant recipients with diabetes

M. Mraz, B. Hagerf, M. Protus, L. Nemetova, J. Franekova, V. Svirlochova, P. Girman, E. Kieslichova, M. Haluzik, A. Jabor, Czech Republic

SHORT ORAL
DISCUSSIONS

817 Effectiveness of real-time continuous glucose monitoring (Dexcom G6) among cardiac surgery patients: a randomised controlled trial

S.-J. Moon, M.-S. Kim, H.-E. Lee, Y.-W. Lee, S.-J. Lee, E.-S. Chung, C.-Y. Park, Republic of Korea

PRESENTER
INDEX

818 Prospective observational study of real-time continuous glucose monitoring in non-ICU hospitalised people with diabetes

L. Rakotoarisoa, L. Meyer, F. Fall-Mostaine, L. Sluzarek, L. Kessler, France

SATELLITE
SYMPOSIA

819 Association of glucose management index with adverse pregnancy outcomes in pregnancies with type 1 diabetes

P. Ling, D. Yang, C. Wang, X. Zheng, S. Luo, H. Deng, X. Yang, W. Xu, J. Yan, J. Weng, China

INDUSTRY

PROGRAMME

EXHIBITION

820 Advanced hybrid closed loop compared to standard insulin therapy in type 1 diabetes during delivery and early postpartum

K. Beunen, N. Van Wilder, D. Ballaux, G. Vanhaverbeke, Y. Taes, X.-P. Aers, L. Van Huffel, J. Marlier, D. Lee, J. Cuyper, V. Preumont, S. Siegelaar, P. Gillard, C. Mathieu, K. Benhalima, Belgium, Netherlands

821 Time in range greater than 60% from the second trimester reduces adverse foetal outcomes in pregnant women diagnosed with type 1 diabetes using automated insulin delivery systems

A. Gómez, D. Henao, B. Grassi, O. Muñoz, M. Rondon, M. García, F. Leon, J. Gómez, M. N. Serrano, Colombia, Chile

822 Health-related quality of life and burden of type 1 diabetes and severe hypoglycaemia in adult continuous glucose monitor users

A. Boateng-Kuffour, P. Callahan, K. Chandarana, D. Barry, L. Chen, C. S. Kelly, H. Nguyen, K. Chapman, E. Cornelius, W. A. Wolf, W. Polonsky, USA

Short Oral Event F

Thursday, 14:00 - 15:00

SO 072 The future of diabetes science is here

823 Development of highly accurate measurement method of salivary glycated albumin by HPLC

M. Aihara, N. Kubota, T. Yamauchi, Japan

824 Performance data of the first algorithm developed for the BOYDSense breath-based glucose estimation device

P. Gourdy, L. Cazals, C. Francois-Marsal, S. Blanc-Calvo, M.-B. Arhainx, T. Schiavi, S. Isz, B. Lepage, F. Flacke, France, Germany

825 A gut on a chip platform to monitor GLP-1 secretion dynamics from primary intestinal tissue

W. Huang, C. Xie, C. Xiang, T. Li, R. L. Young, J. Zhao, H. Ebendorff-Heidepriem, C. K. Rayner, T. Wu, Australia

826 Brain functional reorganisation differs in patients with type 1 or type 2 diabetes

W. YuFan, F. Fang, China

827 Risk modelling for personalised screening interval recommendations for diabetic foot and retinopathy: a retrospective cohort study

W. T. Banas, C. A. Sainsbury, A. Manataki, S. Mercer, S. Cunningham, D. J. Wake, UK

828 Evaluation of the potential of LLM-based generative AIs in nutrition education: a comparative study of ChatGPT and Bing for Japanese registered dietitian licensure exam preparation

M. Kosai, Y. Nagamori, Y. Kawai, H. Marumo, M. Shibuya, T. Negishi, A. Sawai, L. Miyamoto, Japan

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

829 Bridging structured and unstructured data using natural language processing: insights from a French diabetic cohort (CODIA) in a multicentre clinical data warehouse

T. Jolivet, A. Bergès, E. Liu, J.-B. Julla, Y. Abouleka, J. Abecassis, G. Varoquaux, T. Petit-Jean, E. Cosson, E. Larger, A. Hartemann, J.-F. Gautier, C. Estellat, F. Tubach, L. Potier, France

830 Performance of a safety protocol for scuba diving in type 1 diabetic people: the 20-year experience of Diabete Sommerso®

E. Gamarra, G. Careddu, A. Fazi, V. Turra, A. Morelli, E. Cimino, P. Di Bartolo, C. Camponovo, P. Trimboli, U. Valentini, M. Bonomo, Switzerland, Italy

EASD
EFSD

GENERAL
INFO

Short Oral Event A

Tuesday, 12:30 - 13:30

PROGRAMME

TUESDAY

SO 073 Diabetes technology - but at a higher level

831 Efficacy of an image-based automated food analysis app in AID users with type 1 diabetes on glucose control: a randomised controlled trial

C. Piazza, L. Kastrati, C. Nakas, D. Herzig, L. Bally, Switzerland, Greece

832 Identification of missed mealtime insulin in type 1 diabetes using connected insulin pens

E. Dassau, H. Wolpert, J. Xue, C. Chen, M. Davidson, A. Boss, J. Johnson, USA

833 Real-world bolus dose timing and glycaemic impact using the Tempo Platform

J. Johnson, J. Xue, D. Duke, M. Davidson, E. Dassau, USA

834 Continuous glucose monitoring in patients with diabetes type 3c: breaking the myth of “labile diabetes”

G. Rodriguez-Carnero, D. Rivas, M. Serrano-Laguna, L. Gonzalez-Roza, R. Villar-Taibo, A. Ortiz-Zúñiga, M. Senet-Capote, M. Cuesta, S. Gutierrez-Medina, A. Gomez-Perez, A. Ballesteros Martín-Portugués, M. Alejo-Ramos, E. Fernandez-Rubio, Young diabetologists working group, spanish diabetes society, Spain

835 Evaluating a state-of-the-art generative pre-trained transformer model to predict continuous glucose monitoring values at different time intervals

M. E. Shomali, J. Luo, A. Kumbara, A. Iyer, G. Gao, USA

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

836 Simulated commercial flights and the effects of atmospheric pressure changes on insulin pump delivery

K. Fan, M. Paterson, A. Manoli, F. Shojaee-Moradie, V. Edwards, V. Lee, E. Hutchison, G. Koehler, C. Mathieu, J. Mader, B. King, D. Russell-Jones, UK, Australia, Austria, Belgium

837 The Hypo-METRICS app: a quantitative assessment of user experience

M. Cigler, U. Søholm, E. J. Abbink, N. Ali, F. Pouwer, B. E. De Galan, R. Mc Crimmon, P. Choudhary, P. Divilly, J. Speight, E. Renard, S. R. Heller, U. Pedersen-Bjergaard, J. K. Mader, M. Evans, Austria, Denmark, Netherlands, UK, France

838 Relationship of diabetes technology use with prognosis in people with type 1 diabetes awaiting islet or simultaneous islet kidney transplantation

A. Thant, P. Aung, L. Birtles, M. Greenwood-Morgan, M. Rutter, D. Van Dellen, H. Khambalia, S. Azmi, UK

Short Oral Event B

Tuesday, 13:45 - 14:45

SO 074 It is very hard to beat the system - or is it?

839 Real-world evidence of healthcare utilisation and costs for type 1 diabetes in Germany: analysis of a statutory health insurance database

R. Ziegler, Q. Zhang, P. Callahan, C. Vetter, E. Garal-Pantaler, A. De Remigis, L. Chen, W. Rathmann, Germany, USA

840 Implications of healthcare system failures faced by people with diabetes in the United Kingdom

S. Chanen, T. Bell, P. De Piante, R. Wood, USA

841 Closer collaboration between laboratories and general practices can improve diabetes monitoring and outcomes: effect of a real world trial in UK primary care

D. Holland, I. Halsall, M. Stedman, F. Hanna, J. Scargill, A. Heald, T. Fryer, UK

842 Evaluating the effectiveness of same-day screening programme at Steno Diabetes Center north Denmark

A. Nikontovic, T. Schou Andersen, N. Kragh Madsen, H. Ravn Larsen, D. Juhl Hansen, P. Vestergaard, P. Kronholm, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

843 Detecting unmet psycho-social needs in adult persons with diabetes, first data from our national Danish diabetes PROMS questionnaire (DiaProfil)

A. Nikontovic, L. Nørgaard, L. Havbæk Troelsen, N. Ejksjaer, Denmark

844 Impact of diabetes disease management programme on mortality, hospitalisations, and emergency room visits: a retrospective cohort study

R. Mužik, M. Selvek, B. Saal, I. Tkáč, Slovakia

EASD
EFSD

845 Socioeconomic status and diabetes impact mortality disparities across high income countries: a multinational population-based study

J. G. Ter Braake, R. C. Vos, E.-L. Røssell, D. J. Magliano, S. H. Wild, D. Walsh, J. Morton, S. Boel Graversen, H. Støvring, T. Laurberg, Netherlands, Denmark, Australia, UK

GENERAL
INFO

PROGRAMME

TUESDAY

846 Effectiveness and safety of telemonitoring compared with usual care in people with type 2 diabetes treated with insulin: preliminary results from a national multicentre randomised controlled trial

S. Hangaard, T. Kronborg, S. Cohen, A. Kofoed-Enevoldsen2, M. Rasmussen, L. Pedersen, C. Thomsen, T. Aradóttir, S. Kristensen, A. Kaas, H. Bengtsson, C. Dethlefsen, O. Hejlesen, P. Vestergaard, M. Jensen, Denmark, USA

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

Short Oral Event C

Wednesday, 12:45 - 13:45

SO 075 A lesson in diabetes geography

847 The state of carbohydrate metabolism in residents of the de-occupied territories of the Kyiv region

O. Dobrovynska, V. Orlenko, K. Ivaskiva, M. Tronko, Ukraine

848 Switching from sensor augmented pump therapy to mylife CamAPS FX system in a Spanish adult population with type 1 diabetes: impact on glycaemic control and perceived satisfaction

A. Flores Paños, L. Sanchez Canovas, R. Antonio Javier, I. Martin Perez, P. Villalba Armario, L. Marin Martinez, M. Alvarez Martin, A. Pastor Alcaraz, E. Hernandez Alonso, G. Kyriakos, Spain

849 Longitudinal assessment of quality of care in adults with type 1 diabetes in Italy: data from a large, long-term observational cohort

G. Russo, R. Candido, S. De Cosmo, P. Di Bartolo, G. Di Cianni, G. Lucisano, V. Manicardi, A. Nicolucci, A. Rocca, M. Rossi, D. Cucinotta, AMD Annals Study Group, Italy,

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

850 Glycaemic control is not affected by season in MiniMed 780G system users: a real world study from Italy

E. Bosi, B. Voelker, V. Smaniotto, A. Arrieta, J. Castaneda, T. Van den Heuvel, O. Cohen, Italy, Switzerland

851 Real world performance comparison of three hybrid closed loop systems in a semi-rural Welsh cohort

A. Mallipedhi, M. Saeed, A. Zulifiqar, S. Malik, S. Fatima, UK

852 Long-term real-world outcomes of hybrid closed-loop therapy in adults with type 1 diabetes in the UK

A. L. Liarakos, T. S. Crabtree, T. P. Griffin, Y. W. Yap, P. Narendran, M. Karamat, G. Gallen, S. Hussain, J. Elliott, L. Leelarathna, A. Lumb, R. E. Ryder, P. Choudhary, E. G. Wilmot, UK

853 Elevated type 1 diabetes prevalence in the Faroe Islands: exploring glycaemic management by insulin pump use in a unique remote population

H. Johannesen, M. Petersen, B. Joensen, P. Rasmussen, J. Andreassen, Faroe Islands

854 Impact of mental disorders on the all-cause mortality and cardiovascular disease outcomes in adults with new-onset type 1 diabetes: a nationwide cohort study

S. Kim, G. Kim, S. Cho, R. Oh, J. Kim, Y.-B. Lee, S.-M. Jin, K. Hur, J. Kim, Republic of Korea

Short Oral Event D

Wednesday, 14:00 - 15:00

SO 076 Up or down and back

855 The suboptimal management of 541 episodes of severe hypoglycaemia underscores the need for improved services: pilot data from the DEKODE hypoglycaemia study

K. Persad, M. Idrissi, A. Bal, C. Page, S. Sherratt-Mayhew, H. Sheikh, A. Solomon, P. Choudhary, P. Kempegowda, H. DEKODE Team, UK

856 Characteristics of nocturnal hypoglycaemic events and their impact on glycaemia in people with type 1 diabetes

M. Eichenlaub, S. Öter, D. Waldenmaier, B. Kulzer, L. Heinemann, R. Ziegler, O. Schnell, T. Glatzer, G. Freckmann, Germany

857 Investigating the impact of symptomatic and asymptomatic hypoglycaemia on heart rate: an analysis of the HypoMetrics dataset

J. J. Thomas, H. Hadid, V. Koutroukas, G. Martine-Edith, P. Choudhary, Hypo-METRICS Consortium, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

858 Misclassification matters: implementing a clinical prediction model in electronic health records to identify individuals with misclassified diabetes and increased hypoglycaemia and DKA risk
K. G. Young, R. Hopkins, J. Dennis, N. Qureshi, A. Jones, B. Shields, UK

859 Severe hypoglycaemia and diabetic ketoacidosis presenting to a hospital emergency department: young-onset type 2 diabetes has poorer prognosis than type 1 diabetes
S. H. Song, B. M. Frier, UK

EASD
EFSD

GENERAL
INFO

860 Clinical presentation and outcomes of DKA in adults with type 1 diabetes on continuous subcutaneous insulin infusion vs multiple daily injection: results from the DEKODE-DKA study
P. Kempegowda, A. Sharma, L. Rengarajan, R. Thayakaran, P. Narendran, K. Dhatariya, DEKODE-DKA working group, UK

PROGRAMME

TUESDAY

861 Diabetic ketoacidosis guidelines have been poorly adopted and implemented in the UK, with an associated lack of improvement in outcomes

A. Buchipudi, A. Sharma, L. Rengarajan, P. Narendran, K. Dhatariya, P. Kempegowda, DEKODE Working Group, UK

WEDNESDAY

THURSDAY

862 Aggressive descending mode during short-term intensive insulin therapy achieved better glycaemic control with shorter length of hospital stay in newly diagnosed patients with type 2 diabetes

X. Zhang, X. Huang, Y. Cao, Z. Zhang, Y. Li, Z. Huang, China

FRIDAY

SHORT ORAL
DISCUSSIONS

Short Oral Event E

Thursday, 12:45 - 13:45

SO 077 Continuous monitoring of CGM

863 Population-based study on the implementation of continuous glucose monitoring and severe hypoglycaemia in adults with type 1 diabetes

P. Rodríguez de Vera Gómez, E. Mayoral, R. Ravé García, M. De la Cal Ramírez, G. Umpierrez, M. Martínez-Brocca, Spain, USA

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

864 Disparities in initiation of continuous glucose monitoring and impact on glycaemic control in children and adolescents with type 1 diabetes

M. K. Borbjerg, A. Kvist, K. M. Mehta, N. Ejksjaer, J. C. Wong, Denmark, USA

EXHIBITION

865 CGM sensor glucose metrics pre- and post-automated insulin delivery use among adults in the T1D Exchange Online Registry

H. Nguyen, C. S. Kelly, K. M. Miller, N. S. Chaytor, M. E. Hilliard, B. E. Marks, M. L. Litchman, E. M. Cornelius, Y. C. Kudva, K. S. Chapman, A. L. Carlson, D. J. DeSalvo, J. L. Sherr, W. A. Wolf, USA

866 Efficacy of real-time continuous glucose monitoring in adults with diabetic ketoacidosis

M. M. Bogun, C. Wang, P. A. Kurlansky, N. Badeir, G. E. Umpierrez, USA

867 Glucose monitoring profiles in professional football players without diabetes: match analysis and comparison with an active population

K. Skroce, A. Zignoli, N. Mihic, D. Lipman, M. Riddell, H. C. Zisser, Croatia, Italy, Spain, USA, Canada

868 Differences in sensor glucose progression from level 1 to level 2 based on hypoglycaemia awareness, in type 1 and insulin-treated type 2 diabetes: Hypo-METRICS study

V. Koutroukas, J. J. Thomas, H. Hadid, G. Martine-Edith, P. Divilly, N. Zaremba, P. Choudhary, Hypo-RESOLVE Consortium, UK

869 Insights from two weeks of isCGM usage among individuals with non-insulin treated type 2 diabetes

T. Thybo, E. Nielsen, N. Cayuelas i Mateu, A.-M. Wegener, Denmark

870 Real world evaluation of people with type 2 diabetes with a 180-day implantable CGM system

B. Romarowski, K. Tweden, C. E. Mdingi, F. R. Kaufman, USA

Short Oral Event F

Thursday, 14:00 - 15:00

SO 078 More stress on distress

871 Suicide risk comparison among adults with type 1 diabetes, cancer, and the general population: a nationwide cohort study

S. Kim, J. Kim, G. Kim, Republic of Korea

872 Assessment of quality of life, psychological parameters and glycaemic variability in type 1 patients: a real-life experience

E. Resmini, A. V. Cornaghi, V. Turra, G. Massari, S. Dotti, E. Cimino, E. Zarra, M. Sandri, A. Girelli, Italy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

873 Prevalence and incidence of elevated diabetes distress and depressive symptoms at 6, 12 and 18-months in people with diabetes: a cox-regression analysis

D. Ehrmann, G. Lehmann, B. Olesen, L.-S. Priesterroth, T. Roos, T. Haak, N. Hermanns, B. Kulzer, Germany

874 Resting-state neuronal communication, but not cortical structure, is associated with increased diabetes distress in adult type 1 diabetes

E. Van Duinkerken, R. G. IJzerman, M. Demuru, M. Klein, F. Barkhof, A. Hillebrand, F. J. Snoek, Netherlands, UK

EASD
EFSD

GENERAL
INFO

875 Anxiety and depressive symptoms of type 1 diabetes and severe hypoglycaemia in adult continuous glucose monitor users

A. Boateng-Kuffour, P. Callahan, K. Chandarana, T. Gupta, L. Chen, C. S. Kelly, H. Nguyen, K. Chapman, E. Cornelius, W. Wolf, W. Polonsky, USA

PROGRAMME

TUESDAY

876 Can AID systems reduce diabetes-related stress?

B. Kulzer, D. Ehrmann, L. Heinemann, G. Faber-Heinemann, T. Roos, M. Resl, J. Mader, P. Diem, C. Truempy, D. Brandt, N. Hermanns, Germany, Austria, Switzerland

WEDNESDAY

THURSDAY

877 Can psychological situation determine advanced hybrid closed-loop system outcomes?

P. Beato Vibora, E. Gil-Poch, F. J. Arroyo-Diez, Spain

FRIDAY

SHORT ORAL
DISCUSSIONS

878 Associations between sleep patterns and glucose homeostasis in subjects at risk of type 2 diabetes

A. Dardano, G. Daniele, F. Orsolini, U. Faraguna, S. Bruno, G. Giovannini, V. Sancho Bornez, S. Del Prato, Italy

PRESENTER
INDEX

SATELLITE
SYMPOSIA

Short Oral Event A

Tuesday, 12:30 - 13:30

SO 079 From microbiology to MRI in diabetic foot disease

INDUSTRY

PROGRAMME

879 A cluster analysis for stratifying diabetic foot ulcers at baseline: Are those associated with ulcer healing and patient outcome?

R. Naemi, Z. Abbas, UK, Tanzania, United Republic of

EXHIBITION

880 Survival analysis of diabetic foot ulcer patients: a multicenter cohort study integrating structured and unstructured data from a clinical data warehouse

J.-B. Julla, T. Jolivet, A. Bergès, Y. Abouleka, E. Liu, J. Abecassis, G. Varoquaux, E. Cosson, A. Hartemann, E. Larger, J.-F. Gautier, C. Estellat, F. Tubach, L. Potier, France

881 Time in range is closely related to healing time of diabetic foot ulcers

Á. Ortiz Zúñiga, J. Samaniego, F. Cuadra Espinilla, M. Sánchez Bartres, O. Simó Servat, R. Simo, C. Hernández Pascual, Spain

882 Concordance of molecular microbiology and traditional culture techniques for infected diabetic foot ulcer management

F. Game, A. Oates, S. Brown, C. Everett, J. Nixon, T. Sloan, M. Lister, M. Backhouse, B. Lipsky, D. Russell, H. Collier, J. Dennett, R. Gilberts, A. Nelson, UK, USA

883 The use of follow-up MRI in monitoring Charcot Foot and its association with total contact cast treatment duration and long-term outcomes

J. Schoug, E. Uddman, P. Katzman, M. Löndahl, Sweden

884 Hypoxia preconditioned plasma accelerates diabetic wound healing by promoting angiogenesis via increasing growth factors expression

G. Zhou, M. Tao, J. Zhu, S. Li, L. Zhang, China, USA

885 The conjuring of anemia and multidrug resistant bacteria against healing chances in diabetic foot patients

F. Giangreco, E. Iacopi, M. Pogliaghi, A. Leonildi, L. Pieruzzi, S. Barnini, C. Goretti, M. Falcone, A. Piaggese, Italy

886 Is systematic screening for diabetes effective in reducing peri-operative infections in patients undergoing cardiac surgery? The DOCS study

A. Mattina, M. Giusti, E. Conoscenti, M. Morsolini, G. Raffa, A. Mularoni, M. Fazzina, D. Di Carlo, M. Cipriani, F. Musumeci, A. Arcadipane, M. Pilato, P. Conaldi, D. Bellavia, Italy

Short Oral Event B

Tuesday, 13:45 - 14:45

SO 080 Diabetic kidney disease: clinical insights from childhood to frailty

887 Raised prevalence of mental health illnesses and non-white ethnicity in young people with type 2 diabetes and early stage diabetic kidney disease

M. Allen-Taylor, C. Doherty, A. Hodgkinson, A. Rickford, M. Chamley, J. Karalliedde, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

888 Effect of omega-3 fatty acids supplementation on renal glomerular and tubular integrity and subclinical atherosclerosis in adolescents with type 1 diabetes: a randomised controlled trial
E. Abdelrahman Ismail, S. Abdelaal Mohamed¹, N. Elbarbary, Egypt

889 Associations between peripheral augmentation index and renal function decline in adults with type 1 diabetes from the REMOVAL study

EASD
EFSD

D. Chen, A. Januszewski, N. Greenlaw, T. Fernandes, D. Carty, J. G. Boyle, A. D. Hughes, I. Hramiak, C. Stehouwer, A. Jenkins, J. Petrie, Australia, UK, Canada, Netherlands

GENERAL
INFO

890 Cardiac autonomic neuropathy: an independent risk factor for renal decline in diabetic kidney disease

K. Soe, E. J. Robinson, M. A. Oleolo, S. Tesfaye, J. Marques, S. Sourbron, D. Selvarajah, UK, Brazil

PROGRAMME

TUESDAY

891 Decline in kidney function over time in childhood-onset type 1 diabetes

E. Hornbrinck, M. Lundqvist, J. W. Eriksson, M. K. Svensson, Sweden

WEDNESDAY

THURSDAY

892 Efficacy and safety of finerenone in patients with CKD and type 2 diabetes across the frailty spectrum: a FIDELITY post hoc analysis

P. Rossing, A. Birkenfeld, P. Fioretto, J. B. McGill, S. D. Anker, B. Pitt, A. Scalise, C. Scott, G. Filippatos, Denmark, Germany, Italy, USA, Poland, Spain, UK, Greece

FRIDAY

SHORT ORAL
DISCUSSIONS

893 Impact of specialised diabetic team intervention on hospitalised patients with type 2 diabetes undergoing kidney transplant

P. Gil, J. Amigó, F. Cuadra, Á. Ortiz Zúñiga, M. Sánchez Bartres, J. Garcia-Arabehty, C. Hernández Pascual, R. Simo, O. Simo-Servat, Spain

PRESENTER
INDEX

SATELLITE
SYMPOSIA

Short Oral Event C

Wednesday, 12:45 - 13:45

INDUSTRY

SO 081 Advances in diabetic kidney disease from cells to histology

PROGRAMME

894 Histological findings predict kidney failure in diabetes: a retrospective cohort study

K. H. Jensen, M. Blond, F. Persson, I. Bressendorff, D. Hansen, M. Møller, P. Rossing, R. Borg, Denmark

EXHIBITION

895 circ_0054633 knockdown suppresses hyperglycaemia induced extracellular matrix accumulation in renal mesangial cell by regulating the miR-136-5p/SMAD3 signalling

Q. Jiang, X. W. Zhu, L. Xu, W. Tang, China

896 Nrf2 activation attenuates diabetic kidney disease in preclinical in vitro and in vivo mouse model

S. Kwon, M.-J. Kim, J. Moon, C. Oh, J. Hong, H. Kim, H. Yoo, S. Kim, Y.-G. Kwon, J.-H. Kang, H. Seo, J.-I. Pyo, I.-K. Lee, J.-H. Jeon, K. Won, Republic of Korea

897 Plasma fatty acid binding protein 1 and diabetic kidney disease in subjects with type 2 diabetes

M. Giambalvo, D. Lucchesi, M. Capobianco, G. Mancini, S. Del Prato, P. Marchetti, G. Penno, M. Garofolo, Italy

898 The relationship of phenyl sulfate and other factors with renal function status in patients with type 2 diabetes

C.-C. Chen, Z.-L. Lai, H.-L. Kuo, I.-K. Wang, C.-J. Chen, Taiwan

899 Activation of Hippo pathway alleviates kidney injury in type 2 diabetic mice

Y. Wang, L. Wang, Y. Huang, China, Hong Kong

900 Fibroblast growth factor 23 and diabetic kidney disease phenotypes in type 2 diabetes

G. Penno, C. Pelosini, D. Lucchesi, M. Giambalvo, M. Capobianco, G. Mancini, M. R. Sessa, F. Santini, S. Del Prato, P. Marchetti, M. Garofolo, Italy

901 Urinary cell-free DNA for liquid biopsy in diabetic kidney disease

Y. Liu, W. Li, D. Xie, Y. Chen, X. Wang, China

Short Oral Event D

Wednesday, 14:00 - 15:00

SO 082 Predicting and treating renal complications. What's new in 2024?

902 Correlation between triglyceride-glucose index and diabetic kidney disease risk in adults with type 1 diabetes

M. Lei, P. Ling, Y. Zhou, J. Lv, Y. Ni, H. Deng, C. Wang, D. Yang, X. Yang, W. Xu, J. Yan, China

903 Length of telomeres in patients with type 2 diabetes with and without chronic kidney disease

Y. Rebrova, Y. Saienko, O. Monashnenko, D. Krasnienkov, V. Korcheva, O. Kot, B. Mankovsky, Ukraine

904 Treating chronic kidney disease with and without diabetes in Danish primary care: results from the Observational ATLAS study

R. Borg, M. K. Lindhardt, T. Saxild, M. Charles, S. Knudsen, Denmark

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

905 Cystatin C seems to be superior to homocysteine as reliable markers of early diabetic nephropathy

S. Ljubic, A. Jazbec, I. Cudina, M. Tomic, T. Bulum, D. Rahelic, Croatia, Denmark

906 Study of endothelial glycocalyx and vascular function in patients with type 2 diabetes and albuminuria after administration of dulaglutide and dapagliflozin vs DPP-4 inhibitors

E. Korakas, I. Ikonomidis, I. Thymis, A. Kountouri, K. Katogiannis, G. Pavlidis, D. Tsilivarakis, V. Prentza, K. Balampanis, L. Pliouta, F. Kousathana, G. Kostelli, G. Dimitriadis, A. Raptis, V. Lambadiari, Greece

EASD
EFSD

GENERAL
INFO

907 Effects of the launches of GLP-1 RA and SGLT2i and calendar year on yearly change in eGFR: results from an analysis of 48,363 person-years

S. Katoh, Y. Watanabe, K. Yokoyama, Y. Sakamoto, K. Utsunomiya, R. Nishimura, Japan

PROGRAMME

TUESDAY

908 Association between leisure time physical activity and of risk of end-stage renal disease in people with type 2 diabetes

Y.-J. Lai, Y.-F. Yen, P.-W. Ku, L.-J. Chen, Taiwan

WEDNESDAY

THURSDAY

909 Outcomes for MACE, MARE, and mortality in diabetes subgroups with chronic kidney disease

R. Schürfeld, A. Kühnapfel, E. Baratashvili, A. Bachmann, J. Beige, R. Wendt, M. Blüher, M. Stumvoll, A. Tönjes, T. Ebert, Germany

FRIDAY

SHORT ORAL
DISCUSSIONS

Short Oral Event E

Thursday, 12:45 - 13:45

PRESENTER
INDEX

SO 083 The four M's of microvascular complications: MRI, Mitochondria, Models, and iMaging

SATELLITE
SYMPOSIA

910 Quantitative multi-organ imaging stratifies high risk individuals, with cardiac and abdominal phenotypes in individuals with diabetic retinopathy

C. Diamond, T. Waddell, K. Chapman, T. Nguyen, H. Thomaidis Brears, R. Banerjee, I. Yeung, R. Hamilton, UK, USA

INDUSTRY

PROGRAMME

911 New insights into the pathogenesis of diabetic kidney disease (DKD): human amylin aggregates as a potential factor in the development of DKD

S. Iglesias Fortes, C. González-Blanco, A. García-Carrasco, A. Izquierdo-Lahuerta, G. García, A. Lockwood, C. Figaredo, A. García-Aguilar, G. Medina, C. Guillén, Spain

EXHIBITION

912 Construction of a prediction model for non-proliferative retinopathy in type 2 diabetes

Y. Liu, C. Wang, J. Qiao, Y. Li, D. Lv, L. Li, Y. Wang, the China National Diabetic Chronic Complications Study Group, China

913 Prevalence of diabetic retinopathy in people with type 2 diabetes and fast progression of kidney function

T. Alobaid, J. Karalliedde, M. O'Connell, S. Ayis, UK

914 Total and trunk body fat are associated with chronic kidney disease progression in type 2 diabetes patients: a prospective study

T. Zelmanovitz, D. Weber, C. Pavinatto, G. Bello, M. L. Harthmann, R. B. Junior, M. E. De Souza, M. Azevedo, B. L. Dama, S. P. Silveiro, Brazil,

915 Mitochondrial DNA copy number in patients with type 2 diabetes and chronic kidney disease

Y. Saienko, Y. Rebrova, O. Monashnenko, D. Krasnienkov, V. Korcheva, B. Mankovsky, Ukraine

916 Relationship between serum regenerating protein I α and estimated glomerular filtration rate decline slope in diabetic kidney disease: a single-centre cohort study

S. Chen, N. Huang, L. Li, China

917 Retinopathy associates with volume loss in the secondary visual cortex in individuals with type 1 diabetes

T. Claesson, S. Mutter, M. Eriksson, A. Tarkkonen, J. Putaala, E. Salli, P. Summanen, D. Gordin, P.-H. Groop, J. Martola, L. Thorn, on behalf of the FinnDiane Study Group, Finland

Short Oral Event F

Thursday, 14:00 - 15:00

SO 084 Mechanisms and treatment for microvascular complications; nerves, eyes, and blood vessels

918 Onset and progression of hypertension in diabetes patients: a ten year follow up study applying Markov multistate modelling

P. Goswami, D. T R, A. Kulkarni, Y. Shejul, India

919 The role and mechanism of peripheral angiotensin II type 2 receptor in diabetic neuropathic pain

B. Lu, Y. Bai, China

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

920 Topical administration of sitagliptin prevents diabetic retinopathy-like lesions in a new non-diabetic experimental model, the TRPV2^{-/-} rat

H. Ramos, J. Augustine, B. M. Karan, C. Hernández, A. W. Stitt, T. M. Curtis, R. Simó, Spain, UK

921 The dual amylin and calcitonin receptor agonist KBP-336 relieves neuropathic pain and improves glucose control in ZDF rats with obesity and diabetes

K. Mohamed, A. Larsen, M. A. Karsdal, K. Henriksen, Denmark, Switzerland

EASD
EFSD

GENERAL
INFO

922 Autonomic heart function in prediabetes and type 2 diabetes associates to immune activation

S. B. Haugaard, R. Hadad, A. V. Hviid, O. Wendelboe, A. Sajadieh, Denmark

PROGRAMME

TUESDAY

923 Corneal nerve loss and regeneration after GLP-1 therapy in adults with simple and monogenic obesity

H. Gad, E. Elgassim, I. N. Petropoulos, G. Ponirakis, K. Hussain, T. Elhadd, K. Baagar, R. A. Malik, Qatar, UK

WEDNESDAY

THURSDAY

924 Plasma levels of 18 β -glycyrrhetic acid in patients with newly diagnosed type 2 diabetes and its association with blood pressure and blood pressure lowering treatment

P. Asyaei, J. L. Wetche, A. V. Schmedes, A. Sjøgren, M. L. Bergmann, L. H. Fly, J. S. Madsen, E. R. Petersen, M. H. Olsen, K. Højlund, J. V. Stidsen, T. B. Olesen, Denmark

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

Short Oral Event A

Tuesday, 12:30 - 13:30

SATELLITE
SYMPOSIA

SO 085 Clinical data and emerging markers in diabetic foot disease and neuropathy

925 Prediction of mortality in patients with diabetic foot ulcers based on machine learning

R. Li, H. Zhu, China

INDUSTRY

PROGRAMME

926 Thyroid hormone sensitivity index is associated with diabetic peripheral neuropathy in euthyroid patients with type 2 diabetes

W. Wang, Y. Chen, A. Jiang, L. Zhang, China

EXHIBITION

927 Uncovering the burden: underdiagnosis and undertreatment of diabetic peripheral neuropathy in the northern Danish region

J. Roeikjer, A.-M. Wegeberg, A. Nikontovic, C. Brock, P. Vestergaard, Denmark

928 Metabolic decompensation correlates with worse outcomes in diabetic foot patients

F. Giangreco, E. Iacopi, L. Pieruzzi, C. Goretti, A. Piaggese, Italy

929 Leveraging artificial intelligence for predicting placebo vs treatment response in painful diabetic neuropathy

D. Selvarajah, P. Tripathi, K. Teh, S. Zhou, M. N. Suvon, S. Tesfaye, J. Wild, D. Bennett, A. Segerdahl, D. Steel, L. Colvin, H. Lu, UK

930 CODIFI2: randomised controlled trial to compare clinical and cost-effectiveness of swabs vs tissue samples to inform management of infected diabetic foot ulcers

F. Game, C. Bojke, B. Sarah, C. Everett, H. Konwea, A. Oates, H. Collier, M. Backhouse, J. Dennett, R. Gilberts, B. Lipsky, J. Nixon, D. Russell, A. Nelson, UK, USA

Short Oral Event B

Tuesday, 13:45 - 14:45

SO 086 Novel markers and predictors for neuropathy in diabetes

931 Exploring neuroinflammation in diabetic patients: a retrospective analysis of brain imaging data

A. Prakash, S. Ahsan, M. Kumar, India

932 Validation of the histamine-induced axon-reflex flare response in a non-selected population of people with type 1 diabetes

J. Roeikjer, P. Tind, A. Larsen, M. K. Borbjerg, C. D. Mørch, N. Ejksjaer, Denmark

933 Exploring biomarkers for diabetes neuropathy through comprehensive serum proteome analysis

G. Kaur, T. Okdahl, T. Suvitaival, T. Alhuwalia, C. Hansen, P. Karlsson, T. Hansen, M. Kokla, T. Muk, P. Rossing, T. Jensen, B. Brock, C. Legido-Quigley, C. Brock, K. Sulek, Denmark, UK

934 Increased advanced glycation end products measured by skin autofluorescence are associated with diminished sciatic nerve structural integrity in type 2 diabetes

Z. Kender, C. Mooshage, L. Seebauer, D. Tsilingiris, L. Schimpfle, A. Sulaj, J. Szendroedi, S. Heiland, M. Bendszus, S. Kopf, F. T. Kurz, J. Jende, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

935 Attenuation of niacin-induced skin flushing response: a potential clinical adjunctive diagnostic instrument for diabetic peripheral neuropathy

T. Jiang, F. LIU, China

936 Elevated serum Lp-PLA2, a new risk factor, is closely related to diabetic neuropathy in patients with type 2 diabetes

J. Li, H. Lu, Y. Wang, Diabetic Neuropathy Group, China

EASD
EFSD

937 Increased plasma miR27a-3p levels are associated with reduced Netrin-1 and corneal nerve fibre length in diabetic neuropathy

A. Mondal, C. Bose, S. Pramanik, C. Saha, S. Banerjee, B. Mukherjee, L. K. Mondal, R. A. Malik, S. Mukhopadhyay, India, Qatar

GENERAL
INFO

PROGRAMME

Short Oral Event C

Wednesday, 12:45 - 13:45

TUESDAY

SO 087 Clinical studies on the crosstalk between neuropathy and other systems

WEDNESDAY

938 Diminished renal function is linked to a decline in the structural integrity of the sciatic nerve among individuals with type 1 and type 2 diabetes

THURSDAY

L. Seebauer, C. Mooshage, D. Tsilingiris, L. Schimpfle, A. Sulaj, J. Szendroedi, S. Heiland, M. Bendszus, S. Kopf, F. T. Kurz, J. Jende, Z. Kender, Germany

FRIDAY

SHORT ORAL
DISCUSSIONS

939 The association between cardiac autonomic neuropathy and progression of diabetic nephropathy in type 2 diabetic patients

D.-H. Cho, J.-O. Chung, D.-J. Chung, Republic of Korea

PRESENTER
INDEX

940 Assessment of diabetic autonomic neuropathy using pupillometry and corneal confocal microscopy in patients with diabetes and concurrent sexual dysfunction

Z. Linn, R. Pasha, B. Bashir, A. Kamath, A. Kalteniece, S. Azmi, R. A. Malik, H. Soran, M. Ferdousi, UK, Qatar

SATELLITE
SYMPOSIA

INDUSTRY

941 Does small fibre neuropathy contribute to depression in diabetes? A corneal confocal study

M. Ferdousi, R. Pasha, A. Kalteniece, Z. Linn, B. Bashir, H. Soran, S. Azmi, R. A. Malik, UK, Qatar

PROGRAMME

EXHIBITION

942 Complement activation in diabetic neuropathy: insights from high-resolution resonance imaging and spatial microproteomics

T. Fleming, D. Schwarz, M. Marois, A. Peters, R. Longuespee, D. Helm, Z. Kender, J. Szendroedi, Germany

943 Serum pancreatic regeneration protein α potential association between renal injury and metabolic function

Z. Shu, S. Chen, L. Li, China

944 Small fibre damage and autonomic neuropathy are associated with increased mortality after simultaneous pancreas and kidney transplantation in type 1 diabetes

S. Azmi, M. Ferdousi, I. N. Petropoulos, G. Ponirakis, U. Alam, O. Asghar, A. Boulton, T. Augustine, R. A. Malik, UK, Qatar,

945 Periosteal pressure sensitivity a measure of autonomic neuropathy in comparison to other neuropathy measures in people with type 1 diabetes: a DANES cohort study

S. K. Hecquet, H. Mizrak, H. Kufaishi, M. B. Blond, S. Ballegaard, J. Faber, E. Eldrup, T. Hansen, B. Brock, P. Rossing, C. Hansen, Denmark

Short Oral Event D

Wednesday, 14:00 - 15:00

SO 088 Fatty liver in diabetes: pathways and relationships

946 Vitamin D3 in the regulation of autophagy and mitochondrial dynamics in non-alcoholic fatty liver disease induced by type 2 diabetes

O. Lisakovska, A. Khomenko, O. Mezhenska, T. Horid'ko, T. Kuchmerovska, M. Veliky, I. Shymanskyi, Ukraine

947 One-hour plasma glucose concentration during the OGTT is a strong predictor of hepatic steatosis in nondiabetic individuals

F. Al-Mulla, M. Abu-Farha, F. Alajmi, J. Abubaker, M. Ahmed, M. Qaddoumi, M. Shehab, A. John Mclaws, T. Alessa, A. Alhubail, D. Alsaeed, M. Arouj, A. Bennakhi, R. DeFronzo, M. Abdulghani, Kuwait, USA

948 Machine learning approach reveals proteome and lipidome profile in patients with metabolic associated fatty liver disease complicated with poly-vascular plaques

Z. Tu, T. Yue, Y. Ding, X. Zheng, S. Luo, J. Weng, China

949 Antibiotic-induced decline in indoles and their associations with lobular inflammation in patients with metabolic dysfunction-associated steatohepatitis and impaired glucose tolerance

C. J. Teunis, A. S. Meijnikman, H. H. Levels, A. Van de Laar, R. Franken, M. Davids, H. J. Herrema, V. E. Gerdes, M. Nieuwdorp, N. M. Hanssen, Netherlands

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

950 Metabolic dysfunction associated steatotic liver disease, but not visceral adiposity, is a strong and independent determinant of increased plasminogen activator inhibitor-1 levels in humans

K. Kantartzis, J. Machann, F. Schick, S. Hörber, A. Peter, A. L. Birkenfeld, H.-U. Häring, A. Fritsche, N. Stefan, Germany

951 Association between depression and non-alcoholic fatty liver disease according to obese status. The Korean National Health and Nutrition Examination survey 2010-2019

Y. Lyu, S. Kim, Republic of Korea

EASD
EFSD

GENERAL
INFO

952 MASLD and MetALD: the amount of liver fat and number of cardiometabolic risk factors in relation to the risk of type 2 diabetes and cardiovascular disease

G. Alblas, J. H. Van der Velde, M. E. Tushuizen, W. J. Jukema, H. J. Lamb, F. R. Rosendaal, B. Van Hoek, R. De Mutsert, M. J. Coenraad, Netherlands

PROGRAMME

TUESDAY

953 Similar glucagon-stimulated amino acid suppression in obese individuals with and without hepatic steatosis or steatohepatitis

S. Heebøll, G. Wegener, H. Grønbaek, S. Nielsen, Denmark

WEDNESDAY

THURSDAY

FRIDAY

Short Oral Event E

Thursday, 12:45 - 13:45

SO 089 Brain matters in diabetes

954 Loss of thalamic subnuclei volume is related to widespread cortical thinning in middle-aged people with type 1 diabetes, independent of peripheral microangiopathy

E. Van Duinkerken, L. Loureiro, R. IJzerman, J. Landeira-Fernandez, M. Klein, F. Barkhof, F. J. Snoek, Netherlands, Brazil, UK

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

955 Risk factors predisposing to dementia in individuals with type 1 diabetes

S. I. Satuli-Autere, F. Jansson Sigfrids, M. I. Eriksson, A. Ylinen, P.-H. Groop, V. Harjutsalo, L. M. Thorn, Finland

INDUSTRY

PROGRAMME

956 Grey matter reserve modulates the association between diffusion tensor imaging analysis-along the perivascular space index and cognition in patients with type 2 diabetes

X. Yin, Y. Zhang, S. Ge, J. Ma, W. Xia, China

EXHIBITION

957 Does lipid-lowering drugs reduce the risk of dying from dementia in persons with type 2 diabetes: a Danish population-wide nested case-control study

T. Laurberg, S. B. Graversen, K. N. Horn, H. Støvring, Denmark

958 Age-related decrease of hippocampal insulin sensitivity is linked to unhealthy fat distribution in women

L. Sandforth, R. Veit, J. Machann, G. Miller, M. Jiménez-Muñoz, A. Fritsche, M. Heni, A. Birkenfeld, H. Preissl, S. Kullmann, Germany

959 Differences in brain anatomy between diabetes endotypes: results from the UK-Biobank

M. Cerrai Ceroni, J. Hummel, K. Prystupa, H. Müller, H. Yamazaki, J. Kassubek, R. Wagner, M. Heni, Italy, Germany, Japan

960 Investigating CR1 as an indicated gene for mild cognitive impairment in type 2 diabetes

X. Zhou, S. Wang, China

961 Effects of aerobic-strength training on glucose metabolism, cognitive functions, and proteome of circulating EVs in patients with Parkinson's disease

J. Ukropec, L. Slobodová, K. Marček Malenovská, A. Amiri, M. Konečná, I. Straka, T. Kurdiová, O. Mytai, Z. Zdráhal, R. Klepochová, Z. Košutzká, M. Minár, M. Krššák, P. Valkovič, B. Ukropcová, Slovakia, Czech Republic, Austria

Short Oral Event F

Thursday, 14:00 - 15:00

SO 090 Skeletal muscles and subcutaneous adipose tissue: important players in diabetes management

962 Sarcopenia risk in diabetes endotypes

N. Trinks, O. Zaharia, K. Strassburger, S. Schlesinger, R. Wagner, A. Bosy-Westphal, M. Roden, Germany

963 Impact of moderate-to-vigorous physical activity on mortality in sedentary patients with type 2 diabetes using a target trial emulation technique: a nationwide study

S. Park, S. Kim, Y.-B. Lee, S.-M. Jin, K. Hur, J. Kim, G. Kim, Republic of Korea

964 Liver-muscle crosstalk in metabolic dysfunction-associated steatotic liver disease

A. R. Fumo, P. Morigny, H. Ji, A. Maida, C. Von Toerne, A. J. Alfaro, K. Motzler, A. Feuchtinger, M. Rohm, Germany

965 Genetic evidence for causal role of lipodystrophy-like phenotype on diabetes complications of the upper limb

H. D. Green, R. Bala, J. Tyrrell, S. Martin, M. Weedon, I. Barroso, UK, Germany

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

966 Body fat and muscle contributions to heart failure risk: insights from longitudinal epidemiological and cardiac magnetic resonance studies

S. Xu, K. Wan, Q. Xie, H. Yang, Y. Qu, Y. Zeng, H. Song, China

967 Polygenic risk score for partial lipodystrophy based on clustered phenotypes-modelling and validation in the UK Biobank and Oxford Biobank

N. Atabaki Pasdar, D. Coral, M. J. Neville, E. Cresswell, K. E. Pinnick, E. Trichia, A. Viñuela, F. Karpe, UK, Sweden

EASD
EFSD

GENERAL
INFO

968 Differences in cardiac organ damage in individuals with hyperglycaemia and type 2 diabetes identified by 1-hour plasma glucose during an OGTT according to the IDF criteria

A. Riccio, C. M. Cefalo, T. Fiorentino, E. Succurro, F. Andreozzi, A. Sciacqua, G. Sesti, Italy

PROGRAMME

TUESDAY

969 Signs of myocardial fibrosis in patients with type 2 diabetes without cardiovascular disease

I. V. Zubovych, Y. Y. Marushko, Y. A. Saienko, O. G. Halchenko, D. C. Vebs, B. M. Mankovsky, Ukraine

WEDNESDAY

THURSDAY

FRIDAY

Short Oral Event A

Tuesday, 12:30 - 13:30

SO 091 A new look at well-known drugs in type 2 diabetes

970 Multi-omics analysis of the effect and mechanism of sodium-glucose cotransporter 2 inhibitors on metabolic dysfunction-associated fatty liver disease

J. Chen, J. Du, Q. Sun, M. Zhang, T. Haoming, China

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

971 Using machine learning to predict dynamic cardiovascular risks and identify the treatment responses of canagliflozin in type 2 diabetes

Q. Huang, X. Zou, E. J. Boyko, L. Ji, China, USA

INDUSTRY

PROGRAMME

972 Combination use of SGLT2 inhibitors and pioglitazone on risk of metabolic dysfunction-associated steatohepatitis in patients with type 2 diabetes

C. Lee, D. Lui, L. Mak, C. Fong, C. Cheung, W. Chow, Y. Woo, M. Yuen, W. Seto, K. Lam, Hong Kong

EXHIBITION

973 The effect of empagliflozin combined with metformin or semaglutide on hyperglycaemic cardiac cells: a pilot study

P. Senesi, A. Ferrulli, B. Bassani, F. Di Marco, A. Bruno, L. Luzi, Italy

974 Role of endogenous GLP-1 on macrovascular stiffness and renal haemodynamics following bariatric surgery

D. Moriconi, R. Bruno, S. Baldi, E. Rebelos, L. Bonvicini, S. Taddei, M. Nannipieri, Italy, France, Greece

975 Metformin added to intensive insulin therapy improves Neuregulin-4 level and subclinical atherosclerosis in youth with type 1 diabetes

E. Abdelrahman Ismail, M. Atef, N. Elbarbary, Egypt

976 Stearate remodels human non-inflammatory macrophages towards the inflammatory M1 immunometabolic profile: A mitigating role of empagliflozin?

G. Cinquegrani, V. Spigoni, F. Fantuzzi, F. Bagnaresi, M. Marinelli, E. Giordano, A. Dei Cas, R. C. Bonadonna, Italy

977 Glucose-dependent insulinotropic polypeptide prevents palmitate-induced apoptosis, but not autophagy and stress kinase activation in human cardiac progenitor cells

I. Calderoni, R. D'Oria, C. Caccioppoli, C. Colabufo, V. A. Genchi, G. Palma, G. Santarpino, A. D. Milano, T. Bottio, A. Leonardini, A. Natalicchio, S. Perrini, A. Cignarelli, F. Giorgino, L. Laviola, Italy

Short Oral Event B

Tuesday, 13:45 - 14:45

SO 092 Divination from a glass ball or something more? Predictive models, biomarkers, genome analysis

978 Whole-genome and whole-exome sequencing study of serum apolipoprotein C-III concentrations in individuals with type 1 diabetes

E. Valo, A. Antikainen, J. Haukka, F. Jansson Sigfrids, A. Syreeni, P.-H. Groop, N. Sandholm, FinnDiane Study Group, Finland, Australia

979 Diabetes type-specific associations between baseline levels of biomarkers of inflammation and changes in depressive symptoms in three intervention studies

C. Herder, A. Zhu, M. Spagnuolo, A. Schmitt, B. Kulzer, M. Roden, D. Ehrmann, N. Hermanns, Germany

980 Construction and evaluation of a diagnostic prediction model for diabetic cardiomyopathy based on mitophagy-related genes

Z. Wang, China

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

981 A comprehensive analysis of predictive factors for cardiovascular risk in type 2 diabetes: insights from the UK Biobank
M. Lugner, A. Rawshani, B. Eliasson, Sweden

982 Influence of sex and risk factors on myocardial microvascular function in individuals with type 2 diabetes free of overt cardiovascular disease: the DiaHeart study

A.-C. Skriver-Møller, I. K. Rasmussen, M. B. Blond, V. S. Wasehuus, M. C. Lassen, M. K. Lindhardt, A. Kofoed-Enevoldsen², U. L. Kielgast, E. H. Zobel, P. Hasbak, T. Biering-Sørensen, P. Rossing, R. S. Ripa, A. Kjær, T. W. Hansen, Denmark

EASD
EFSD

GENERAL
INFO

983 Circadian heart rate fluctuations predict 21-year cardiovascular and all-cause mortality in type 2 and type 1 diabetes

L. Nesti, M. Chiriaco, L. Sacchetta, D. Moriconi, L. Santoni, S. Gallo, N. Cimbalo, G. Forotti, G. Chiriaco, A. Natali, A. Solini, D. Trico, Italy

PROGRAMME

TUESDAY

984 Next-generation sequencing supports the role of hyaluronic acid for ischaemic stroke in type 1 diabetes

A. Syreeni, A. A. Antikainen, J. Haukka, V. Harjutsalo, J. Putaala, P.-H. Groop, L. M. Thorn, N. Sandholm, FinnDiane Study Group, Finland

WEDNESDAY

THURSDAY

985 From genes to gestation: tracing the genetic footprints of pregnancy

D. Galuška, K. Chalásová, L. Pacal, V. Bartakova, K. Kankova, Czech Republic

FRIDAY

SHORT ORAL
DISCUSSIONS

Short Oral Event C

Wednesday, 12:45 - 13:45

PRESENTER
INDEX

SO 093 A non-classical look at type 1 diabetes

986 High-risk individuals with type 1 diabetes demonstrate highly pathological extracellular volume fraction and T1 relaxation times on whole left ventricular cardiac MRI

P. Novodvorský, M. Dubský, N. Marhefková, T. Adla, R. Roland, M. Pazderník, M. Haluzík, P. Garg, Czech Republic, UK

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

987 Sleep and glucose: unravelling the association between glycaemic variability and sleep disorders among children with type 1 diabetes

N. Salah, A. Abido, H. Rashed, Egypt

EXHIBITION

988 Prevalence of cognitive impairment in people with diabetes type 1 and 2 and associations to metabolic control and complications

A. Hilger, B. Weber, C. Kloos, K. Heimrich, C. Kellner, S. Schmidt, G. Wolf, N. Müller, Germany

989 Hepatic steatosis with significant fibrosis is associated with preclinical carotid atherosclerosis in patients with type 1 diabetes

M. Claro Brandner, C. Milad, D. Ayala, C. Figueredo, C. Viñals, I. Conget, T. Serés-Noriega, V. Perea, A. Mesa, L. Boswell, A. Blanco Carrasco, E. Esmatjes, M. Giménez, A. Amor Fernandez, Spain

990 Beyond hyperglycaemia: double diabetes and adiposity in the population with newly diagnosed type 1 diabetes and its impact on metabolic goals: observations from the prospective InLipoDiab1 study

A. Zawiejska, A. Uruska, A. Duda-Sobczak, M. Miętkiewska-Dolecka, A. Grzelka-Woźniak, J. Flotyńska, D. Zozulinska-Ziółkiewicz, Poland

991 Gastrointestinal symptoms in type 1 diabetes are associated with distinct clinical, fecal microbiome and plasma metabolite profiles

C. M. Fuhri Snethlage, O. Akinrimisi, P. De Groen, M. Davids, B. Voermans, E. Rampanelli, M. Nieuwdorp, N. Hanssen, Netherlands

992 Association of remnant cholesterol levels and microvascular complications in adult patients with type 1 diabetes

J. Brandts, S. Tittel, P. Bramlage, J. Weiskorn, N. Weh, C. Wagner, M. Femerling, M. Huptas, R. Holl, D. Müller-Wieland, Germany

Short Oral Event D

Wednesday, 14:00 - 15:00

SO 094 Cohorts, trials and cardiovascular disease

993 The association between time-in-target haemoglobin A_{1c} range and cardiovascular disease in a population-based cohort of 68,165 individuals with diabetes in Canada

P. Kaul, L. Chu, D. A. Dover, R. O. Yeung, D. Lau, D. Eurich, P. A. Senior, S. Butalia, Canada, Hong Kong

994 Cardiac phenotypes and cardiovascular risk in patients with type 2 diabetes and chronic coronary artery disease: a Chinese retrospective cohort study

R. Sun, S. Wang, China

995 BMI variability and cardiovascular outcomes within clinical trial and real-world environments in type 2 diabetes: an IMI2 Sophia study

R. J. Massey, Y. Chen, M. Panova-Noeva, M. Mattheus, M. K. Siddiqui, N. Schloot, A. Ceriello, E. R. Pearson, A. Y. Dawed, UK, USA, Germany, Italy

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

996 Effect of 10-year intervention on type 2 diabetic patients with central obesity in Beijing community based on cardiovascular risk stratification

X.-L. Zhang, G.-H. Wang, S.-Y. Yuan, Beijing Communities Diabetes Study Group, China

997 Improvement in kidney function mediates part of fenofibrate cardiovascular effects in patients with type 2 diabetes: a post-hoc analysis of the ACCORD-Lipid trial

M. Morieri, H. N. Ginsberg, G. Fadini, A. Avogaro, A. Doria, Italy, USA

EASD
EFSD

GENERAL
INFO

998 Screening for previously unknown dysglycaemia and its prognostic impact in patients with coronary artery disease; results from the EUROASPIRE programme

G. Ferrannini, J. Tuomilehto, G. De Backer, K. Kotseva, L. Mellbin, O. Schnell, D. Wood, D. De Bacquer, L. Rydén, Sweden, Finland, Belgium, UK, Germany, Ireland

PROGRAMME

TUESDAY

WEDNESDAY

999 Impact of early detection and treatment of hyperglycaemia in pregnancy: systematic review and meta-analysis of randomised controlled trials

R. Corcoy, M. Balsells, I. Sola, A. García-Patterson, Spain

THURSDAY

FRIDAY

1000 Suboptimal physician adherence to guideline recommendations in patients with diabetes and established cardiorenal diseases

Z.-Y. Shen, H.-Y. Ou, Taiwan

SHORT ORAL
DISCUSSIONS

Short Oral Event E

Thursday, 12:45 - 13:45

PRESENTER
INDEX

SO 095 Other complications of type 2 diabetes

1001 Role of exosomes in human amylin secretion: link between diabetes and Alzheimer's disease and the protective effects of resveratrol

A. C. Lockwood López, C. González-Blanco, S. Iglesias-Fortes, C. Figaredo, A. García-Aguilar, G. García, C. Guillén, Spain

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

1002 Burden of diabetic ketoacidosis among people living with type 2 diabetes: a systematic review

C. H. Wysham, Y. Poon, A. Bindal, USA, Canada,

EXHIBITION

1003 Glycaemic gap as an indicator of prognosis in critically ill patients with diabetes

R. Ahmed, A. Baidya, M. Bera, India

1004 Diabetes and risk of readmission in patients with community-acquired pneumonia

A. Jensen, A. Dungu, M. Olsen, C. Ryrsø, M. Hegelund, R. Krogh-Madsen, P. Kristensen, D. Faurholt-Jepsen, B. Lindegaard, Denmark

1005 Impaired adaptive responses to hypoxia in patients with diabetes

X. Zheng, A. Di Toro, S. Eliasson Angelstig, C. Xu, I. Botusan, N. Rajamand Ekberg, A. Zhao, B. Yan, Z. Liu, J. Grünler, N. Widén, Q. Deng, N. Xu Landén, L. Bernardi, S.-B. Catrina, Sweden, Italy

1006 Sex differences in mechano-energetics of type 2 diabetic cardiac muscle

M. Rahmani, T. Pham, D. Crossman, A. Taberner, K. Tran, J.-C. Han, New Zealand

1007 Reduced LC3 expression without Beclin 1 alteration in diabetic patients' right atrial appendage during coronary artery bypass surgery

R. Jha, A. Kumar, P. K. Jha, India

1008 MicroRNA promotes cardiac mitochondrial dysfunction and heart failure by dynamically regulating specific target genes during different disease stage

Q. Su, H. Wade, UK

Short Oral Event F

Thursday, 14:00 - 15:00

SO 096 A non-traditional look at type 2 diabetes

1009 Liver steatosis and fibrosis in lean type 2 diabetes patients compared to obese type 2 diabetes patients: Different mechanisms!

W. Tao, L. Li, China

1010 Association between vascular endothelial dysfunction and higher 10-year atherosclerotic cardiovascular disease risk in young-onset type 2 diabetes: a cross-sectional study in China

Y. Hu, S. Shen, S. Liu, J. Zheng, Y. Lei, C. Yan, X. Wu, China

1011 Microrna profile analysis in pericoronary adipose tissue of type 2 diabetes patients with significant coronary artery disease

N. Katsiki, G. Kochiadakis, A. Plevritaki, J. Kontaraki, P. Kalogerakos, E. Kampanieris, S. Zervakis, S. Maragkoudakis, K. Fragkiadakis, E. Savva, J. Kritsotakis, G. Lazopoulos, M. Marketou, Greece

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

1012 In-depth microbiological characterisation of urine from subjects with type 2 diabetes

A. Mengozzi, M. Calvigioni, D. Mazzantini, F. Celandroni, E. Biancalana, C. Rossi, E. Ghelardi, A. Solini, Italy, Switzerland

1013 Association between serum uric acid to HDL-cholesterol ratio and incidence of vascular events in type 2 diabetes: a 13-year prospective observation

M. Garofolo, D. Lucchesi, M. Giambalvo, M. Capobianco, G. Mancini, P. Francesconi, S. Del Prato, P. Marchetti, G. Penno, Italy

1014 Prevalence of hepatic fibrosis and effect of PPAR- α/γ agonism in type 2 diabetes patients of different ethnicities

V. D. De Jong, I. C. Schrieks, M. Alings, J.-C. Tardif, A. M. Lincoff, G. G. Schwartz, D. E. Grobbee, M. Castro Cabezas, Netherlands, Canada, USA

1015 Myocardial steatosis and improvement of cardiac function after glycaemic optimisation treatment in newly diagnosed type 2 diabetes subjects

Á. Rosales, P. Gil, T. Julian, A. Teis, B. Pedraz, J. Sanchez, J. Julve, D. Mauricio, A. Perez, N. Alonso, Spain, Germany

1016 Prevalence of sarcopenia in type 2 diabetic and non-diabetic older adults: an observational study

R. Kumar, A. Garg, R. Dewan, A. Kakar, T. Batra, India

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

Short Oral Event A

Tuesday, 12:30 - 13:30

SO 097 Pathogenesis of diabetes complications

1017 Acid-sensing ion channel 1a in the glutamate neuron of the anterior cingulate cortex contributes to diabetes-related pain

A. Jiang, W. Wang, China

1018 Blood monocyte frequency and phenotype are subclinical markers of cardiovascular risk in people with type 2 diabetes

J. Julla, D. Girard, M. Diedisheim, F. Alzaid, J.-F. Gautier, N. Venteclef, France

1019 COX-2 inhibition constrains Oncostatin-M production and granulopoiesis in diabetic mice

M. Albiero, C. Boscaro, A. Rodella, G. P. Fadini, Italy

1020 Eicosapentaenoic acid inhibits lipoprotein(a) oxidation under normal and high glucose conditions in vitro

P. Mason, P. Libby, R. L. Dunbar, D. Bhatt, S. C. Sherratt, USA

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

1021 Defining the role of NOX5 as a biomarker in the Cardiovascular-Kidney-Metabolic syndrome

J. Pinzon-Cortes, K. C. Sourris, T. J. Block, A. Kincses, J. C. Jha, M. E. Cooper, J. Shaw, K. Jandeleit-Dahm, Australia, Germany

1022 Sestrin2 alleviates obesity-associated heart failure with preserved ejection fraction by modulating the sigma-1 receptor-mediated IRE1 α -XBP1 axis and antioxidant system

K. Zhang, J. Zhang, C. Kan, G. Xiong, F. Han, N. Hou, X. Sun, China

1023 Astrocyte SCAP/SREBP2-mediated cholesterol homeostasis imbalance in diabetic cognitive impairment via up-regulating LCN2

K. Liu, W. Zhu, T. Niu, S. Wang, China

1024 The lysine methyltransferase SET7 regulates novel molecular pathways in hyperglycaemia-induced endothelial dysfunction

J. Sánchez Ceinos, D. Sánchez Fernandez, M. Jakobsson, A. Vegvari, F. Cosentino, Sweden

1025 Application of adipose tissue-derived stem cell therapy with a clinically relevant dose does not significantly affect atherosclerotic plaque characteristics in a hyperglycaemia mouse model

A. Korn, S. Simsek, M. D. Fiet, I. S. Waas, H. W. Niessen, P. A. Krijnen, Netherlands

Short Oral Event B

Tuesday, 13:45 - 14:45

SO 098 Cancer and diabetes

1026 Circulating levels of interleukin-6 predict risk of obesity-related cancers in patients with recently diagnosed type 2 diabetes

M. D. Bennetsen, J. V. Stidsen, J. S. Nielsen, M. H. Olsen, S. L. Domazet, T. Laurberg, K. Højlund, R. W. Thomsen, T. B. Olesen, Denmark

1027 New users of sodium-glucose cotransporter 2 inhibitors are at low risk of incident prostate cancer: a nationwide propensity score-matched cohort study

Y. Cho, S. Kim, M. Kim, S.-H. Go, W. Lee, Y.-J. Kim, C. Jung, Republic of Korea

1028 Increased skin autofluorescence predicts future cancer development

B. H. Wolffenbuttel, H. E. Boersma, G. Sidorenkov, B. Van der Vegt, A. Paterson, A. J. Smit, G. H. De Bock, M. M. Van der Klauw, Netherlands, Canada

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

1029 Cancer incidence in Japanese patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists

R. Ishibashi, M. Koshizaka, T. Ishikawa, J. Sato, H. Yoshimoto, M. Kitsuregawa, K. Goda, K. Yokote, N. Mitsutake, Japan

1030 Associations of alcohol consumption with all-cause mortality and cancer mortality in Korean patients with type 2 diabetes: a nationwide cohort study

D.-Y. Lee, S.-J. Moon, K.-W. Oh, C.-Y. Park, S.-E. Park, H.-M. Kwon, H.-N. Jang, J.-H. Ko, K.-D. Han, E.-J. Rhee, W.-Y. Lee, Republic of Korea

EASD
EFSD

GENERAL
INFO

1031 Increased risk of pancreatic cancer with diabetes and smoking in non-alcoholic fatty liver disease: a nationwide cohort study

H. Jung, J. Huh, E. Roh, K.-D. Han, J. Kang, S. Lee, S.-H. Ihm, Republic of Korea

PROGRAMME

TUESDAY

1032 Post-authorisation safety study to assess the risk of urinary tract cancer in patients with type 2 diabetes initiating empagliflozin: a multi-country European study

N. Schmedt, A. Alhamdow, G. Tskhvarashvili, L. Saarelainen, X. Qiao, M. Lobier, F. Hoti, Germany, Estonia, Finland

WEDNESDAY

THURSDAY

1033 Distinct plasma MALDI-TOF MS spectrum and serum extracellular vesicle profile between pancreatic ductal adenocarcinoma-related diabetes and type 2 diabetes

L. H. Matheus, L. C. Lázari, C. Donnarumma, R. D. Peixoto, M. R. Matos, S. Oba-Shinjo, M. C. Machado, M. A. Machado, A. A. Reis, P. R. Donado, C. B. Angeli, J. M. Silva, S. K. Marie, G. Palmisano, M. L. Correa-Giannella, Brazil

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

Short Oral Event C

Wednesday, 12:45 - 13:45

SATELLITE
SYMPOSIA

SO 099 A non-traditional look at type 1 diabetes

1034 Intestinal fatty acid binding protein is associated with coronary artery disease in long-term type 1 diabetes: the Dialong study

M. Narum, I. Seljeflot, T. J. Berg, K. A. Sveen, Norway

INDUSTRY

PROGRAMME

1035 Clustering of type 1 diabetes patients by CGM profiles: higher insulin resistance and risk of MAFLD assessed by surrogate markers in patients with poorly controlled glycaemia

A. Fedulovs, L. Pahirko, J. Sokolovska, Latvia

EXHIBITION

1036 Type 1 diabetes: Is silent myocardial ischaemia associated with blinded continuous glucose monitoring metrics? Results from a pilot study

A. Cano, O. Giménez-Palop, R. Pareja, L. Albert, V. Arsentales, I. Mazarico, A. Rodríguez-Revuelto, J. Puntí, J. Vendrell, J. M. González-Clemente, Spain

1037 Association of remnant cholesterol levels and the prevalence of the metabolic syndrome in adult patients with type 1 diabetes

M. Kortemeier, S. Tittel, J. Brandts, P. Bramlage, J. Weiskorn, C. Wagner, M. Femerling, M. Huptas, N. Weh, R. Holl, Germany, USA

1038 Non-classical risk factors are associated with preclinical atherosclerosis in younger individuals with type 1 diabetes: insights from over eight hundred cardiovascular risk assessments

C. Sola, C. Viñals, T. Serés-Noriega, V. Perea, E. Esmatjes, L. Boswell, J. Blanco, I. Vinagre, A. Mesa, C. Milad, I. Conget, M. Giménez, A. J. Amor, Spain

1039 The safe management of people with type 1 diabetes and eating disorders study (STEADY) feasibility randomised controlled trial

M. Stadler, N. Zaremba, J. Brown, A. Harrison, D. Pillay, R. Tan, S. Ayis, G. Robert, D. Hopkins, J. Treasure, K. Ismail, UK

1040 Risk factors for fractures in patients with type 1 diabetes

S. I. Chisalita, E. Paulsson, E. Gauffin, H. Arnqvist, Sweden

1041 Factors involved in the progression of preclinical atherosclerosis in people with type 1 diabetes

C. Viñals, I. Conget, M. Granados, C. Solà, D. Ayala, A. Mesa, T. Serés-Noriega, L. Boswell, J. Blanco, V. Perea, I. Vinagre, E. Esmatjes, M. Giménez, A. J. Amor, Spain

Short Oral Event D

Wednesday, 14:00 - 15:00

SO 100 Correlates of fatty liver disease in diabetes

1042 Efficacy of dapagliflozin on hepatic fibrosis and steatosis in patients of type 2 diabetes with non alcoholic fatty liver disease

S. Das, V. Das, B. Prusty, V. Agarwal, D. Sahoo, S. Sahu, D. Meher, A. Choudhury, J. Swain, India

1043 A prospective study on the prevalence of steatotic liver disease and advanced fibrosis in people with type 2 diabetes

D. M. Williams, J. Nagaraj, J. W. Stephens, T. Min, UK

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

1044 The role and mechanism of IGF2 deficiency in promoting metabolic associated fatty liver disease

W. Gui, C. Zhou, X. Lin, China

1045 Prevalence of metabolic dysfunction associated fatty liver disease in people with type 1 diabetes

V. Bellido, S. Amuedo, P. Remón-Ruiz, C. Roque-Cuellar, A. Jiménez-Sánchez, N. Gros-Herguido, G. López-Gallardo, A. Piñar-Gutiérrez, A. Soto-Moreno, Spain

EASD
EFSD

1046 Association of non-alcoholic fatty liver disease and liver fibrosis with cardiometabolic risk profile in lean and non-lean patients with type 2 diabetes

H. Yu, L. Li, China

GENERAL
INFO

1047 Atherosclerosis rather than arteriosclerosis mediates the incremental association between blood markers of liver fibrosis with cardiovascular risk: a mediation analysis

S. Athanasopoulos, G. Georgiopoulos, G. Mavraganis, C. Konstantaki, M. Papaioannou, K. Sopova, D. Delialis, L. Angelidakis, G. Zervas, C. Moustou, A. Kalogeropoulos, C. Kalogeropoulos, A. Mitrakou, K. Stellos, K. Stamatelopoulos, Greece, Germany

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

1048 Implications of steatotic liver disease on cardiovascular disease morbidity and overall survival

I. P. Karhiaho, S. H. Kurki, L. Kullamaa, N. Matikainen, T. Tuomi, Finland

SHORT ORAL
DISCUSSIONS

1049 Hepatic fibrosis and not hepatic steatosis determines cardiovascular risk in type 2 diabetes independent from other cardiovascular risk factors: a report from the AleCardio trial

W. Xu, V. D. De Jong, M. Alings, J.-C. Tardif, A. M. Lincoff, G. G. Schwartz, D. E. Grobbee, M. C. Cabezas, Netherlands, Canada, USA

PRESENTER
INDEX

SATELLITE
SYMPOSIA

Short Oral Event E

Thursday, 12:45 - 13:45

INDUSTRY

PROGRAMME

SO 101 MASLD: now an established complication of diabetes

1050 Properties of free fatty acids, not only the circulating levels, are associated with MASLD

S. Ciardullo, M. Vergani, M. Rizzo, A. Oltolini, A. Bongo, E. Muraca, G. Perseghin, Italy

1051 High-fat induced MASLD beyond the liver: metabolic profiling of mice extrahepatic tissues as analysed by ¹H-NMR

J. G. Silva, L. C. Tavares, G. D. Belew, A. M. Gil, J. G. Jones, Portugal, USA

EXHIBITION

1052 Elongation factor 1A1 inhibition elicits changes in lipid droplet size, the bulk transcriptome, and cell type-associated gene expression in MASLD mouse liver

R. B. Wilson, Y. Chen, R. Zhang, S. Maini, M. Schuurman, T. S. Andrews, R. Wang, N. M. Borradaile, Canada

1053 Role of small extracellular vesicles in liver and pancreas in MASLD linked to type 2 diabetes

I. Garcia-Martinez, R. Alén, R. Francés, R. Aller, Á. M. Valverde, Spain

1054 The molecular mechanisms of ZBED3 activating ASK1-JNK/p38 signalling pathway to promote NASH progression

Y. Wu, X. Luo, China

1055 Systemic creatine depletion attenuates hepatic steatosis and fibrosis by modulating food intake and energy expenditure in mice

H.-S. Yi, Republic of Korea

1056 Activation of γ -aminobutyric acid receptor type A as a novel first-in-class approach for MASH therapy

E. Rohbeck, L. Koester, J. Eckel, Germany

1057 Efficacy of dodecanedioic acid for insulin resistance and MASH prevention

S. Russo, G. Angelini, G. Mingrone, Italy

Short Oral Event F

Thursday, 14:00 - 15:00

SO 102 Addressing risk and consequences of liver pathology in diabetes

1058 Is hypoglycaemic treatment better than liver protection? A systematic review and network meta-analysis of randomised controlled trials

Y. Wang, H. Yi, W. Sun, H. Yu, W. Tao, L. Li, China

1059 Metabolic characteristics associated with the bariatric surgery-mediated improvement of liver pathology in Japanese participants with morbid obesity

D. Matsubara, Y. Takeshita, M. Mori, S. Tokuno, M. Okumura, H. Goto, Y. Nakano, T. Takamura, Japan

1060 Increased glycosuria reduces the risk of metabolic associated fatty liver disease in subjects with newly diagnosed diabetes: a cross-sectional study

J. Chen, Z. Sun, J. Yu, X. Zhou, J. Ge, China

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

1061 Diabetic dyslipidaemia and insulin resistance are more closely associated with liver steatosis than liver fibrosis in type 2 diabetes patients

W. Xu, V. D. De Jong, M. Alings, J.-C. Tardif, A. M. Lincoff, G. G. Schwartz, D. E. Grobbee, M. C. Cabezas, Netherlands, Canada, USA

1062 Gender disparities in metabolic dysfunction associated steatotic liver disease: transcriptomic results from the BARIA longitudinal cohort study

M. Koning, N. M. Hanssen, J. Verheij, M. Doukas, A. Van de Laar, S. Bruin, H. Herrema, V. Gerdes, A. S. Meijnikman, M. Nieuwdorp, Netherlands

1063 Development of a machine learning-based model to identify risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease

W. Zhang, T. Yue, Y. Ding, J. Weng, X. Zheng, S. Luo, China

1064 Mitogen inducible gene 6 (Mig-6), a surrogate for dysglycaemia and dyslipidaemia in type 2 diabetes

B. Mukherjee, C. Bose, S. Kundu, S. Pramanik, C. Saha, A. Mondal, S. Roy, S. Mukhopadhyay, India

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS


PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION



PRESENTING AUTHORS OF ORALS AND SHORT ORAL DISCUSSIONS

Last Name, Initials, Presentation Number

	Abdalla, M. A.	270	Antikainen, A. A.	42
	Abdelalim, E. M.	391	Apalaki, P.	596
	Abdelrahman I. E.	888, 975	Arage, G.	291
EASD EFSO	Abdelsalam, A.	335	Ariëns, B.	719
	Abou Azar, F.	650	Arnardottir, E.	364
	Abu-Farha, M.	655	Arni, A. M.	297
GENERAL INFO	Abuqwider, J.	685	Arum, P.	497
	Acosta Manzano, P.	500	Asatiani, N. G.	466
PROGRAMME	Acreman, S.	419	Asyaei, P.	924
TUESDAY	Ahluwalia, T. S.	263	Atabaki Pasdar, N.	967
	Ahmad, S.	293	Atawneh, F.	70
WEDNESDAY	Ahmed, R.	1003	Athanasiadou, K. I.	469
	Ahmed, S.	226	Athanasopoulos, S.	1047
THURSDAY	Ahuja, V.	369	Avolio, A.	440
	Ai, F.	318	Azmi, S.	944
FRIDAY	Aihara, M.	823	Bajaj, H.	10
	Akerkar, A.	338	Balaz, M.	201
SHORT ORAL DISCUSSIONS	Al-Mrabeh, A. H.	614	Baldassarre, M.	255
	Al-Mulla, F.	947	Ballesteros-Pla, C.	441
PRESENTER INDEX	Al-Sharefi, A.	304	Banah, A. K.	239
	Albiero, M.	1019	Banas, W. T.	827
	Alblas, G.	952	Bannon, C.	538
	Ali, S. Rana.	50	Barchetta, I.	680
	Allen, L. A.	32	Barouti, A. A.	695
SATELLITE SYMPOSIA	Allen-Taylor, M.	887	Barraud, S.	341
	Almeida-Oliveira, F.	605	Beato Vibora, P.	877
INDUSTRY	Alobaid, T.	158, 913	Bellido, V.	1045
PROGRAMME	Alonso, L.	268	Bem, R.	773
EXHIBITION	Alonso-Sampedro, M.	379	Bennetsen, M. D.	1026
	Álvarez Hernández, E.	9	Bergdal, R.	90
	Alves, E. B.	459	Bergental, R. M.	191
	Amendolara, R.	644	Beunen, K.	820
	Amikishieva, K.	549	Bhagtani, D.	569
	Ampudia-Blasco, F. J.	251	Bhattacha, S. N.	734
	An, Q.	399	Bi, Y.	21, 23
	Andersson, J.	45	Bianchi, C.	473
	Angelini, G.	760	Biancolin, A. D.	482, 764
	Anjum, B.	593	Bitencourt, F. V.	93
	Antal, M.	214	Bitterman, O.	465

Last Name, Initials, Presentation Number

Bizzotto, R.	543	Cataldo, L.	428
Bjerregaard-Andersen, M.	139	Caussy, C.	229
Blangero, F.	632	Cen, H.	529
Block, T. J.	550	Cerrai Ceroni, M.	959
Boateng-Kuffour, A.	822, 875	Chanen, S.	840
Bódis, K. B.	209	Chapeau, D.	451
Bogun, M. M.	866	Chen, C.-C.	898
Bonnet, J.-B.	264	Chen, D.	889
Bonvicini, L.	563	Chen, J.	1060
Borbjerg, M.	61	Chen, J.	970
Borbjerg, M. K.	864	Chen, S.-P.	513
Borg, R.	904	Chen, S.	916
Bosi, E.	850	Chen, T.	320
Boudra, Z.	548	Chen, W.	7
Bowden Davies, K. A.	689	Cheng, A.	809
Braffett, B.	65	Cheng, A. Y. Y.	784
Brandts, J.	992	Cherkaoui, I.	299
Breitfeld, J.	222	Cheung, N.	351
Briand, F.	76	Chimienti, R.	168, 446
Briggs, J. K.	444	Chiriaco, M.	716
Brings, S.	705	Chisalita, S. I.	1040
Brøsen, J. M. B.	815	Chisbert, M.	687
Brugnara, L.	502	Cho, D.-H.	939
Brunetti, M.	427	Cho, Y.	673, 1027
Bsharat, S.	437	Choudhary, P.	805
Buchipudi, A.	861	Christensen, M. H.	180
Busch, C. B. E.	699	Christiansen, M.	806
Cai, Z.	581	Christie, H. E.	174
Calderon, E.	400	Churm, R.	295
Calderoni, I.	977	Ciardullo, S.	1050
Callahan, P.	104	Cigler, M.	837
Cámara-Torres, P.	207	Cimbalo, N.	682
Canha, D.	355	Cinquegrani, G.	976
Cano, A.	1036	Cintra, D. E.	595
Cantley, J.	667	Citro, F.	275
Cao, X.	533	Claesson, T.	917
Caramelo, B.	640	Clark, M.	616
Cardoso, P.	407	Claro Brandner, M.	989
Carr, A. L. J.	388, 445	Colhoun, H. M.	146
Carstensen, B.	100	Coll, B.	749
Caruso, I.	753	Conserva, F.	194
Castelblanco, E.	144	Cookson, T. A.	154

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Last Name, Initials, Presentation Number

	Corcoy, R.	999	Ebekozien, O.	484, 813
	Corrado, A.	779	Eckstein, Y.	671
	Corrales, P.	477	Edelman, S.	114
	Cosentino, C.	598	Eerdekens, M.	64
	Cosson, E.	345, 470	Ehrmann, D.	873
	Costa-Junior, J. M.	506	Eichenlaub, M.	856
EASD EFSD	Crabtree, T. S. J.	778	Ejskjaer, N.	795
	Csanalosi Artigas, M.	383	Elbarbary, N.	665
	Cuevas-Ramos, D.	727	Eriksson Hogling, D.	121
GENERAL INFO	Dagdelen, S.	652	Evans, M.	735
	Dai, X.-Q.	456	Fadini, G.	1
PROGRAMME	Daniels Gatward, L. F.	457	Faggionato, E.	206
TUESDAY	Dardano, A.	878	Fagherazzi, G.	365
	Das, S.	1042	Fan, B.	271
	Dassau, E.	832	Fan, K.	836
WEDNESDAY	Davis, T. M. E.	181	Fauzi, M.	237
	Davis, W. A.	161	Fazli, G. S.	315
THURSDAY	Dayan, C.	704	Fedulovs, A.	1035
	de Jong, V. D.	1014	Ferdousi, M.	941
FRIDAY	De Meulemeester, J.	117, 188	Ferdousi, T.	481
	De Vito, F.	626	Ferguson, L. D.	332
	de Wit, D. F.	326	Fernández-García, P.	653
SHORT ORAL DISCUSSIONS	Deden, L. 171,	564	Ferrannini, G.	998
	DeFronzo, R.	109	Ferrara, A.	177
	Dei Cas, A.	676	Ferraro, G.	643
PRESENTER INDEX	Demir, S.	514	Ferreira, S. G.	25
	Deng, K.	232	Ferreira, V.	58
	Deng, Y.	474	Fierabracchi, A.	384
SATELLITE SYMPOSIA	Di Giuseppe, G.	155	Figueredo Burgos, N. S.	59
	di Piazza, F.	250	Filatov, E.	165
	Diamond, C.	910	Firneisz, G.	267
INDUSTRY	Dickerson, M.	425	Fisher, S. J.	108
PROGRAMME	Dischinger, U.	765	Fitzpatrick, A. L.	127
	Do, D. Q.	772	Fleming, T.	942
	Dobrovynska, O.	847	Flores Paños, A.	848
	Dobson, J. R.	215	Flotynska, J.	504
	Domazet, S. L.	184	Foster, H. R.	414
	dos Santos, T.	245	Franek, E.	681
	Drzazga, A. K.	686	Franzén, E.	339
	Du, J.	527	Fuhri Snethlage, C. M.	991
	Dubsky, M.	39	Fumo, A. R.	964
	Dyachok, O.	411	Gabe, M. B. N.	561

Last Name, Initials, Presentation Number

Gad, H.	763, 923	Groop, P.-H.	337
Gaffuri, A.-L.	219	Guay, C.	600
Gaglio, A.	493	Guerrero-Wyss, M. T.	356
Galli, A.	408	Gui, W.	1044
Galuška, D.	985	Gullaksen, S.	91
Gamarra, E.	830	Gupta, S.	329
Game, F.	882, 930	Hadad, R.	62
Gan, S.	711	Hadjadj, S.	122
Ganla, M.	363	Hagelqvist, P. G.	37, 38
Ganslmeier, M.	325	Hakaste, L.	380
Gao, L.	744	Haluzík, M.	759, 791
Gao, R.	246	Hamdan, S.	485
Garcia Toscano, M.	431	Hameete, A.	314
Garcia-Calzon, S.	43	Han, J.	381
Garcia-Martinez, I.	1053	Han, S.	316
García-Pérez, L.-E.	756	Hangaard, S.	846
Garg, S.	190	Hannelius, U.	331
Garg, S.	679	Hansen, A. L.	285
Garofolo, M.	1013	Harder, M.	313
Gasiorek, A.	74	Hardikar, A.	312
Gasperikova, D.	298	Hardin, M.	722
Geisler, C.	378	Harer, C. M.	442
Geng, S.	525	Harris, S.	811
Gheibi, S.	588	Haugaard, S. B.	922
Giambalvo, M.	897	Hayman, M. M. E.	129
Giangreco, F.	885, 928	He, J.	395
Gibb, F. W.	234, 800	He, L.	292, 362
Gil, P.	893	Heald, A.	288
Giosuè, A.	366	Hecquet, S. K.	945
Go, S.-H.	582	Heebøll, S.	953
Göbl, C.	499	Heerspink, H.	743
Gokulakrishnan, K.	279	Heerspink, H. J. L.	741
Goldenberg, R.	11	Heianza, Y.	367
Golubic, R.	333, 354	Heida, J.	576
Gómez, A.	768, 821	Heise, T.	8
Gong, Y.	495	Hendriks, A. E. J.	140
Gosmanov, A. R.	724	Hendriksz, M. S.	106
Goswami, P.	918	Hentilä, J.	586
Gourdy, P.	824	Herder, C.	979
Grassi, B. A.	781	Herrero, P.	252
Green, H. D.	965	Hesp, A. C.	509
Grill, V.	342	Heymsfield, S.	557

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Last Name, Initials, Presentation Number

	Hilger, A.	988	Januszewski, A. S.	523
	Hill, T. G.	248	Jara, C.	193
	Hirlemann, M.	565	Jashi, L.	151
	Hodgson, S.	179	Jendle, J.	783
	Holland, D.	841	Jensen, A.	1004
	Hopkins, R.	347	Jensen, K. H.	894
EASD	Hornbrinck, E.	891	Jha, J.	197
EFSD	Hornigold, D.	707	Jha, R.	1007
	Hosseini Marnani, E.	80	Ji, L.	147, 149
GENERAL	Htoo, P.	52	Jiang, A.	1017
INFO	Hu, Y.	1010	Jiang, C.	706
PROGRAMME	Huan, Z.	449	Jiang, H.	733
TUESDAY	Huang, H.	241	Jiang, Q.	895
WEDNESDAY	Huang, M. L. H.	48	Jiang, T.	935
THURSDAY	Huang, N.	160	Jiménez-Sánchez, C.	417
FRIDAY	Huang, P.	672	Jin, Z.	433
SHORT ORAL	Huang, Q.	195	Joglekar, M. V.	634
DISCUSSIONS	Huang, Q.	971	Johannesen, H.	853
PRESENTER	Huang, W.	416, 825	Johansen, M. S.	94
INDEX	Huang, Y.	583	Johnson, J.	833
SATELLITE	Huber, E.	310	Jolivet, T.	829
SYMPOSIA	Hui, W.	701	Jones, S. A. W.	99
INDUSTRY	Hukema, F.	60	Joshi, S.	796
PROGRAMME	Hummel, S.	307	Julla, J.	1018
EXHIBITION	Hussain, S.	770	Julla, J.-B.	880
	Huttasch, M.	169	Junaidi, M. K.	736
	Hüttl, M.	617	Jung, H.	1031
	Hviid Klæbel, J.	35	Kabbani, N.	483
	Hwang, Y.-C.	101	Kahleova, H.	694
	Hwu, C.-M.	49	Kahn, S. E.	757
	Iglesias Fortes, S.	911	Takehi, S.	133
	Ilham, S.	810	Kamruzzaman, M.	693
	Imura, M.	675	Kaneko, K.	196
	Incedal Nilsson, C.	212	Kantartzis, K.	950
	Inoue, T.	134	Kanzaki, M.	503
	Iqbal, A.	776	Káplár, M.	601
	Ishibashi, R.	1029	Karagiannis, T.	145
	Jager, J.	599	Karayiannides, S.	186
	Jagroep, S. T.	204	Karhiahio, I. P.	1048
	Jalleh, R. J.	79, 84	Katoh, S.	907
	Jang, M.	182	Katsiki, N.	1011
	Jansz, T.	5	Katte, J. C.	301

Last Name, Initials, Presentation Number

Kaul, P.	993	Kruse, C.	401
Kaur, G.	933	Kuhre, R. E.	73
Kavin, N.	636	Kulzer, B.	876
Kawahara, R.	210	Kumar, N.	520, 526
Kempegowda, P.	860	Kumar, R.	1016
Kender, Z.	934	Kumar, V.	340
Keysendal, E.	327	Kundu, R.	668
Khalil, A.	130	Kwan, A. YM.	758
Khamis, A.	585	Kwon, H.-S.	715
Khare, S.	392	Kwon, S.	896
Kim, G.	353	Laborit Labrada, B.	578
Kim, H.	51	Labour, A.	507
Kim, M.-K.	663	Lai, Y.-J.	908
Kim, S.-H.	524	Lalama, E.	545
Kim, S.	580	Lampousi, A.-M.	294
Kim, S.	646	Langer, S.	554
Kim, S.	714	Larger, E.	69, 541
Kim, S.	854, 871	Larsen, A. T.	556
Kim, T.	654	Laterveer, R.	628
Kim, W.	498	Lau, N. S.	725
Kimura, T.	766	Laurberg, T.	957
Kislev, N.	651	Laursen, D. H.	235
Kizilkaya, H.	47	Lavens, A.	343
Klepac-Bartl, K.	562	Layne, J. E.	814
Kloeckener, T.	82	Lazzaroni, E.	352
Knupp, J.	300	Lee, C.	972
Ko, J.	812	Lee, D.-Y.	1030
Koci, M.	83	Lee, D.-H.	403
Koefoed-Hansen, F.	172	Lee, E. Y.	742
Koene, E. J. C.	13	Lee, H. L.	334
Koning, M.	1062	Lee, K.-W.	639
Koprivica, I.	242	Lee, M. H.	319
Korakas, E.	906	Legøy, T. A.	372
Korn, A.	709, 1025	Lei, M.	902
Kortemeier, M.	1037	Leohr, J.	789
Kosai, M.	828	Levitt, C. H.	418
Kosiborod, M. N.	710	Li, J.	448
Kountouri, A.	594	Li, J.	670
Koutroukas, V.	868	Li, J.	936
Kražek, M.	574	Li, L.	603
Kragelund Nielsen, K.	178	Li, R.	925
Kruit, J. K.	476	Li, Y.	606

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Last Name, Initials, Presentation Number

	Li, Y.	790	Mader, J. K.	249
	Liarakos, A. L.	852	Maedler, K.	387
	Lietzén, M.	522	Maguolo, A.	273
	Lim, C.-E.	406	Mäkinen, S.	208
	Lim, H.	296	Makino, H.	6
	Lin, J.	95	Malbert, C.	535
EASD	Lin, X.	615	Mallipedhi, A.	851
EFSD	Linares-Pineda, T.	276	Manco, M.	224
	Linder, T.	467	Marcelino-Rodriguez, I.	386
GENERAL	Ling, P.	819	Marcovecchio, L.	328
INFO	Linge, J.	123	Marechal, A.	746
	Lingvay, I.	785	Marrano, N.	540
PROGRAMME	Linn, Z.	940	Marsal-Beltran, A.	16
	Lisakovska, O.	946	Marshall-Andon, T. F. A.	97
TUESDAY	Lithovius, R.	66	Martens, P.-J.	72
	Liu, C.	691	Martínez, E.	621
WEDNESDAY	Liu, K.	1023	Mason, P.	1020
	Liu, L.	732	Massey, R. J.	995
THURSDAY	Liu, Q.	394, 397	Mastrocola, R.	259
	Liu, X.	423	Mastrototaro, L.	135
FRIDAY	Liu, Y.	63	Matas-Aguado, D.	443
	Liu, Y.	901	Mathara Diddhenipothage, S. A. D.	92
SHORT ORAL	Liu, Y.	912	Mateu, N. C.	102
DISCUSSIONS	Ljubic, S.	905	Mather, K.	740
	Lobato, C. B.	571	Matheus, L. H. G.	1033
	Lockwood López, A. C.	1001	Mathiesen, D. S.	265
PRESENTER	Loh, K.	409	Matsubara, D.	1059
INDEX	López-Pedrosa, J. M.	544, 552	Mattina, A.	886
	Lorza-Gil, E.	77	Matulewicz, N.	635
SATELLITE	Louvet, I.	302	Mba, C. M.	290
SYMPOSIA	Lu, B.	919	McCarthy, O. M.	505
	Lugner, M.	981	Meek, C. L.	175, 494
INDUSTRY	Luk, C.	530	Mehra, C.	797
PROGRAMME	Luo, X.	669	Mejaddam, A.	566
	Lupoli, R.	40	Melena, I.	213
EXHIBITION	Lutz, T. A.	128	Mellbye, F. D.	28
	Lv, Y.	546, 547	Mendez Cardenas, D. M.	231
	Lyu, Y.	951	Menéndez Torre, E. L.	771
	Maagensen, H.	228	Mengozzi, A.	630, 1012
	Maanaoui, M.	217	Mennens, L.	501
	MacConell, L.	708	Menzaghi, C.	357, 393
	MacGregor, K.	138	Merolla, A.	185

Last Name, Initials, Presentation Number

Milad, C.	86	Nemlekar, P.	803
Minab, R.	434	Nesti, L.	983
Minelli Faiao, V.	284	Nguewa, J.-L.	542
Mir, B. A.	515	Nguyen, H.	865
Mirasierra, M.	633	Nguyen, N. N.	359
Mohamed, K.	921	Nguyen, T. N.	659
Mohammed, A. G.	317	Nie, X.	660
Mohan, S.	247	Nielsen, N. S.	137
Mokari-Yamchi, A.	798	Nigro, C.	453
Møller, P. M.	521	Nigro, P.	200
Mondal, A.	937	Nikontovic, A.	842, 843
Monfort-Pires, M.	572	Niu, J.	202
Monteillet, L.	429	Noguchi, M.	282
Moon, S.-J.	817	Nouira, S.	471
Morciano, C.	713	Novodvorský, P.	808, 986
Mori, M.	516	Nowak, A.	718
Moriconi, D.	974	Nygård, K.	346
Morieri, M.	997	O, C.	374
Moser, O.	490	O'Reilly, S. L.	472
Motohashi, K.	534	Oetsch, K. M.	688
Mourin, M.	613	Oh, B.-C.	528
Mraz, M.	816	Ohwaki, K.	748
Mužik, R.	844	Onetto, M. T.	774
Mueller, A.	211	Ortiz Zúñiga, Á.	881
Mukherjee, B.	1064	Otero, Y. F.	698
Mukherjee, O.	143	Oualla-Bachiri, W.	658
Mukunda, A.	468	Paget, D.	645
Müller, L.	570	Pahwa, H.	385
Munoz, F. A.	412	Paliaries, I. C.	89
Muntoni, S.	435	Pallo, L. P.	71
Muralidharan, S.	390	Palma, G.	608
Murdasov, Y.	421	Pandya, S.	475, 492
Murray Leech, J.	225	Pang, M.	589
Muthukumar, A.	162	Park, K.-S.	458
Mutter, S.	159	Park, S.	963
Naaman, C. H.	157	Patel, H.	755
Naemi, R.	879	Patsoukaki, V.	183
Nag, S.	260	Pedace, E.	309
Nanan, R.	436	Penesová, A.	661
Narum, M.	1034	Penfornis, A.	777
Nathan, R.	703	Penno, G.	900
Navarrete, J.	396	Pereira, M. J.	623

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Last Name, Initials, Presentation Number

	Perrier, Q.	218	Ried-Larsen, M.	696
	Persad, K.	855	Rimpeläinen, K.	461
	Petersen, E. A.	555	Rios-Morales, M.	15
	Petkovic, M.	262	Riserus, U.	30
	Petrelli, A.	306	Ritz, P.	799
	Petrovski, G.	780	Riveline, J.-P.	115, 119
EASD	Piazza, C.	831	Rivera, K.	439
EFSD	Picard, F.	536	Rizvi, A.	674
	Pinzon-Cortes, J.	1021	Roberts, A.	223
	Pipella, J.	68	Roca-Rivada, A.	389, 452
GENERAL	Pirro, V.	730	Rodriguez, A.	754
INFO	Pistorio, V.	624	Rodriguez, L.	402
PROGRAMME	Pivovarova-Ramich, O.	29, 649	Rodriguez, L. A.	404
	Pliouta, L.	22	Rodríguez de Vera Gómez, P.	863
TUESDAY	Prakash, A.	931	Rodriguez-Carnero, G.	834
	Puente-Ruiz, S.	637	Roekjær, J.	927, 932
WEDNESDAY	Putcha, V.	782	Rohbeck, E.	1056
	Putula, E.	111	Rohmann, N.	153
THURSDAY	Qin, G.	2	Romarowski, B.	870
	Qiu, S.	14	Rondinone, C. M.	81
FRIDAY	Quansah, D.	491	Rosales, Á.	1015
	Quinn, L.	311	Rosendo-Silva, D.	641
SHORT ORAL	Rahmani, M.	1006	Rossi, C.	619
DISCUSSIONS	Rajamand Ekberg, N.	349	Rossing, P.	892
	Rakotoarisoa, L.	818	Roumans, K. H. M.	17
PRESENTER	Ramos, H.	920	Ruotolo, G.	150, 737
INDEX	Rasmussen, M. G. B.	405	Russo, G.	24, 849
	Rasmussen, N.	602	Russo, S.	1057
SATELLITE	Ravier, M. A.	413	Ryder, R. E. J.	792
SYMPOSIA	Rebelos, E.	731	Saari, T.	573
	Rebrova, Y.	903	Sabatini, S.	230
INDUSTRY	Redondo, M. J.	112, 324	Sacchetta, L.	793
PROGRAMME	Reis-Costa, A.	199	Sacre, J. W.	98
	Renard, E.	118	Saienko, Y.	915
	Renaud, C.	438	Salah, N.	987
EXHIBITION	Resi, V.	460	Salle, L.	87
	Resmini, E.	120, 872	Samakidou, G.	261
	Rewers, A.	486	Sánchez Ceinos, J.	1024
	Rewers, M.	36	Sandforth, L.	958
	Rial, S.	657	Sanfilippo, S.	136
	Riccio, A.	968	Santoni, L.	761
	Riddell, M. C.	787	Santos-Clemente, R.	597

Last Name, Initials, Presentation Number

Santos-Hernandez, M.	173	Shukla, N.	430
Sanyal, A.	739	Sibiak, R.	253
Sanz Villanueva, L.	432	Silva, J. G.	1051
Saponaro, C.	762	Silva, L. V.	518
Sarabhai, T.	53	Silva-Tinoco, R.	358
Saravanan, P.	254	Simo, R.	96
Sarma, S.	517	Sims, E.	67, 113
Sarnobat, D.	607	Singh, P.	802
Sarwat, S.	216	Sipter, E.	648
Sato, D.	221	Siracusano, G.	166
Sato, H.	508	Skriver-Møller, A.-C.	982
Satuli-Autere, S. I.	955	Skroce, K.	867
Sbierski-Kind, J.	479	Smati, S.	192
Schmedt, N.	1032	Smidtslund, P.	41
Schmidtke, M.	303	Smyth, L. J.	278
Schön, M.	266	Snel, L. I. P.	717
Schoug, J.	883	Snell-Bergeon, J.	243
Schupp, E.	187	Soe, K.	890
Schuppelius, B.	591	Soghomonian, A.	794
Schürfeld, R.	909	Søholm, J. C.	462, 463
Schut, K.	125	Sola, C.	1038
Schweitzer, L.	683	Soldovieri, L.	142
Scidà, G.	690	Song, P.-S.	126
Secher, A.	75	Song, S. H.	859
Seebauer, L.	938	Soto-Pedre, E.	88
Sehgal, R.	656	Sourij, H.	9
Seigner, J.	205	Sourris, K. C.	198
Selvarajah, D.	929	Speksnijder, E. M.	551
Semeia, L.	56	Sriram, A.	227
Senesi, P.	973	Stadler, M.	1039
Seno, Y.	612	Stedman, M.	801
Shaik, A.	274	Steens, I. L. M.	348
Shamanna, P.	236	Stene, L. C.	33
Shamansurova, Z.	568	Storey, R.	720
Shankar, A.	625	Stöver, H.	220
Sharma, S.	280	Stow, D.	370
Shehadeh, N.	729	Su, Q.	1008
Shen, Z.-Y.	1000	Su, Y.	496
Shin, H.	631	Sugawara, L.	638
Shin, J. J.	775	Sugiyama, M.	629
Shomali, M. E.	835	Suleiman, M.	604
Shu, Z.	943	Sun, J.	767

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Last Name, Initials, Presentation Number

	Sun, R.	994	Tsimihodimos, V.	721
	Sun, X.	609	Tsitsou, S.	26
	Sun, Y.	170, 553	Tu, Z.	948
	Suur, B. E.	664	Tuluc, P.	424
	Svehlikova, E.	244, 723	Tuomilehto, J.	176
	Svensson, S. I. A.	203	U-Din, M.	577
EASD	Swiderska, E.	712	Ueda, M.	678
EFSD	Syreeni, A.	984	Ukropec, J.	961
	Szekely, K.	587	Ulanowska, M.	584
GENERAL	Talamonti, E.	560	Ung, M.	769
INFO	Tan, H.	308	Unger, L.	415
	Tao, W.	1009	Vähäkangas, E.	163
PROGRAMME	Tapia, G.	31	Valderas, J. P.	4
	Tara, Y.	410	Valo, E.	978
TUESDAY	Tavajoh, S.	662	Vambergue, A.	464
	Teixeira, P. D. S.	510	van de Bunt, M.	156
WEDNESDAY	Templeman, E.	336	van den Burg, E. L.	27
	Templeman, E. L.	34	Van der Kolk, B. W.	592
THURSDAY	ter Braake, J. G.	845	van der Velde, J. H. P.	283
	Tesi, M.	454	van Duinkerken, E.	874, 954
FRIDAY	Teunis, C. J.	949	Vandenbempt, V.	167
	Tham, L.	745	Vanweert, F.	531
SHORT ORAL	Thant, A.	838	Varkevisser, R.	105
DISCUSSIONS	Thennati, R.	738, 751	Veedfald, S.	537
	Thirumorthy, C.	277	Vellanki, P.	487, 511
	Thomaides-Brears, H.	110	Vera-Ramos, J.	321
PRESENTER	Thomas, A. M.	539	Vergara Ucin, J.	420, 422
INDEX	Thomas, J. J. C.	857	Verma, M.	618
	Thomas, M. K.	131	Verma, S.	124
SATELLITE	Thomas, N.	322	Vernstrøm, L.	3
SYMPOSIA	Thomsen, R. W.	807	Vessari, H.	344
	Thorius, I. H.	256	Vestergaard, B.	558, 78
INDUSTRY	Thybo, T.	869	Vianna, A. G. D.	786
PROGRAMME	Tijani, O. K.	377	Vijayakumar, A.	610, 611
	Tokgöz, S.	152	Vila Bedmar, R.	666
EXHIBITION	Tokuno, S.	726	Villanueva-Carmona, T.	702
	Tomas, A.	132	Villena, J. A.	575
	Tonin, G.	272	Vilsbøll, T.	12
	Toniolli, M.	323	Viñals, C.	1041
	Triatin, R. D.	44	Vinci, C.	164
	Trico, D.	107	Virtanen, S. M.	289
	Trinks, N.	962	Vivoli, A.	559

Last Name, Initials, Presentation Number

Vuong, B. T.	258	Yajnik, C. S.	20, 286
Waage, C.	373	Yamamoto, K.	677
Wada, N.	567	Yang, A.	376
Wada, T.	257	Yang, M.	57
Wagh, R. H.	371	Yasuda, T.	728
Wan, X.	642	Yi, H.-S.	1055
Wang, H.	426	Yin, X.	956
Wang, J.	622	Ylinen, A.	330
Wang, K.	350	Yoo, J.	360
Wang, Q.	747	Yoon, M.-S.	627
Wang, R.	189	Young, K. G.	858
Wang, S.	361	Yu, G.	46
Wang, W.	926	Yu, H.	1046
Wang, X.	788	Yu, M.	141
Wang, Y.	1058	Yu, X.	512
Wang, Y.	899	Yuan, C.	692
Wang, Z.	620	Yuan, H.	480
Wang, Z.	980	YuFan, W.	826
Wei, Y.	85	Zaharia, O. P.	287
Weksler-Zangen, S.	697	Zapardiel-Gonzalo, J.	305
Wilkinson, F.	368	Zawiejska, A.	990
Williams, D. M.	1043	Zelmanovitz, T.	914
Wilmot, E. G.	116	Zhang, K.	1022
Wilson, R. B.	1052	Zhang, W.	1063
Witkowski, P.	447	Zhang, X.	862
Wolffenbuttel, B. H. R.	1028	Zhang, X.-L.	996
Wong, W. K. M.	455	Zhang, Y.	375
Wrublewsky, S.	450	Zhang, Y.	700
Wu, H.	398	Zhao, L.	233
Wu, J.	519	Zhao, X.	382
Wu, P.	489	Zheng, J.	488, 590
Wu, X.	532	Zheng, W.	281
Wu, Y.	1054	Zheng, X.	1005
Wysham, C. H.	1002	Zhi, M.	478
Xia, J.	579	Zhijian, Z.	18
Xiang, C.	238	Zhou, C.	647
Xie, C.	54, 684	Zhou, G.	884
Xu, S.	148	Zhou, X.	269
Xu, S.	966	Zhou, X.	960
Xu, W.	1049, 1061	Zhu, Y.	55
Xu, Y.	804	Ziegler, R.	103, 839
Xue, S.	240	Zubovych, I. V.	969

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

INVITED SPEAKERS

Last Name, First Name, Page

	Adler, Amanda I.	49	Hansen, Torben	71
	Adriaenssens, Alice E.	72	Hansen, Dominique	50
	Aguilar-Salinas, Carlos A.	71	Heinemann, Lutz	75
	Ahlqvist, Emma	113	Heinonen, Sini M.	73
EASD	Andersen, Ulrik B.	74	Hussain, Sufyan	50
EFSD	Arai, Yusuke	75	Hyöty, Heikki A.	49
	Aronne, Louis J.	84	Izquierdo, Mikel	50
GENERAL	Baier, Leslie J.	71	Jastreboff, Ania M.	46
INFO	Bajaj, Harpreet S.	45	Ji, Linong	69
PROGRAMME	Bergental, Richard	45	Johnson, Randi K.	49
	Berney, Thierry	111	Kamenov, Zdravko A.	70
	Billings, Liana K.	69	Kernan, Fiona.	95
TUESDAY	Blüher, Matthias	84	Kieffer, Timothy J.	74
	Börgeson, Emma	95	Kilpeläinen, Tuomas O.	113
WEDNESDAY	Bradley, Cathy J.	94	King, Bruce.	98
	Breton, Marc D.	113	Knudsen, Jakob G.	112
THURSDAY	Busetto, Luca	95	Kokoszka, Andrzej W.	46
	Colleluori, Georgia	73	Krook, Anna	60
FRIDAY	Cota, Daniela	70	Kropp, Martina	74
	D'Alessio, David A.	112	Liesa-Roig, Marc	71
SHORT ORAL	Danne, Thomas	75	Lingvay, Ildiko.	69
DISCUSSIONS	Davies, Melanie J.	45	Lord, Simon	94
	De Franco, Elisa.	68	Lutz, Thomas	46
PRESENTER	Dean, Danielle	112	Mader, Julia K.	98
INDEX	Del Prato, Stefano	45	Maltese, Giuseppe	46
	Dennis, John	113	Martinez-Tellez, Borja	73
SATELLITE	Dewitte, Marieke	70	Mathieu, Chantal	28, 113
SYMPOSIA	Dinneen, Sean	75	McCrimmon, Rory	69
	Egan, Aoife M.	58	McGuire, Darren K.	49
INDUSTRY	Espeland, Mark	49	Mejhert, Niklas	45
PROGRAMME	Evans, Mark	75	Morganstein, Daniel.	58
	Flodstrom Tullberg, Malin.	96	Murphy, Helen R.	113
EXHIBITION	Folgueira Cobos, Cintia	73	Nakada, Haruka	75
	Frühbeck, Gema	95	Natarajan, Rama	74
	Gauthier, Benoit	60	Nauck, Michael A.	72
	Gimeno, Ruth	72	Nogueiras, Ruben	70, 100
	Goodyear, Laurie J.	45	Perkins, Bruce A.	105
	Griffin, Simon J.	49	Pinhas-Hamiel, Orit	47
	Griffin, Tomas	50	Pop-Busui, Rodica	44
	Haluzik, Martin	105	Raun, Kirsten	46

Last Name, First Name, Page

Reichman, Trevor W.	74
Richardson, Sarah J.	96
Rickford, Alice	46
Rodriguez-Calvo, Teresa	49
Rorsman, Patrik	112
Rossing, Peter	69
Rubino, Francesco.	84
Russell-Jones, David	98
Rydén, Mikael	95
Sandholm, Niina.	100
Sanyal, Arun.	71
Scharfmann, Raphael	99
Shah, Amy	47
Shapiro, Allison L. B.	47
Shaw, James A. M.	74
Shulman, Gerald I.	71
Simo, Rafael.	99
Sinclair, Alan J.	113
Sivaprasad, Sobha.	99
Sordi, Valeria	99
Sparks, Lauren M.	50
Srivastava, Anand	69
Steinberg, Gregory R.	70
Sussel, Lori	48
Tack, Cees J.	45
Tangri, Navdeep.	50
Taube, Magdalena	94
Taylor, Roy	28
Thabit, Hood.	113
Thomas, Stephen.	58
Thyfault, John P.	50
Tuomi, Tiinamaija	96
Uruska, Aleksandra	70
Venditti, Paola	71
Willaing, Tapager, Ingrid.	75
Williamson, Alice	45
Wojtuszczyzn, Anne	111
Wysham, Carol.	45
Yaghootkar, Hanieh	100
Ziegler, Anette-Gabriele	112
Zierath, Juleen R.	93

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS


PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION



**SATELLITE
SYMPOSIA
ON THE
OCCASION
OF THE
60TH
EASD
ANNUAL
MEETING**

PCDE SYMPOSIUM

Mon, 9 September 2024

09:00 - 10:30

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

D&CVD SYMPOSIUM

Mon, 9 September 2024

11:00 - 13:00

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

DFSG SYMPOSIUM

Mon, 9 September 2024

13:30 - 15:00

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

PSAD SYMPOSIUM

Mon, 9 September 2024

15:30 - 17:30

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

INCSG SYMPOSIUM

Tue, 10 September 2024

09:30 - 11:00

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

DIABETES INDIA SYMPOSIUM

Tue, 10 September 2024

11:30 - 13:30

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

DPSG SYMPOSIUM

Tue, 10 September 2024

14:00 - 16:00

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

#dedoc° SYMPOSIUM
What we wish you knew - and why

Tue, 10 September 2024

16:30 - 18:30

Retiro Hall

Chairs: Renza Scibilia, Australia; Bastian Hauck, Germany

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

DESG SYMPOSIUM

Wed, 11 September 2024

09:00 - 11:00

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

ExPAS SYMPOSIUM

Wed, 11 September 2024

11:30 - 13:30

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EUDF SYMPOSIUM

Diabetes data and registries: Enabling high quality diabetes care

Wed, 11 September 2024

14:00 - 16:00

Retiro Hall

EASD
EFSD

Chairs: Stefano Del Prato, Italy; Chantal Mathieu, Belgium

Speaker: Stefano Del Prato, Italy: **Welcome and introduction**

GENERAL
INFO

Khamlesh Khunti, UK: **Why registries?**

The different roles of registries in research and diabetes care:

PROGRAMME

TUESDAY

Juliana Chan, Hong Kong: **Clinical: Hong Kong Diabetes Register**

WEDNESDAY

Anette-Gabriele Ziegler, Germany: **Research: European pre-T1D Registry**

THURSDAY

Katarina Eeg-Olofsson, Sweden: **National: Swedish National Diabetes Register**

FRIDAY

Olga Kordonouri, Germany: **Care: SWEET Registry**

SHORT ORAL
DISCUSSIONS

Round Table: how to leverage existing research registries for clinical purposes

PRESENTER
INDEX

The policy perspective on data and registries:

Jill Farrington, Denmark: **WHO EURO: How to measure and monitor progress towards the global diabetes targets**

Massimo Massi Benedetti, Italy: **EU Commission: Collaborative Health Information European Framework (CHIEF)**

INDUSTRY

PROGRAMME

Hector Bueno, Spain: **JACARDI: Data availability, quality, accessibility and sharing**

EXHIBITION

Carla Torre, Portugal: **European Regulator: Opportunities and challenges of registries for regulatory decision-making**

Chantal Mathieu, Belgium: **Wrap-up and next steps**

DASG SYMPOSIUM

Wed, 11 September 2024

16:30 - 18:30

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

NEUROdiab SYMPOSIUM

Thu, 12 September 2024

09:00 - 11:00

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

IDF EUROPE SYMPOSIUM
Personalisation of care - the way forward

Thu, 12 September 2024

11:30 - 13:00

Retiro Hall

Chair: João F. Raposo, Portugal

Speaker: Nebojsa M. Lalic, Serbia:

Welcome and introduction

Juan A. Giménez Bastida, Spain; Cajsja Lindberg, Belgium:

What does personalisation of care mean and what is needed to drive this? - Dialogue between a T2D advocate and T1D advocate

Katharine Barnard-Kelly, UK; Sufyan Hussain, UK;
Pinar Topsever, Turkey:

Getting to know healthcare system users, how do you make a science of it? - Conversation between a psychologist, endocrinologist and GP

Antonio Ceriello, Italy; Oliver Schnell, Germany:

Transforming and standardising healthcare systems for optimum personalisation - Conversation between two HCPs from different health systems

Pedro Gullón, Spain:

Breaking barriers - Enabling change - Policy maker's perspective

Panel discussion and Q&A

Tadej Battelino, Slovenia:

Wrap up and closing remarks

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

HSRHE-SG SYMPOSIUM

Thu, 12 September 2024

14:00 - 16:00

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

IHSG SYMPOSIUM

Thu, 12 September 2024

16:30 - 18:30

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

DNSG SYMPOSIUM

Fri, 13 September 2024

09:00 - 11:00

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EASD/SFD SYMPOSIUM

Thu, 12 September 2024

11:30 - 13:00

Retiro Hall

Chair: TBA

Speaker: TBA

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION



Industry Sessions

on the occasion of the

60th ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES

9–13 September 2024 • Madrid, Spain



www.easd-industry.com

Organised by



INTERPLAN
media & service gmbh

INDUSTRY SYMPOSIA SCHEDULE

Monday, 9 September 2024

	Madrid Hall	Berlin Hall	Cairo Hall	Sofia Hall	Sydney Hall
09:00	Novo Nordisk A/S 09:00 – 11:00	SANOFI 10:30 – 16:00	Eli Lilly and Company 13:00 – 14:30	Astra Zeneca 12:00 – 13:00	Abbott Diabetes Care 10:30 – 12:00
09:30					
10:00					
10:30					
11:00					
11:30					
12:00					
12:30					
13:00					
13:30					
14:00	Astra Zeneca 13:30 – 15:00	Medtronic International Trading Sàrl 13:30 – 15:00			
14:30					
15:00	Astra Zeneca 15:30 – 17:00	Eli Lilly and Company 16:30 – 18:00			
15:30					
16:00	GSK 16:30 – 18:00	Eli Lilly and Company 16:30 – 18:00			
16:30					
17:00	GSK 16:30 – 18:00	Eli Lilly and Company 16:30 – 18:00			
17:30					
18:00					

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

INDUSTRY SYMPOSIA SCHEDULE

Monday, 9 September 2024

Vienna Hall	Lima Hall	Mumbai Hall	Warsaw Hall	
				09:00
				09:30
				10:00
				10:30
				11:00
				11:30
				12:00
	Bayer AG 12:00 – 13:30			12:30
				13:00
Roche Diabetes Care GmbH 13:30 – 15:00		Dexcom 13:00 – 14:30	The Leona M. and Harry B. Helmsley Charitable Trust 09:00 – 18:00	13:30
				14:00
				14:30
				15:00
	Boehringer Ingelheim International GmbH 15:00 – 16:30			15:30
				16:00
		Sinocare Meditech Inc. 16:00 – 17:00		16:30
				17:00
Menarini Group 17:00 – 18:00				17:30
				18:00

All stated times in CEST / Status June 2024, details are subject to change.

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

INDUSTRY SYMPOSIA SCHEDULE

Tuesday, 10 September 2024

	Spotlight Stage	Lima Hall
08:45 ..		
EASD EFSD		
08:55 ..		
12:00 ..	Eli Lilly and Company 12:00 – 12:30	
GENERAL INFO		
12:30 ..		
PROGRAMME		
14:45 ..	Abbott 14:45 – 15:15	
TUESDAY		
15:15 ..		
WEDNESDAY		
18:30 ..		
THURSDAY		
19:00 ..		Novo Nordisk A/S 18:30 – 20:00
FRIDAY		
19:30 ..		
20:00 ..		
SHORT ORAL DISCUSSIONS		
PRESENTER INDEX		
SATELLITE SYMPOSIA		
INDUSTRY		
PROGRAMME		
EXHIBITION		

INDUSTRY SYMPOSIA SCHEDULE

Tuesday, 10 September 2024

Mumbai Hall	Warsaw Hall	Virtual only	
		iCare 08:45 – 08:55	08:45
			08:55
			12:00
			12:30
			14:45
			15:15
			18:30
Merck KGaA 18:30 – 19:30	Servier medical affairs 18:30 – 19:30		19:00
			19:30
			20:00

All stated times in CEST / Status June 2024, details are subject to change.

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

INDUSTRY SYMPOSIA SCHEDULE

Wednesday, 11 September 2024

	Spotlight Stage	Lima Hall
EASD EFSD		Boehringer Ingelheim and Eli Lilly and Company 07:45 – 08:45
GENERAL INFO		
PROGRAMME		
TUESDAY		
WEDNESDAY		
THURSDAY		
FRIDAY		
SHORT ORAL DISCUSSIONS		
PRESENTER INDEX		
SATELLITE SYMPOSIA		
INDUSTRY PROGRAMME		
EXHIBITION		

07:45		
08:15		
08:45		
12:15		
12:45	Novo Nordisk A/S 12:15 – 12:45	
15:00		
15:30	Dexcom 15:00 – 15:30	
17:00		
17:30	Eli Lilly and Company 17:00 – 17:30	
18:45		
19:15		
19:45		
20:15		Novo Nordisk A/S 18:45 – 20:15

INDUSTRY SYMPOSIA SCHEDULE

Wednesday, 11 September 2024

Mumbai Hall	Bejing Hall	Warsaw Hall	
Insulet 07:45 – 08:45	Tandem Diabetes Care, Inc. 08:15 – 08:45	Abbott 07:45 – 08:45	07:45
			08:15
			08:45
			12:15
			12:45
			15:00
			15:30
			17:00
			17:30
Institute for Medical and Nursing Education, Inc. (INME) 18:45 – 20:15		Vertex Pharmaceuticals, Inc. 18:45 – 20:15	18:45
			19:15
			19:45
			20:15

All stated times in CEST / Status June 2024, details are subject to change.

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

INDUSTRY SYMPOSIA SCHEDULE

Thursday, 12 September 2024

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

	Spotlight Stage	Lima Hall
12:15 ..	Medtronic International Trading Sàrl 12:15 – 12:45	
12:45 ..		
15:00 ..	Roche Diabetes Care GmbH 15:00 – 15:30	
15:30 ..		
18:45 ..		AKH Inc. and Catalyst Medical Education, LLC. 18:45 – 19:45
19:15 ..		
19:45 ..		
20:15 ..		

Friday, 13 September 2024

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

	Spotlight Stage	
10:00 ..	Boehringer Ingelheim International GmbH 10:00 – 10:30	
10:30 ..		
11:30 ..	Ypsomed AG 11:30 – 12:00	
12:00 ..		

INDUSTRY SYMPOSIA SCHEDULE

Thursday, 12 September 2024

Mumbai Hall	Warsaw Hall	
		12:15
		12:45
		15:00
		15:30
		18:45
DAIICHI SANKYO EUROPE GmbH 18:45 – 19:45	Novo Nordisk A/S and Echosens 18:45 – 19:15	19:15
	Novo Nordisk A/S 19:45 – 20:15	19:45
		20:15

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

All stated times in CEST / Status June 2024, details are subject to change.

MONDAY, 9 SEPTEMBER 2024

09:00 – 11:00
MADRID HALL

**INNOVATION IN ACTION: MOVING FORWARD
WITH BASAL INSULINS IN T2D**

- Chair:** Esteban Jodar (ESP)
- 09:00 – 09:10 Welcome and introduction**
Esteban Jodar (ESP)
- 09:10 – 09:30 Basal insulin treatment in T2D:
where is the innovation taking us?**
Athena Philis-Tsimikas (USA)
- 09:30 – 09:50 Continuous glucose monitoring in T2D:
what is the added value?**
Harpreet Singh Bajaj (CAN)
- 09:50 – 10:00 Q&A**
Athena Philis-Tsimikas (USA)
Harpreet Singh Bajaj (CAN)
- 10:00 – 10:20 Once weekly basal insulins across T2D populations:
what do we know so far?**
Monika Kellerer (DEU)
- 10:20 – 10:40 Once weekly basal insulin in a changing environment**
Alice Cheng (CAN)
Harpreet Singh Bajaj (CAN)
- 10:40 – 11:00 Discussion and Q&A**
All faculty

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Novo Nordisk A/S**

MONDAY, 9 SEPTEMBER 2024

09:00 – 18:00
WARSAW HALL

UNDERSTANDING AND PREVENTING HYPOGLYCEMIA IN DIABETES

Welcome and Introduction

09:00 – 09:15 **Welcome and Introduction**
Alvin C. Powers (USA)

EASD
EFSD

Genetic and gene expression studies that aim to understand the cause of glucagon secretion defects in diabetes.

GENERAL
INFO

09:15 – 09:45 **Alphabet(a) soup: Unraveling cell fate decisions in the islet.**
Lori Sussel (USA)

PROGRAMME

09:45 – 10:00 **Q&A**
Lori Sussel (USA)

TUESDAY

10:00 – 10:30 Joan Camuñas-Soler (SWE)

WEDNESDAY

10:30 – 10:45 **Q&A**
Joan Camuñas-Soler (SWE)

THURSDAY

Short talks from on submitted abstracts

FRIDAY

11:00 – 11:15 **Short talk from on submitted abstracts 1**

SHORT ORAL
DISCUSSIONS

11:15 – 11:20 **Q&A**

11:20 – 11:35 **Short talk from on submitted abstracts 2**

PRESENTER
INDEX

11:35 – 11:40 **Q&A**

11:40 – 11:55 **Short talk from on submitted abstracts 3**

SATELLITE
SYMPOSIA

11:55 – 12:00 **Q&A**

INDUSTRY

PROGRAMME

EXHIBITION

MONDAY, 9 SEPTEMBER 2024

09:00 – 18:00
WARSAW HALL

UNDERSTANDING AND PREVENTING HYPOGLYCEMIA IN DIABETES

Understanding and restoring alpha cell function in T1D and T2D: Intrinsic, paracrine, and in vivo consequences in humans.

EASD
EFSD

13:00 – 13:30 Patrik Rorsman (GBR)

GENERAL
INFO

13:30 – 13:45 **Q&A**
Patrik Rorsman (GBR)

13:45 – 14:15 **Understanding and restoring alpha cell function in type 1 diabetes**
Michael Rickles (USA)

14:15 – 14:30 **Q&A**
Michael Rickles (USA)

Clinical progress and regulatory perspectives regarding pharmacological strategies to prevent hypoglycemia.

Chair: Marjana Marinac (USA)

14:45 – 14:50 **Introduction**
Marjana Marinac (USA)

14:50 – 15:05 Asger Lund (DNK)

15:05 – 15:20 Richard Liggins (CAN)

15:20 – 15:35 TBD

15:35 – 15:45 Marjana Marinac (USA)

15:45 – 16:30 **Discussion session**
All Faculty

16:30 – 17:00 **Closing Remarks**

Poster Session

17:00 – 18:00 **Poster Session**

Organised by: **The Leona M. and Harry B. Helmsley Charitable Trust**

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

MONDAY, 9 SEPTEMBER 2024

**10:30 – 12:00
SYDNEY HALL**

EARLY USE OF CGM IN TYPE 2 DIABETES

10:30 – 10:45 A Data-Driven Rationale for the Early Deployment of Continuous Glucose Monitoring (CGM)

**EASD
EFSD**

10:45 – 11:05 Is CGM The Key to Managing Healthcare Utilization in Persons with Diabetes?

**GENERAL
INFO**

11:05 – 11:25 Moving Beyond HbA1c—Optimizing Time-in-Range for Persons with Type 2 Diabetes

PROGRAMME

TUESDAY

11:25 – 11:55 Interactive Case-Based Clinic: Early Application of CGM to Proactively Manage Type 2 Diabetes in the Real World

WEDNESDAY

THURSDAY

11:55 – 12:00 Question and Answer Session

FRIDAY

**SHORT ORAL
DISCUSSIONS**

**PRESENTER
INDEX**

**SATELLITE
SYMPOSIA**

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Abbott Diabetes Care

MONDAY, 9 SEPTEMBER 2024

10:30 – 16:00
BERLIN HALL

**PEOPLE, POPULATIONS AND PRACTICE:
EXPLORING THE JOURNEY ACROSS DIABETES CARE**

SESSION 1

Chair: Stefano Del Prato (ITA)

10:30 – 10:40 Welcome and introduction
Stefano Del Prato (ITA)

10:40 – 10:50 A case of timing: Current outlook in those with ACSVD with Type 2 diabetes
Klaus Parhofer (DEU)

10:50 – 11:05 Stepping back: Understanding very high CV risk populations
Emilio Ortega (ESP)

11:05 – 11:15 Moving forwards: The importance of proactivity in ASCVD and Type 2 diabetes
Manuel Castro Cabezas (NLD)

11:15 – 11:25 Panel discussion
All faculty

11:25 – 11:30 Meeting close: Summary and conclusions
Stefano Del Prato (ITA)

SESSION 2

Chair: Stefano Del Prato (ITA)

11:30 – 11:35 Welcome and introduction
Stefano Del Prato (ITA)

11:35 – 11:50 Establishing a renewed approach: Recognising needs across Type 2 diabetes
Stefano Del Prato (ITA)

11:50 – 12:15 Navigating simplified paths with insulin-based therapies
Rory McCrimmon (GBR)

12:15 – 12:35 Exploring personalized approaches in basal insulin management
Camille Vatier (FRA)

12:35 – 12:50 The focal point: Empowering self-management
Othmar Moser (DEU)
Virginia Bellido (ESP)

12:50 – 13:00 Panel discussion
All faculty

13:00 – 13:15 Break

13:15 – 14:00 The importance of hypoglycemia in the real world
Stewart Harris (CAN)
Alexandria Ratzki-Leewing (CAN)

14:00 – 14:30 Break

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

MONDAY, 9 SEPTEMBER 2024

10:30 – 16:00
BERLIN HALL

**BRINGING EARLY AUTOIMMUNE T1D CENTER STAGE:
EXPLORING RECENT ADVANCES AND EXPERT PERSPECTIVES**

- Chair:** Colin Dayan (GBR)
- 14:30 – 14:35** **Welcome**
Colin Dayan (GBR)
- 14:35 – 14:50** **Setting the Stage: Autoimmune Pathophysiology of Autoimmune T1D**
Colin Dayan (GBR)
- 14:50 – 14:55** **Panel Discussion**
All faculty
- 14:55 – 15:10** **Shining a Spotlight on Screening: Clinical and Real-world Experience**
Anette Ziegler (DEU)
- 15:10 – 15:15** **Panel Discussion**
All faculty
- 15:15 – 15:30** **Taking the Next Step: Management Options for People With Early-Stage Autoimmune T1D**
• Monitoring and Education for People with Early-Stage Autoimmune T1D
Linda DiMeglio (USA)
- 15:30 – 15:45** **Taking the Next Step: Management Options for People With Early-Stage Autoimmune T1D**
• The Evolving Treatment Landscape: Preservation of Beta-cell Function
Emily Sims (USA)
- 15:45 – 15:55** **Panel Discussion**
All faculty
- 15:55 – 16:00** **Session Close**
Colin Dayan (GBR)

Organised by: **SANOFI**

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

MONDAY, 9 SEPTEMBER 2024

12:00 – 13:00
SOFIA HALL

**NO SMOKE WITHOUT FIRE –
OBESITY AS AN UNDERLYING CAUSE OF DISEASE**

EASD EFSD	12:00 – 12:05	Welcome and introductions
GENERAL INFO	12:05 – 12:15	Smoke signals – The link between obesity and related comorbidities
PROGRAMME	12:15 – 12:30	Putting out the fire – Current and future management of obesity
TUESDAY		
WEDNESDAY	12:30 – 12:45	Inspiring global change – Weight management and health equity/equality
THURSDAY		
FRIDAY	12:45 – 12:55	Q&A All faculty
SHORT ORAL DISCUSSIONS	12:55 – 13:00	Summary and close
PRESENTER INDEX		
SATELLITE SYMPOSIA		
INDUSTRY		
PROGRAMME		
EXHIBITION		

Organised by: [AstraZeneca](#)

MONDAY, 9 SEPTEMBER 2024

12:00 – 13:30

LIMA HALL

EMERGING THERAPIES IN HEART AND KIDNEY DISEASE: BENEFITS AND CLINICAL IMPLICATIONS OF FINERENONE

- Chairs:** Javier Escalada San Martin (ESP)
Paola Fioretto (ITA)
- 12:00 – 12:05** **Welcome & introduction**
Javier Escalada San Martin (ESP)
- 12:05 – 12:25** **Finerenone for the spectrum of patients with T2D and CKD:
improving cardiovascular and kidney outcomes**
Paola Fioretto (ITA)
- 12:25 – 12:45** **Real-world benefits of finerenone: from guidelines to clinical
practice**
Katharina Schuett (DEU)
- 12:45 – 13:05** **Expanding the reach of finerenone: focus on heart failure**
Mikhail Kosiborod (USA)
- 13:05 – 13:25** **Beyond T2D: exploring the role of finerenone in patients with
T1D and CKD**
Richard Pratley (USA)
- 13:25 – 13:30** **Discussion & close**
All faculty

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Bayer AG**

MONDAY, 9 SEPTEMBER 2024

13:00 – 14:30
CAIRO HALL

THE THREE GS IN THE CONTEXT OF GUT HORMONE MULTIAGONISM

Chair: Melanie Davies (GBR)

13:00 – 13:10 Welcome and introductions
Melanie Davies (GBR)

13:10 – 13:30 GLP-1 in the context of gut hormone multiagonism
John Wilding (GBR)

13:30 – 13:50 GIP in the context of gut hormone multiagonism
Philipp Scherer (USA)

13:50 – 14:10 Glucagon in the context of gut hormone multiagonism
Eleuterio Ferrannini (ITA)

14:10 – 14:28 Panel discussion
All faculty

14:28 – 14:30 Wrap up
Melanie Davies (GBR)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: [Eli Lilly and Company](#)

MONDAY, 9 SEPTEMBER 2024

13:00 – 14:30
MUMBAI HALL

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Dexcom**

MONDAY, 9 SEPTEMBER 2024

13:30 – 15:00

SOFIA HALL

OPTIMISING CARDIORENAL OUTCOMES THROUGH EARLY INITIATION OF SGLT2 INHIBITORS

EASD
EFSD

13:30 – 13:45 **Achieving Impactful Goals of Care**

GENERAL
INFO

13:45 – 14:05 **Maximising Cardiorenal Protection With SGLT2 Inhibition in Diverse Patient Populations**

PROGRAMME

14:05 – 14:25 **SGLT2is in Heart Failure, CKD And T2D – What Does The Evidence Say?**

TUESDAY

WEDNESDAY

14:25 – 14:45 **SGLT2i Benefits on Renal Outcomes – Real World Evidence**

THURSDAY

14:45 – 15:00 **SGLT2is In Clinical Practice**

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **AstraZeneca**

MONDAY, 9 SEPTEMBER 2024

13:30 – 15:00
SYDNEY HALL

**EXPANDING HORIZONS IN INSULIN THERAPY:
APPLICATIONS OF MINIMED™ 780G SYSTEM AND MDI SOLUTIONS**

- Chair:** Ohad Cohen (CHE)
- 13:30 – 13:40** Meeting the needs of diverse populations
Ohad Cohen (CHE)
- 13:40 – 14:00** The MiniMed 780G System Study in Very Young Children with Type 1 Diabetes – First results from the LENNY study
- 14:00 – 14:20** Using MiniMed™ 780G system in Pregestational Type 1 Diabetes
- 14:20 – 14:35** The MiniMed 780G system performance in people living with type 2 diabetes requiring insulin treatment
- 14:35 – 14:50** The Smart MDI system: maximizing the benefits of MDI therapy
- 14:50 – 15:00** Q&A

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Medtronic International Trading Sàrl

MONDAY, 9 SEPTEMBER 2024

13:30 – 15:00

VIENNA HALL

PREPARE, PREVENT & ACT: ADVANCING IN-TIME GLYCAEMIC CONTROL BY UTILISING THE POWER OF PREDICTION

EASD
EFSD

Chairs: Ana Isabel Chico Ballesteros (ESP)
Jackie Elliott (GBR)

GENERAL
INFO

13:30 – 13:35 Introduction
Jackie Elliott (GBR)

PROGRAMME

TUESDAY

13:35 – 14:00 Close up: Common yet underrated challenges in daily diabetes therapy
Pratik Choudhary (GBR)

WEDNESDAY

14:00 – 14:25 In Focus: Patient-centric innovation taking diabetes therapy to a new level with a novel CGM solution
Guido Freckmann (DEU)

THURSDAY

14:25 – 14:50 Spot on: AI-trained predictive algorithms designed for preventive action and improved therapy control
Lutz Heinemann (DEU)

FRIDAY

14:50 – 15:00 Discussion & Closing
All faculty

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Roche Diabetes Care GmbH

MONDAY, 9 SEPTEMBER 2024

15:00 – 16:30

LIMA HALL

THE GLUCAGON PHILHARMONIC: ORCHESTRATING METABOLIC HARMONY IN OBESITY, LIVER DISEASE AND HEALTH

- Chairs:** Melanie Davies (GBR)
Josep Vidal (ESP)
- 15:00 – 15:05** **Setting the stage**
Melanie Davies (GBR)
- 15:05 – 15:10** **The conductor's call**
Josep Vidal (ESP)
- 15:10 – 15:20** **Tuning in to obesity and scaling the challenge of cardiovascular-renal-metabolic diseases**
Josep Vidal (ESP)
- 15:20 – 15:35** **Metabolism overture: Discerning glucagon in ensemble**
Daniel Drucker (CAN)
- 15:35 – 15:55** **The allegro of liver health: Accelerating innovations in metabolic management**
Mazen Nouredin (USA)
- 15:55 – 16:10** **Concerted care in metabolic health**
Ania Jastreboff (USA)
- 16:10 – 16:30** **Moving the conversation**
Melanie Davies (GBR)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Boehringer Ingelheim International GmbH**

MONDAY, 9 SEPTEMBER 2024

15:30 – 17:00

SOFIA HALL

EXPLORING THERAPEUTIC MECHANISMS TO IMPROVE ORGAN FUNCTION IN CVRM DISEASE

Chair: Hiddo Heerspink (NLD)

15:30 – 15:35 Introduction
Hiddo Heerspink (NLD)

15:35 – 15:55 Beneficial effects of GLP-1 – weight loss mediated versus direct action?
Carel le Roux (IRL)

15:55 – 16:15 Mechanistic synergies of the actions of SGLT2i's and GLP1Ra's on heart and liver
Ildiko Lingvay (USA)

16:15 – 16:35 Mechanistic synergies of the actions of SGLT2i's and GLP1Ra's on kidney protection
Hiddo Heerspink (NLD)

16:35 – 16:55 How can we utilize the mechanistic insights to further improve treatments of patients?
All Faculty

16:55 – 17:00 Summary and close
Hiddo Heerspink (NLD)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: [AstraZeneca](#)

MONDAY, 9 SEPTEMBER 2024

16:00 – 17:00
MUMBAI HALL

**ICAN REAL TIME CGM SYSTEM,
AN OPTION FOR ALL PATIENT GROUPS**

- Chair:** Lutz Heinemann (DEU)
- 16:00 – 16:05** **Welcome and introduction**
Lutz Heinemann (DEU)
- 16:05 – 16:15** **AID systems**
Partha Kar (GBR)
- 16:15 – 16:30** **CGM accuracy assessments**
Guido Freckmann (DEU)
- 16:30 – 16:40** **iCan real time CGM system performance**
Jiangfeng Fei (CHN)
- 16:40 – 16:55** **Current situation of CGM in Spain and new approaches for DM2 management**
Martín Cuesta Hernández (ESP)
- 16:55 – 17:00** **Q&A**
Lutz Heinemann (DEU)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Sinocare Meditech Inc.**

MONDAY, 9 SEPTEMBER 2024

16:30 – 18:00
SYDNEY HALL

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Eli Lilly and Company**

MONDAY, 9 SEPTEMBER 2024

16:30 – 18:00
CAIRO HALL

**EXPERT INSIGHTS ON THE VALUE OF PROTECTION AGAINST
VACCINE-PREVENTABLE DISEASE IN PATIENTS WITH DIABETES**

- 16:30 – 16:35** **Welcome and Introduction**
- 16:35 – 16:45** **Burden and Outcomes of Vaccine-Preventable Diseases in Patients with Diabetes**
- 16:45 – 17:05** **Preventing Severe Outcomes of RSV Infection in Patients with Diabetes: A Case Study**
- 17:05 – 17:25** **Maintaining Baseline through Herpes Zoster Prevention in Patients with Diabetes: A Case Study**
- 17:25 – 17:40** **Preventing RSV and HZ in Patients with Diabetes: Guideline Recommendations and Implementation Considerations**
- 17:40 – 17:50** **Panel Discussion**
- 17:50 – 18:00** **Q&A and Closing Remarks**

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **GSK**

MONDAY, 9 SEPTEMBER 2024

17:00 – 18:00
VIENNA HALL

TRIPLE PROTECTION OF SGLT2I: ACT2DAY FOR PATIENTS' FUTURE

Chairs: John Wilding (GBR), Xavier Cos (ESP)

- 17:00 – 17:02 Introduction**
John Wilding (GBR)
- 17:02 – 17:10 Early glycaemic control with SGLT-2 inhibitors and its long-lasting benefits**
John Wilding (GBR)
- 17:10 – 17:18 Blunting the progression of renal disease in diabetic patients with Canagliflozin: How, when and who?**
Hiddo L. Heerspink (NLD)
- 17:18 – 17:26 Getting to the heart of the matter: Canagliflozin cardiovascular benefits in T2D**
David Matthews (GBR)
- 17:26 – 17:34 Cardio-renal-metabolic care in T2D: be holistic!**
Apostolos Tsapas (GRC)
- 17:34 – 18:00 Round table: addressing barriers for early initiation of the therapy and Closing remarks**
All faculty

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Menarini Group

TUESDAY, 10 SEPTEMBER 2024

08:45 – 08:55
VIRTUAL ONLY

**AI-ASSISTED SCREENING FOR DIABETIC RETINOPATHY –
REAL-LIFE OUTCOMES**

08:45 – 08:55 **AI-assisted screening for diabetic retinopathy –
real-life outcomes**
Nina Hautala (FIN)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **iCare**

TUESDAY, 10 SEPTEMBER 2024

12:00 – 12:30
SPOTLIGHT STAGE

BETA-CELL DYSFUNCTION IN T2D – IS IT IRREVOCABLE?

Chair: Jonathan Rachman (GBR)

12:00 – 12:30 **Beta-cell dysfunction in T2D – is it irrevocable?**
David Matthews (GBR)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Eli Lilly and Company**

TUESDAY, 10 SEPTEMBER 2024

14:45 – 15:15
SPOTLIGHT STAGE

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Abbott**

TUESDAY, 10 SEPTEMBER 2024

18:30 – 19:30
MUMBAI HALL

THE RIGHT TIME FOR METFORMIN

Chairs: Harry Howlett (GBR)
Ian Campbell (GBR)

18:30 – 18:35 Welcome & Introduction

Harry Howlett (GBR)
Ian Campbell (GBR)

18:35 – 18:50 Early metformin: Diabetes prevention

Rosangela Rea (BRA)

18:50 – 19:05 Ongoing metformin: Diabetes treatment

Juliana Chan (CHN)

19:05 – 19:25 Legacy Metformin: UKPDS 91

Rury Holman (GBR)

19:25 – 19:30 Questions/Answers

All faculty

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Merck KGaA**

TUESDAY, 10 SEPTEMBER 2024

18:30 – 19:30
WARSAW HALL

IMPROVING ADHERENCE, GLYCEMIC CONTROL AND OUTCOMES FOR PEOPLE LIVING WITH DIABETES

Chair: Kamlesh Khunti (GBR)

18:30 – 18:35 Introduction
Kamlesh Khunti (GBR)

18:35 – 18:47 Achieving early glyceimic control for cardio renal protection: is there a link?
Somia Iqtadar (PAK)

18:47 – 18:59 What to do for people living with diabetes and cardiovascular diseases
Otavio Berwanger (GBR)

18:59 – 19:11 What about people living with diabetes and dyslipidemia?
Salah Abusnana (ARE)

19:11 – 19:23 Why therapeutic adherence matter for better outcomes?
Bart Torbeyns (BEL)

19:23 – 19:30 Panel discussion & conclusion
All faculty

Organised by: Servier medical affairs

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

TUESDAY, 10 SEPTEMBER 2024

18:30 – 20:00
LIMA HALL

**AT THE CROSSROADS OF SPECIALTIES:
EXPLORING THE TRENDS IN THE HOLISTIC, PERSON-CENTRED
APPROACH IN CARDIOVASCULAR-KIDNEY-METABOLIC DISEASE**

Chair: Sue Pedersen (CAN)

18:30 – 18:45 **Welcome and introductions: Connecting the dots between cardiovascular, kidney and metabolic diseases**
Sue Pedersen (CAN)

18:45 – 19:35 **Multidisciplinary care in cardiovascular, kidney and metabolic diseases: A panel discussion across specialties**
All Faculty

19:35 – 19:55 **Panel Q&A**
All Faculty

19:55 – 20:00 **Closing**
Sue Pedersen (CAN)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Novo Nordisk A/S**

WEDNESDAY, 11 SEPTEMBER 2024

07:45 – 08:45

LIMA HALL

CONVERSATIONS BETWEEN SPECIALTIES: THE IMPORTANCE OF SGLT2 INHIBITOR INITIATION FOR THE INTERDISCIPLINARY MANAGEMENT OF CARDIO, RENAL AND METABOLIC CONDITIONS

Chair:	Silvio Inzucchi (USA)
07:45 – 07:50	Communication between CRM conditions and specialties Silvio Inzucchi (USA)
07:50 – 08:00	Striking up a conversation on the importance of early treatment Rikke Borg (DNK) Richard Hobbs (GBR)
08:00 – 08:10	A breakdown in communication: the consequences of treatment inertia Rikke Borg (DNK) Erin Michos (USA)
08:10 – 08:35	Deep in conversation between specialties All faculty
08:35 – 08:45	Audience Q&A and closing remarks Silvio Inzucchi (USA)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Boehringer Ingelheim and Eli Lilly and Company**

WEDNESDAY, 11 SEPTEMBER 2024

07:45 – 08:45
MUMBAI HALL

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Insulet**

WEDNESDAY, 11 SEPTEMBER 2024

07:45 – 08:45
WARSAW HALL

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Abbott**

WEDNESDAY, 11 SEPTEMBER 2024

08:15 – 08:45
BEIJING HALL

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Tandem Diabetes Care, Inc.**

WEDNESDAY, 11 SEPTEMBER 2024

12:15 – 12:45
SPOTLIGHT STAGE

T2D CARE IN THE DIGITAL ERA: EVIDENCE WITH ONCE-WEEKLY INSULINS, CGM AND OTHER DIGITAL HEALTH TOOLS

- Chair:** Harpreet S. Bajaj (CAN)
- 12:15 – 12:22** **Welcome and introduction**
Harpreet S. Bajaj (CAN)
- 12:22 – 12:30** **Navigating T2D treatment: combining once-weekly insulins and CGM**
André G. Daher Vianna (BRA)
- 12:30 – 12:38** **Data-driven dosing: digital titration tools for managing T2D**
Susanne Reger-Tan (DEU)
- 12:38 – 12:45** **Interactive discussion: integrating once-weekly insulins and digital health tools**
All faculty

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Novo Nordisk A/S

WEDNESDAY, 11 SEPTEMBER 2024

15:00 – 15:30
SPOTLIGHT STAGE

HOT TOPIC SESSION

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Dexcom**

WEDNESDAY, 11 SEPTEMBER 2024

17:00 – 17:30
SPOTLIGHT STAGE

THE NEED TO LOOK BEYOND BMI

Chair: Rachel Batterham (GBR)

17:00 – 17:02 Introduction
Rachel Batterham (GBR)

17:02 – 17:07 Why do we need to change – Limitations on the current definition of obesity
John Wilding (GBR)

17:07 – 17:12 Why is it important to change – Practical implications for the future of obesity management
Francesco Rubino (GBR)

17:12 – 17:28 Q&A
All Faculty

17:28 – 17:30 Closing
Rachel Batterham (GBR)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: [Eli Lilly and Company](#)

WEDNESDAY, 11 SEPTEMBER 2024

18:45 – 20:15
LIMA HALL

**OBESITY MANAGEMENT IN THE SPOTLIGHT:
HOW CAN WE ACHIEVE PATIENT-CENTRICITY?**

EASD
EFSD

18:45 – 18:52 **Welcome**

GENERAL
INFO

18:52 – 19:02 **Why should obesity be treated as a serious chronic disease?**

PROGRAMME

19:02 – 19:17 **Panel discussion**
All Faculty

TUESDAY

19:17 – 19:27 **Looking beyond the numbers: what are the additional benefits of losing weight?**

WEDNESDAY

19:27 – 19:42 **Panel discussion**
All Faculty

THURSDAY

19:42 – 19:52 **What are the best practical approaches in obesity management?**

SHORT ORAL
DISCUSSIONS

19:52 – 20:07 **Panel discussion**
All Faculty

PRESENTER
INDEX

20:07 – 20:15 **Key takeaways and closing remarks**
All Faculty

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Novo Nordisk A/S**

WEDNESDAY, 11 SEPTEMBER 2024

18:45 – 20:15
MUMBAI HALL

**EMBRACING INNOVATION IN A NEW ERA OF DIABETES CARE:
A CME SYMPOSIUM**

- Chair:** Tina Vilsbøll (DNK)
- 18:45 – 18:55 Introduction**
Tina Vilsbøll (DNK)
- 18:55 – 19:10 Current goals of type 2 diabetes treatment: Is good glycemic control enough?**
Kamlesh Khunti (GBR)
- 19:10 – 19:35 Are current strategies delivering the holistic treatment approach for people living with T2D?**
Melanie Davies (GBR)
- 19:35 – 19:55 Innovative treatment strategies: will they make a difference, or more of the same?**
Tina Vilsbøll (DNK)
- 19:55 – 20:15 Panel discussion**
All faculty

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Institute for Medical and Nursing Education, Inc. (IMNE) // supported by an educational grant from Novo Nordisk A/S

WEDNESDAY, 11 SEPTEMBER 2024

18:45 – 20:15
WARSAW HALL

**FROM BURDEN TO BREAKTHROUGH: REIMAGINING TYPE 1 DIABETES
TREATMENT WITH CELL-BASED APPROACHES**

Chair: Stephanie Amiel (GBR)

18:45 – 18:55 Welcome and Introduction
Stephanie Amiel (GBR)

**18:55 – 19:15 Type 1 Diabetes Treatment in the Era of Technology:
Improvements in Clinical Care and the Continuing Need for
Innovation**
Jennifer Sherr (USA)

**19:15 – 19:35 A View From the Clinic: Long-term Experience with
Islet Cell Therapy for T1D**
Peter Senior (CAN)

19:35 – 19:55 The Possibilities of Stem-cell-Derived Islets
Eelco de Koning (NLD)

19:55 – 20:10 Q&A/Panel Discussion
Stephanie Amiel (GBR)

20:10 – 20:15 Summary of Key Takeaways
Stephanie Amiel (GBR)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Vertex Pharmaceuticals, Inc.

THURSDAY, 12 SEPTEMBER 2024

12:15 – 12:45
SPOTLIGHT STAGE

**ADDRESSING THE NEEDS OF ALL PEOPLE LIVING WITH
TYPE 1 DIABETES**

12:15 – 12:30 **The MiniMed™ 780G system addressing the needs
of every population**

12:30 – 12:45 **Maximizing the benefits of MDI therapy: the Smart MDI system**

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Medtronic International Trading Sàrl

THURSDAY, 12 SEPTEMBER 2024

15:00 – 15:30
SPOTLIGHT STAGE

HOT TOPIC SESSION

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Roche Diabetes Care GmbH

THURSDAY, 12 SEPTEMBER 2024

18:45 – 19:15
WARSAW HALL

**BREAKING THE BARRIERS: ADDRESSING THE METABOLIC IMPACT
OF MASH WITH MULTIDISCIPLINARY CARE**

Chairs: Irene Bretón (ESP)
Helena Cortez-Pinto (PRT)

EASD
EFSD

18:45 – 18:47 Introduction
Irene Bretón (ESP)
Helena Cortez-Pinto (PRT)

GENERAL
INFO

18:47 – 18:57 MASH as a metabolic disease
Irene Bretón (ESP)
Helena Cortez-Pinto (PRT)

PROGRAMME

TUESDAY

18:57 – 19:07 Multidisciplinary care in MASH
Irene Bretón (ESP)
Helena Cortez-Pinto (PRT)

WEDNESDAY

19:07 – 19:13 Q & A
Irene Bretón (ESP)
Helena Cortez-Pinto (PRT)

THURSDAY

FRIDAY

19:13 – 19:15 Summary and close
Irene Bretón (ESP)
Helena Cortez-Pinto (PRT)

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Novo Nordisk A/S and Echosens

THURSDAY, 12 SEPTEMBER 2024

18:45 – 19:45

LIMA HALL

**ENTERING A NEW ERA IN METABOLIC DYSFUNCTION-ASSOCIATED
STEATOHEPATITIS: EXAMINING THE CLINICAL IMPLICATIONS OF
EMERGING DISEASE-SPECIFIC THERAPIES**

EASD
EFSD

Chair: Meena Bansal (USA)

GENERAL
INFO

**18:45 – 18:55 Introduction. The Growing Burden of MASLD/MASH:
A Call to Action**
Meena Bansal (USA)

PROGRAMME

TUESDAY

**18:55 – 19:10 THR- β Agonists and Other Disease-specific Therapies Poised to
Change the Paradigm**
Elisabetta Bugianesi (ITA)

WEDNESDAY

**19:10 – 19:20 Rising to the Need to Improve Diagnosis in the Era of
Disease-specific Therapy**

THURSDAY

**19:20 – 19:40 Clinical Case Challenge: Integrating MASLD/MASH-Specific
Therapy into Practice**
Meena Bansal (USA)

FRIDAY

SHORT ORAL
DISCUSSIONS

19:40 – 19:45 Q&A
All faculty

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **AKH Inc., Advancing Knowledge in Healthcare and Catalyst
Medical Education, LLC. // supported by an educational grant
from Madrigal Pharmaceuticals**

THURSDAY, 12 SEPTEMBER 2024

18:45 – 19:45
MUMBAI HALL

**CHOLESTEROL LOWERING IN HIGH CARDIOVASCULAR RISK
PATIENTS WITH COMORBIDITIES: CLOSING GAPS AND FUTURE
OPPORTUNITIES**

Chair: Klaus Parhofer (DEU)

18:45 – 18:50 **Welcome and introduction**
Klaus Parhofer (DEU)

18:50 – 19:00 **LDL lowering in patients with diabetes and other metabolic diseases**
Luis Masana (ESP)

19:00 – 19:15 **Unmet needs: Real-world evidence reveals treatment gaps in patients with diabetes and obesity**
Anna Solini (ITA)

19:15 – 19:30 **Closing the Gap: Advancing lipid management in high-risk patients with comorbidities**
Dirk Mueller-Wieland (DEU)

19:30 – 19:45 **Panel discussion and Q&A**
All faculty

Organised by: **DAIICHI SANKYO EUROPE GmbH**

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

THURSDAY, 12 SEPTEMBER 2024

19:45 – 20:15
WARSAW HALL

MANAGEMENT OF CKD IN T2D – WHERE ARE WE TODAY?

Chairs: Paola Fioretto (ITA), Jose Luis Górriz (ESP)

19:45 – 19:46 Introduction
Paola Fioretto (ITA)

19:46 – 19:48 Global burden of CKD and T2D
Jose Luis Górriz (ESP)

19:48 – 19:52 Evolution of clinical guidelines in CKD and T2D
Paola Fioretto (ITA)

19:52 – 19:55 Kidney outcome trials in patients with CKD and T2D
Jose Luis Górriz (ESP)

19:55 – 20:15 Discussion: Practical considerations for the management of patients with CKD and T2D – endocrinologist and nephrologist perspectives
Paola Fioretto (ITA)
Jose Luis Górriz (ESP)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: Novo Nordisk A/S

FRIDAY, 13 SEPTEMBER 2024

10:00 – 10:30
SPOTLIGHT STAGE

HOT TOPIC SESSION

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Boehringer Ingelheim International GmbH**

FRIDAY, 13 SEPTEMBER 2024

11:30 – 12:00
SPOTLIGHT STAGE

**ENABLING WOMEN WITH TYPE 1 DIABETES TO ACHIEVE THEIR GOALS
WITH AUTOMATED INSULIN DELIVERY**

Chair: Helen Murphy (GBR)

11:30 – 11:45 **mylife CamAPS FX : a unique solution while planning and throughout pregnancy**
Helen Murphy (GBR)

11:45 – 12:00 **Application in the clinical practice : insights from a center initiating the journey with mylife CamAPS FX**
Pilar Beato Vibora (ESP)

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

Organised by: **Ypsomed AG**

SPONSORS LIST

A. Menarini Diagnostics
 Abbott
 ACON Laboratories Inc.
 Ascensia Diabetes Care
 AstraZeneca
 Bayer AG
 Bionime Corporation
 Boehringer Ingelheim and Eli Lilly and Company
 Boehringer Ingelheim International GmbH
 Capteur Protect
 CREATION.co
 DAIICHI SANKYO EUROPE GmbH
 Dexcom
 Diabeloop
 DiagnOptics Technologies BV
 Diamyd Medical AB
 ECHOSENS
 Eli Lilly and Company
 EPS Bio Technology Corp.
 Eva Pharma
 GC Medical Science Corp.
 GSK
 iCare
 Innovation Zed
 Inreda Diabetic
 Institute for Medical and Nursing Education, Inc. (IMNE)
 Insulet
 InsulinSaver AB
 i-SENS
 Madrigal Pharmaceuticals
 Mcure Co., Ltd
 Medtronic International Trading Sàrl
 Medtrum Technologies Inc.

Menarini Group
 Merck KGaA
 MESI, development of medical devices
 MicroTech Medical
 Nightingale Health
 Ningbo Medsun Medical Co., Ltd.
 Nova Biomedical
 Novo Nordisk A/S
 PATIA
 ProSciento, Inc.
 Roche Diabetes Care GmbH
 SANOFI
 Servier International / Servier medical affairs
 SIBIONICS CGM
 Sinocare Meditech Inc.
 SOOIL Development Co., Ltd
 Syai Health GmbH
 Tandem Diabetes Care, Inc.
 Vertex Pharmaceuticals, Inc.
 Wisepress Medical Bookshop
 Ypsomed AG
 Yuwell-POCTech

EASD
EFSD

GENERAL
INFO

PROGRAMME

TUESDAY

WEDNESDAY

THURSDAY

FRIDAY

SHORT ORAL
DISCUSSIONS

PRESENTER
INDEX

SATELLITE
SYMPOSIA

INDUSTRY

PROGRAMME

EXHIBITION

EASD AND EFSD ACKNOWLEDGEMENTS

The European Association for the Study of Diabetes (EASD) is most grateful to the following companies and organisations for their ongoing support of the prestigious prizes awarded on the occasion of the EASD Annual Meeting.

Lilly

The Albert Renold Prize is generously supported by Lilly.

The Minkowski Prize is generously supported by Lilly.

Novo Nordisk

The Camillo Golgi Prize is generously supported by Novo Nordisk.

The Rising Star Symposium and Fellowship is generously supported by Novo Nordisk.

Novo Nordisk Foundation

The Diabetes Prize for Excellence is generously supported by the Novo Nordisk Foundation.

Sanofi

The Claude Bernard Prize is generously supported by Sanofi.

The European Foundation for the Study of Diabetes (EFSD) is greatly indebted to the following companies and organisations for their most generous support of European diabetes research.

Boehringer Ingelheim

EFSD/Boehringer Ingelheim European Research Programme on “Multi- System Challenges in Diabetes”

This Programme is intended to stimulate and accelerate European research on the interrelation and crosstalk of different organs e.g. heart, kidney, pancreas, gut, liver and brain and related pathophysiology in diabetes, obesity and cardiometabolic disease, and the impact of therapeutic interventions for these complex conditions.

Japan Diabetes Society

EFSD/JDS Reciprocal Travel Research Fellowships

The objective of these Fellowships is to encourage collaborative research between Europe and Japan in the field of diabetes.

Lilly

EFSD/Lilly European Diabetes Research Programme

This Programme aims to promote increased European diabetes research and to raise public awareness and political understanding of the magnitude and burden of the disease. Grants are offered for any area of basic or clinical diabetes research.

EFSD/Lilly Young Investigator Research Award Programme

The objective of these Young Investigator Research Awards is to encourage innovative research in the field of diabetes and its complications, and to promote excellence in medical education.

Novo Nordisk

EFSD/Novo Nordisk Programme for Diabetes Research in Europe

This Programme aims to promote high-quality diabetes research in Europe and accepts applications from all fields of clinical and basic diabetes research.

EASD Rising Star Symposium & EFSD Research Fellowship Programme supported by Novo Nordisk

This combined EASD/EFSD initiative aims to identify promising and innovative young researchers in basic and clinical diabetes research.

Novo Nordisk Foundation

EFSD/Novo Nordisk Foundation Future Leaders Award Programme

This Programme is intended to identify outstanding clinical and basic scientists in European diabetes research in the transition from post-doctoral/clinical fellow to a tenured academic appointment in diabetes research in Europe and support them through significant career development awards over 5 years and fostering their development into the leaders of tomorrow.

Sanofi

EFSD and Sanofi European Diabetes Research Programme on autoimmunity in type 1 diabetes

The Programme is intended to stimulate and accelerate European research aimed at understanding of any aspect of autoimmunity in type 1 diabetes, its pathogenesis, screening and monitoring, its clinical course and its interventions.

In addition, the **EFSD Albert Renold Travel Fellowships** enables young scientists to stay at other institutions in order to learn new techniques in basic or clinical diabetes research.

#EASD2024

**POST LIVE AND FOLLOW THE DISCUSSION
ON SOCIAL MEDIA**

